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OBJECTIVE 
The Controlling Dangerous Pathogens Project of the Center for International Security 
Studies at Maryland (CISSM) outlines a prototype oversight system for ongoing microbiological 
research to control its possible misapplication. This so-called Biological Research Security 
System (BRSS) foresees the creation of regional, national, and international oversight bodies that 
review, approve, or reject those proposed microbiological research projects that would fit three 
BRSS-defined categories: Potentially Dangerous Activities (PDA), Moderately Dangerous 
Activities (MDA), and Extremely Dangerous Activities (EDA). It is the objective of this working 
paper to assess these categories qualitatively and quantitatively. To do so, published US research 
of the years 2000-present (early- to mid-2005) will be screened for science reports that would 
have fallen under the proposed oversight system had it existed already. Qualitatively, these 
selective reports will be sorted according to the subcategories of each individual Dangerous 
Activity, broken down by microbiological agent, and year. Quantitatively, institutes and 
researchers, which conducted research that would have fallen under review by BRSS, will be 
listed according to category and year. Taken together, the results of this survey will give an 
overview of the number of research projects, institutes, and researchers that would have been 
affected had the new proposed system existed, and thus should allow estimating the potential 
impact of BRSS on US microbiological academic and industrial research in the future. 
Furthermore, this working paper might aid refining the proposed system. 
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INTRODUCTION 
Over the last years, the number of scientific advances and inventions has increased 
exponentially. To date, there is no effective mechanism to evaluate the potential implications of 
the ever-growing number of scientific experiments. Benign and legitimate research might lead to 
results, which, in the wrong hands, could be misused to threaten entire human, animal, or plant 
populations. This holds true especially for microbiological and genomic research.  
Recently, a prototype oversight system (“Controlling Dangerous Pathogens Project”) has been 
proposed by a working group of the Center for International Security Studies at Maryland 
(CISSM). This Biological Research Security System (BRSS) aims to achieve more protection 
against deliberate or inadvertent misapplication of microbiological research.1 BRSS envisions 
complementing the 1972 Biological Toxins and Weapons Convention. It is supposed to be legally 
binding to countries that would choose to abide to the system, which foresees the creation of 
international, national, and regional governmental oversight bodies.  
It is impossible to survey the complete microbiological literature on a regular basis. 
However, certain experiments are more likely to yield results that could be misused than others. 
Similarly, certain microbiological agents are more likely to be considered for illegitimate 
purposes than others. The Controlling Dangerous Pathogens Project has established three 
categories, which outline the most critical research to be controlled. These Potentially Dangerous 
Activities (PDA), Moderately Dangerous Activities (MDA), and Extremely Dangerous Activities 
                                                 
1 Steinbruner, John, Elisa D. Harris, Nancy Gallagher, and Stacy Gunther. 2003. Controlling Dangerous 
Pathogens: A Prototype Protective Oversight System. Center for International Security Studies at Maryland, USA. 
[Online.] http://www.cissm.umd.edu/documents/pathogensmonograph.pdf  
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(EDA) would be monitored by the governmental oversight bodies. These Dangerous Activities 
are currently defined as follows: 
 
Potentially Dangerous Activities (PDA): 
 
1. Work with listed agent— or exempt avirulent, attenuated, or vaccine strain of select 
agent — not covered by EDA/MDA 
2. Increasing virulence of non-listed agent 
3. Increasing transmissibility or environmental stability of non-listed agent 
4. Powder or aerosol production of non-listed agent  
5. Powder or aerosol dispersal of non-listed agent  
6. De novo synthesis of non-listed agent 
7. Genome transfer, genome replacement, or cellular reconstitution of non-listed agent 
 
Moderately Dangerous Activities (MDA): 
 
1. Increasing virulence of listed agent or related agent 
2. Insertion of host genes into listed agent or related agent 
3. Increasing transmissibility or environmental stability of listed agent or related agent 
4. Powder or aerosol production of listed agent or related agent 
5. Powder or aerosol dispersal of listed agent or related agent 
6. De novo synthesis of listed agent or related agent 
7. Construction of antibiotic- or vaccine-resistant related agent 
8. Genome transfer, genome replacement, or cellular reconstitution of listed agent or 
related agent  
 
Extremely Dangerous Activities (EDA):1 
 
1. Work with eradicated agent (eradicated agent includes work with the 1918 Influenza A 
virus, derivatives of the 1918 Influenza A virus, and chimeric influenza virus with at 
least one gene from the 1918 Influenza A virus) 
                                                 
1 In a previous version of the Controlling Dangerous Pathogens Project’s categories, an EDA subcategory “Work 
with revived extinct agent related to listed agent” was included. The author suggests to reintroduce this subcategory, 
because such work is potentially dangerous; and scientific success has been achieved in this field by US groups (e.g. 
the revival of ancient Bacillus, Halobacterium, and other bacterial strains from amber and other materials). 
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2. Work with agent requiring Biosafety Level-4 
3. De novo synthesis of eradicated agent/agent requiring Biosafety Level-4 
4. Expanding host range of agent to new host (in humans, other animals and plants) or 
changing the tissue range of a listed agent 
5. Construction of antibiotic- or vaccine-resistant listed agent 
 
 
For these categories, an “agent” has been defined as a “fungus, protist, rickettsia, 
bacterium, virus, viroid, or prion; or genetic element, recombinant nucleic acid, or recombinant 
organism”. A “listed agent” has been defined as an “agent on [the] CDC Select Agent list, USDA 
High-Consequence Livestock Pathogens list, or USDA/APHIS/PPQ Plant Pathogens list” with 
the exception of toxins. The Centers for Disease Control and Prevention (CDC) Select Agent and 
US Department of Agriculture (USDA) High-Consequence Livestock Pathogens lists overlap.1 
The agents that are listed on the three different lists are, in alphabetical order, the following: 
 
CDC/DHSS NON-OVERLAP SELECT AGENTS2 
- Crimean-Congo hemorrhagic fever virus 
- Coccidioides posadasii 
- Cercopithecine herpesvirus 1 
- Filoviruses 
- Kyasanur forest disease virus  
- Lassa virus 
- Monkeypox virus 
- Omsk hemorrhagic fever virus  
- Rickettsia prowazekii 
- Rickettsia rickettsii 
- South American hemorrhagic fever viruses (Flexal virus, Guanarito virus, Junín virus, 
Machupo virus, Sabiá virus) 
- Tick-borne encephalitis virus (Far Eastern, and Western European subtypes) 
- Variola virus  
                                                 
1 [Online.] http://www.aphis.usda.gov/programs/ag_selectagent/index.html, and 
http://www.cdc.gov/od/sap/docs/salist.pdf.  
2 The list has been modified to fit the current taxonomy of the listed agents (see Method section). 
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- Yersinia pestis 
 
HIGH CONSEQUENCE LIVESTOCK PATHOGENS/SELECT AGENTS (OVERLAP 
AGENTS) 
- Bacillus anthracis 
- Brucella melitensis (strains abortus, melitensis, and suis) 
- Burkholderia mallei 
- Burkholderia pseudomallei  
- Clostridium botulinum (neurotoxin-producing) 
- Coccidioides immitis 
- Coxiella burnetii 
- Eastern equine encephalitis virus 
- henipaviruses 
- Francisella tularensis 
- Rift Valley fever virus 
- Venezuelan equine encephalitis virus 
 
USDA HIGH CONSEQUENCE LIVESTOCK PATHOGENS (NON-OVERLAP AGENTS) 
- African horse sickness virus 
- Akabane virus 
- Alcelaphine herpesvirus 1,2 (formerly known as Malignant catarrhal fever viruses, exotic 
strains only) 
- African swine fever virus 
- Bluetongue virus (exotic) 
- Bovine spongiform encephalopathy prion 
- Camelpox virus 
- Classical swine fever virus 
- Ehrlichia ruminantium (formerly known as Cowdria ruminantium)  
- Foot-and-mouth disease virus 
- Goatpox virus  
- Human enterovirus B (strain Human coxsackievirus B5 (formerly Swine vesicular disease 
virus) 
- Lumpy skin disease virus 
- Influenza A virus (avian highly pathogenic strains; eradicated agent according to table 
above) 
- Japanese encephalitis virus  
- Menangle virus 
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- Mycoplasma capricolum 
- Mycoplasma mycoides capri 
- Mycoplasma mycoides mycoides 
- Newcastle disease virus  
- Peste-des-petits-ruminants virus 
- Rinderpest virus 
- Sheeppox virus 
- Vesicular stomatitis virus (exotic) 
 
LISTED PLANT PATHOGENS 
- “Candidatus Liberobacter africanus“ 
- “Candidatus Liberobacter asiaticus“ 
- Peronosclerospora phillippinensis 
- Phakopsora pachyrhizi 
- Plum pox virus 
- Ralstonia solanacearum race 3, biovar 2 
- Sclerophthora rayssiae var. zeae 
- Synchytrium endobioticum 
- Xanthomonas oryzae 
- Xylella fastidiosa (citrus variegated chlorosis strain) 
 
Biosafety Level (BSL)-4 refers to those agents, which have been classified as especially 
dangerous by the CDC/DHSS and the National Institutes of Health (NIH).1 These are: 
 
- Certain Arenaviruses (Guanarito virus, Junín virus, Lassa virus, Machupo virus) 
- Crimean-Congo hemorrhagic fever virus 
- Filoviruses 
- Kyasanur Forest disease virus 
- Omsk hemorrhagic fever virus 
- Tick-borne encephalitis virus (Far Eastern, and Western European subtypes) 
 
                                                 
1 U. S. Department of Health and Human Services (Public Health Service), Centers for Disease Control and 
Prevention, and National Institutes of Health. 1999. Biosafety in Microbiological and Biomedical Laboratories, 
4th ed. HHS Publication No. (CDC) 93-8395. U.S. Government Printing Office, Washington, DC, USA [Online.] 
http://bmbl.od.nih.gov/ 
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Furthermore, Cercopithecine herpesvirus 1, hantaviruses, and henipaviruses (Hendra and 
Nipah viruses) are classified as BSL-4 viruses when animal experiments are performed or “large” 
quantities are used. Western European subtype strains of tick-borne encephalitis virus are BSL-3 
agents if the researcher is vaccinated against them.1 
 
A “related agent” has been defined “for fungi, protists, rickettsiae, or bacteria, an agent in 
the same genus as a listed agent; for viruses, viroids, or prions, an agent in the same family as a 
listed agent; for genetic elements, recombinant nucleic acids, or recombinant organisms, an agent 
orthologous to a listed agent. (This category includes any avirulent, attenuated, or vaccine strain 
of a listed agent, if said strain is exempt under the CDC Select Agent list, the USDA High-
Consequence Livestock Pathogens list, or USDA/APHIS/PPQ Plant Pathogens list.)”. According 
to this definition the following agents are “related agents”: 
 








Buthus occitanus reovirus 
Carcinus mediterraneus W2 virus 
Ceratitis capitata reovirus 
Changuinola virus 
                                                 
1 This biosafety classification is somewhat old. Recently discovered agents like Alkhumra virus, also known as 
Alkhurma or Fakeeh virus (related to Kyasanur Forest disease virus), and Garrissa virus (a novel Ngari virus 




Chobar Gorge virus 
Choristoneura fumiferana cypovirus 
Chub reovirus Germany 
Cimex lactularius reovirus 
Codajas virus 
Colorado tick fever virus 
Corriparta virus 
Cypovirus 1-14 
Dacus oleae reovirus 
Diadromus pulchellus reovirus 
Drosophila reoviruses 
Duck reovirus 
Echinochloa ragged stunt virus 
Epizootic hemorrhagic disease virus 
Equine encephalosis virus 
Eubenangee virus 
Eyach virus 
Fiji disease virus 
Garlic dwarf virus 
Grass carp reovirus 
Great Island virus 
Hard clam reovirus 
Heliothis armigera cypovirus  







Lake Clarendon virus 
Landlocked salmon reovirus 
Lebombo virus 
Macropipus depurator P reovirus 
Maize rough dwarf virus 
Mal del Rio Cuarto virus 
Mammalian orthoreovirus 
Matucare virus 
Musca domestica reovirus 
Ndelle virus 
Nelson Bay orthoreovirus 
Nilaparvata lugens reovirus 
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Oat sterile dwarf virus 
Orungo virus 
Palyam virus 
Pangola stunt virus 
Peruvian horse virus 
Peruvian rodent virus 
Porcelio dilatatus reovirus 
Python orthoreovirus 
Rattlesnake orthoreovirus 
Rice black streaked dwarf virus 
Rice dwarf virus 
Rice gall dwarf virus 
Rice ragged stunt virus 
Rotavirus A-G 
St Croix River virus 
Tembe virus 
Tench reovirus 
Tobacco leaf enation phytoreovirus 
Tracambe virus 
Umatilla virus 




Wound tumor virus 
 
Related to African swine fever virus: 
None. 
 






Anopheles A virus 
Anopheles B virus 
Antequera virus 






















Caddo Canyon virus 
Caimito virus 
California encephalitis virus 








Chrysanthemum stem necrosis virus 
Corfou virus 
Dera Ghazi Khan virus 
Dobrava-Belgrade virus 
Dugbe virus 
El Moro Canyon virus 
Enseada virus 
Estero Real virus 
Forecariah virus 
Frijoles virus 
Gabek Forest virus 
Gamboa virus 
Gan Gan virus 
Garissa virus 
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Gloxinia tospovirus  
Gordil virus 
Groundnut bud necrosis virus 
Groundnut chlorotic fan-spot virus 
Groundnut ringspot virus  






Impatiens necrotic spot virus  
Iris yellow spot virus 
Isla Vista virus 
Issyk-Kul virus 
Itaporanga virus 









Laguna Negra virus 
Lanjan virus 
Leanyer virus 
Lone Star virus 
Madrid virus 





Melon yellow spot virus 
Minatitlan virus 
Mojui dos Campos virus 
M'Poko virus 
Muleshoe virus 
Nairobi sheep disease virus 











Physalis severe mottle virus 
Prospect Hill virus 





Rio Grande virus 
Rio Mamore virus 





Sandfly fever Naples virus 








Sin Nombre virus 















Tomato chlorotic spot virus  









Watermelon bud necrosis virus 






Zucchini lethal chlorosis virus 
 
Related to Alcelaphine herpesvirus 1,2 (exotic), Cercopithecine herpesvirus 1: 
Acciptrid herpesvirus 1 
Acipenserid herpesvirus 1,2 
Anatid herpesvirus 1 
Anguillid herpesvirus 1 
Aotine herpesvirus 1,3 
Ateline herpesvirus 1-3 
Boid herpesvirus 1  
Bovine herpesvirus 1,2,4,5 
Bubaline herpesvirus 1 
Callitrichine herpesvirus 1-3 
Canid herpesvirus 1 
Caprine herpesvirus 1 
Caviid herpesvirus 1,3 
Cebine herpesvirus 1,2 
Cercopithecine herpesvirus 2-5,8,10-17  
Cervid herpesvirus 1,2 
Chelonid herpesvirus 1-4 
Ciconiid herpesvirus 1  
Columbid herpesvirus 1 
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Cricetid herpesvirus  
Cyprinid herpesvirus 1,2 
Elapid herpesvirus 1 
Elephantid herpesvirus 1 
Equid herpesvirus 1-9 
Erinaceid herpesvirus 1 
Esocid herpesvirus 1 
Falconid herpesvirus 1  
Felid herpesvirus 1  
Gallid herpesvirus 1-3 
Gruid herpesvirus 1  
Hippotragine herpesvirus 1 
Human herpesvirus 1-8 
Ictalurid herpesvirus 1 
Lacertid herpesvirus 1  
Leporid herpesvirus 1-3 
Lorisine herpesvirus 1  
Macropodid herpesvirus 1,2 
Marmomid herpesvirus 1 
Meleagrid herpesvirus 1 
Murid herpesvirus 1-6 
Mustelid herpesvirus 1 
Ostreid herpesvirus 1  
Percid herpesvirus 1  
Perdicid herpesvirus 1  
Phalacrocoracid herpesvirus 1 
Phocid herpesvirus 1 
Pleuronectid herpesvirus  
Pongine herpesvirus 1-4 
Psittacid herpesvirus 1  
Ranid herpesvirus 1,2 
Saimiriine herpesvirus 1,2 
Salmonid herpesvirus 1,2 
Sciurid herpesvirus 1,2 
Sphenicid herpesvirus 1 
Strigid herpesvirus 1 
Suid herpesvirus 1,2 
Tupaiid herpesvirus 1 
 
Related to Bacillus anthracis: 
Bacillus aeolius  
Bacillus agaradhaerens  
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Bacillus alcalophilus  
Bacillus amyloliquefaciens 
Bacillus aquimaris  
Bacillus arseniciselenatis  
Bacillus atrophaeus 
Bacillus azotoformans  
Bacillus badius  
Bacillus barbaricus  
Bacillus bataviensis  
Bacillus benzoevorans  
Bacillus carboniphilus  
Bacillus cereus 
Bacillus chitinolyticus  
Bacillus circulans 
Bacillus clarkii  
Bacillus clausii  
Bacillus coagulans 
Bacillus cohnii  
Bacillus decolorationis  
Bacillus drentensis  
Bacillus edaphicus  
Bacillus endophyticus  
Bacillus fastidiosus  
Bacillus firmus  
Bacillus flexus  
Bacillus fumarioli  
Bacillus funiculus  
Bacillus fusiformis  
Bacillus gibsonii  
Bacillus globisporus  
Bacillus halmapalus  
Bacillus haloalkaliphilus  
Bacillus halodenitrificans  
Bacillus halodurans 
Bacillus halophilus  
Bacillus horikoshii  
Bacillus horti 
Bacillus infernus  
Bacillus insolitus  
Bacillus jeotgali  
Bacillus krulwichiae  
Bacillus laevolacticus  
Bacillus lentus  
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Bacillus licheniformis 
Bacillus luciferensis  
Bacillus marisflavi  
Bacillus megaterium 
Bacillus methanolicus  
Bacillus mojavensis  
Bacillus mucilaginosus  
Bacillus mycoides 
Bacillus naganoensis  
Bacillus nealsonii  
Bacillus neidei  
Bacillus niacini  
Bacillus novalis  
Bacillus odysseyi  
Bacillus okuhidensis  
Bacillus oleronius  
Bacillus pallidus  
Bacillus pantothenticus  
Bacillus pseudalcaliphilus  
Bacillus pseudofirmus  
Bacillus pseudomycoides  
Bacillus psychrodurans  
Bacillus psychrosaccharolyticus  
Bacillus psychrotolerans  
Bacillus pumilus 
Bacillus pycnus  
Bacillus schlegelii  
Bacillus selenitireducens  
Bacillus silvestris  
Bacillus simplex 
Bacillus siralis  
Bacillus smithii  
Bacillus soli  
Bacillus sonorensis  
Bacillus sphaericus 
Bacillus sporothermodurans  
Bacillus subterraneus  
Bacillus subtilis 
Bacillus thermantarcticus  
Bacillus thermoamylovorans  
Bacillus thermocloacae  
Bacillus thuringiensis  
Bacillus tuscia  
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Bacillus vallismortis  
Bacillus vedderi  
Bacillus vireti  
Bacillus vulcani  
Bacillus weihenstephanensis  
 
Related to Bluetongue virus: 
See African horse sickness virus 
 
Related to Bovine spongiform encephalopathy prion: 
Prions (Chronic wasting disease prion, Creutzfeldt-Jakob disease prion, Exotic ungulate 
encephalopathy prion, Fatal familial insomnia prion, Feline spongiform encephalopathy prion, 
Gerstmann-Sträussler-Scheinker syndrome prion, Kuru prion, Scrapie prion, Transmissible mink 
encephalopathy prion) 
 
Related to Brucella melitensis (strains abortus, melitensis, suis): 
Brucella melitensis (strains canis, neotomae, ovis) 
 
Related to Burkholderia mallei, Burkholderia pseudomallei: 
Burkholderia ambifaria  
Burkholderia andropogonis  
Burkholderia anthina  
Burkholderia caledonica  
Burkholderia caribensis  
Burkholderia caryophylli  
Burkholderia cenocepacia  
Burkholderia cepacia 
Burkholderia cocovenenans  
Burkholderia fungorum  
Burkholderia gladioli  
Burkholderia glathei  
Burkholderia glumae  
Burkholderia graminis  
Burkholderia hospita  
Burkholderia kururiensis  
Burkholderia multivorans 
Burkholderia phenazinium  
Burkholderia phymatum  
Burkholderia plantarii  
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Burkholderia pyrrocinia  
Burkholderia sacchari  
Burkholderia sordidicola  
Burkholderia stabilis  
Burkholderia terricola  
Burkholderia thailandensis  
Burkholderia tuberum  
Burkholderia ubonensis  
Burkholderia vandii  
Burkholderia vietnamiensis 
 
Related to Camelpox virus, Goatpox virus, Monkeypox virus, Lumpy skin disease virus, 
Sheeppox virus, Variola virus: 
Acrobasis zelleri entomopoxvirus 'L' 
Aedes aegypti entomopoxvirus 
Amsacta moorei entomopoxvirus 'L' 
Anomala cuprea entomopoxvirus 
Aphodius tasmaniae entomopoxvirus 
Arphia conspersa entomopoxvirus 'O' 
Auzduk disease virus 
Bovine papular stomatitis virus 
California harbor seal poxvirus 
Camptochironomus tentans entomopoxvirus 
Canarypox virus 
Chamois contagious ecthyma virus 
Chironomus attenuatus entomopoxvirus 
Chironomus luridus entomopoxvirus 
Chironomus plumosus entomopoxvirus 
Choristoneura biennis entomopoxvirus 'L' 
Choristoneura conflicta entomopoxvirus 'L' 
Choristoneura diversuma entomopoxvirus 'L' 
Choristoneura fumiferana entomopoxvirus 'L' 




Demodema boranensis entomopoxvirus 




Figulus subleavis entomopoxvirus 
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Fowlpox virus 
Geotrupes sylvaticus entomopoxvirus 
Goeldichironomus haloprasimus entomopoxvirus 
Grey kangaroo poxvirus 
Hare fibroma virus 
Heliothis armigera entomopoxvirus 'L' 
Ips typographus entomopoxvirus 
Juncopox virus 
Locusta migratoria entomopoxvirus 'O' 
Marmoset poxvirus 
Melanoplus sanguinipes entomopoxvirus 'O' 
Melolontha melolontha entomopoxvirus 
Molluscum contagiosum virus 
Molluscum-like poxvirus 
Mule deer poxvirus 
Mynahpox virus 
Myxoma virus 
Nile crocodile poxvirus 
Oedaleus senigalensis entomopoxvirus 'O' 
Operophtera brumata entomopoxvirus 'L' 
Orf virus 
Othnonius batesi entomopoxvirus 
Parapoxvirus of red deer in New Zealand 
Peacockpox virus 
Penguinpox virus 
Phyllopertha horticola entomopoxvirus 
Pigeonpox virus 





Rabbit fibroma virus 
Raccoonpox virus 
Red kangaroo poxvirus 
Salanga poxvirus 
Schistocera gregaria entomopoxvirus 'O' 
Sealpox virus 
Sparrowpox virus 
Spectacled caiman poxvirus 











Yaba monkey tumor virus 
Yoka poxvirus 
 
Related to “Candidatus Liberobacter africanus”, “Candidatus Liberobacter asiaticus”: 
None. 
 
Related to Classical swine fever virus, Japanese encephalitis virus, Kyasanur Forest disease 
virus, Omsk hemorrhagic fever virus, Tick-borne encephalitis virus (Far Eastern, and 
Western European subtypes): 
Apoi virus 
Aroa virus 
Bagaza virus  
Banzi virus 
Border disease virus 
Bouboui virus 
Bovine viral diarrhea virus 1,2 
Bukalasa bat virus 
Cacipacore virus 
Carey Island virus 
Cowbone Ridge virus 
Dakar bat virus 
Dengue virus 
Edge Hill virus 
Entebbe bat virus 
Gadgets Gully virus 
GB virus A,B,C 
GB virus C troglodytes 
GBV-A-like agents 
Hepatitis C virus 
Hepatitis G virus 
HGV-Iowan 
Ilheus virus 









Louping ill virus 
Meaban virus 
Modoc virus 
Montana myotis leukoencephalitis virus 
Murray Valley encephalitis virus 
Ntaya virus 
Phnom Penh bat virus 
Powassan virus 
Rio Bravo virus 
Royal Farm virus 
Saboya virus 
Sal Vieja virus 
San Perlita virus 
Saumarez Reef virus 
Sepik virus 
St. Louis encephalitis virus 
Tembusu virus 
Tick-borne encephalitis virus 
Tyuleniy virus 
Uganda S virus 
Usutu virus 
Wesselsbron virus 
West Nile virus 
Yaounde virus 




Related to Clostridium botulinum (neurotoxin-producing): 
Clostridium absonum  
Clostridium aceticum  
Clostridium acetireducens  
Clostridium acetobutylicum  
Clostridium acidisoli  
Clostridium acidurici  
Clostridium aerotolerans  
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Clostridium akagii  
Clostridium aldrichii  
Clostridium algidicarnis  
Clostridium algidixylanolyticum  
Clostridium aminophilum  
Clostridium aminovalericum  
Clostridium amygdalinum  
Clostridium arcticum  
Clostridium argentinense  
Clostridium aurantibutyricum  
Clostridium baratii  
Clostridium beijerinckii 
Clostridium bifermentans 
Clostridium botulinum  
Clostridium bowmanii  
Clostridium butyricum 
Clostridium cadaveris  
Clostridium caminithermale  
Clostridium carnis  
Clostridium celatum  
Clostridium celerecrescens  
Clostridium cellobioparum  
Clostridium cellulofermentans  
Clostridium cellulolyticum  
Clostridium cellulosi  
Clostridium cellulovorans  
Clostridium chartatabidum  
Clostridium chauvoei  
Clostridium clostridioforme  
Clostridium coccoides  
Clostridium cochlearium  
Clostridium cocleatum  
Clostridium colicanis  
Clostridium colinum  
Clostridium collagenovorans  
Clostridium cylindrosporum  
Clostridium difficile 
Clostridium diolis  
Clostridium disporicum  
Clostridium estertheticum  
Clostridium fallax  
Clostridium felsineum  
Clostridium fimetarium  
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Clostridium formicaceticum  
Clostridium frigidicarnis  
Clostridium frigoris  
Clostridium gasigenes  
Clostridium ghonii  
Clostridium glycolicum  
Clostridium grantii  
Clostridium haemolyticum  
Clostridium halophilum  
Clostridium hastiforme  
Clostridium hathewayi  
Clostridium herbivora 
Clostridium histolyticum 
Clostridium homopropionicum  
Clostridium hungatei  
Clostridium hylemonae  
Clostridium indolis  
Clostridium innocuum  
Clostridium intestinale  
Clostridium irregulare  
Clostridium isatidis  
Clostridium josui  
Clostridium kluyveri  
Clostridium lactatifermentans  
Clostridium lacusfryxellense  
Clostridium lentocellum  
Clostridium lentoputrescens  
Clostridium leptum  
Clostridium limosum  
Clostridium litorale  
Clostridium lituseburense  
Clostridium ljungdahlii  
Clostridium magnum  
Clostridium malenominatum  
Clostridium mangenotii  
Clostridium mayombei  
Clostridium methoxybenzovorans  
Clostridium methylpentosum  
Clostridium neopropionicum  
Clostridium nexile  
Clostridium novyi  
Clostridium oceanicum  
Clostridium orbiscindens  
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Clostridium oroticum  
Clostridium papyrosolvens  
Clostridium paradoxum  
Clostridium paraputrificum  
Clostridium pascui  
Clostridium pasteurianum  
Clostridium peptidivorans  
Clostridium perenne  
Clostridium perfringens  
Clostridium phytofermentans  
Clostridium piliforme  
Clostridium polysaccharolyticum  
Clostridium populeti  
Clostridium propionicum  
Clostridium proteoclasticum  
Clostridium proteolyticum  
Clostridium psychrophilum  
Clostridium puniceum  
Clostridium purinilyticum  
Clostridium putrefaciens  
Clostridium putrificum  
Clostridium quinii  
Clostridium ramosum  
Clostridium rectum  
Clostridium roseum  
Clostridium saccharobutylicum  
Clostridium saccharolyticum  
Clostridium saccharoperbutylacetonicum  
Clostridium sardiniense  
Clostridium sartagoforme  
Clostridium scatologenes  
Clostridium scindens  
Clostridium septicum 
Clostridium sordellii 
Clostridium sphenoides  
Clostridium spiroforme  
Clostridium sporogenes 
Clostridium sporosphaeroides  
Clostridium stercorarium  
Clostridium sticklandii  
Clostridium subterminale  
Clostridium symbiosum  
Clostridium termitidis  
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Clostridium tertium  
Clostridium tetani 
Clostridium tetanomorphum  
Clostridium thermoalcaliphilum  
Clostridium thermobutyricum  
Clostridium thermocellum 
Clostridium thermopalmarium  
Clostridium thermopapyrolyticum  
Clostridium thermosuccinogenes  
Clostridium thiosulfatireducens  
Clostridium tyrobutyricum  
Clostridium uliginosum  
Clostridium ultunense  
Clostridium vincentii  
Clostridium viridae  
Clostridium xylanolyticum  
Clostridium xylanovorans  
 
Related to Coccidioides immitis, Coccidioides posadasii: 
None. 
 
Related to Coxiella burnetii: 
None. 
 
Related to Eastern equine encephalitis virus, Venezuelan equine encephalitis virus: 
78V3531 virus 
AG80-663 virus  
Aura virus  
Barmah Forest virus 
Bebaru virus  
Cabassou virus  
Chikungunya virus  
Everglades virus  
Fort Morgan virus  
Getah virus  
Highlands J virus  
Mayaro virus  
Middelburg virus  
Mucambo virus  
Ndumu virus  
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O’nyong-nyong virus  
Pixuna virus  
Ross River virus 
Rubella virus 
Salmon pancreas disease virus  




Una virus  
Western equine encephalitis virus 
Whataroa virus  
 





Ehrlichia muris  
 
Related to Foot-and-mouth disease virus, Human enterovirus B (strain Human 
coxsackievirus B5: 
Acid-stable equine picornavirus 
Aichi virus 
Avian encephalomyelitis-like virus 
Avian entero-like virus 2-4 
Avian nephritis virus 1-3 
Barramundi virus-1 
Bovine enterovirus 
Bovine rhinovirus 1-3 
Cockatoo entero-like virus 
Duck hepatitis virus 1,4 
Encephalomyocarditis virus 
Equine rhinitis A virus 
Equine rhinitis B virus 
Equine rhinovirus 3 
Guineafowl transmissible enteritis virus 
Harbour seal picorna-like virus 
Hepatitis A virus 
Human enterovirus A,B,C,D,E 
Human parechovirus 
 29
Human rhinovirus A,B 
Ljungan virus 
Poliovirus 
Porcine enterovirus A,B 




Syr-Daria Valley fever virus 
Taura syndrome virus of marine penaeid shrimp 
Theilovirus 
Turbot virus-1 
Turkey entero-like virus 
Turkey hepatitis virus 
Turkey pseudo enterovirus 1,2 
 
















Whitewater Arroyo virus 
 




Related to Hendra virus, Menangle virus, Newcastle disease virus, Nipah virus, Peste-des-
petits-ruminants virus, Rinderpest virus: 
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Avian paramyxovirus 2-9 
Bovine parainfluenza virus 2,3,4 
Bovine respiratory syncytial virus 




Human parainfluenza virus 1,3 





Murine pneumonia virus 
Nariva virus 
Ovine respiratory syncytial virus 
Phocine distemper virus 
Porcine rubulavirus 
Sendai virus 
Simian parainfluenza virus 5,41 
Simian virus 10 
Tioman virus 
Tupaia virus 
Turkey rhinotracheitis virus 
 
Related to Influenza A virus (avian highly pathogenic strains H5 and H7): 
Batken virus 
Dhori virus 
Infectious salmon anemia virus 
Influenza A virus 
Influenza B virus 
Influenza C virus 
Thogoto virus 
 
Related to Lake Victoria marburgvirus, Côte d’Ivoire ebolavirus, Reston ebolavirus, Sudan 
ebolavirus, Zaire ebolavirus: 
None. 
 
Related to Mycoplasma capricolum capripneumoniae, Mycoplasma mycoides capri, 
Mycoplasma mycoides mycoides: 
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Mycoplasma adleri  
Mycoplasma agalactiae 
Mycoplasma agassizii  
Mycoplasma alkalescens  
Mycoplasma alligatoris  
Mycoplasma alvi  
Mycoplasma anatis  
Mycoplasma anseris  
Mycoplasma arginini  
Mycoplasma arthritidis  
Mycoplasma auris  
Mycoplasma bovigenitalium  
Mycoplasma bovirhinis  
Mycoplasma bovis 
Mycoplasma bovoculi  
Mycoplasma buccale  
Mycoplasma buteonis  
Mycoplasma californicum  
Mycoplasma canadense  
Mycoplasma canis  
Mycoplasma capricolum  
Mycoplasma capricolum capricolum  
Mycoplasma caviae  
Mycoplasma cavipharyngis  
Mycoplasma citelli  
Mycoplasma cloacale  
Mycoplasma collis  
Mycoplasma columbinasale  
Mycoplasma columbinum  
Mycoplasma columborale  
Mycoplasma conjunctivae  
Mycoplasma corogypsi  
Mycoplasma cottewii  
Mycoplasma cricetuli  
Mycoplasma crocodyli  
Mycoplasma cynos  
Mycoplasma dispar  
Mycoplasma edwardii  
Mycoplasma elephantis  
Mycoplasma equigenitalium  
Mycoplasma equirhinis  
Mycoplasma falconis  
Mycoplasma fastidiosum  
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Mycoplasma faucium  
Mycoplasma felifaucium  
Mycoplasma feliminutum  
Mycoplasma felis 
Mycoplasma fermentans 
Mycoplasma flocculare  
Mycoplasma gallinaceum  
Mycoplasma gallinarum  
Mycoplasma gallisepticum 
Mycoplasma gallopavonis  
Mycoplasma gateae  
Mycoplasma genitalium 
Mycoplasma glycophilum  
Mycoplasma gypis  
Mycoplasma haemocanis  
Mycoplasma haemofelis  
Mycoplasma hominis 
Mycoplasma hyopharyngis  
Mycoplasma hyopneumoniae 
Mycoplasma hyorhinis 
Mycoplasma hyosynoviae  
Mycoplasma imitans  
Mycoplasma indiense  
Mycoplasma iners  
Mycoplasma iowae  
Mycoplasma lagogenitalium  
Mycoplasma leonicaptivi  
Mycoplasma leopharyngis  
Mycoplasma lipofaciens  
Mycoplasma lipophilum  
Mycoplasma maculosum  
Mycoplasma meleagridis  
Mycoplasma microti  
Mycoplasma moatsii  
Mycoplasma mobile  
Mycoplasma molare  
Mycoplasma muris  
Mycoplasma mustelae  
Mycoplasma neurolyticum  
Mycoplasma opalescens  
Mycoplasma orale  
Mycoplasma ovipneumoniae  
Mycoplasma oxoniensis  
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Mycoplasma penetrans  
Mycoplasma phocicerebrale  
Mycoplasma phocidae  
Mycoplasma phocirhinis  
Mycoplasma pirum  
Mycoplasma pneumoniae 
Mycoplasma primatum  
Mycoplasma pullorum  
Mycoplasma pulmonis 
Mycoplasma putrefaciens 
Mycoplasma salivarium  
Mycoplasma simbae  
Mycoplasma spermatophilum  
Mycoplasma spumans  
Mycoplasma sturni  
Mycoplasma sualvi  
Mycoplasma sualvi  
Mycoplasma subdolum  
Mycoplasma suis  
Mycoplasma synoviae 
Mycoplasma testudinis  
Mycoplasma verecundum  
Mycoplasma wenyonii  
Mycoplasma yeatsii  
 
Related to Peronosclerospora philippinensis: 
Peronosclerospora heteropogoni  
Peronosclerospora maydis  
Peronosclerospora northii 
Peronosclerospora sacchari 
Peronosclerospora sorghi  
Peronosclerospora zeae 
 















Related to Plum pox virus: 
Agropyron mosaic virus 
Alstroemeria mosaic virus  
Alstroemeria streak virus 
Amaranthus leaf mottle virus  
Amazon lily mosaic virus  
Aneilema mosaic virus  
Anthoxanthum mosaic virus 
Aquilegia necrotic ringspot virus  
Araujia mosaic virus  
Arracacha virus Y  
Artichoke latent virus  
Asparagus virus 1  
Asystasia gangetica mottle virus  
Banana bract mosaic virus  
Barley mild mosaic virus 
Barley yellow mosaic virus 
Bean common mosaic necrosis virus  
Bean common mosaic virus  
Bean yellow mosaic virus 
Beet mosaic virus 
Bidens mosaic virus  
Bidens mottle virus  
Bramble yellow mosaic virus  
Brome streak mosaic virus 
Bryonia mottle virus  
Calanthe mild mosaic virus  
Canary reed mosaic virus  
Canavalia maritima mosaic virus  
Cardamom mosaic virus  
Cardamom mosaic virus 
Carnation vein mottle virus  
Carrot mosaic virus  
Carrot thin leaf virus  
Cassava brown streak virus 
Cassia yellow spot virus  
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Celery mosaic virus  
Celery yellow mosaic virus  
Ceratobium mosaic virus  
Chickpea bushy dwarf virus  
Chickpea filiform virus  
Chilli veinal mottle virus  
Clitoria yellow mosaic virus  
Clover yellow vein virus  
Cocksfoot streak virus  
Colombian Datura virus  
Commelina mosaic virus  
Cowpea aphid-borne mosaic virus  
Cowpea green vein banding virus  
Cowpea rugose mosaic virus  
Crinum mosaic virus 
Cucumber vein yellowing virus 
Cypripedium calceolus virus 
Daphne virus Y  
Dasheen mosaic virus  
Datura distortion mosaic virus  
Datura mosaic virus 
Datura necrosis virus  
Datura shoestring virus  
Datura virus 437  
Desmodium mosaic virus  
Dioscorea trifida virus  
Dipladenia mosaic virus  
Dock mottling mosaic virus  
Eggplant green mosaic virus  
Eggplant severe mottle virus  
Endive necrotic mosaic virus  
Euphorbia ringspot virus  
Fig leaf chlorosis virus  
Freesia mosaic virus  
Gloriosa stripe mosaic virus  
Groundnut eyespot virus  
Guar symptomless virus  
Guinea grass mosaic virus  
Habenaria mosaic virus  
Helenium virus Y  
Henbane mosaic virus  
Hippeastrum mosaic virus  
Holcus streak virus 
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Hordeum mosaic virus 
Hungarian Datura innoxia virus 
Hyacinth mosaic virus 
Indian Pepper mottle virus  
Iris fulva mosaic virus  
Iris mild mosaic virus 
Iris severe mosaic virus  
Isachne mosaic virus 
Johnsongrass mosaic virus  
Kalanchoë mosaic virus  
Kennedya virus Y  
Konjac mosaic virus  
Leek yellow stripe virus  
Lettuce mosaic virus  
Lily mild mottle virus  
Lily mottle virus  
Maclura mosaic virus 
Maize dwarf mosaic virus  
Malva vein clearing virus  
Marigold mottle virus  
Melilotus mosaic virus  
Melon vein-banding mosaic virus  
Moroccan watermelon mosaic virus  
Mungbean mosaic virus 
Mungbean mottle virus  
Narcissus degeneration virus  
Narcissus late season yellows virus  
Narcissus latent virus 
Narcissus yellow stripe virus  
Nerine virus  
Nerine virus Y  
Nerine yellow stripe virus  
Nothoscordum mosaic virus  
Oat mosaic virus 
Oat necrotic mottle virus 
Onion yellow dwarf virus  
Ornithogalum mosaic virus  
Palm mosaic virus 
Papaya leaf distortion mosaic virus  
Papaya ringspot virus  
Parsnip mosaic virus  
Passionfruit mottle virus  
Passionfruit ringspot virus  
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Passionfruit woodiness virus  
Patchouli mottle virus  
Pea seed-borne mosaic virus  
Peanut green mottle virus  
Peanut mottle virus  
Pecteilis mosaic virus  
Pepper mild mosaic virus  
Pepper mottle virus  
Pepper severe mosaic virus  
Pepper vein banding virus  
Pepper veinal mottle virus  
Perilla mottle virus  
Peru tomato mosaic virus  
Plantain virus 7  
Pleioblastus mosaic virus  
Pokeweed mosaic virus  
Poplar decline virus  
Potato virus A  
Potato virus V  
Potato virus Y 
Primula mosaic virus  
Primula mottle virus  
Radish vein clearing virus  
Ranunculus mottle virus  
Rice necrosis mosaic virus 
Rudbeckia mosaic virus  
Ryegrass mosaic virus 
Shallot yellow stripe virus  
Sorghum mosaic virus  
Soybean mosaic virus 
Spartina mottle virus 
Sri Lankan passionfruit mottle virus  
Sugarcane mosaic virus  
Sunflower mosaic virus  
Sweet potato feathery mottle virus  
Sweet potato latent virus  
Sweet potato mild mottle virus 
Sweet potato mild speckling virus  
Sweet potato vein mosaic virus  
Sweet potato yellow dwarf virus 
Sword bean distortion mosaic virus  
Tamarillo mosaic virus  
Taro feathery mottle virus  
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Teasel mosaic virus  
Telfairia mosaic virus  
Tobacco etch virus 
Tobacco vein banding mosaic virus  
Tobacco vein mottling virus  
Tobacco wilt virus  
Tongan vanilla virus  
Tradescantia mosaic virus  
Trichosanthes mottle virus  
Tropaeolum mosaic virus  
Tropaeolum virus 1,2  
Tuberose mild mosaic virus  
Tulip band breaking virus  
Tulip breaking virus  
Turnip mosaic virus 
Ullucus mosaic virus  
Vallota mosaic virus  
Watermelon mosaic virus  
Wheat spindle streak mosaic virus 
Wheat streak mosaic virus 
Wheat yellow mosaic virus 
White bryony virus  
Wild potato mosaic virus  
Wisteria vein mosaic virus  
Yam mosaic virus  
Zoysia mosaic virus 
Zucchini yellow fleck virus  
Zucchini yellow mosaic virus 
 
Related to Ralstonia solanacearum (race 3 biovar 2): 
Ralstonia basilensis  
Ralstonia campinensis  
Ralstonia gilardii  
Ralstonia insidiosa  
Ralstonia mannitolilytica  
Ralstonia metallidurans  
Ralstonia oxalatica  
Ralstonia paucula  
Ralstonia pickettii 
Ralstonia respiraculi  
Ralstonia solanacearum 
Ralstonia taiwanensis  
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Related to Rickettsia prowazekii, Rickettsia rickettsii: 
Rickettsia aeschlimannii  
Rickettsia africae  
Rickettsia akari  
Rickettsia australis  
Rickettsia bellii 
Rickettsia canadensis  
Rickettsia conorii 
Rickettsia felis  
Rickettsia helvetica  
Rickettsia honei  
Rickettsia japonica 
Rickettsia massiliae  
Rickettsia montanensis  
Rickettsia parkeri  
Rickettsia peacockii  
Rickettsia rhipicephali  
Rickettsia sibirica  
Rickettsia slovaca  
Rickettsia typhi 
 





























































































Synchytrium erigerontis  





















































































Synchytrium ovale var. giganteum 
Synchytrium ovalis 



























































































Related to Vesicular stomatitis Alagoas/Indiana virus (exotic): 
Adelaide River virus  
Australian bat lyssavirus 
Bahia Grande virus  
Barley yellow striate mosaic virus  
BeAn 157575 virus  
Beet leaf curl virus  
Berrimah virus  
Boteke virus  
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Bovine ephemeral fever virus 
Broccoli necrotic yellows virus  
Calchaqui virus  
Callistephus chinensis chlorosis virus  
Carajas virus 
Carnation bacilliform virus  
Carrot latent virus  
Cassava symptomless virus  
Cereal chlorotic mottle virus  
Chandipura virus 
Chrysanthemum frutescens virus  
Chrysanthemum vein chlorosis virus  
Citrus leprosis virus  
Clover enation virus  
Cocal virus 
Coffee ringspot virus  
Colocasia bobone disease virus  
Coriander feathery red vein virus  
Cow parsnip mosaic virus  
Cynara virus  
Dendrobium leaf streak virus  
Digitaria striate virus  
Duvenhage virus  
Eel virus American  
Eel virus B12  
Eel virus C26 
Eggplant mottled dwarf virus  
Euonymus fasciation virus  
European bat lyssavirus 1,2  
Festuca leaf streak virus  
Finger millet mosaic virus  
Gerbera symptomless virus  
Gomphrena virus  
Gray Lodge virus  
Hirame rhabdovirus 
Holcus lanatus yellowing virus  
Infectious hematopoietic necrosis virus 
Iris germanica leaf stripe virus  
Isfahan virus 
Ivy vein clearing virus  
Jurona virus  
Kimberley virus  
Klamath virus  
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Kwatta virus  
La Joya virus  
Laelia red leafspot virus  
Lagos bat virus  
Launea arborescens stunt virus  
Lemon scented thyme leaf chlorosis virus  
Lettuce necrotic yellows virus  
Lolium ryegrass virus  
Lotus stem necrosis virus  
Lucerne enation virus  
Lupin yellow vein virus  
Maize mosaic virus 
Maize sterile stunt virus  
Malakal virus  
Malpais Spring virus  
Malva silvestris virus  
Maraba virus 
Melilotus latent virus  
Melon variegation virus  
Mokola virus  
Mount Elgon bat virus  
Northern cereal mosaic virus  
Oat striate mosaic virus  
Parsley virus  
Perinet virus  
Phalaenopsis chlorotic spot virus  
Pigeon pea proliferation virus  
Pike fry rhabdovirus  
Pineapple chlorotic leaf streak virus  
Piry virus 
Pisum virus  
Plantain mottle virus  
Porton virus 
Potato yellow dwarf virus  
Puchong virus  
Rabies virus 
Radi virus  
Ranunculus repens symptomless virus  
Raphanus virus  
Raspberry vein chlorosis virus  
Red clover mosaic virus  
Rice yellow stunt virus  
Rochambeau virus 
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Sainpaulia leaf necrosis virus  
Sambucus vein clearing virus  
Sarracenia purpurea virus  
Snakehead rhabdovirus 
Sonchus virus  
Sonchus yellow net virus  
Sorghum virus  
Soursop yellow blotch virus  
Spring viremia of carp virus  
Strawberry crinkle virus  
Triticum aestivum chlorotic spot virus  
Tupaia virus  
Ulcerative disease rhabdovirus  
Vesicular stomatitis Indiana virus 
Vesicular stomatitis New Jersey virus 
Vigna sinensis mosaic virus  
Viral hemorrhagic septicemia virus 
Wheat American striate mosaic virus  
Wheat chlorotic streak virus  
Wheat rosette stunt virus  
Winter wheat Russian mosaic virus  
Yug Bogdanovac virus  
Zea mays virus 
 
Related to Xanthomonas oryzae (pathovar Oryzicola): 
Xanthomonas albilineans 
Xanthomonas arboricola  
Xanthomonas axonopodis 
Xanthomonas bromi Vauterin  
Xanthomonas campestris 
Xanthomonas cassavae  
Xanthomonas citri 
Xanthomonas codiaei  
Xanthomonas cucurbitae  
Xanthomonas cynarae  
Xanthomonas fragariae  
Xanthomonas hortorum  
Xanthomonas hyacinthi  
Xanthomonas melonis  
Xanthomonas oryzae  
Xanthomonas phaseoli  
Xanthomonas pisi  
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Xanthomonas populi  
Xanthomonas populi  
Xanthomonas sacchari  
Xanthomonas theicola  
Xanthomonas translucens  
Xanthomonas vasicola  
Xanthomonas vesicatoria  
 
Related to Xylella fastidiosa (citrus variegated chlorosis strain):  
Xylella fastidiosa 
 
Related to Yersinia pestis: 
Yersinia aldovae  
Yersinia aleksiciae 
Yersinia bercovieri  
Yersinia enterocolitica 
Yersinia frederiksenii  
Yersinia intermedia  
Yersinia kristensenii  
Yersinia mollaretii  
Yersinia pseudotuberculosis 
Yersinia rohdei  
Yersinia ruckeri  
 
A “non-listed agent” is an agent other than a listed agent or related agent. “Antibiotic” is 
defined as “antibiotic or therapeutic utility against listed agent”. Similarly, “vaccine” is defined as 
“vaccine or therapeutic utility against listed agent”. A “powder” has been defined as a “powder 
other than lyophilized reference specimen (<10 mg)”. 
 
The “Interim Final Rule for Possession, Use, and Transfer of Select Agents” defines 
"genetic elements, recombinant nucleic acids, and recombinant organisms" as: 
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- “select agent viral nucleic acids (synthetic or naturally derived, contiguous or fragmented, 
in host chromosomes or in expression vectors that can encode infectious and/or 
replication competent forms of any of the select agent viruses; 
- nucleic acids (synthetic or naturally derived) that encode for the functional form(s) of any 
of the toxins listed … if the nucleic acids: (i) are in a vector or host chromosome; (ii) can 
be expressed in vivo or in vitro; or (iii) are in a vector or host chromosome and can be 
expressed in vivo or in vitro”. 
 
According to senior managers (conversation with Elisa Harris and Richard Ebright) of the 
“Controlling Dangerous Pathogens Project”, this definition is too narrow. Hence, the following 
definition is used:  
 
"Genetic elements, recombinant nucleic acids, and recombinant organisms" are 
- “Nucleic acids (synthetic or naturally derived) comprising at least 15% of the genome of 
an agent”; 
- “Nucleic acids (synthetic or naturally derived) encoding a virulence factor, or virulence-
factor subunit, of an agent”. 
 
Local, national, and international oversight bodies, provisionally named Local Pathogens 
Research Committee (LPRC), National Pathogens Research Authority (NPRA), and International 
Pathogens Research Agency (IPRA) would review PDA, MDA, and EDA, respectively. PDA 
would be subject to institutional review through a biosafety officer who would decide whether 
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approval by LPRC is necessary for a particular project. MDA would require national approval 
through the NRPA, which would also review the work of LPRC. EDA would have to be 
reviewed, accepted and continuously monitored by IPRA, which for that purpose would involve a 
special advisory Committee on Biological Research Activities (COBRA) comprised of experts in 
high-consequence microbiological science. 
 
 In the latest draft of the proposed oversight system, the risk of scientific work with an 
agent is based on its lethality, infectivity, and rate of means of transmission. The purpose of this 
working paper is to predict what research proportion would fall into the PDA, MDA, and EDA 
categories to further refine their definition and to estimate the potential impact of the oversight 
system on overall research activities, and economy. For a first approximation, relevant US 






This working paper focuses on validly and peer-reviewed publications, but does not 
include conference abstracts, book chapters, theses, dissertations, or patents – all of which might 
describe work with select (“listed”) or “related” or “non-listed” agents that is not published. The 
author suspects the list of such missed described experiments as rather short, but possibly 
important. The publications cited in this paper are referenced according to the standards 
established by the American Society for Microbiology (ASM). They are adapted to suggestions 
given in the ASM Style Manual for Journals and Books (American Society for Microbiology, 
Washington, DC, USA, 1991) and Robert A. Day’s How to Write and Publish a Scientific Paper, 
5th edition (Oryx Press, Phoenix, Arizona, USA, 1998). The citation style excludes first names of 
authors but lists their initials; omits issue numbers of journal articles; and abbreviates journal 
titles. Full author names and issue numbers can be easily obtained by copy-pasting an article title 
in the search field of the used databases and accessing the article (this action, however, requires 
full-text access, i.e. subscription to the database and the journal by one’s institution). 
Virus/Viroid/Virusoid/Satellite/Prion names are used according to the rules established by 
the International Committee on Taxonomy of Viruses (ICTV). They are in reference to the 7th 
Report of the ICTV published in 2000 (Virus Taxonomy. Seventh Report of the International 
Committee for the Taxonomy of Viruses. Academic Press, New York, New York, USA), and 
articles published on behalf of the ICTV in the journal Archives of Virology (Springer-Verlag, 
Vienna, Austria) in the years before the 7th report and thereafter. Bacterial names are used 
according to the rules established by the Bacteriological Code. They are in reference to articles 





(Society for General Microbiology, Reading, UK) and the latest edition of Bergey’s Manual of 
Systematic Bacteriology (Springer-Verlag, Vienna, Austria, various years for different volumes).  
 
Used databases for research reports: 
Only the most common databases, and only those to which the author had electronic access, were 
used for this working paper. These were: 
- Ingenta’s Ingenta Connect: http://www.ingentaconnect.com/  
- National Center for Biotechnology Information’s (NCBI’s) PubMed: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?  
- OCLC’s First Search: http://www.oclc.org/firstsearch/  
- Thomson’s ISI Web of Science: http://www.isinet.com/products/citation/wos/  
The majority (the author’s guess: about 99%) of “US” publications are listed in those databases 
used. Hence, even a much more thorough screen would most likely not retrieve many 
publications that should be listed in this working paper. However, it is possible that many “US” 
publications on plant pathogens, which should be included in this working paper, are not – this is 
because the author could not find an accessible electronic database covering this work, and it is 
possible that this work is not included in the databases used for this working paper. 
 
Used database for NIH grants: 
Although an original aim of this working paper, the list of grants in this working paper is rather 
incomplete because of the inaccessibility of electronic grant databases. Only the NIH database 
could be screened using The Sunshine Project’s CRISPER 
(http://www.cbwtransparency.org/crisper/index2.html) and here, only abstracts of grants were 





agents or not; which strain (exotic or not) was used; and whether it actually pertained to the agent 
itself rather than just listing it in the abstract to make the grant sound more interesting. The author 
had to guess whether to list particular grants in this working paper and used his limited 
knowledge to guide his guessing. Grant authors and the affiliated institutions were not listed in 




All searches were first performed using the database PubMed.  
Retrieved publications that had to be classified as a Dangerous Activity were those from the US, 
having been performed between 2000 and 2005, and fitting the Dangerous Activity subcategories 
described above.  
“US” publications were identified by using the provided institute affiliations of the authors of a 
given publication. Hence, a “US author” in this working paper is any author of a publication, for 
whom a US institution was listed as affiliation. However, this does not mean that a listed author 
actually is/was an American citizen. Only the affiliation provided by the abstract in a database 
was considered in the case of articles for which full-text electronic versions were not accessible 
by the author. Databases usually only provide the lead institution, i.e. the affiliation of the last 
and/or first author. Hence, in these cases either all authors were considered “US” or none at all. 
The affiliation of the lead (first or last) authors were listed when two or more affiliations were 
provided for one given author.  
The author list of a given article usually does not provide information on who actually worked 
with infectious agent and who merely provided support (through discussions, reagent sharing 





authors in articles with a foreign lead institution. These articles were listed in this working paper, 
but one could make a case that they shouldn’t – in which the list of “US” publications in this 
working paper would become shorter 
Retrieved publications were downloaded into the database management program Endnote 8 
(Thomson Research Soft, Carlsbad, California). Then, secondary searches were performed using 
the other databases. Retrieved papers were downloaded into Endnote, and duplicates were 
eliminated. Full-text versions of the retrieved articles, if available online using the Harvard 
Medical School journal subscriptions, were screened for the PDA/1 subcategory and all EDA 
subcategories. In contrast to those subcategories, which on average demanded screening of 
<1,000 articles per any one of the few agents/subcategory, several ten thousand articles needed to 
be screened for all other subcategories (PDA/2-7, MDA/1-8). Hence, only article titles and 
abstracts were screened for these subcategories. 
 
Specific: 
At first, subcategory PDA/1 (Work with listed agent— or exempt avirulent, attenuated, or 
vaccine strain of select agent — not covered by EDA/MDA) was examined. This subcategory 
includes all select agents listed above. Following a discussion with Elisa Harris and Richard 
Ebright, only papers dealing with “life”, i.e. infectious agents were considered (purely 
epidemiological or case reports were not considered). Identified publications, which fit another 
subcategory of either MDA or EDA were removed and placed accordingly. To search for select 
agents, the following search terms were used either singularly, or in Boolean combination: 






2. African swine fever virus: “african swine fever or asfarviridae or asfarviruses or asfivirus 
or BA71V virus or malawi LIL20/1 virus or E70 virus or peste porcine africaine or fiebre 
porcina africana or maladie de montgomery” 
3. Akabane virus: “akabane virus or sabo virus or tinaroo virus or yaba-7 virus or congenital 
arthrogryposis-hydrancephaly syndrome or A-H syndrome or acorn calves or silly calves 
or curly lamb disease or curly calf disease or dummy calf disease”  
4. Alcelaphine herpesvirus 1, 2: “alcelaphine or bovide herpesvirus 3 or ovine herpesvirus 2 
or malignant catarrhal fever or snotsiekte or malignant catarrh or malignant head catarrh” 
5. Bacillis anthracis: “Bacillus anthracis or anthrax or woolsorter’s disease” 
6. Bluetongue virus: “bluetongue or blue tongue” 
7. Bovine spongiform encephalopathy prion: “BSE or bovine spongiform encephalopathy or 
prion” 
8. Brucella melitensis: “Brucella” 
9. Burkholeria mallei and pseudomallei: “burkholderia or glanders or malleus or farcy or 
droes or melioidosis” 
10. Camelpox virus: “camelpox” 
11. Candidatus Liberobacter africanus/asiaticus: “liberobacter or liberibacter or 
huanglongbing” 
12. Cercopithecine herpesvirus 1: “cercopithecine herpesvirus 1 or herpes b virus or 
herpesvirus simiae or monkey b virus” 
13. Classical swine fever virus: “classical swine fever” 
14. Clostridium botulinum: “clostridium botulinum or botulism or botulinum toxin” 






16. Coxiella burneti: “coxiella or q fever” 
17. Easter equine encephalitis virus: “eastern equine encephalitis or eeev” 
18. Ehrlichia ruminantium: “ehrlichia ruminantium or cowdria ruminantium or heartwater” 
19. Flexal virus: “flexal or BeAn 293022” 
20. Foot-and-mouth disease virus: “foot-and-mouth or foot and mouth or afta epizootica or 
bek-en-klouseer or fiebra aftosa or fievre aphteuse or Maul-und-Klauenseuche” 
21. Francisella tularensis: “francisella or tularemia or rabbit fever” 
22. Goatpox virus: “goatpox or goat pox or capripox” 
23. Hendra virus: “hendra virus or henipavirus or equine morbillivirus” 
24. Human enterovirus B: ”classical swine fever or hog cholera or peste du porc or colera 
porcina or Virusschweinepest” 
25. Influenza A virus: “influenza a virus or fowl plague” 
26. Japanese encephalitis virus: “Japanese encephalitis or Japanese b encephalitis” 
27. Lumpy skin disease virus: “lumpy skin disease or capripox or pseudo-urticaria or 
Neethling virus disease or exanthema nodularis bovis or knopvelsiekte” 
28. Menangle virus: “menangle virus” 
29. Monkeypox virus “monkeypox or monkey pox” 
30. Mycoplasma capricolum: “mycoplasma capricolum” 
31. Mycoplasma mycoides capri/mycoides: “mycoplasma mycoides or contagious caprine 
pleuropneumonia” 
32. Newcastle disease virus: “Newcastle disease” 
33. Nipah virus: “nipah virus or henipavirus” 
34. Peronosclerospora philippinensis: “peronosclerospora or sclerospora philippinensis or 





35. Peste-des-petits-ruminants virus: “Peste-des-petits-ruminants or peste des petits ruminants 
or stomatitis-pneumoenteritis or pseudorinderpest or kata” 
36. Phakopsora pachyrhizi: “phakopsora or soybean rust” 
37. Plum pox virus: “plum pox or sharka” 
38. Ralstonia solanacearum: “ralstonia solanacearum or pseudomonas solanacearum” 
39. Rickettsia prowazekii: “Rickettsia prowazekii” 
40. Rickettsia rickettsiae: “Rickettsia rickettsiae” 
41. Rift Valley fever virus “rift valley fever or ZH548 or MM12 or Belterra virus or Icoaraci 
virus or infectious enzootic hepatitis” 
42. Rinderpest virus: “rinderpest” 
43. Sabiá virus: “sabia virus or SPH114202 or brazilian hemorrhagic fever” 
44. Sclerophthora raissae: “sclerophthora or sclerospora or brown stripe downy mildew” 
45. Sheeppox virus: “sheeppox or sheep pox or capripox” 
46. Synchytrium endobioticum: “synchytrium endobioticum or synchytriaceae or potato wart 
disease or potato tubers or gale verruqueuse de la pomme de terre or kartoffelkrebs or 
sarna verrugosa de la patata” 
47. Venezuelan equine encephalitis virus: “Venezuelan equine encephalitis or peste loca” 
48. Vesicular stomatitis Alagoas/Indiana virus: “vesicular stomatitis alagoas or vesicular 
stomatitis cocal or vesicular stomatitis piry or cocal virus or piry virus or indiana-2 or 
indiana-3” 
49. Xanthomonas oryzae: “xanthomonas oryzae” 
50. Xylella fastidiosa: “xylella and citrus variegated chlorosis” 






After screening for subcategory PDA/1, screening for subcategories EDA/1 and EDA/2 followed. 
To search for research falling into category EDA/1 (Work with eradicated agent…), the following 
search terms were used either singularly, or in Boolean combination: 
1. Variola virus: “variola or smallpox or alastrim” 
2. “1918 Influenza virus”: “1918 influenza or influenza H1N1 or Spanish influenza” 
 
To search for research falling into category EDA/2 (Work with agent requiring Biosafety Level-
4), the following search terms were used either singularly, or in Boolean combination: 
1. Côte d’Ivoire ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, Lake 
Victoria marburgvirus: “ebola or ebolavirus or marburg virus or marburgvirus or filovirus 
or filoviridae”  
2. Crimean-Congo hemorrhagic fever virus: “crimean-congo or congo-crimean or CCHF or 
Hazara or Kodzha or Khasan” 
3. Guanarito virus: “guanarito or INH-95551 or venezuelan hemorrhagic fever or venezuelan 
haemorrhagic fever” 
4. Hendra virus, Nipah virus: “hendra virus or nipah virus or henipavirus or equine 
morbillivirus” 
5. Junín virus: “junin virus or MC2 virus or XJ virus or argentine hemorrhagic fever or 
argentine haemorrhagic fever” 
6. Kyasanur Forest disease virus: “kyasanur or alkhurma or alkhumra or fakeeh virus” 
7. Lassa virus: “lassa or GA391 virus or LP virus or Josiah virus” 
8. Machupo virus: “machupo or AA288-77 or Brazilian hemorrhagic fever or brazilian 
haemorrhagic fever” 





10. Tick-borne encephalitis virus: “tick-borne encephalitis or tbe or fsme” 
 
Then, all publications employing the “related agents” listed above were screened, and appropriate 
papers were placed into the remaining subcategories of MDA and EDA.  
 
The taxonomy of microbes changes constantly. It is possible that some of the related agents have 
by now been moved to different genera or families, thus excluding them from the evaluated 
oversight system; or that additional related agents have been discovered. Because of the number 
of related agents that had to be screened (1,725), no Boolean researches were performed. Instead, 
only the agent name, as listed above, was used for searches. For 61 related agents out of 1,725, 
keyword/shotgun searches (“agent AND resistence”; or “agent AND cDNA” etc.) had to be 
performed because the overall number of retrieved papers per agent fitting the criteria of this 
working paper was larger than 1,000 (and, at times, larger than 10,000). Hence, several papers, 
which should have been included in this working paper, might have been missed. The 61 agents 
in question were: 
 
- Aquareovirus A-F 
- Bacillus cereus 
- Bacillus subtilis 
- Bacillus thuringiensis  
- Clostridium difficile 
- Cypovirus 1-14 
- Dengue virus 
- Hepatitis C virus 
- Human enterovirus A,B,C,D,E 
- Human herpesvirus 1-8 
- Human parainfluenza virus 1,3 
- Influenza A virus 
- Measles virus 
- Murid herpesvirus 1-6 






- Prions (Chronic wasting disease prion, Creutzfeldt-Jakob disease prion, Exotic ungulate 
encephalopathy prion, Fatal familial insomnia prion, Feline spongiform encephalopathy 
prion, Gerstmann-Sträussler-Scheinker syndrome prion, Kuru prion, Scrapie prion, 
Transmissible mink encephalopathy prion) 
- Rotavirus A-G 
- Vaccinia virus 
- West Nile virus 
 
To identify NIH grants, the above-described search strategies for select agents, eradicated agents, 
and BSL-4 agents were used. NIH Grants for related and non-listed agents were not screened 
because of the number of agents. 
 
The term “exotic” in the US Select Agent list 
The term "exotic" in context of biological agents is more a political terminus for the purpose of 
keeping trade barriers than it is a scientificly verifiable and discrete terminus for the purpose of 
strain distinction. It is most commonly used with animal viruses. It’s a holdover from times when 
virology was largely descriptive and not experimental, and a reflection of the view of livestock as 
property and commodities and not as entities with inherent value like humans. As a guideline, the 
author consulted The Gray Book (Committee on Foreign Animal Diseases of the United States 
Animal Health Association, Richmond, Virgina, 1998) and the web pages of the World 
Organisation of Animal Health (http://www.oie.int/eng/en_index.htm) to decide which agents 
were to be considered “exotic” for the purpose of this working paper. In the case of the 
alcelaphine herpesviruses it remained unclear to the author what strains were considered to be 
exotic – hence, all US research dealing with these agents was included. The World Health 
Organisation of Animal Health considers the Indiana-1 strain of vesicular stomatitis Indiana virus 
and the New Jersey strain of vesicular stomatitis New Jersey virus as endemic to the US, whereas 
the Indiana-2 (Cocal), Indiana-3 (Alagoas) and Piry “strains” are to be considered exotic. 





status (Cocal virus and Piry viruses of the species Cocal virus and Piry virus, respectively), and 
hence are not to be considered vesicular stomatitis viruses anymore. Nevertheless, they were 
considered as such for this working paper. 
 
 “Increasing virulence” (MDA/1, PDA/2) 
The author assumed that “increasing virulence” refers to the achievement of increasing virulence 
of an agent for its host organism. Projects with agents, which were naturally or artificially 
attenuated in their virulence, and were then reconstituted to become as virulent as the parental 
strain, were not considered for this subcategory. 
 
“Powder or aerosol production/Powder or aerosol disperal” (MDA/4/5, PDA/4/5) 
The difference of production and dispersal of an aersol was unclear to the author or difficult to 
differentiate in the retrieved articles. Hence, these subcategories were combined. 
 
“De novo synthesis” (EDA/3, MDA/6, PDA/6) 
The meaning of “de novo synthesis” was unclear to the author. Synthesis of an agent in a test tube 
from scratch without other living materials (de novo synthesis sensu stricto) has so far only been 
reported two times from the US and from Canada. One more paper reporting the “synthesis” of a 
phage (no other microbes have been “synthesized” yet) referred to the de novo synthesis of a viral 
genome with subsequent particle formation in living cells transfected or infected with this 
genome. These papers are listed in this working paper. De novo synthesis sensu lato usually 
refers to the establishment of reverse genetics or so-called cDNA clones based on infectious 





in particle formation, sometimes being dependent on helper plasmids. These kind of papers are 
not listed in this working paper. 
 
“Insertion of host genes” (MDA/2) 
The author assumed that “insertion of host genes” refers to the insertion of a gene derived from 
the natural host(s) of a particular agent. Hence, papers reporting the insertion of, for instance, 
green fluorescent protein (GFP) into an agent were not considered for this subcategory, because 
this protein is naturally encoded by a jelly fish, which is not infectable by the GFP-recombinant 
viruses and bacteria created. 
 
 “Eradicated” (EDA/1) 
The term “eradicated” is not clearly defined. To the author’s knowledge, only one agent counts as 
being eradicated: Variola virus. The “1918 Influenza A virus” simply disappeared after the 
devastating pandemic of 1918 was over/contained. Also, “1918 Influenza A virus” is a colloquial 
term – it probably should be changed to regular influenzavirus nomenclature (e.g. Influenza A 
virus H1N1/1918 or the like). For this working paper, both and only “1918 Influenza A virus” 
and Variola virus were considered “eradicated”. 
 
Unscreened Subcategories PDA/2-5 
Categories PDA/2 (Increasing virulence of non-listed agent), PDA/3 (Increasing transmissibility 
or environmental stability of non-listed agent), and PDA/4/5 (Powder or aerosol 
production/disperal of non-listed agent) remained unscreened because of the overall number of 
agents; the overall number of research papers to be screened; and the lack of a suitable search 







POTENTIALLY DANGEROUS ACTIVITIES (PDA) 
1 Work with listed agent – or exempt avirulent, attenuated, or vaccine strain 
of select agent – not covered by EDA/MDA 
African horse sickness virus 
Taxonomy: Family Reoviridae, Genus Orbivirus, Species African horse sickness virus. Virus: 
African horse sickness virus 1-9. 
Publications: None identified. 
NIH Grants: None identified. 
 
African swine fever virus 
Taxonomy: Family Asfarviridae, Genus Asfivirus, Species African swine fever virus. Virus: 
African swine fever virus, BA71V virus, Malawi LIL20/1 virus, E70 virus. 
Publications: 
1. Lewis, T., L. Zsak, T. G. Burrage, Z. Lu, G. F. Kutish, J. G. Neilan, and D. L. Rock. 
2000. An African swine fever virus ERV1-ALR homologue, 9GL, affects virion 
maturation and viral growth in macrophages and viral virulence in swine. J Virol 
74:1275-85. 
This paper reports the identification and isolation of a viral protein encoded by the gene 
9GL. 9GL-deletion mutans of AFSFV were established and shown to be less virulent for 





2. Zsak, L., Z. Lu, T. G. Burrage, J. G. Neilan, G. F. Kutish, D. M. Moore, and D. L. 
Rock. 2001. African swine fever virus multigene family 360 and 530 genes are novel 
macrophage host range determinants. J Virol 75:3066-76. 
This paper reports the identification of fragmented genes in AFSFV isolates adapted to 
grow in monkey cell lines. It is shown that substitution of the fragmented gene with the 
full gene of native isolates restores their ability to grow in macrophages. 
3. Neilan, J. G., L. Zsak, Z. Lu, G. F. Kutish, C. L. Afonso, and D. L. Rock. 2002. Novel 
swine virulence determinant in the left variable region of the African swine fever virus 
genome. J Virol 76:3095-104. 
This paper reports the identification of novel virulence determinants in various AFSFV 
isolates. 
4. Afonso, C. L., M. E. Piccone, K. M. Zaffuto, J. Neilan, G. F. Kutish, Z. Lu, C. A. 
Balinsky, T. R. Gibb, T. J. Bean, L. Zsak, and D. L. Rock. 2004. African Swine Fever 
Virus Multigene Family 360 and 530 Genes Affect Host Interferon Response. J Virol 
78:1858-64. 
This paper reports the results of macrophage transcriptional responses to infection with 
ASFV. The results are presented as a first step of the elucidation of the function of certain 
ASFV virulence determinants 
5. Burrage, T. G., Z. Lu, J. G. Neilan, D. L. Rock, and L. Zsak. 2004. African swine 
fever virus multigene family 360 genes affect virus replication and generalization of 
infection in Ornithodoros porcinus ticks. J Virol 78:2445-53. 
This paper reports the introduction of a MGF360/530 gene deletion into a mutant ASFV 
isolate, the characterization of its impaired growth characteristics in ticks, and the 
conclusion that the 350 and 530 genes are important host range determinants of ASFV. 
6. Neilan, J. G., L. Zsak, Z. Lu, T. G. Burrage, G. F. Kutish, and D. L. Rock. 2004. 
Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not 
sufficient for antibody-mediated protection. Virology 319:337-42. 
This paper reports the immunogenic properties of three viral proteins expressed from 
baculoviruses, and their inability to protect swine from challenge with African swine fever 
virus despite the induction of neutralizing antibodies. 
7. Zsak, L., M. V. Borca, G. R. Risatti, A. Zsak, R. A. French, Z. Lu, G. F. Kutish, J. G. 
Neilan, J. D. Callahan, W. M. Nelson, and D. L. Rock. 2005. Preclinical diagnosis of 
African swine fever in contact-exposed swine by a real-time PCR assay. J Clin Microbiol 
43:112-9. 
This paper reports the establishment of a fluorogenic probe hydrolysis TaqMan PCR assay 
for the diagnosis of African swine fever virus. 
 








Taxonomy: Family Bunyaviridae, Genus Orthobunyavirus, Species Akabane virus. Virus: 
Akabane virus, Sabo virus, Tinaroo virus, Yaba-7 virus. 
Publications: None identified. 
NIH Grants: None identified.  
 
Alcelaphine herpesvirus 1,2 (exotic) 
Taxonomy: Family Herpesviridae, Subfamily: Gammaherpesvirinae, Genus Rhadinovirus, 
Species Alcelaphine herpesvirus 1, Alcelaphine herpesvirus 2. Virus: Alcelaphine herpesvirus 1, 
Malignant catarrhal fever virus, Alcelaphine herepesvirus 2, Hartebeest malignant catarrhal fever virus, 
Ovine herpesvirus 2. 
Publications: 
1. Li, H., G. Snowder, D. O'Toole, and T. B. Crawford. 2000. Transmission of ovine 
herpesvirus 2 among adult sheep. Vet Microbiol 71:27-35. 
This paper reports the evaluation of transmission routes of AlHV-2 in sheep and 
concludes that the susceptibility is not restricted to lambs but that older sheep can transmit 
the virus as well. 
2. Dunowska, M., G. J. Letchworth, J. K. Collins, and J. C. DeMartini. 2001. Ovine 
herpesvirus-2 glycoprotein B sequences from tissues of ruminant malignant catarrhal 
fever cases and healthy sheep are highly conserved. J Gen Virol 82:2785-90. 
This paper reports the sequencing and comparison of AlHV-2 glycoprotein B derived 
from AlHV-2 DNA isolated from bovines and bisons with malignant catarrhal fever and 
healthy sheep. 
3. Li, H., Y. Hua, G. Snowder, and T. B. Crawford. 2001. Levels of ovine herpesvirus 2 
DNA in nasal secretions and blood of sheep: implications for transmission. Vet Microbiol 
79:301-10. 
This paper reports the evaluation of a PCR assay for AlHV-2 virus detection and the 
examination of virus DNA levels in nasal secretions and peripheral blood leukocytes of 
lambs and adult sheep. 
4. Li, H., T. C. McGuire, U. U. Muller-Doblies, and T. B. Crawford. 2001. A simpler, 
more sensitive competitive inhibition enzyme-linked immunosorbent assay for detection 





This paper reports the improvement and evaluation of a CI-ELISA for the detection of 
antibodies to AlHV.  
5. Li, H., G. D. Snowder, and T. B. Crawford. 2002. Effect of passive transfer of maternal 
immune components on infection with ovine herpesvirus 2 in lambs. Am J Vet Res 
63:631-3. 
This paper reports the observation regarding antibody development to AlHV-2 in lambs 
born to AlHV-2-infected and AlHV-2-free ewes after introduction into an AlHV-2-
positive flock. 
6. Kim, O., H. Li, and T. B. Crawford. 2003. Demonstration of sheep-associated 
malignant catarrhal fever virions in sheep nasal secretions. Virus Res 98:117-22. 
This paper reports the identification of cell-free AlHV-2 virions in nasal secretions of 
infected sheep identified by PCR. 
 
NIH Grants: None identified. 
 
Bacillus anthracis 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Bacilli, Order Bacillales, Family 
Bacillaceae. 
Publications: 
1. Dixon, T. C., A. A. Fadl, T. M. Koehler, J. A. Swanson, and P. C. Hanna. 2000. Early 
Bacillus anthracis-macrophage interactions: intracellular survival survival and escape. 
Cell Microbiol 2:453-63. 
 This paper examines the interaction of the bacillus with macrophages. 
2. Elliott, J. L., J. Mogridge, and R. J. Collier. 2000. A quantitative study of the 
interactions of Bacillus anthracis edema factor and lethal factor with activated protective 
antigen. Biochemistry 39:6706-13. 
 This paper examines the function of toxins of the bacillus. 
3. Keim, P., L. B. Price, A. M. Klevytska, K. L. Smith, J. M. Schupp, R. Okinaka, P. J. 
Jackson, and M. E. Hugh-Jones. 2000. Multiple-locus variable-number tandem repeat 
analysis reveals genetic relationships within Bacillus anthracis. J Bacteriol 182:2928-36. 
 This paper reports the phylogenetic relationships of different strains of the bacillis. 
4. Kiel, J. L., J. E. Parker, J. L. Alls, J. Kalns, E. A. Holwitt, L. J. Stribling, P. J. 
Morales, and J. G. Bruno. 2000. Rapid recovery and identification of anthrax bacteria 
from the environment. Ann N Y Acad Sci 916:240-52. 
 This paper reports a method to isolate the bacillus from environmental samples. 
5. Park, S., and S. H. Leppla. 2000. Optimized production and purification of Bacillus 





 This paper reports a method to isolate a toxin of the bacillus. 
6. Schupp, J. M., A. M. Klevytska, G. Zinser, L. B. Price, and P. Keim. 2000. vrrB, a 
hypervariable open reading frame in Bacillus anthracis. J Bacteriol 182:3989-97. 
 This paper reports a potential gene in the bacillus. 
7. Smith, K. L., V. DeVos, H. Bryden, L. B. Price, M. E. Hugh-Jones, and P. Keim. 
2000. Bacillus anthracis diversity in Kruger National Park. J Clin Microbiol 38:3780-4. 
 This paper reports the isolation of different strains of the bacillus. 
8. Stopa, P. J. 2000. The flow cytometry of Bacillus anthracis spores revisited. Cytometry 
41:237-44. 
 This paper reports the use of flow cytometry to sort spores of the bacillus. 
9. Brook, I., T. B. Elliott, R. A. Harding, S. S. Bouhaouala, S. J. Peacock, G. D. Ledney, 
and G. B. Knudson. 2001. Susceptibility of irradiated mice to Bacillus anthracis sterne 
by the intratracheal route of infection. J Med Microbiol 50:702-11. 
 This paper reports the effect of the bacillus on irradiated mice. 
10. Brook, I., T. B. Elliott, H. I. Pryor, 2nd, T. E. Sautter, B. T. Gnade, J. H. Thakar, 
and G. B. Knudson. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, 
macrolides and quinolones. Int J Antimicrob Agents 18:559-62. 
 This paper reports the resistence of a strain of the bacillus to various antibiotics. 
11. Brumlik, M. J., U. Szymajda, D. Zakowska, X. Liang, R. J. Redkar, G. Patra, and V. 
G. Del Vecchio. 2001. Use of long-range repetitive element polymorphism-PCR to 
differentiate Bacillus anthracis strains. Appl Environ Microbiol 67:3021-8. 
 This paper reports a PCR-based method to differentiate between different strains of the 
bacillus. 
12. Dang, J. L., K. Heroux, J. Kearney, A. Arasteh, M. Gostomski, and P. A. Emanuel. 
2001. Bacillus spore inactivation methods affect detection assays. Appl Environ 
Microbiol 67:3665-70. 
 This paper reports the effects of spore inactivation methods on diagnostic tests. 
13. Duesbery, N. S., J. Resau, C. P. Webb, S. Koochekpour, H. M. Koo, S. H. Leppla, 
and G. F. Vande Woude. 2001. Suppression of ras-mediated transformation and 
inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic 
inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 98:4089-94. 
 This paper reports the effect of a toxin of the bacillus on signal transduction pathways. 
14. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. 
M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and 
rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical 
origin. Vaccine 19:3241-7. 
 This paper reports the evaluation of a vaccine candidate. 
15. Keim, P., K. L. Smith, C. Keys, H. Takahashi, T. Kurata, and A. Kaufmann. 2001. 
Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin 
Microbiol 39:4566-7. 
 This paper reports the characterization of a strain of the bacillus. 
16. Le Fleche, P., Y. Hauck, L. Onteniente, A. Prieur, F. Denoeud, V. Ramisse, P. 





for bacterial genomes: application to the genotyping of Yersinia pestis and Bacillus 
anthracis. BMC Microbiol 1:2. 
 This paper reports a method to differentiate strains of the bacillus. 
17. Liu, W. T., A. D. Mirzabekov, and D. A. Stahl. 2001. Optimization of an 
oligonucleotide microchip for microbial identification studies: a non-equilibrium 
dissociation approach. Environ Microbiol 3:619-29. 
 This paper reports a diagnostic system for the identification of the bacillus. 
18. Qi, Y., G. Patra, X. Liang, L. E. Williams, S. Rose, R. J. Redkar, and V. G. 
DelVecchio. 2001. Utilization of the rpoB gene as a specific chromosomal marker for 
real-time PCR detection of Bacillus anthracis. Appl Environ Microbiol 67:3720-7. 
 This paper reports the development of PCR-based diagnostic system for the detection of 
the bacillus. 
19. Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of 
antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early 
stages of infection by anthrax spores. Microbiology 147:1677-85. 
 This paper reports the evaluation of antibodies and anthrax toxin as preventive 
therapeutics. 
20. Bell, C. A., J. R. Uhl, T. L. Hadfield, J. C. David, R. F. Meyer, T. F. Smith, and F. R. 
Cockerill, 3rd. 2002. Detection of Bacillus anthracis DNA by LightCycler PCR. J Clin 
Microbiol 40:2897-902. 
 This paper reports the development of a PCR-based diagnostic assay for the detection of 
the bacillus. 
21. Castillo, U. F., G. A. Strobel, E. J. Ford, W. M. Hess, H. Porter, J. B. Jensen, H. 
Albert, R. Robison, M. A. Condron, D. B. Teplow, D. Stevens, and D. Yaver. 2002. 
Munumbicins, wide-spectrum antibiotics produced by Streptomyces NRRL 30562, 
endophytic on Kennedia nigriscans. Microbiology 148:2675-85. 
 This paper reports the effect of novel antibiotics on the bacillus. 
22. Coker, P. R., K. L. Smith, and M. E. Hugh-Jones. 2002. Antimicrobial susceptibilities 
of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 46:3843-5. 
 This paper reports the antibiotic susceptibility of different strains of the virus. 
23. De, B. K., S. L. Bragg, G. N. Sanden, K. E. Wilson, L. A. Diem, C. K. Marston, A. R. 
Hoffmaster, G. A. Barnett, R. S. Weyant, T. G. Abshire, J. W. Ezzell, and T. 
Popovic. 2002. A two-component direct fluorescent-antibody assay for rapid 
identification of Bacillus anthracis. Emerg Infect Dis 8:1060-5. 
 This paper reports the development of diagnostic assay for the detection of the bacillus. 
24. Elliott, T. B., I. Brook, R. A. Harding, S. S. Bouhaouala, M. O. Shoemaker, and G. B. 
Knudson. 2002. Antimicrobial therapy for bacillus anthracis-induced polymicrobial 
infection in (60)Co gamma-irradiated mice. Antimicrob Agents Chemother 46:3463-71. 
 This paper reports an antibiotic treatment regimen for irradiated mice infected with the 
bacillus. 
25. Espy, M. J., J. R. Uhl, L. M. Sloan, J. E. Rosenblatt, F. R. Cockerill, 3rd, and T. F. 
Smith. 2002. Detection of vaccinia virus, herpes simplex virus, varicella-zoster virus, and 
Bacillus anthracis DNA by LightCycler polymerase chain reaction after autoclaving: 





 This paper reports the development of a PCR-based diagnostic system for the detection of 
the bacillus. 
26. Fellows, P. F., M. K. Linscott, S. F. Little, P. Gibbs, and B. E. Ivins. 2002. Anthrax 
vaccine efficacy in golden Syrian hamsters. Vaccine 20:1421-4. 
 This paper reports the avluation of a vaccine candidate. 
27. Fouet, A., K. L. Smith, C. Keys, J. Vaissaire, C. Le Doujet, M. Levy, M. Mock, and 
P. Keim. 2002. Diversity among French Bacillus anthracis isolates. J Clin Microbiol 
40:4732-4. 
 This paper reports differences between strains of the bacillus. 
28. Hart, M. K., R. A. Del Giudice, and G. W. Korch, Jr. 2002. Absence of mycoplasma 
contamination in the anthrax vaccine. Emerg Infect Dis 8:94-6. 
 This paper reports the quality control of the anthrax vaccine. 
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Initiation of Germination  
Total: $364,000  
 $169,500 | 2003 | Krulwich, Terry A | MOUNT SINAI SCHOOL OF 
MEDICINE OF NYU | NEW YORK, NY  
 $194,500 | 2002 | Krulwich, Terry A | MOUNT SINAI SCHOOL OF 







01 TRAWICK, JOHN 
A novel platform to discover 
biodefense therapeutics  
Total: $331,141  
 $331,141 | 2003 | Trawick, John D | ELITRA PHARMACEUTICALS, INC. | 
SAN DIEGO, CA  
14 41 
1Z01BJ003016-
01 BURNS, DRUSILLA 
Pathogenesis of Bordetella 
pertussis and Bacillus anthra  
15 41 
1R01AI057472-
01 FISCHETTI, VINCENT 
Isolaton of new phage enzymes to 
kill B. anthracis  
Total: $759,282  
 $380,157 | 2005 | Fischetti, Vincent A | ROCKEFELLER UNIVERSITY | NEW 
YORK, NY  
 $379,125 | 2004 | Fischetti, Vincent A | ROCKEFELLER UNIVERSITY | NEW 
YORK, NY  
16 41 
1R43AI052587-
01 GOLDMAN, MARK 
Inhibitors of Anthrax Lethal 
Factor Metalloproteinase  
Total: $295,510  
 $295,510 | 2002 | Goldman, Mark E | HAWAII BIOTECH, INC. | AIEA, HI  
17 41 
1R01AI055860-
01 HOCH, JAMES 
Signal Transduction Networks in 
Bacillus anthracis  
Total: $1,278,384  
 $523,462 | 2005 | Hoch, James A | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $508,215 | 2004 | Hoch, James A | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $246,707 | 2003 | Hoch, James A | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
18 41 
1U54AI057156-
010001 KOEHLER, THERESA 
Bacillus Anthracis - Host 
Interactions  
Total: $27,834,107 *  
 $12,024,542 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $11,566,950 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $4,242,615 | 2003 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
19 41 
1R21AI061702-
01 LARNER, ANDREW 
The Effects of Interferons on 
Anthrax Toxicity  
Total: $153,000  
 $153,000 | 2004 | Larner, Andrew C | CLEVELAND CLINIC LERNER 
COL/MED-CWRU | CLEVELAND, OH  
20 41 
1Z01BJ003017-
01 MERKEL, TOD 
Pathogenic Mechanisms of 
Bacterial Respiratory Pathogens  
21 41 
1Z01BP005026-
01 NAKHASI, HIRA 
Molecular Mechanism and 







01 RAO, VENIGALLA 
A Multicomponent Anthrax 
Vaccine using Phage T4 Display  
Total: $1,678,602  
 $695,043 | 2005 | Rao, Venigalla B | CATHOLIC UNIVERSITY OF AMERICA 
| WASHINGTON, DC  
 $666,736 | 2004 | Rao, Venigalla B | CATHOLIC UNIVERSITY OF AMERICA 
| WASHINGTON, DC  
 $316,823 | 2003 | Rao, Venigalla B | CATHOLIC UNIVERSITY OF AMERICA 
| WASHINGTON, DC  
23 41 
2R44AI045237-
02A1 RIDEOUT, DARRYL 
Non-Peptides Inhibitors of 
Anthrax Lethal Factor  
Total: $754,259  
 $383,032 | 2003 | Rideout, Darryl C | CENGENT THERAPEUTICS, INC. | 
SAN DIEGO, CA  
 $371,227 | 2002 | Rideout, Darryl C | STRUCTURAL BIOINFORMATICS, 
INC. | SAN DIEGO, CA  
24 41 
1Z01BJ005018-
01 STIBITZ, E. 
Molecular Genetics and Regulation 
of Bacterial Pathogene  
25 41 
1Z01BJ004013-
01 VANN, WILLIE 




01 GOLDFINE, HOWARD 
Escape of Bacillus anthracis from 
the phagosome  
Total: $475,500  
 $237,750 | 2004 | Goldfine, Howard | UNIVERSITY OF PENNSYLVANIA | 
PHILADELPHIA, PA  
 $237,750 | 2003 | Goldfine, Howard | UNIVERSITY OF PENNSYLVANIA | 






Optimization of Mariner 
Transposon for Bacillus  
Total: $146,000  
 $73,000 | 2005 | Haldenwang, William G | UNIVERSITY OF TEXAS HLTH 
SCI CTR SAN ANT | SAN ANTONIO, TX  
 $73,000 | 2004 | Haldenwang, William G | UNIVERSITY OF TEXAS HLTH 
SCI CTR SAN ANT | SAN ANTONIO, TX  
28 38 
2R44AI055079-
02 LEMIEUX, BERTRAND 
A Hand-Held System for Live 
Anthrax Spore Detection  
Total: $1,999,861  
 $792,489 | 2005 | Lemieux, Bertrand | IQUUM, INC. | ALLSTON, MA  
 $1,207,372 | 2004 | Lemieux, Bertrand | IQUUM, INC. | ALLSTON, MA  
29 38 
1R43ES012993-
01 NAKHAI, BITA 
Novel Devices for Processing 
Bioterrorism Agents  
Total: $149,976  
 $149,976 | 2004 | Nakhai, Bita | SERACARE LIFE SCIENCES, INC. | 
OCEANSIDE, MD  





22 RACHEL Polysaccharide-protein Conjugat  
31 38 
2R44AI052926-
02 STORHOFF, JAMES 
Nanoparticle Probe Assay for 
Biological Threat Agents  
Total: $374,900  




01 BASHIR, RASHID 
Rapid Determination of Viability 
of Anthrax Spores  
Total: $450,000  
 $225,000 | 2003 | Bashir, Rashid | PURDUE UNIVERSITY WEST LAFAYETTE 
| WEST LAFAYETTE, IN  
 $225,000 | 2002 | Bashir, Rashid | PURDUE UNIVERSITY WEST LAFAYETTE 
| WEST LAFAYETTE, IN  
33 31 
1P01CI000095-
01 BOKOCH, GARY 
Regulation of the Innate Immune 
Response to B Anthracis  
34 31 
1U19AI056575-
010004 CAFFREY, MICHAEL 
Development of Inhibitors for B. 
anthracis Protective Antigen  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $1,807,245 | 2003 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
35 31 
1R21AI056061-
01 CARLSON, RUSSELL 
Bacillus anthracis cell surface 
carbohydrates  
Total: $588,800  
 $294,400 | 2004 | Carlson, Russell W | UNIVERSITY OF GEORGIA | 
ATHENS, GA  
 $294,400 | 2003 | Carlson, Russell W | UNIVERSITY OF GEORGIA | 






B cell related prophylaxis and 
therapeutics  
Total: $21,685,329 *  
 $8,996,537 | 2005 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  
 $8,717,880 | 2004 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  




010005 COOK, JAMES 
Therapeutics for the Anthrax-
Macrophage Shock Syndrome  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  





CHICAGO | CHICAGO, IL  
38 31 
1R43AI052499-
01 DEAN, DAVID 
Development of a device for rapid 
detection of anthrax  
Total: $160,042  




01 DRIKS, ADAM 
IDENTIFICATION OF B. ANTRACIS 
SPORE-SURFACE PROTEINS  
Total: $222,000  
 $222,000 | 2002 | Driks, Adam | LOYOLA UNIVERSITY MEDICAL CENTER | 
MAYWOOD, IL  
40 31 
1Z01BP005021-
01 DUNCAN, ROBERT 
Pathogen Chip for Detection of 
Bioterrorism Agents in Bl  
41 31 
1U54AI057157-
010005 HANNA, PHILIP 
Control of Bacillus Anthracis 
Spore Formation  
Total: $24,284,241 *  
 $10,247,734 | 2005 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, 
NC  
 $9,829,455 | 2004 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
 $4,207,052 | 2003 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
42 31 
1R43AI052886-
01 HILFINGER, JOHN 
Development of an Oral Anthrax 
Vaccine  
Total: $203,609  
 $203,609 | 2002 | Hilfinger, John M | TSRL, INC. | ANN ARBOR, MI  
43 31 
1R21AI058051-
01A2 HUANG, ZHEN 
Bacillus anthracis Detection with 
RNA Microchip  
44 31 
1U19AI056575-
01 JOHNSON, MICHAEL 
Novel Therapeutics for Bacillus 
anthracis  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $1,807,245 | 2003 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
45 31 
1U19AI056575-
010003 JOHNSON, MICHAEL 
Structure-Based Design of Novel 
B. anthracis Therapeutic Agents  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $1,807,245 | 2003 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 







01 KAPLAN, GILLA 
Cytokines in Pathogenesis of 
Anthrax Infection  
Total: $466,800  
 $233,400 | 2005 | Kaplan, Gilla | PUBLIC HEALTH RESEARCH INSTITUTE | 
NEWARK, NJ  
 $233,400 | 2004 | Kaplan, Gilla | PUBLIC HEALTH RESEARCH INSTITUTE | 
NEWARK, NJ  
47 31 
1P01AI057699-
01A1 KEARNEY, JOHN 
Immunity to Bacillus anthracis: 
Spore-Host Interactions  
Total: $1,018,127  
 $1,018,127 | 2004 | Kearney, John F | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
48 31 
1R01GM060795-
01 KEIM, PAUL 
ANTHRAX MOLECULAR 
EVOLUTION, DIVERSITY AND 
EPIDEMIOLOGY  
Total: $1,141,231  
 $290,343 | 2003 | Keim, Paul S | NORTHERN ARIZONA UNIVERSITY | 
FLAGSTAFF, AZ  
 $284,723 | 2002 | Keim, Paul S | NORTHERN ARIZONA UNIVERSITY | 
FLAGSTAFF, AZ  
 $282,924 | 2001 | Keim, Paul S | NORTHERN ARIZONA UNIVERSITY | 
FLAGSTAFF, AZ  
 $283,241 | 2000 | KEIM, PAUL S | Department Name | Project Title, Major 
Component, AZ  
49 31 
1U01AI053860-
01 KOKAI-KUN, JOHN 
Nisin-based topical formulation 
for treatment of anthrax  
Total: $796,091  
 $388,596 | 2003 | Kokaikun, John F | BIOSYNEXUS, INC. | 
GAITHERSBURG, MD  
 $407,495 | 2002 | Kokai-Kun, John F | BIOSYNEXUS, INC. | 
GAITHERSBURG, MD  
50 31 
1Z01AI000929-
02 LEPPLA, STEPHEN 
Targeted Cytotoxic Proteins 
Derived From Bacterial Toxin  
51 31 
1P01AI056295-
01A1 LYONS, C. 
Pulmonary responses to 
Bioweapon Category A Pathogens  
Total: $1,890,737  
 $1,890,737 | 2005 | Lyons, C Rick | UNIVERSITY OF NEW MEXICO 






Evaluation of Portable Samplers 
for Viable Bioaerosols  
53 31 
2R44AI052587-
02 MCCLELLAND, ALAN 
Inhibitors of Anthrax Lethal 
Factor Metalloproteinase  
Total: $3,951,250  
 $1,953,830 | 2005 | Mcclelland, Alan | HAWAII BIOTECH, INC. | AIEA, HI  










Genetic Analysis of Bacillus 
Anthracis Secretory Pathway  
Total: $20,734,800 *  
 $8,532,653 | 2005 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $8,543,253 | 2004 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $3,658,894 | 2003 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
55 31 
1U19AI056575-
010002 NEYFAKH, ALEX 
Genetic Identification of Drug 
Targets in B. anthracis  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $1,807,245 | 2003 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
56 31 
1R43AI052936-
01 PADHYE, NISHA 
Rapid PCR of Bacillus anthracis 
DNA  
Total: $98,330  
 $98,330 | 2002 | Padhye, Nisha V | MEGABASE RESEARCH PRODUCTS | 
LINCOLN, NE  
57 31 
1R21AI053442-
01A1 RYAN, EDWARD 
Application of IVIAT to Bacillus 
anthracis  
Total: $616,810  
 $343,810 | 2004 | Ryan, Edward T | MASSACHUSETTS GENERAL HOSPITAL 
| BOSTON, MA  
 $273,000 | 2003 | Ryan, Edward T | MASSACHUSETTS GENERAL HOSPITAL 






Role of BrrA-BrrB in Anthrax  
Total: $1,354,051 *  
 $670,963 | 2004 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
 $683,088 | 2003 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
59 31 
1Z01BJ004007-
02 SCHMITT, MICHAEL 
Characterization of iron regulon in 
Bacillus anthracis  
60 31 
1Z01DK015500-
42 SHILOACH, JOSEPH 
Large-scale Production & 
Purification Of Compounds  
61 31 
1Z01DK015500-
43 SHILOACH, JOSEPH 
Large-scale Production & 
Purification Of Compounds With  
62 31 
1R21AI053359-
01A1 STEINHAUER, DAVID 






Total: $608,000  
 $304,000 | 2004 | Steinhauer, David A | EMORY UNIVERSITY | ATLANTA, 
GA  




13 STERNBERG, ESTHER 
Role Of Neuroendocrine Stress 
Response In Inflammatory A  
64 31 
1Z01MH002585-
14 STERNBERG, ESTHER 
Neuroendocrine Stress Response 
in Inflammatory/Behavior  
65 31 
1R41AI061901-
01 TUROS, EDWARD 
A Mechanistically Novel Antibiotic 
for Anthrax  
Total: $99,750  
 $99,750 | 2004 | Turos, Edward | NANOPHARMA TECHNOLOGIES, INC. | 
TAMPA, FL  
66 31 
1Z01BJ004006-
01 VANN, WILLIE 
Biosynthesis of polysaccharides in 
Bacillus anthracis  
67 31 
1Z01BJ004006-
02 VANN, WILLIE 
Biosynthesis of polysaccharides in 
Bacillus anthracis  
68 31 
1R01AI055556-
01 WARD, E 
Antibody engineering: targeting 
Bacillus anthracis  
Total: $819,000  
 $351,000 | 2005 | Ward, E Sally | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $351,000 | 2004 | Ward, E Sally | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $117,000 | 2003 | Ward, E Sally | UNIVERSITY OF TEXAS SW MED 






Bacillus anthracis clone set  
Total: $99,510  
 $99,510 | 2002 | Weinstock, George M | SEQWRIGHT, LLC | HOUSTON, TX  
70 31 
1R21AI061555-
01 XU, YI 
Cell wall protein in Bacillus 
anthracis pathogenesis  
Total: $181,875  
 $181,875 | 2004 | Xu, Yi | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR 
| COLLEGE STATION, TX  
71 31 
1R43AI053009-
01 YOUNGMAN, PHILIP 
Target and antibiotic discovery in 
Bacillus anthracis  
Total: $100,000  
 $100,000 | 2002 | Youngman, Philip J | ELITRA PHARMACEUTICALS, INC. | 
SAN DIEGO, CA  
72 31 
1R21AI053554-
01A1 ZHOU, DAOGUO 
Germination of Bacillus anthracis 
Spores in Macrophages  





| WEST LAFAYETTE, IN  
 $225,000 | 2003 | Zhou, Daoguo | PURDUE UNIVERSITY WEST LAFAYETTE 
| WEST LAFAYETTE, IN  
73 26 
1R21AI059798-
01 NEPOM, GERALD 
MHC tetramers for epitopes of B 
anthracis PA  
Total: $702,000  
 $351,000 | 2005 | Nepom, Gerald T | BENAROYA RESEARCH INST AT 
VIRGINIA MASON | SEATTLE, WA  
 $351,000 | 2004 | Nepom, Gerald T | BENAROYA RESEARCH INST AT 






Human Immune Response To 
Polysaccharide-protein Conjugat  
75 26 
1U19AI056543-
010003 SHAPIRO, DANIEL Diagnostics  
Total: $6,264,376  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | BOSTON, 
MA  




01A1 WANG, JULIA 
Dually Active Anthrax Vaccine 
Against Bacilli and Toxins  
Total: $821,200  
 $412,425 | 2005 | Wang, Julia Y | BRIGHAM AND WOMEN'S HOSPITAL | 
BOSTON, MA  
 $408,775 | 2004 | Wang, Julia Y | BRIGHAM AND WOMEN'S HOSPITAL | 
BOSTON, MA  
77 26 
1F32GM070400-
01 WILLBY, MELISA 
Germination of Bacillus subtilis 
spores  
Total: $91,272  
 $48,296 | 2005 | Willby, Melisa J | EMORY UNIVERSITY | ATLANTA, GA  
 $42,976 | 2004 | Willby, Melisa J | EMORY UNIVERSITY | ATLANTA, GA  
78 21 
1R43AI052905-
01A1 AFONINA, IRINA 
MGB Eclipse Probe Detection of 
Category A Organisms  
Total: $100,000  
 $100,000 | 2003 | Afonina, Irina A | EPOCH BIOSCIENCES, INC. | 
BOTHELL, WA  
79 21 
1R21HD044861-
01 BALLARD, JIMMY 
Impact of Anthrax Toxin on 
Embryonic Development  
Total: $581,559  
 $290,954 | 2004 | Ballard, Jimmy D | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
 $290,605 | 2003 | Ballard, Jimmy D | UNIVERSITY OF OKLAHOMA 







01A1 BOHM, A 
Molecular Basis for Inhibition of 
Edema Factor  
Total: $430,894  
 $208,500 | 2005 | Bohm, A Andrew | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $222,394 | 2004 | Bohm, A Andrew | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
81 21 
2R01AI043197-
06 BOYAKA, PROSPER 
MOLECULAR ADJUVANTS FOR 
NALT-BASED IMMUNITY TO 
ANTHRAX  
Total: $2,062,631  
 $362,500 | 2005 | Boyaka, Prosper N | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $362,500 | 2004 | Boyaka, Prosper N | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $362,500 | 2003 | Mcghee, Jerry R | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $333,549 | 2002 | Mcghee, Jerry R | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $324,960 | 2001 | Mcghee, Jerry R | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $316,622 | 2000 | MCGHEE, JERRY R | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
82 21 
1R01AI057870-
01 BRADLEY, KENNETH 
CHARACTERIZATION OF ANTHRAX 
TOXIN RECEPTOR INTERACTIONS  
Total: $682,140  
 $342,156 | 2005 | Bradley, Kenneth Alan | UNIVERSITY OF CALIFORNIA 
LOS ANGELES | LOS ANGELES, CA  
 $339,984 | 2004 | Bradley, Kenneth Alan | UNIVERSITY OF CALIFORNIA 
LOS ANGELES | LOS ANGELES, CA  
83 21 
1R43AI053048-
01 BROWN, MARK 
Antibiotic Screen for Isoprenoid 
Pathway in B.anthracis  
Total: $98,560  
 $98,560 | 2002 | Brown, Mark J | ECHELON BIOSCIENCES, INC. | SALT 
LAKE CITY, UT  
84 21 
1R43AI058423-
01 BRUNO, JOHN 
Nuclease-Resistant Aptamers for 
Anthrax Opsonization  
Total: $99,934  
 $99,934 | 2004 | Bruno, John G | OPERATIONAL TECHNOLOGIES 
CORPORATION | SAN ANTONIO, TX  
85 21 
1Z01BJ003014-
01 BURNS, DRUSILLA 
PATHOGENESIS OF B ANTHRACIS 
AND PROTECTIVE IMMUNITY  
86 21 
1Z01BJ003014-
02 BURNS, DRUSILLA 
Studies on the Pathogenesis of B. 
anthracis and Protecti  
87 21 
1Z01BJ003014-
03 BURNS, DRUSILLA 
Studies on the Pathogenesis of B. 







01 CHAN, JOANNE 
Attacking anthrax action by 
blocking receptor signaling  
Total: $677,965  
 $342,000 | 2004 | Chan, Joanne | DANA-FARBER CANCER INSTITUTE | 
BOSTON, MA  
 $335,965 | 2003 | Chan, Joanne | DANA-FARBER CANCER INSTITUTE | 
BOSTON, MA  
89 21 
1R43AI052909-
01 CHAPPLE, JOANNE 
Inhibitors of Bacterial 
Undecaprenyl 
DiphosphateSynthase  
Total: $258,814  
 $258,814 | 2002 | Chapple, Joanne P | CUBIST PHARMACEUTICALS, INC. | 
LEXINGTON, MA  
90 21 
1Z01BO002008-
01 CLOUSE-STREBEL, K. 
Identifying biological agents that 
counteract the effect  
91 21 
1U54AI057159-
010001 COLLIER, R. 
Direct Inhibition of Anthrax Toxin 
Action  
Total: $26,169,985 *  
 $10,173,756 | 2005 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $11,843,830 | 2004 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $4,152,399 | 2003 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
92 21 
1R01AI056047-
01 COLLINS, GREG 
Sensitive Diagnosis of Biowarfare 
Agents on a Microchip  
Total: $1,154,639  
 $456,719 | 2005 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 
WASHINGTON, DC  
 $455,617 | 2004 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 
WASHINGTON, DC  
 $242,303 | 2003 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 
WASHINGTON, DC  
93 21 
1U54AI057158-
010002 CRYSTAL, RONALD Vaccine Platforms  
Total: $21,685,329 *  
 $8,996,537 | 2005 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  
 $8,717,880 | 2004 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  




01 DALY, DON 
Microbial Fingerprinting Chip and 
Automated Analysis  
Total: $526,794  
 $262,537 | 2003 | Daly, Don S | BATTELLE PACIFIC NORTHWEST 
LABORATORIES | RICHLAND, WA  





LABORATORIES | RICHLAND, WA  
95 21 
2R01AI043321-
06 DIETRICH, WILLIAM 
Genetic Analysis of Lethal Factor 
Sensitivity  
Total: $1,330,769  
 $423,750 | 2005 | Dietrich, William F | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $211,719 | 2004 | Dietrich, William F | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $210,000 | 2003 | Dietrich, William F | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $166,348 | 2002 | Dietrich, William F | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $161,723 | 2001 | Dietrich, William F | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $157,229 | 2000 | DIETRICH, WILLIAM F | RAZZAQUE A OCULAR 
PEMPHIGOID--MECHANISM OF PATHOGENESIS | 5 R01EY008379-11 
AHMED, MA  
96 21 
1U01AI057315-
01 DRMANAC, RADOJE 
Comprehensive pathogen 
diagnostics with rSBH system  
Total: $2,305,894  
 $725,838 | 2005 | Drmanac, Radoje | CALLIDA GENOMICS, INC. | 
SUNNYVALE, CA  
 $903,169 | 2004 | Drmanac, Radoje | CALLIDA GENOMICS, INC. | 
SUNNYVALE, CA  




01A1 DRUSANO, GEORGE 
Choosing Drug Doses for 
Biodefence Pathogens  
98 21 
1Z01CL008066-
01 EICHACKER, PETER 
Fluid Treatment in B. Anthracis 
Lethal Toxin Rat Model  
99 21 
1Z01CL008067-
01 EICHACKER, PETER 




01 FLAJNIK, MARTIN 
Highly Stable, Anthrax-specific 
Shark Antibody Fragment  
Total: $538,481  
 $263,178 | 2004 | Flajnik, Martin F | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $275,303 | 2003 | Flajnik, Martin F | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
101 21 
1R21AI053578-
01A1 FREYTAG, LUCY 
NOVEL IMMUNIZATION 
STRATEGIES AGAINST ANTHRAX  
Total: $594,000  
 $297,000 | 2004 | Freytag, Lucy C | TULANE UNIVERSITY OF LOUISIANA | 
NEW ORLEANS, LA  
 $297,000 | 2003 | Freytag, Lucia C | TULANE UNIVERSITY OF LOUISIANA | 







01 FUJII, GARY 
Rapid Vaccine Development 
System  
Total: $131,960  
 $131,960 | 2002 | Fujii, Gary | MOLECULAR EXPRESS, INC. | LOS 
ANGELES, CA  
103 21 
1R43AI055120-
01 GULNIK, SERGEI 
Broadly active inhibitors of high 
priority pathogens  
Total: $802,627  
 $310,030 | 2004 | Gulnik, Sergei | SEQUOIA PHARMACEUTICALS, INC. | 
GAITHERSBURG, MD  
 $492,597 | 2003 | Gulnik, Sergei | SEQUOIA PHARMACEUTICALS, INC. | 
GAITHERSBURG, MD  
104 21 
1P01AI056293-
010001 HACKETT, NEIL 
iNTERACTION OF ALVEOLAR 
MACROPHAGE WITH ANTHRAX 
TOXIN  
Total: $3,474,964  
 $1,388,080 | 2005 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $1,344,411 | 2004 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $742,473 | 2003 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF CORNELL 
UNIV | NEW YORK, NY  
105 21 
1R01AI045740-
01A1 HANNA, PHILIP 
EARLY ESTABLISHMENT STAGES 
OF ANTHRAX INFECTION  
Total: $1,096,196  
 $222,897 | 2004 | Hanna, Philip C | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
 $222,897 | 2003 | Hanna, Philip C | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
 $13,000 | 2002 | Hanna, Philip C | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
 $189,463 | 2002 | Hanna, Philip C | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
 $223,612 | 2001 | Hanna, Philip C | UNIVERSITY OF MICHIGAN | ANN 
ARBOR, MI  
 $224,327 | 2000 | HANNA, PHILIP C | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
106 21 
1U01AI054374-
01 HENRICKSON, KELLY 
Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 
| MILWAUKEE, WI  
 $391,730 | 2004 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 
| MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 
| MILWAUKEE, WI  
107 21 
1R43AI056761-
01 HERRMANN, JOHN 
Therapeutic antibodies for lethal 





Total: $263,086  
 $263,086 | 2003 | Herrmann, John E | ANTIBODY SCIENCE, INC. | 
WORCESTER, MA  
108 21 
1U54AI057168-
010001 HEWLETTE, ERIK 
BACTERIAL ANTIGENS AND 
ANTHRAX VACCINE 
DEVELOPMENT  
Total: $22,072,698  
 $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
109 21 
1R21AI056113-
01 HUGHES, MOLLY 
Studies on Macrophage 
Resistance to Anthrax Lethal 
Toxin  
Total: $560,235  
 $266,219 | 2004 | Hughes, Molly A | UNIVERSITY OF VIRGINIA 
CHARLOTTESVILLE | CHARLOTTESVILLE, VA  
 $294,016 | 2003 | Hughes, Molly A | UNIVERSITY OF VIRGINIA 
CHARLOTTESVILLE | CHARLOTTESVILLE, VA  
110 21 
1R21AI059231-
01A1 IMPERIALE, MICHAEL 
Recombinant Adenovirus Vaccines 
Against B. anthracis  
Total: $301,502  
 $301,502 | 2005 | Imperiale, Michael J | UNIVERSITY OF MICHIGAN AT 
ANN ARBOR | ANN ARBOR, MI  
111 21 
1U01AI061271-
01 JANDA, KIM 
Human Monoclonal IgG for 
Protection against Anthrax  
Total: $676,414  
 $317,177 | 2005 | Janda, Kim D | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $359,237 | 2004 | Janda, Kim D | SCRIPPS RESEARCH INSTITUTE | LA 






Small Molecule Blockers of B. 
anthracis Toxin  
Total: $106,498  
 $106,498 | 2002 | Karginov, Vladimir | ADVANCED BIOSYSTEMS, INC. | 
MANASSAS, VA  
113 21 
1R01AI061712-
01 KARIN, MICHAEL 
How Anthrax lethal factor kills 
macrophages  
Total: $754,800  
 $380,000 | 2005 | Karin, Michael | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
 $374,800 | 2004 | Karin, Michael | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  





01 activated macrophages  
Total: $450,800  
 $228,000 | 2003 | Karin, Michael | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
 $222,800 | 2002 | Karin, Michael | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | SAN DIEGO, CA  
115 21 
1R43AI052963-
01 KENNEY, RICHARD 
Transcutaneous Immunization for 
an Anthrax Vaccine  
Total: $666,550  
 $376,150 | 2003 | Kenney, Richard T | IOMAI CORPORATION | 
GAITHERSBURG, MD  
 $290,400 | 2002 | Kenney, Richard T | IOMAI CORPORATION | 
GAITHERSBURG, MD  
116 21 
1R43AI052892-
01 KITTRELL, JAMES 
Destruction of Air-Borne 
Pathogenic Bacteria  
Total: $100,000  
 $100,000 | 2002 | Kittrell, James R | KSE, INC. | AMHERST, MA  
117 21 
1R21AI053376-
01 KLEMPNER, MARK 
New Method for Detecting Bacillus 
Anthracis Spores  
Total: $433,468  
 $216,368 | 2003 | Klempner, Mark S | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $217,100 | 2002 | Klempner, Mark S | BOSTON MEDICAL CENTER | 
BOSTON, MA  
118 21 
1R01AI066506-
01 KNAP, ANIA 
Broad Spectrum Agents Against 
Cat A Bacterial Pathogens  
Total: $1,450,688  
 $1,450,688 | 2005 | Knap, Ania | MAXTHERA, INC. | READING, MA  
119 21 
1R43AI053021-
01 KOCHI, SIMS 
Live Attenuated Bacterial 
Vaccines Against Anthrax  
Total: $120,511  
 $120,511 | 2002 | Kochi, Sims K | AVANT IMMUNOTHERAPEUTICS, INC. | 
NEEDHAM, MA  
120 21 
1Z01BJ005013-
02 KOPECKO, DENNIS 




01 KOZEL, THOMAS 
B. anthracis:passive immunization 
with anticapsular mAb  
Total: $893,577  
 $447,683 | 2005 | Kozel, Thomas R | UNIVERSITY OF NEVADA RENO | 
RENO, NV  
 $445,894 | 2004 | Kozel, Thomas R | UNIVERSITY OF NEVADA RENO | 






PRIMATE MODEL AND 






Total: $495,897  
 $495,897 | 2005 | Kurosawa, Shinichiro | OKLAHOMA MEDICAL RESEARCH 
FOUNDATION | OKLAHOMA CITY, OK  
123 21 
1R21AI059489-




Total: $630,000  
 $315,000 | 2005 | Lewis, Kim A | NORTHEASTERN UNIVERSITY | BOSTON, 
MA  




01A1 LI, XING-XIANG 
A Rapid, Sensitive and Fully 
Automated Anthrax Test  
Total: $294,393  
 $294,393 | 2005 | Li, Xingxiang | CELLEX, INC. | ROCKVILLE, MD  
125 21 
1U01AI054774-
01 LIN, AUGUSTINE 
Development of a Novel Retrogen 
Vaccine for Anthrax  
Total: $536,817  
 $178,309 | 2004 | Lin, Augustine Y | MITHRAGEN, INC. | HOUSTON, TX  
 $358,508 | 2003 | Lin, Augustine Y | MITHRAGEN, INC. | HOUSTON, TX  
126 21 
1R01AI066504-
01 LING, LOSEE 
Novel Antibiotics from 
Unculturable Actinomycetes  
Total: $932,873  
 $932,873 | 2005 | Ling, Losee Lucy | NOVOBIOTIC PHARMACEUTICALS, 
LLC | CAMBRIDGE, MA  
127 21 
1U01AI061314-
01 LOWY, ISRAEL 
Development of Fully Human 
mAbs as Anthrax Antitoxins  
Total: $781,093  
 $781,093 | 2004 | Lowy, Israel | MEDAREX, INC. | PRINCETON, NJ  
128 21 
2R42AI052670-
02 LUXEMBOURG, ALAIN 
Potentiating an Anthrax DNA 
Vaccine with Electroporation  
Total: $1,128,919  
 $1,128,919 | 2004 | Luxembourg, Alain T | ICHOR MEDICAL SYSTEMS, 
INC. | SAN DIEGO, CA  
129 21 
1R43AI053936-
01A1 LUXEMBOURG, ALAIN 
Application Protocols for a DNA 
Vaccine Against Anthrax  
Total: $299,919  
 $299,919 | 2003 | Luxembourg, Alain T | ICHOR MEDICAL SYSTEMS, INC. 
| SAN DIEGO, CA  
130 21 
1R21AI053360-
01 MADDOCK, JANINE 
Proteomics of B anthracis 





Total: $444,187  
 $225,775 | 2003 | Maddock, Janine R | UNIVERSITY OF MICHIGAN AT ANN 
ARBOR | ANN ARBOR, MI  
 $218,412 | 2002 | Maddock, Janine R | UNIVERSITY OF MICHIGAN AT ANN 






Multivalent display of anthrax 
toxin inhibitors  
Total: $4,988,380  
 $2,060,333 | 2005 | Manchester, Marianne | SCRIPPS RESEARCH 
INSTITUTE | LA JOLLA, CA  
 $2,000,047 | 2004 | Manchester, Marianne | SCRIPPS RESEARCH 
INSTITUTE | LA JOLLA, CA  
 $928,000 | 2003 | Manchester, Marianne | SCRIPPS RESEARCH INSTITUTE 






New Antibiotic Inhibitors of the B. 
anthracis Ribosome  
Total: $8,548,157 *  
 $3,420,271 | 2005 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $3,320,641 | 2004 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $1,807,245 | 2003 | Johnson, Michael E | UNIVERSITY OF ILLINOIS AT 






PTE-based drug for antibiotic-
resistant anthrax  
Total: $3,189,520  
 $1,156,790 | 2005 | Burns, Christopher | PROTEZ PHARMACEUTICALS, 
INC. | MALVERN, PA  
 $1,284,387 | 2004 | Markham, Penelope N | PROTEZ PHARMACEUTICALS, 
INC. | MALVERN, PA  






Engineered alkaline phosphatases 
as biosensors  
Total: $532,000  
 $266,000 | 2004 | Matsumura, Ichiro | EMORY UNIVERSITY | ATLANTA, GA 
 $266,000 | 2003 | Matsumura, Ichiro | EMORY UNIVERSITY | ATLANTA, GA 
135 21 
1F32AI055245-
01 MAYNARD, JENNIFER 
Bacterial Adenylate Cyclase 
Toxins: Role in Pathogenesis  
Total: $41,608  
 $41,608 | 2003 | Maynard, Jennifer A | STANFORD UNIVERSITY | 
STANFORD, CA  
136 21 
1Z01BJ007008-
01 MEADE, BRUCE 
Development and evaluation of 
laboratory methods that as  
137 21 
1U54AI057159-
010003 MEKALANOS, JOHN 
Microbial Vectors for Antigen 
Delivery  





SCHOOL) | BOSTON, MA  
 $11,843,830 | 2004 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $4,152,399 | 2003 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
138 21 
1R21AI059520-
01 METODIEV, METODI 
Yeast based model of anthrax 
lethal factor toxicity  
Total: $193,750  
 $193,750 | 2004 | Metodiev, Metodi V | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
139 21 
1U01AI056546-
01 MOGRIDGE, JEREMY 
Development and testing of 
anthrax toxin inhibitors  
Total: $3,026,916  
 $1,155,989 | 2005 | Mogridge, Jeremy S | UNIVERSITY OF TORONTO | 
CANADA - TORONTO  
 $1,122,727 | 2004 | Mogridge, Jeremy S | UNIVERSITY OF TORONTO | 
CANADA - TORONTO  
 $748,200 | 2003 | Mogridge, Jeremy S | UNIVERSITY OF TORONTO | 
CANADA - TORONTO  
140 21 
1R43AI053959-
01 NYE, STEVEN 
Combinatorial rat panels that 
genetically screen anthrax  
Total: $312,536  
 $312,536 | 2003 | Nye, Steven H | PHYSIOGENIX, INC. | WAUWATOSA, WI 
141 21 
1R21AI053397-
01 O'BRIEN, ALISON 
Immunoprotective monoclonals to 
B anthracis spores  
Total: $446,100  
 $223,050 | 2003 | Obrien, Alison D | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $223,050 | 2002 | O'Brien, Alison D | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | BETHESDA, MD  
142 21 
2R44AI052936-
02 PADHYE, NISHA 
A PCR Jet for Rapid Detection of 
Special pathogens  
Total: $394,873  
 $394,873 | 2004 | Padhye, Nisha V | MEGABASE RESEARCH PRODUCTS | 






Anthrax Vaccine Formulations 
Combining PA/Spore Epitopes  
Total: $728,648  
 $291,720 | 2005 | Palecanda, Aiyappa M | LIGOCYTE PHARMACEUTICALS, 
INC. | BOZEMAN, MT  
 $436,928 | 2004 | Palecanda, Aiyappa M | LIGOCYTE PHARMACEUTICALS, 
INC. | BOZEMAN, MT  
144 21 
1R03AI054622-
01 PETERS, WENDY 
Role of Chemokines in Anthrax 
Pathogenesis  





SAN FRANCISCO, CA  
 $89,500 | 2003 | Peters, Wendy | J. DAVID GLADSTONE INSTITUTES | 
SAN FRANCISCO, CA  
145 21 
1R21AI056110-
01 PETERS, WENDY 
Chemokines and their Receptors 
in Anthrax Infection  
Total: $498,519  
 $242,953 | 2004 | Peters, Wendy | J. DAVID GLADSTONE INSTITUTES | 
SAN FRANCISCO, CA  
 $255,566 | 2003 | Peters, Wendy | J. DAVID GLADSTONE INSTITUTES | 
SAN FRANCISCO, CA  
146 21 
1U01AI053858-
01 PETERSON, JOHNNY 
Development of Therapeutic 
Inhibitors to Anthrax Toxins  
Total: $1,540,401  
 $441,167 | 2004 | Peterson, Johnny W | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $728,317 | 2003 | Peterson, Johnny W | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $370,917 | 2002 | Peterson, Johnny W | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
147 21 
1R21AI053292-
01 PIZZO, SALVATORE 
Alpha2-Macroglobulin-PA 
Complexes: Novel Anthrax 
Vaccin*  
Total: $462,000  
 $231,000 | 2003 | Pizzo, Salvatore V | DUKE UNIVERSITY | DURHAM, NC  
 $231,000 | 2002 | Pizzo, Salvatore | DUKE UNIVERSITY | DURHAM, NC  
148 21 
1R01AI056499-
01 PULENDRAN, BALI 
ANTHRAX TOXIN, DENDRITIC 
CELLS AND ADAPTIVE IMMUNITY  
Total: $950,625  
 $380,250 | 2005 | Pulendran, Bali | EMORY UNIVERSITY | ATLANTA, GA  
 $380,250 | 2004 | Pulendran, Bali | EMORY UNIVERSITY | ATLANTA, GA  
 $190,125 | 2003 | Pulendran, Bali | EMORY UNIVERSITY | ATLANTA, GA  
149 21 
1Z01BM006014-
01 PURI, RAJ 
Activity of extracellular domain of 
anthrax toxin  
150 21 
1R01AI054444-
01 RAMAN, C 
Structural Biology of Prokaryotic 
NO Synthases  
Total: $830,063  
 $259,875 | 2005 | Raman, C S | UNIVERSITY OF TEXAS HLTH SCI CTR 
HOUSTON | HOUSTON, TX  
 $259,875 | 2004 | Raman, C S | UNIVERSITY OF TEXAS HLTH SCI CTR 
HOUSTON | HOUSTON, TX  
 $310,313 | 2003 | Raman, C S | UNIVERSITY OF TEXAS HLTH SCI CTR 
HOUSTON | HOUSTON, TX  
151 21 
1R01AI066508-
01 REASON, DONALD 
Human monoclonal panel 






Total: $722,405  
 $722,405 | 2005 | Reason, Donald C | CHILDREN'S HOSPITAL & RES CTR 






Human Abs to B. Anthracis in 
Cloned Transgenic Cattle  
Total: $137,316  
 $137,316 | 2003 | Sathiyasseelan, Thillainayagam | HEMATECH, LLC | 
WESTPORT, CT  
153 21 
1R21AI056229-
01 SCANDURRO, ALINE 
Discovery of New Cellular Targets 
of Anthrax Toxin  
Total: $445,500  
 $222,750 | 2004 | Scandurro, Aline B | TULANE UNIVERSITY OF 
LOUISIANA | NEW ORLEANS, LA  
 $222,750 | 2003 | Scandurro, Aline B | TULANE UNIVERSITY OF 








Bioterrorism Agents  
Total: $1,354,051 *  
 $670,963 | 2004 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
 $683,088 | 2003 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
155 21 
1Z01BJ004007-
01 SCHMITT, MICHAEL 
Characterization of the iron 
regulon in Bacillus anthrac  
156 21 
1Z01BJ004012-
01 SCHMITT, MICHAEL 
Identification of virulence 
determinants in Corynebacter  
157 21 
1R41AI059138-
01A1 SCHOEN, CHRISTIAN 
Automated, portable, concurrent, 
WMD detection system  
Total: $994,832  
 $500,000 | 2005 | Schoen, Christian | CONCURRENT ANALYTICAL, INC. | 
Kailua, HI  
 $494,832 | 2004 | Schoen, Christian | CONCURRENT ANALYTICAL, INC. | 
Kailua, HI  
158 21 
1P30AR050948-
010002 SHI, ZHONGKAI 
E. coli filtrates as Adjuvant for 
Topical Anthrax Vaccin  
Total: $571,940  
 $571,940 | 2004 | Elmets, Craig A | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
159 21 
1Z01DK015500-
41 SHILOACH, JOSEPH 
Large-scale Production & 
Purification Of Compounds With  
160 21 
1R21AI053524-
01 SIMON, SANFORD 
Treatment of Anthrax with 
Nonantimicrobial Tetracyclines  
Total: $451,500   $225,750 | 2003 | Simon, Sanford R | STATE UNIVERSITY NEW YORK 





 $225,750 | 2002 | Simon, Sanford R | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
161 21 
1R21AI059436-
01 STEWART, GEORGE 
Function of the Bacillus anthracis 
Spore Carboydrate  
Total: $535,000  
 $48,789 | 2005 | Stewart, George C | UNIVERSITY OF MISSOURI 
COLUMBIA | COLUMBIA, MO  
 $240,257 | 2005 | Stewart, George C | UNIVERSITY OF MISSOURI 
COLUMBIA | COLUMBIA, MO  
 $245,954 | 2004 | Stewart, George C | KANSAS STATE UNIVERSITY | 
MANHATTAN, KS  
162 21 
1Z01BJ005015-
01 STIBITZ, E. 
Development of genetic tools for 
the manipulation of Bac  
163 21 
1Z01BJ005015-
02 STIBITZ, E. 
Development of genetic tools for 
the manipulation of Bac  
164 21 
1R43AI058410-
01 SURBER, MARK 
Antibacterial Therapy by 
Pathogen Osmolality Disruption  
Total: $265,985  
 $265,985 | 2004 | Surber, Mark W | MPEX PHARMACEUTICALS, INC. | SAN 
DIEGO, CA  
165 21 
1U01AI055010-
01A1 SYKES, KATHRYN 
Discovery of new anti-bacteremia 
vaccines for anthrax  
Total: $3,453,389  
 $1,114,614 | 2005 | Sykes, Kathryn F | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $1,225,780 | 2004 | Sykes, Kathryn F | MACROGENICS, INC. | DALLAS, TX 
 $1,112,995 | 2003 | Sykes, Kathryn F | MACROGENICS, INC. | DALLAS, TX 
166 21 
1R01GM062548-
01 TANG, WEI-JEN 
CALMODULIN REGULATION OF 
ANTHRAX AND ADENYLYL 
CYCLASES  
Total: $1,107,848  
 $278,077 | 2004 | Tang, Weijen | UNIVERSITY OF CHICAGO | CHICAGO, IL 
 $270,527 | 2003 | Tang, Weijen | UNIVERSITY OF CHICAGO | CHICAGO, IL 
 $31,310 | 2002 | Tang, Wei-Jen | UNIVERSITY OF CHICAGO | CHICAGO, IL 
 $263,192 | 2002 | Tang, Wei-Jen | UNIVERSITY OF CHICAGO | CHICAGO, 
IL  




01 TEUSCHER, CORY 
Genetics of Suscptibility to 
Anthrax Toxin in vivo  
Total: $757,500  
 $378,750 | 2005 | Teuscher, Cory | UNIVERSITY OF VERMONT & ST AGRIC 
COLLEGE | BURLINGTON, VT  
 $378,750 | 2004 | Teuscher, Cory | UNIVERSITY OF VERMONT & ST AGRIC 








VAN DER GOOT, 
FRANCOISE 
Anthrax toxin-host cell 
interactions  
Total: $300,000  
 $150,000 | 2004 | Vandergoot, Francoise G | UNIVERSITY OF GENEVA | 
SWITZERLAND - GENEVA  
 $150,000 | 2003 | Vandergoot, Francoise G | UNIVERSITY OF GENEVA | 
SWITZERLAND - GENEVA  
169 21 
1U01AI056559-
01 VAN NEST, GARY 
Advanced anthrax vaccine made 
with ISS DNA formulations  
Total: $1,507,236  
 $816,464 | 2005 | Vannest, Gary A | DYNAVAX TECHNOLOGIES 
CORPORATION | BERKELEY, CA  
 $456,128 | 2004 | Vannest, Gary A | DYNAVAX TECHNOLOGIES 
CORPORATION | BERKELEY, CA  
 $234,644 | 2003 | Vannest, Gary A | DYNAVAX TECHNOLOGIES 
CORPORATION | BERKELEY, CA  
170 21 
1R41AI052916-
01 VODOVOTZ, YORAM 
Mathematical Modeling of Anthrax 
Infection  
Total: $100,000  




01 VOGT, PETER 
Potent inhibitors of Anthrax 
Lethal Factor  
Total: $555,600  
 $277,800 | 2003 | Vogt, Peter K | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $277,800 | 2002 | Vogt, Peter K | SCRIPPS RESEARCH INSTITUTE | SAN 
DIEGO, CA  
172 21 
1R03AI059500-
01 WANG, JULIA 
Chemical Structure of Anthrax 
Spore Polysaccharide  
Total: $86,500  
 $86,500 | 2004 | Wang, Julia Y | BRIGHAM AND WOMEN'S HOSPITAL | 
BOSTON, MA  
173 21 
1R21AI053369-
01 WANG, JULIA 
DEVELOPMENT OF MULTIVALENT 
ANTHRAX TOXIN INHIBITORS  
Total: $506,473  
 $254,025 | 2003 | Wang, Julia Y | BRIGHAM AND WOMEN'S HOSPITAL | 
BOSTON, MA  
 $252,448 | 2002 | Wang, Julia Y | BRIGHAM AND WOMEN'S HOSPITAL | 
BOSTON, MA  
174 21 
1U01AI061297-
01 WOLINSKY, STEVEN 
Detection of Category A 
Pathogens by Gold Nanoparticles  
Total: $1,316,780  
 $1,316,780 | 2004 | Wolinsky, Steven M | NORTHWESTERN UNIVERSITY | 
CHICAGO, IL  





01A1 novel lentiviral vector  
Total: $131,792  




01A1 WYCOFF, KEITH 
Immunotherapy for Pulmonary 
Anthrax  
Total: $109,500  
 $109,500 | 2003 | Wycoff, Keith L | PLANET BIOTECHNOLOGY, INC. | 
HAYWARD, CA  
177 21 
1R43AI053018-
01 YING, BAOLING 
Development of a virus vector 
vaccine against anthrax  
Total: $140,710  
 $140,710 | 2002 | Krajcsi, Peter | VIRRX, INC. | ST. LOUIS, MO  
178 21 
1R01AI048489-
01 YOUNG, JOHN 
STRATEGIES TO INHIBIT 
CELLULAR UPTAKE OF ANTHRAX 
TOXIN  
Total: $2,638,183 *  
 $581,627 | 2005 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $586,123 | 2004 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $449,673 | 2003 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $346,383 | 2002 | Young, John A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $359,538 | 2001 | Young, John A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $314,839 | 2000 | YOUNG, JOHN A | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
179 21 
2R01AI048489-
06 YOUNG, JOHN Anthrax Toxin Entry into Cells  
Total: $2,638,183 *  
 $581,627 | 2005 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $586,123 | 2004 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $449,673 | 2003 | Young, John At | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $346,383 | 2002 | Young, John A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $359,538 | 2001 | Young, John A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $314,839 | 2000 | YOUNG, JOHN A | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
180 21 
1R21AI057889-
01 ZANETTI, MAURIZIO 
Conformationally-Constrained PA 
Anthrax Vaccine  





DIEGO | LA JOLLA, CA  
181 21 
1R03AI053598-
01 ZENG, MINGTAO 
Multi-component and easily 
administrated anthrax vaccine  
Total: $157,500  
 $78,750 | 2003 | Zeng, Mingtao | UNIVERSITY OF ROCHESTER | 
ROCHESTER, NY  
 $78,750 | 2002 | Zeng, Mingtao | UNIVERSITY OF ROCHESTER | 







Resistance of B anthracis  
Total: $302,833  
 $151,500 | 2004 | Zhang, Hongzhong | UNIVERSITY OF CALIFORNIA SAN 
FRANCISCO | SAN FRANCISCO, CA  
 $151,333 | 2003 | Zhang, Hongzhong | UNIVERSITY OF CALIFORNIA SAN 






Human Monoclonal Antitoxin to 
Anthrax Protective Antigen  
Total: $506,250  
 $253,500 | 2003 | Zollapazner, Susan B | NEW YORK UNIVERSITY SCHOOL 
OF MEDICINE | NEW YORK, NY  
 $252,750 | 2002 | Zolla-Pazner, Susan | NEW YORK UNIVERSITY SCHOOL 
OF MEDICINE | NEW YORK, NY  
184 13 
1R43AI052508-
01 BRADLEY, BRUCE 
Vacuum Collection and 
Containment of 
Anthrax/Pathogens  
Total: $100,000  
 $100,000 | 2002 | Bradley, Bruce J | ROCKY MOUNTAIN RESOURCE LABS, 














RNA Ligase Function and Use in 
DNA Synthesis  
Total: $2,003,500  
 $347,979 | 2005 | Cozzarelli, Nicholas R | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $348,911 | 2004 | Cozzarelli, Nicholas R | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $315,941 | 2003 | Cozzarelli, Nicholas R | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $306,951 | 2002 | Cozzarelli, Nicholas R | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $364,983 | 2001 | Cozzarelli, Nicholas R. | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $318,735 | 2000 | COZZARELLI, NICHOLAS R | UNIVERSITY OF 










STRUCTURAL STUDIES ON THE 
ANTHRAX LETHAL TOXIN  
Total: $1,706,250  
 $341,250 | 2004 | Liddington, Robert C | BURNHAM INSTITUTE | LA JOLLA, 
CA  
 $341,250 | 2003 | Liddington, Robert C | BURNHAM INSTITUTE | LA JOLLA, 
CA  
 $341,250 | 2002 | Liddington, Robert C | BURNHAM INSTITUTE | SAN 
DIEGO, CA  
 $341,250 | 2001 | Liddington, Robert C | BURNHAM INSTITUTE | SAN 
DIEGO, CA  
 $341,250 | 2000 | LIDDINGTON, ROBERT C | BURNHAM INSTITUTE | SAN 
DIEGO, CA  
188 13 
1R21AI053517-
01 LINDBERG, IRIS 
Blockade of Anthrax Cytotoxicity 
Using Furin Inhibitors  
Total: $382,100  
 $177,500 | 2003 | Lindberg, Iris | LOUISIANA STATE UNIV HSC NEW 
ORLEANS | NEW ORLEANS, LA  
 $204,600 | 2002 | Lindberg, Iris | LOUISIANA STATE UNIV HSC NEW 
ORLEANS | NEW ORLEANS, LA  
189 10 
1R43AI058627-
01A1 ALEKSHUN, MICHAEL Novel Therapeutics for Biodefense 
Total: $1,684,306  
 $854,748 | 2005 | Alekshun, Michael N | PARATEK PHARMACEUTICALS | 
BOSTON, MA  
 $829,558 | 2004 | Alekshun, Michael N | PARATEK PHARMACEUTICALS | 
BOSTON, MA  
190 10 
1R43AI066437-
01 ALIBEK, KEN 
New Generation of Anthrax 
Prophylaxis and Therapy  
Total: $432,829  
 $432,829 | 2005 | Alibek, Ken | ADVANCED BIOSYSTEMS, INC. | 






Novel Approaches to the 
Inhibition of Anthrax Toxin  
Total: $461,700  
 $230,850 | 2003 | Artenstein, Andrew W | UNIVERSITY OF RHODE ISLAND 
| KINGSTON,, RI  
 $230,850 | 2002 | Artenstein, Andrew W | MEMORIAL HOSPITAL OF 
RHODE ISLAND | PAWTUCKET, RI  
192 10 
1R43AI054060-
01 BACKER, JOSEPH 
Targeted delivery of anti-anthrax 
therapeutics  
Total: $107,000  
 $107,000 | 2003 | Backer, Joseph M | SIBTECH, INC. | NEWINGTON, CT  
193 10 
1U19AI056578-
010001 BAILLIE, LESLIE 
Rational Design of an Anthrax 
Toxin Neutralizing Vaccine  
Total: $4,457,410   $1,930,417 | 2005 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 





 $1,881,608 | 2004 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $645,385 | 2003 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
194 10 
1P01CI000095-
010001 BEUTLER, BRUCE 
Genes Required for Responses to 
Anthrax Lethal Factor  
195 10 
1U01AI057232-
01 BOCHNER, BARRY 
Detection of Bioterrorism Agents 
with PM Technology  
Total: $1,864,722  
 $550,250 | 2005 | Bochner, Barry R | BIOLOG, INC. | HAYWARD, CA  
 $920,940 | 2004 | Bochner, Barry R | BIOLOG, INC. | HAYWARD, CA  
 $393,532 | 2003 | Bochner, Barry R | BIOLOG, INC. | HAYWARD, CA  
196 10 
1P01CI000095-
010004 BOKOCH, GARY 
Regulation of Human Leukocyte 






Human Antibody Therapeutics 
Against Anthrax  
Total: $737,620  
 $737,620 | 2004 | Bowdish, Katherine S | ALEXION ANTIBODY 






Statistical Models for Anthrax  
Total: $490,500  
 $245,250 | 2003 | Brookmeyer, Ronald S | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
 $245,250 | 2002 | Brookmeyer, Ronald S | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
199 10 
1R43AI060348-
01A1 BUTLER, MICHELLE 
DEVELOPMENT OF SCREENS FOR 
BACILLUS ANTHRACIS TARGETS  
Total: $386,681  




01 CAPRA, J 
Molecular and Immunologic 
Analysis of the Pathobiology of 
Anthrax  
Total: $2,786,653  
 $26,472 | 2005 | Capra, J Donald | OKLAHOMA MEDICAL RESEARCH 
FOUNDATION | OKLAHOMA CITY, OK  
 $2,760,181 | 2004 | Capra, J Donald | OKLAHOMA MEDICAL RESEARCH 
FOUNDATION | OKLAHOMA CITY, OK  
201 10 
1R21AI059233-
01 CHEN, ZHENG T cell immunity to B. anthracis  
Total: $340,000  
 $340,000 | 2004 | Chen, Zheng W | BETH ISRAEL DEACONESS MEDICAL 







01 CLEMENTS, JOHN 
Combinatorial vaccines against 
anthrax and plague  
Total: $610,500  
 $313,500 | 2004 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $297,000 | 2003 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
203 10 
1U01AI056452-
01 CLEMENTS, JOHN 
Novel adjuvants for biodefense 
vaccines  
Total: $1,759,403  
 $270,779 | 2005 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $460,814 | 2004 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $1,027,810 | 2003 | Clements, John D | TULANE UNIVERSITY OF 
LOUISIANA | NEW ORLEANS, LA  
204 10 
1R43AI052891-
01 COESHOTT, CLAIRE 
A novel adjuvant/delivery system 
for anthrax vaccine  
Total: $224,518  
 $224,518 | 2002 | Coeshott, Claire M | RXKINETIX, INC. | LOUISVILLE, CO  
205 10 
1P01CI000095-
010005 CROSS, ANDREW 
NOX Proteins and Resistance to 
Infectious Disease  
206 10 
1R21AI060941-
01 DAVIS, GEORGE 
Function of CMG-2, an Anthrax 
Toxin Receptor  
Total: $363,750  
 $181,875 | 2005 | Davis, George E | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
 $181,875 | 2004 | Davis, George E | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
207 10 
1U01AI061199-
01 DUBENSKY, THOMAS 
Psoralen-Killed, Metabolically-
Active Anthrax Vaccine  
Total: $1,461,608  
 $1,461,608 | 2004 | Dubensky, Thomas W | CERUS CORPORATION | 
CONCORD, CA  
208 10 
1P20RR015564-
01 DYER, DAVID 
FUNCTIONAL 
GENOMIC/PROTEOMICS OF 
BACTERIAL HOST INTERACT  
Total: $9,678,543  
 $1,931,192 | 2004 | Iandolo, John J | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
 $1,932,056 | 2003 | Iandolo, John J | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
 $1,945,714 | 2002 | Iandolo, John J | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
 $33,548 | 2001 | Dyer, David W | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
 $1,906,517 | 2001 | Dyer, David W | UNIVERSITY OF OKLAHOMA HLTH 





 $1,929,516 | 2000 | DYER, DAVID W | UNIVERSITY OF OKLAHOMA HLTH 
SCIENCES CTR | OKLAHOMA CITY, OK  
209 10 
1R01CI000099-
01 ECKER, DAVID 
Automated Simultaneous 
Detection of Bioterrorism Agents  
210 10 
1Z01CL008068-
01 EICHACKER, PETER 
Pretreatment Sublethal B. 
Anthracis Lethal Toxin in Rats  
211 10 
1R43AI052941-
01 FATHI, ZAKARYAE 
Sterilization of Mail using Variable 
Frequency Microwave  
Total: $97,866  
 $97,866 | 2002 | Fathi, Zakaryae | LAMBDA TECHNOLOGIES, INC. | 
MORRISVILLE, NC  
212 10 
1U19AI056510-
01 FISCHETTI, VINCENT 
Pathogen-specific drug targets for 
weaponized bacteria  
Total: $3,399,387  
 $1,349,740 | 2005 | Fischetti, Vincent A | ROCKEFELLER UNIVERSITY | 
NEW YORK, NY  
 $1,317,962 | 2004 | Fischetti, Vincent A | ROCKEFELLER UNIVERSITY | 
NEW YORK, NY  
 $731,685 | 2003 | Fischetti, Vincent A | ROCKEFELLER UNIVERSITY | NEW 
YORK, NY  
213 10 
1Z01BO002009-
01 FRUCHT, DAVID 
Host Factors that Modulate 
Anthrax Lethal Toxin  
214 10 
2R44AI052963-
03 GLENN, GREGORY 
Transcutaneous Immunization for 
an Anthrax Vaccine  
Total: $1,985,771  
 $985,771 | 2005 | Glenn, Gregory M | IOMAI CORPORATION | 
GAITHERSBURG, MD  
 $1,000,000 | 2004 | Glenn, Gregory M | SIGNAIGO, KATHLEEN | 
GAITHERSBURG, MD  
215 10 
1R01AI054796-
01 HAN, JIAHUAI 
Molecular Mechanisms of Anthrax-
Induced Macrophage Death  
Total: $1,126,200  
 $375,400 | 2005 | Han, Jiahuai | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $375,400 | 2004 | Han, Jiahuai | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $375,400 | 2003 | Han, Jiahuai | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
216 10 
1R41AI053060-
01 HOBART, PETER 
Prophylactic Anthrax Toxin 
Vaccine  
Total: $462,918  










Total: $3,841,474  
 $1,945,441 | 2004 | Hobart, Peter M | VICAL, INC. | SAN DIEGO, CA  






Respirable ciprofloxacin aerosol 
for inhaled anthrax  
Total: $77,000  
 $77,000 | 2004 | Hybertson, Brooks M | UNIVERSITY OF COLORADO 
DENVER/HSC AURORA | AURORA, CO  
219 10 
1R21AI055968-
01 JOHN, MANOHAR 
Anthrax spore-surface antigens 
for biosensor development  
Total: $605,500  
 $302,750 | 2004 | John, Manohar | MASSACHUSETTS GENERAL HOSPITAL 
| BOSTON, MA  
 $302,750 | 2003 | John, Manohar | MASSACHUSETTS GENERAL HOSPITAL 
| BOSTON, MA  
220 10 
1R21AI053506-
01A1 KANE, RAVI 
The Design of Inhibitors of 
Anthrax Toxin  
Total: $507,034  
 $246,929 | 2004 | Kane, Ravi S | RENSSELAER POLYTECHNIC INSTITUTE | 
TROY, NY  
 $260,105 | 2003 | Kane, Ravi S | RENSSELAER POLYTECHNIC INSTITUTE | 
TROY, NY  
221 10 
1R43AI058458-
01 KANG, ANGRAY 
Human Antibodies for 
Exposure/Protection from 
Anthrax  
Total: $750,263  
 $350,348 | 2005 | Scholz, Wolfgang W | AVANIR PHARMACEUTICALS | 
SAN DIEGO, CA  
 $399,915 | 2004 | Kang, Angray S | AVANIR PHARMACEUTICALS | SAN 






Small Molecule Blockers of B. 
anthracis Toxin  
Total: $1,500,659  
 $912,224 | 2005 | Karginov, Vladimir | INNOVATIVE BIOLOGICS, INC. | 
MANASSAS, VA  
 $588,435 | 2004 | Karginov, Vladimir | INNOVATIVE BIOLOGICS, INC. | 
MANASSAS, VA  
 
Bluetongue virus (exotic) 
Taxonomy: Family Reoviridae, Genus Orbivirus, Species Bluetongue virus. Virus: Bluetongue 






1. Taus, Wilson W. C., H. C. Ma, E. H. Venter, A. A. van Djik, B. S. Seal, and J. O. 
Mecham. 2000. Phylogenetic relationships of bluetongue viruses based on gene S7. Virus 
Res 67:141-51. 
This paper reports the phylogenetic analysis of the L3 gene segment of various 
Bluetongue virus isolates. 
2. Bonneau, K. R, N. Z. Zhang, W. C. Wilson, J. B. Zhu, F. Q. Zhang, Z. H. Li, K. L. 
Zhang, L. Xiao, W. B. Xiang, and N. J. MacLachlan. 2000. Phylogenetic analysis of 
the S7 gene does not segregate Chinese strains of bluetongue virus into a single topotype. 
Arch Virol 145:1163-71. 
This paper reports the phylogenetic comparison of the S7 gene segment of exotic 
Bluetongue virus isolates with US-endemic strains. 
3. Meissner, J. D., J. O. Mecham, and W. C. Wilson. 2001. Verification of bluetongue 
virus S9 segment nucleotide sequences. Virus Res 81:93-101. 
This paper reports the phylogenetic comparison of the S9 gene segment of exotic 
Bluetongue virus isolates with US-endemic strains. 
 
NIH grants: None identified. 
 
Bovine spongiform encephalopathy prion 
Taxonomy: Prion. 
Publications: 
1. Koo, H. C., Y. H. Park, B. C. Lee, C. Chae, K. I. O'Rourke, and T. V. Baszler. 2001. 
Immunohistochemical detection of Prion protein (PrP-Sc) and epidemiological study of 
BSE in Korea. J Vet Sci 2:25-31. 
 This paper reports the immunohistochemical detection of the prion in bovine tissues. 
2. Lloyd, S. E., J. B. Uphill, P. V. Targonski, E. M. Fisher, and J. Collinge. 2002. 
Identification of genetic loci affecting mouse-adapted bovine spongiform encephalopathy 
incubation time in mice. Neurogenetics 4:77-81. 
 This paper reports genomic characteristics of mice that influence the outcome of infection 
with the prion. 
3. Safar, J. G., M. Scott, J. Monaghan, C. Deering, S. Didorenko, J. Vergara, H. Ball, 
G. Legname, E. Leclerc, L. Solforosi, H. Serban, D. Groth, D. R. Burton, S. B. 
Prusiner, and R. A. Williamson. 2002. Measuring prions causing bovine spongiform 
encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat 
Biotechnol 20:1147-50. 





4. Lasmezas, C. I., E. Comoy, S. Hawkins, C. Herzog, F. Mouthon, T. Konold, F. 
Auvre, E. Correia, N. Lescoutra-Etchegaray, N. Sales, G. Wells, P. Brown, and J. P. 
Deslys. 2005. Risk of oral infection with bovine spongiform encephalopathy agent in 
primates. Lancet 365:781-3. 
 This paper reports the characterization of oral transmission of the prion in primates. 
5. Scott, M. R., D. Peretz, H. O. Nguyen, S. J. Dearmond, and S. B. Prusiner. 2005. 
Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol 
79:5259-71. 








Generation of Prion Knockout Cattle  
Total: $299,336  
 $164,835 | 2004 | Eyestone, Willard H | VIRGINIA POLYTECHNIC INST AND 
ST UNIV | BLACKSBURG, VA  
 $134,501 | 2003 | Eyestone, Willard H | VIRGINIA POLYTECHNIC INST AND 
ST UNIV | BLACKSBURG, VA  
2 19 
2P01AG014359-
060005 SINGH, NEENA 
PRP-SCRAPIE TRANSPORT--
INTESTINAL & BLOOD BRAIN BARRIER  
Total: $7,768,728 *  
 $1,559,093 | 2004 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,519,120 | 2003 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,500,000 | 2002 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $300,000 | 2002 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $99,500 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,000,000 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $905,844 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $885,171 | 2000 | GAMBETTI, PIERLUIGI | CASE WESTERN RESERVE 






TRANSGENETIC STUDIES OF PRION 
DISEASE IN CERVIDS  
Total: $1,954,959  
 $335,792 | 2005 | Telling, Glenn C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $289,600 | 2002 | Telling, Glenn C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $750,000 | 2001 | Telling, Glenn C. | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  





LEXINGTON, KY  
 $289,967 | 2000 | TELLING, GLENN C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
4 10 
1Z01BP005002-
01 ASHER, DAVID 
INFECTIONS WITH TRANSMISSIBLE 
SPONGIFORM ENCEPHALOPATHY  
5 10 
1Z01BP005002-
02 ASHER, DAVID 




03 ASHER, DAVID 
Susceptibility of genetically modified 
candidate cell su  
7 10 
1Z01BP005003-
04 ASHER, DAVID 
VALIDATE TRANSGENIC MICE TO 
DETECT SPONGIFORM ENCEPHALOP  
8 10 
1Z01BP005018-
01 ASHER, DAVID 
Effects of leukofiltration on cells 
experimentally infec  
9 10 
1Z01BP005027-
01 ASHER, DAVID 
Transmissible Spongiform 
Encephalopathies: Product Safet  
10 10 
1Z01NS002957-













Identification of anti-scrapie drugs  
Total: $8,127,226 *  
 $1,535,853 | 2005 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,503,420 | 2004 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,289,807 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,255,043 | 2002 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $123,004 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $1,048,805 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $145,840 | 2000 | OLDSTONE, MICHAEL B | SCRIPPS RESEARCH INSTITUTE 
| SAN DIEGO, CA  
 $1,225,454 | 2000 | OLDSTONE, MICHAEL B | SCRIPPS RESEARCH 






Functional Genetics of Susceptibility to 
Prions  
Total: $6,297,239  
 $1,572,933 | 2004 | Carlson, George A | MC LAUGHLIN RESEARCH INS 
TITUTE | GREAT FALLS, MT  
 $1,569,184 | 2003 | Carlson, George A | MC LAUGHLIN RESEARCH INS FOR 
BIOMED SCIS | GREAT FALLS, MT  
 $1,561,788 | 2002 | Carlson, George A | MC LAUGHLIN RESEARCH INS FOR 





 $1,593,334 | 2001 | Carlson, George A | MC LAUGHLIN RESEARCH INS FOR 






Biochemical Detection of Prions in 
Blood  
Total: $61,910  
 $61,910 | 2004 | Castilla, Joaquin | UNIVERSITY OF TEXAS MEDICAL BR 












Biochemistry Of Scrapie Pathogenesis  
17 10 
2P01AG014359-
060003 CHEN, SHU 
MOLECULAR STUDIES OF HUMAN AND 
ANIMAL PRION PROTEINS  
Total: $7,768,728 *  
 $1,559,093 | 2004 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,519,120 | 2003 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,500,000 | 2002 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $300,000 | 2002 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $99,500 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $1,000,000 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $905,844 | 2001 | Gambetti, Pierluigi | CASE WESTERN RESERVE 
UNIVERSITY | CLEVELAND, OH  
 $885,171 | 2000 | GAMBETTI, PIERLUIGI | CASE WESTERN RESERVE 



























Interaction of Prions with Dendritic 
Cells  
Total: $60,270  







Transmission of Prions Within and 
Between Species  
Total: $152,938   $77,280 | 2005 | Harrington, Robert D | WASHINGTON STATE UNIVERSITY | 





 $75,658 | 2004 | Harrington, Robert D | WASHINGTON STATE UNIVERSITY | 






Analysis of Cytoplasmic Prion Protein 
Toxicity  
Total: $42,976  
 $42,976 | 2004 | Jackson, Walker S | WHITEHEAD INSTITUTE FOR 






Defining the prion domain of PrP  
Total: $1,030,467  
 $348,959 | 2005 | Mastrianni, James A | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $344,557 | 2004 | Mastrianni, James A | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $336,951 | 2003 | Mastrianni, James A | UNIVERSITY OF CHICAGO | 








Total: $8,127,226 *  
 $1,535,853 | 2005 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,503,420 | 2004 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,289,807 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,255,043 | 2002 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $123,004 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $1,048,805 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $145,840 | 2000 | OLDSTONE, MICHAEL B | SCRIPPS RESEARCH INSTITUTE 
| SAN DIEGO, CA  
 $1,225,454 | 2000 | OLDSTONE, MICHAEL B | SCRIPPS RESEARCH 






Transgenic models of transmissible 
spongiform encephalop  
Total: $8,127,226 *  
 $1,535,853 | 2005 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,503,420 | 2004 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,289,807 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
 $1,255,043 | 2002 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $123,004 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $1,048,805 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  





| SAN DIEGO, CA  
 $1,225,454 | 2000 | OLDSTONE, MICHAEL B | SCRIPPS RESEARCH 






Pathogenesis Studies in Scrapie (TSE 
Diseases)  
Total: $347,245  
 $347,245 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | 
LA JOLLA, CA  
28 10 
1R43HL070399-
01 ORSER, CINDY A Catalytic Conformational Prion Sensor 
Total: $102,362  









































TRANSGENIC MOUSE MODELS FOR 
PRION DISEASE TREATMENT  
Total: $12,384,078  
 $4,792,766 | 2005 | Prusiner, Stanley B | UNIVERSITY OF CALIFORNIA SAN 
FRANCISCO | SAN FRANCISCO, CA  
 $4,778,184 | 2004 | Prusiner, Stanley B | UNIVERSITY OF CALIFORNIA SAN 
FRANCISCO | SAN FRANCISCO, CA  
 $2,813,128 | 2003 | Prusiner, Stanley B | UNIVERSITY OF CALIFORNIA SAN 
FRANCISCO | SAN FRANCISCO, CA  
35 10 
1Z01AI000265-
19 RACE, RICHARD 




20 RACE, RICHARD 




21 RACE, RICHARD 




01 RIEK, ROLAND 
Structural Investigations of the Prion 
Protein het-s  
Total: $936,654  
 $312,218 | 2005 | Riek, Roland P | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
 $312,218 | 2004 | Riek, Roland P | SALK INSTITUTE FOR BIOLOGICAL 





 $312,218 | 2003 | Riek, Roland P | SALK INSTITUTE FOR BIOLOGICAL 
STUDIES | LA JOLLA, CA  
39 10 
1R01NS044209-
01A2 SINGH, NEENA 
PrP-scrapie transport across intestinal 
& BBB  
Total: $267,750  
 $267,750 | 2004 | Singh, Neena | CASE WESTERN RESERVE UNIVERSITY | 
CLEVELAND, OH  
40 10 
1R01NS049173-
01A1 SOTO, CLAUDIO 
Cyclic Amplification of Prion Protein 
Misfolding  
Total: $304,834  
 $304,834 | 2005 | Soto, Claudio A | UNIVERSITY OF TEXAS MEDICAL BR 






A NOVEL TOPOLOGICAL FORM OF PRP 
IN PRION DISEASE  
Total: $83,708  
 $46,192 | 2002 | Stewart, Richard S | VIRRX, INC. | ST. LOUIS, MO  
 $37,516 | 2000 | STEWART, RICHARD S | WASHINGTON UNIVERSITY | ST. 
LOUIS, MO  
42 10 
1R01NS045981-
01 SY, MAN-SUN 
Intercellular transfer of prion in prion 
disease  
Total: $1,079,895  
 $370,656 | 2005 | Sy, Mansun M | CASE WESTERN RESERVE UNIVERSITY | 
CLEVELAND, OH  
 $359,859 | 2004 | Sy, Mansun M | CASE WESTERN RESERVE UNIVERSITY | 
CLEVELAND, OH  
 $349,380 | 2003 | Sy, Mansun M | CASE WESTERN RESERVE UNIVERSITY | 
CLEVELAND, OH  
 
Brucella melitensis (strains abortus, melitensis, suis) 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Alphaproteobacteria, Order 
Rhizobiales, Family Brucellaceae. 
Publications: 
1. Baloglu, S., T. E. Toth, G. G. Schurig, N. Sriranganathan, and S. M. Boyle. 2000. 
Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing 
Brucella abortus GroEL does not correlate with protection against a B. abortus challenge. 
Vet Microbiol 76:193-9. 
 This paper reports the evaluation of a vaccine candidate. 
2. Bricker, B. J. 2000. Characterization of the three ribosomal RNA operons rrnA, rrnB, 





 This paper reports the characterization of three gene clusters of the bacterium. 
3. Bricker, B. J., D. R. Ewalt, A. P. MacMillan, G. Foster, and S. Brew. 2000. Molecular 
characterization of Brucella strains isolated from marine mammals. J Clin Microbiol 
38:1258-62. 
 This paper reports the characterization of new strains of the bacterium. 
4. Capsel, R. L., S. C. Olsen, N. F. Cheville, and C. O. Thoen. 2000. Survival of Brucella 
abortus strain RB51 lyophilized and as liquid vaccine under different storage conditions. 
Biologicals 28:209-15. 
 This paper reports the evaluation of different storage conditions for freeze-dried brucella 
vaccine. 
5. Cook, W. E., E. S. Williams, E. T. Thorne, T. J. Kreeger, G. W. Stout, G. Schurig, L. 
A. Colby, F. Enright, and P. H. Elzer. 2000. Safety of Brucella abortus strain RB51 in 
bull elk. J Wildl Dis 36:484-8. 
 This paper reports the evaluation of a vaccine candidate. 
6. Edmonds, M., N. Booth, S. Hagius, J. Walker, F. Enright, R. M. Roop, 2nd, and P. 
Elzer. 2000. Attenuation and immunogenicity of a Brucella abortus htrA cycL double 
mutant in cattle. Vet Microbiol 76:81-90. 
 This paper reports the evaluation of a vaccine candidate. 
7. Ewalt, D. R., and B. J. Bricker. 2000. Validation of the abbreviated Brucella AMOS 
PCR as a rapid screening method for differentiation of Brucella abortus field strain 
isolates and the vaccine strains, 19 and RB51. J Clin Microbiol 38:3085-6. 
 This paper reports the evaluation of a PCR-based diagnostic assay. 
8. Eze, M. O., L. Yuan, R. M. Crawford, C. M. Paranavitana, T. L. Hadfield, A. K. 
Bhattacharjee, R. L. Warren, and D. L. Hoover. 2000. Effects of opsonization and 
gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal 
macrophages in vitro. Infect Immun 68:257-63. 
 This paper reports the effects of a cytokine and the immune reponse on growth of the 
bacterium in macrophages. 
9. Forbes, L. B., O. Nielsen, L. Measures, and D. R. Ewalt. 2000. Brucellosis in ringed 
seals and harp seals from Canada. lforbes@em.agr.ca. J Wildl Dis 36:595-8. 
 This paper reports the isolation and characterization of strains of the bacterium. 
10. Gall, D., K. Nielsen, L. Forbes, D. Davis, P. Elzer, S. Olsen, S. Balsevicius, L. Kelly, 
P. Smith, S. Tan, and D. Joly. 2000. Validation of the fluorescence polarization assay 
and comparison to other serological assays for the detection of serum antibodies to 
Brucella abortus in bison. J Wildl Dis 36:469-76. 
 This paper reports the evaluation of a diagnostic system. 
11. Gidlewski, T., N. F. Cheville, J. C. Rhyan, L. D. Miller, and M. J. Gilsdorf. 2000. 
Experimental Brucella abortus induced abortion in a llama: pathologic effects. Vet Pathol 
37:77-82. 
 This paper reports the pathology of llama abortion due to the bacterium. 
12. Hong, P. C., R. M. Tsolis, and T. A. Ficht. 2000. Identification of genes required for 
chronic persistence of Brucella abortus in mice. Infect Immun 68:4102-7. 






13. Hornsby, R. L., A. E. Jensen, S. C. Olsen, and C. O. Thoen. 2000. Selective media for 
isolation of Brucella abortus strain RB51. Vet Microbiol 73:51-60. 
 This paper reports the development of special media for the isolation of a strain of the 
bacterium. 
14. Izadjoo, M. J., Y. Polotsky, M. G. Mense, A. K. Bhattacharjee, C. M. Paranavitana, 
T. L. Hadfield, and D. L. Hoover. 2000. Impaired control of Brucella melitensis 
infection in Rag1-deficient mice. Infect Immun 68:5314-20. 
 This paper reports the effects of a gene knock-out in mice on infection with the bacterium. 
15. Kim, J. A., and J. Mayfield. 2000. Identification of Brucella abortus OxyR and its role in 
control of catalase expression. J Bacteriol 182:5631-3. 
 This paper reports the identification of a protein of the bacterium. 
16. Kim, J. A., Z. Sha, and J. E. Mayfield. 2000. Regulation of Brucella abortus catalase. 
Infect Immun 68:3861-6. 
 This paper reports specifics of the regulation of an enzyme of the bacterium. 
17. Ko, J., and G. A. Splitter. 2000. Brucella abortus tandem repeated ATP-binding 
proteins, BapA and BapB, homologs of haemophilus influenzae LktB, are not necessary 
for intracellular survival. Microb Pathog 29:245-53. 
 This paper reports that two proteins of the bacterium are not necessary for its intracellular 
survival. 
18. Ko, J., and G. A. Splitter. 2000. Residual virulence of Brucella abortus in the absence of 
the cytochrome bc(1)complex in a murine model in vitro and in vivo. Microb Pathog 
29:191-200. 
 This paper reports the effect of deletion of a protein complex on virulence of the 
bacterium. 
19. Kreeger, T. J., M. W. Miller, M. A. Wild, P. H. Elzer, and S. C. Olsen. 2000. Safety 
and efficacy of Brucella abortus strain RB51 vaccine in captive pregnant elk. J Wildl Dis 
36:477-83. 
 This paper reports the evaluation of a vaccine candidate. 
20. LeVier, K., R. W. Phillips, V. K. Grippe, R. M. Roop, 2nd, and G. C. Walker. 2000. 
Similar requirements of a plant symbiont and a mammalian pathogen for prolonged 
intracellular survival. Science 287:2492-3. 
 This paper reports the identification of factors necessary for intracellular survival of the 
bacterium. 
21. Olsen, S. C. 2000. Responses of adult cattle to vaccination with a reduced dose of 
Brucella abortus strain RB51. Res Vet Sci 69:135-40. 
 This paper reports the evaluation of a vaccine candidate. 
22. Onate, A., E. Andrews, A. Beltran, G. Eller, G. Schurig, and H. Folch. 2000. Frequent 
exposure of mice to crude Brucella abortus proteins down-regulates immune response. J 
Vet Med B Infect Dis Vet Public Health 47:677-82. 
 This paper reports the effect of proteins of the bacterium on the immune system of mice. 
23. Robertson, G. T., M. E. Kovach, C. A. Allen, T. A. Ficht, and R. M. Roop, 2nd. 2000. 
The Brucella abortus Lon functions as a generalized stress response protease and is 
required for wild-type virulence in BALB/c mice. Mol Microbiol 35:577-88. 





24. Robertson, G. T., A. Reisenauer, R. Wright, R. B. Jensen, A. Jensen, L. Shapiro, and 
R. M. Roop, 2nd. 2000. The Brucella abortus CcrM DNA methyltransferase is essential 
for viability, and its overexpression attenuates intracellular replication in murine 
macrophages. J Bacteriol 182:3482-9. 
 This paper reports the identification of an important DNA-modifying enzyme that is 
essential for the viability of the bacterium. 
25. Samartino, L. E., M. Fort, R. Gregoret, and G. G. Schurig. 2000. Use of Brucella 
abortus vaccine strain RB51 in pregnant cows after calfhood vaccination with strain 19 in 
Argentina. Prev Vet Med 45:193-9. 
 This paper reports the evaluation of a vaccine candidate. 
26. Sathiyaseelan, J., X. Jiang, and C. L. Baldwin. 2000. Growth of Brucella abortus in 
macrophages from resistant and susceptible mouse strains. Clin Exp Immunol 121:289-
94. 
 This paper reports the characterization of growth of the bacterium in macrophages from 
different mouse strains. 
27. Soberon-Mobarak, A., E. Diaz-Aparicio, J. Torres-Armenta, L. G. Adams, and F. 
Suarez-Guemes. 2000. Absence of shedding of two B. abortus strains in goats after 
vaccination with live vaccines. Vaccine 18:3018-20. 
 This paper reports the evaluation of vaccine candidates. 
28. Sreevatsan, S., J. B. Bookout, F. Ringpis, V. S. Perumaalla, T. A. Ficht, L. G. Adams, 
S. D. Hagius, P. H. Elzer, B. J. Bricker, G. K. Kumar, M. Rajasekhar, S. Isloor, and 
R. R. Barathur. 2000. A multiplex approach to molecular detection of Brucella abortus 
and/or Mycobacterium bovis infection in cattle. J Clin Microbiol 38:2602-10. 
 This paper reports the development of a PCR-based diagnostic system. 
29. Uza, F. A., L. Samartino, G. Schurig, A. Carrasco, K. Nielsen, R. F. Cabrera, and H. 
R. Taddeo. 2000. Effect of vaccination with Brucella abortus strain RB51 on heifers and 
pregnant cattle. Vet Res Commun 24:143-51. 
 This paper reports the evaluation of a vaccine candidate. 
30. Vemulapalli, R., S. Cravero, C. L. Calvert, T. E. Toth, N. Sriranganathan, S. M. 
Boyle, O. L. Rossetti, and G. G. Schurig. 2000. Characterization of specific immune 
responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton 
outer membrane protein of Brucella abortus. Clin Diagn Lab Immunol 7:114-8. 
 This paper reports the evaluation of a vaccine candidate. 
31. Vemulapalli, R., Y. He, S. M. Boyle, N. Sriranganathan, and G. G. Schurig. 2000. 
Brucella abortus strain RB51 as a vector for heterologous protein expression and 
induction of specific Th1 type immune responses. Infect Immun 68:3290-6. 
 This paper reports the evaluation of a vaccine candidate. 
32. Vemulapalli, R., Y. He, L. S. Buccolo, S. M. Boyle, N. Sriranganathan, and G. G. 
Schurig. 2000. Complementation of Brucella abortus RB51 with a functional wboA gene 
results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough 
phenotype and attenuation. Infect Immun 68:3927-32. 





33. Vemulapalli, R., Y. He, S. Cravero, N. Sriranganathan, S. M. Boyle, and G. G. 
Schurig. 2000. Overexpression of protective antigen as a novel approach to enhance 
vaccine efficacy of Brucella abortus strain RB51. Infect Immun 68:3286-9. 
 This paper reports the evaluation of a vaccine candidate. 
34. Adone, R., F. Ciuchini, and S. Olsen. 2001. Field validation of the use of RB51 as 
antigen in a complement fixation test to identify calves vaccinated with Brucella abortus 
RB51. Clin Diagn Lab Immunol 8:385-7. 
 This paper reports the evaluation of a diagnostic system. 
35. Barthel, R., J. Feng, J. A. Piedrahita, D. N. McMurray, J. W. Templeton, and L. G. 
Adams. 2001. Stable transfection of the bovine NRAMP1 gene into murine RAW264.7 
cells: effect on Brucella abortus survival. Infect Immun 69:3110-9. 
 This paper reports a bovine protein as a protective factor against infection with the 
bacterium. 
36. Edmonds, M. D., L. E. Samartino, P. G. Hoyt, S. D. Hagius, J. V. Walker, F. M. 
Enright, G. G. Schurig, and P. Elzer. 2001. Oral vaccination of sexually mature pigs 
with Brucella abortus vaccine strain RB51. Am J Vet Res 62:1328-31. 
 This paper reports the evaluation of a vaccine candidate. 
37. Endley, S., D. McMurray, and T. A. Ficht. 2001. Interruption of the cydB locus in 
Brucella abortus attenuates intracellular survival and virulence in the mouse model of 
infection. J Bacteriol 183:2454-62. 
 This paper reports the identification of a protein that is important for intracellular survival 
of the bacterium and its virulence. 
38. Fernandez-Prada, C. M., M. Nikolich, R. Vemulapalli, N. Sriranganathan, S. M. 
Boyle, G. G. Schurig, T. L. Hadfield, and D. L. Hoover. 2001. Deletion of wboA 
enhances activation of the lectin pathway of complement in Brucella abortus and Brucella 
melitensis. Infect Immun 69:4407-16. 
 This paper reports the importance of a protein of the bacterium for one of its metabolic 
pathways. 
39. Gilsdorf, M. J., C. O. Thoen, R. M. Temple, T. Gidlewski, D. Ewalt, B. Martin, and 
S. B. Henneger. 2001. Experimental exposure of llamas (Lama glama) to Brucella 
abortus: humoral antibody response. Vet Microbiol 81:85-91. 
 This paper reports the antibody response of llamas to infection with the bacterium. 
40. He, Y., R. Vemulapalli, A. Zeytun, and G. G. Schurig. 2001. Induction of specific 
cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infect Immun 
69:5502-8. 
 This paper reports the evaluation of a vaccine candidate. 
41. Lee, I. K., S. C. Olsen, and C. A. Bolin. 2001. Effects of exogenous recombinant 
interleukin-12 on immune responses and protection against Brucella abortus in a murine 
model. Can J Vet Res 65:223-8. 
 This paper reports the evaluation of a treatment regimen. 
42. Mense, M. G., L. L. Van De Verg, A. K. Bhattacharjee, J. L. Garrett, J. A. Hart, L. 
E. Lindler, T. L. Hadfield, and D. L. Hoover. 2001. Bacteriologic and histologic 






 This paper reports the pathology of mice after infection with the bacterium. 
43. Murphy, E. A., M. Parent, J. Sathiyaseelan, X. Jiang, and C. L. Baldwin. 2001. 
Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol 
Med Microbiol 32:85-8. 
 This paper reports the immune response of a mouse strain to a strain of the bacterium. 
44. Redkar, R., S. Rose, B. Bricker, and V. DelVecchio. 2001. Real-time detection of 
Brucella abortus, Brucella melitensis and Brucella suis. Mol Cell Probes 15:43-52. 
 This paper reports the development of a PCR-based diagnostic system. 
45. Rhyan, J. C., T. Gidlewski, T. J. Roffe, K. Aune, L. M. Philo, and D. R. Ewalt. 2001. 
Pathology of brucellosis in bison from Yellowstone National Park. J Wildl Dis 37:101-9. 
 This paper reports the pathology of bison after infection with the bacterium. 
46. Roop, R. M., 2nd, R. W. Phillips, S. Hagius, J. V. Walker, N. J. Booth, W. T. Fulton, 
M. D. Edmonds, and P. H. Elzer. 2001. Re-examination of the role of the Brucella 
melitensis HtrA stress response protease in virulence in pregnant goats. Vet Microbiol 
82:91-5.  
 This paper reports the evaluation of the important of a protein for virulence of the 
bacterium in goats. 
47. Scharf, O., I. Agranovich, K. Lee, N. L. Eller, L. Levy, J. Inman, D. E. Scott, and B. 
Golding. 2001. Ontogeny of Th1 memory responses against a Brucella abortus conjugate. 
Infect Immun 69:5417-22. 
 This paper reports the evaluation of a vaccine candidate. 
48. Zhou, H., A. J. Buitenhuis, S. Weigend, and S. J. Lamont. 2001. Candidate gene 
promoter polymorphisms and antibody response kinetics in chickens: interferon-gamma, 
interleukin-2, and immunoglobulin light chain. Poult Sci 80:1679-89. 
 This paper reports the immune response of chickens to infection with the bacterium. 
49. Bae, J. E., G. G. Schurig, and T. E. Toth. 2002. Mice immune responses to Brucella 
abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect 
cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as 
immunogens. Vet Microbiol 88:189-202. 
 This paper reports the evaluation of a vaccine candidate. 
50. Baldwin, C. L., and M. Parent. 2002. Fundamentals of host immune response against 
Brucella abortus: what the mouse model has revealed about control of infection. Vet 
Microbiol 90:367-82. 
 This paper reports the characteristics of the immune response of mice to infection with the 
bacterium. 
51. Bardenstein, S., M. Mandelboim, T. A. Ficht, M. Baum, and M. Banai. 2002. 
Identification of the Brucella melitensis vaccine strain Rev.1 in animals and humans in 
Israel by PCR analysis of the PstI site polymorphism of its omp2 gene. J Clin Microbiol 
40:1475-80. 
 This paper reports the identification of a strain of the bacterium with a PCR-based 
diagnostic system. 
52. Bhattacharjee, A. K., L. Van de Verg, M. J. Izadjoo, L. Yuan, T. L. Hadfield, W. D. 





immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with 
Neisseria meningitidis group B outer membrane protein. Infect Immun 70:3324-9. 
 This paper reports the evaluation of a vaccine candidate.  
53. Chirgwin, S. R., P. H. Elzer, S. U. Coleman, J. M. Nowling, S. D. Hagius, M. D. 
Edmonds, and T. R. Klei. 2002. Infection outcome and cytokine gene expression in 
Brugia pahangi- infected gerbils (Meriones unguiculatus) sensitized with Brucella 
abortus. Infect Immun 70:5938-45. 
 This paper reports the cytokine response of filarial-infected gerbils sensitized with the 
bacterium. 
54. Colby, L. A., G. G. Schurig, and P. H. Elzer. 2002. An indirect ELISA to detect the 
serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain 
RB51. J Wildl Dis 38:752-9. 
 This paper reports a detection method. 
55. Cook, W. E., E. S. Williams, E. T. Thorne, T. J. Kreeger, G. Stout, K. Bardsley, H. 
Edwards, G. Schurig, L. A. Colby, F. Enright, and P. H. Elzer. 2002. Brucella abortus 
strain RB51 vaccination in elk. I. Efficacy of reduced dosage. J Wildl Dis 38:18-26. 
 This paper reports the evaluation of a vaccine candidate. 
56. DelVecchio, V. G., V. Kapatral, R. J. Redkar, G. Patra, C. Mujer, T. Los, N. 
Ivanova, I. Anderson, A. Bhattacharyya, A. Lykidis, G. Reznik, L. Jablonski, N. 
Larsen, M. D'Souza, A. Bernal, M. Mazur, E. Goltsman, E. Selkov, P. H. Elzer, S. 
Hagius, D. O'Callaghan, J. J. Letesson, R. Haselkorn, N. Kyrpides, and R. Overbeek. 
2002. The genome sequence of the facultative intracellular pathogen Brucella melitensis. 
Proc Natl Acad Sci U S A 99:443-8. 
 This paper reports the genomic sequence of the bacterium. 
57. Edmonds, M. D., A. Cloeckaert, and P. H. Elzer. 2002. Brucella species lacking the 
major outer membrane protein Omp25 are attenuated in mice and protect against Brucella 
melitensis and Brucella ovis. Vet Microbiol 88:205-21. 
 This paper reports the evaluation of a vaccine candidate. 
58. Edmonds, M. D., A. Cloeckaert, S. D. Hagius, L. E. Samartino, W. T. Fulton, J. V. 
Walker, F. M. Enright, N. J. Booth, and P. H. Elzer. 2002. Pathogenicity and 
protective activity in pregnant goats of a Brucella melitensis Deltaomp25 deletion mutant. 
Res Vet Sci 72:235-9. 
 This paper reports the evaluation of a vaccine candidate. 
59. Elzer, P. H., S. D. Hagius, D. S. Davis, V. G. DelVecchio, and F. M. Enright. 2002. 
Characterization of the caprine model for ruminant brucellosis. Vet Microbiol 90:425-31. 
 This paper reports a goat model for brucellosis. 
60. Eschenbrenner, M., M. A. Wagner, T. A. Horn, J. A. Kraycer, C. V. Mujer, S. 
Hagius, P. Elzer, and V. G. DelVecchio. 2002. Comparative proteome analysis of 
Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16M. J Bacteriol 184:4962-
70. 
 This paper reports the proteomes of different strains of the bacterium. 
61. He, Y., R. Vemulapalli, and G. G. Schurig. 2002. Recombinant Ochrobactrum anthropi 





infection only after switching of immune responses to Th1 type. Infect Immun 70:2535-
43. 
 This paper reports the evaluation of a vaccine candidate. 
62. Ko, J., A. Gendron-Fitzpatrick, T. A. Ficht, and G. A. Splitter. 2002. Virulence 
criteria for Brucella abortus strains as determined by interferon regulatory factor 1-
deficient mice. Infect Immun 70:7004-12. 
 This paper reports specifics of the immune response to the bacterium. 
63. Ko, J., A. Gendron-Fitzpatrick, and G. A. Splitter. 2002. Susceptibility of IFN 
regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to 
brucellosis. J Immunol 168:2433-40. 
 This paper reports specifics of the immune response to the bacterium. 
64. Kreeger, T. J., W. E. Cook, W. H. Edwards, P. H. Elzer, and S. C. Olsen. 2002. 
Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent 
abortion. J Wildl Dis 38:27-31. 
 This paper reports the evaluation of a vaccine candidate. 
65. Kreeger, T. J., T. J. DeLiberto, S. C. Olsen, W. H. Edwards, and W. E. Cook. 2002. 
Safety of Brucella abortus strain RB51 vaccine in non-target ungulates and coyotes. J 
Wildl Dis 38:552-7. 
 This paper reports the evaluation of a vaccine candidate. 
66. Mujer, C. V., M. A. Wagner, M. Eschenbrenner, T. Horn, J. A. Kraycer, R. Redkar, 
S. Hagius, P. Elzer, and V. G. Delvecchio. 2002. Global analysis of Brucella melitensis 
proteomes. Ann N Y Acad Sci 969:97-101. 
 This paper reports proteomes of strains of the bacterium. 
67. Murphy, E., G. T. Robertson, M. Parent, S. D. Hagius, R. M. Roop, 2nd, P. H. Elzer, 
and C. L. Baldwin. 2002. Major histocompatibility complex class I and II expression on 
macrophages containing a virulent strain of Brucella abortus measured using green 
fluorescent protein-expressing brucellae and flow cytometry. FEMS Immunol Med 
Microbiol 33:191-200. 
 This paper reports the immunological response of macrophages to infection with the 
bacterium. 
68. Olsen, S. C., T. J. Kreeger, and M. V. Palmer. 2002. Immune responses of elk to 
vaccination with Brucella abortus strain RB51. J Wildl Dis 38:746-51. 
 This paper reports the evaluation of a vaccine candidate. 
69. Olsen, S. C., T. J. Kreeger, and W. Schultz. 2002. Immune responses of bison to 
ballistic or hand vaccination with Brucella abortus strain RB51. J Wildl Dis 38:738-45. 
 This paper reports the evaluation of a vaccine candidate. 
70. Parent, M. A., B. H. Bellaire, E. A. Murphy, R. M. Roop, 2nd, P. H. Elzer, and C. L. 
Baldwin. 2002. Brucella abortus siderophore 2,3-dihydroxybenzoic acid (DHBA) 
facilitates intracellular survival of the bacteria. Microb Pathog 32:239-48. 
 This paper reports the identification of a virulence factor of the bacterium. 
71. Pasquali, P., R. Adone, L. C. Gasbarre, C. Pistoia, and F. Ciuchini. 2002. Effect of 
exogenous interleukin-18 (IL-18) and IL-12 in the course of Brucella abortus 2308 
infection in mice. Clin Diagn Lab Immunol 9:491-2. 





72. Rosinha, G. M., D. A. Freitas, A. Miyoshi, V. Azevedo, E. Campos, S. L. Cravero, O. 
Rossetti, G. Splitter, and S. C. Oliveira. 2002. Identification and characterization of a 
Brucella abortus ATP-binding cassette transporter homolog to Rhizobium meliloti ExsA 
and its role in virulence and protection in mice. Infect Immun 70:5036-44. 
 This paper reports the characterization of a virulence factor of the bacterium. 
73. Sun, Y. H., A. B. den Hartigh, R. L. Santos, L. G. Adams, and R. M. Tsolis. 2002. 
virB-Mediated survival of Brucella abortus in mice and macrophages is independent of a 
functional inducible nitric oxide synthase or NADPH oxidase in macrophages. Infect 
Immun 70:4826-32. 
 This paper reports characteristics of the intracellular survival of the bacterium. 
74. Wagner, M. A., M. Eschenbrenner, T. A. Horn, J. A. Kraycer, C. V. Mujer, S. 
Hagius, P. Elzer, and V. G. DelVecchio. 2002. Global analysis of the Brucella 
melitensis proteome: Identification of proteins expressed in laboratory-grown culture. 
Proteomics 2:1047-60. 
 This paper reports the analysis of the proteome of the bacterium. 
75. Yokum, T. S., R. P. Hammer, M. L. McLaughlin, and P. H. Elzer. 2002. Peptides with 
indirect in vivo activity against an intracellular pathogen: selective lysis of infected 
macrophages. J Pept Res 59:9-17. 
 This paper reports the development of a potential inhibitor. 
76. Bellaire, B. H., P. H. Elzer, C. L. Baldwin, and R. M. Roop, 2nd. 2003. Production of 
the siderophore 2,3-dihydroxybenzoic acid is required for wild-type growth of Brucella 
abortus in the presence of erythritol under low-iron conditions in vitro. Infect Immun 
71:2927-832. 
 This paper reports the production of a virulence factor of the bacterium. 
77. Bellaire, B. H., P. H. Elzer, S. Hagius, J. Walker, C. L. Baldwin, and R. M. Roop, 
2nd. 2003. Genetic organization and iron-responsive regulation of the Brucella abortus 
2,3-dihydroxybenzoic acid biosynthesis operon, a cluster of genes required for wild-type 
virulence in pregnant cattle. Infect Immun 71:1794-803. 
 This paper reports the regulation of the production of a virulence factor of the bacterium. 
78. Bricker, B. J., D. R. Ewalt, and S. M. Halling. 2003. Brucella 'HOOF-Prints': strain 
typing by multi-locus analysis of variable number tandem repeats (VNTRs). BMC 
Microbiol 3:15. 
 This paper reports a method to differentiate strains of the bacterium. 
79. Bricker, B. J., D. R. Ewalt, S. C. Olsen, and A. E. Jensen. 2003. Evaluation of the 
Brucella abortus species-specific polymerase chain reaction assay, an improved version of 
the Brucella AMOS polymerase chain reaction assay for cattle. J Vet Diagn Invest 
15:374-8. 
 This paper reports the evaluation of a detection system. 
80. Contreras-Rodriguez, A., B. Ramirez-Zavala, A. Contreras, G. G. Schurig, N. 
Sriranganathan, and A. Lopez-Merino. 2003. Purification and characterization of an 
immunogenic aminopeptidase of Brucella melitensis. Infect Immun 71:5238-44. 
 This paper reports the isolation and characterization of an immunogen of the bacterium. 
81. Eskra, L., A. Mathison, and G. Splitter. 2003. Microarray analysis of mRNA levels 





 This paper reports the transcriptional response of macrophages to infection with the 
bacterium. 
82. Fernandez-Prada, C. M., E. B. Zelazowska, M. Nikolich, T. L. Hadfield, R. M. Roop, 
2nd, G. L. Robertson, and D. L. Hoover. 2003. Interactions between Brucella melitensis 
and human phagocytes: bacterial surface O-Polysaccharide inhibits phagocytosis, 
bacterial killing, and subsequent host cell apoptosis. Infect Immun 71:2110-9. 
 This paper reports the identification of a virulence factor of the bacterium. 
83. Fosgate, G. T., A. A. Adesiyun, D. W. Hird, W. O. Johnson, S. K. Hietala, G. G. 
Schurig, J. Ryan, and M. D. Diptee. 2003. Evaluation of brucellosis RB51 vaccine for 
domestic water buffalo (Bubalus bubalis) in Trinidad. Prev Vet Med 58:211-25. 
 This paper reports the evaluation of a vaccine candidate. 
84. Olsen, S. C., and S. D. Holland. 2003. Safety of revaccination of pregnant bison with 
Brucella abortus strain RB51. J Wildl Dis 39:824-9. 
 This paper reports the evaluation of a vaccine candidate. 
85. Olsen, S. C., A. E. Jensen, W. C. Stoffregen, and M. V. Palmer. 2003. Efficacy of 
calfhood vaccination with Brucella abortus strain RB51 in protecting bison against 
brucellosis. Res Vet Sci 74:17-22. 
 This paper reports the evaluation of a vaccine candidate. 
86. Pasnik, D. J., R. Vemulapalli, S. A. Smith, and G. G. Schurig. 2003. A recombinant 
vaccine expressing a mammalian Mycobacterium sp. antigen is immunostimulatory but 
not protective in striped bass. Vet Immunol Immunopathol 95:43-52. 
 This paper reports the development of a mycobacterium vaccine based on the bacterium. 
87. Alcantara, R. B., R. D. Read, M. W. Valderas, T. D. Brown, and R. M. Roop, 2nd. 
2004. Intact purine biosynthesis pathways are required for wild-type virulence of Brucella 
abortus 2308 in the BALB/c mouse model. Infect Immun 72:4911-7. 
 This paper reports a metabolic pathway of the bacterium that is important for virulence. 
88. Campos, M. A., G. M. Rosinha, I. C. Almeida, X. S. Salgueiro, B. W. Jarvis, G. A. 
Splitter, N. Qureshi, O. Bruna-Romero, R. T. Gazzinelli, and S. C. Oliveira. 2004. 
Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to 
Brucella abortus infection in mice. Infect Immun 72:176-86. 
 This paper reports specifics on the response of the innate immune system to infection with 
the bacterium. 
89. Canavessi, A. M., J. Harms, N. de Leon Gatti, and G. A. Splitter. 2004. The role of 
integrase/recombinase xerD and monofunctional biosynthesis peptidoglycan 
transglycosylase genes in the pathogenicity of Brucella abortus infection in vitro and in 
vivo. Microb Pathog 37:241-51. 
 This paper reports specifics of the peptidoglycan synthesis of the bacterium. 
90. den Hartigh, A. B., Y. H. Sun, D. Sondervan, N. Heuvelmans, M. O. Reinders, T. A. 
Ficht, and R. M. Tsolis. 2004. Differential requirements for VirB1 and VirB2 during 
Brucella abortus infection. Infect Immun 72:5143-9. 
 This paper reports the role of virulence factors of the bacterium. 
91. Ferguson, G. P., A. Datta, J. Baumgartner, R. M. Roop, 2nd, R. W. Carlson, and G. 





Sinorhizobium and Brucella BacA affect lipid-A fatty acids. Proc Natl Acad Sci U S A 
101:5012-7. 
 This paper reports the similarity of a virulence factor of the bacterium to that of a related 
bacterium. 
92. Gee, J. E., B. K. De, P. N. Levett, A. M. Whitney, R. T. Novak, and T. Popovic. 2004. 
Use of 16S rRNA gene sequencing for rapid confirmatory identification of Brucella 
isolates. J Clin Microbiol 42:3649-54. 
 This paper reports a detection method. 
93. Izadjoo, M. J., A. K. Bhattacharjee, C. M. Paranavitana, T. L. Hadfield, and D. L. 
Hoover. 2004. Oral vaccination with Brucella melitensis WR201 protects mice against 
intranasal challenge with virulent Brucella melitensis 16M. Infect Immun 72:4031-9. 
 This paper reports the evaluation of a vaccine candidate. 
94. Olsen, S. C., J. Rhyan, T. Gidlewski, J. Goff, and W. C. Stoffregen. 2004. Safety of 
Brucella abortus strain RB51 in black bears. J Wildl Dis 40:429-33. 
 This paper reports the evaluation of a vaccine candidate. 
95. Pei, J., and T. A. Ficht. 2004. Brucella abortus rough mutants are cytopathic for 
macrophages in culture. Infect Immun 72:440-50. 
 This paper reports the effect of certain strains of the bacterium on cultured macrophages. 
96. Probert, W. S., K. N. Schrader, N. Y. Khuong, S. L. Bystrom, and M. H. Graves. 
2004. Real-time multiplex PCR assay for detection of Brucella spp., B. abortus, and B. 
melitensis. J Clin Microbiol 42:1290-3. 
 This paper reports the evaluation of a detection system. 
97. Rajashekara, G., J. D. Glasner, D. A. Glover, and G. A. Splitter. 2004. Comparative 
whole-genome hybridization reveals genomic islands in Brucella species. J Bacteriol 
186:5040-51. 
 This paper reports the sequence comparison of genomes of strains of the bacterium. 
98. Covert, J., L. Eskra, and G. Splitter. 2005. Isolation of Brucella abortus total RNA 
from B. abortus-infected murine RAW macrophages. J Microbiol Methods 60:383-93. 






01 ENNIS, D 
ANALYSIS OF DNA REPAIR AND SOS 
REGULATION IN BRUCELLA  
Total: $117,628  
 $117,628 | 2000 | ENNIS, D G | UNIVERSITY OF LOUISIANA AT LAFAYETTE 






Development of Novel Brucella Vaccine 
Candidates  











Improved Brucella Vaccine Strains  
Total: $1,222,200 *  
 $363,750 | 2005 | Ficht, Thomas A | TEXAS AGRICULTURAL EXPERIMENT 
STATION | COLLEGE STATION, TX  
 $291,000 | 2003 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 
COLLEGE STATION, TX  
 $276,450 | 2002 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 
COLLEGE STATION, TX  
 $291,000 | 2001 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 






Subversion of innate immune responses 
by Brucella  
5 100 
1R21AI057875-
01 HE, YONGQUN 
GENE EXPRESSION IN BRUCELLA-
INFECTED MACROPHAGES  
Total: $601,167  
 $301,167 | 2005 | He, Yongqun | VIRGINIA POLYTECHNIC INST AND ST 
UNIV | BLACKSBURG, VA  
 $300,000 | 2004 | He, Yongqun | VIRGINIA POLYTECHNIC INST AND ST 
UNIV | BLACKSBURG, VA  
6 100 
1R21AI057952-
01A1 HIGH, KEVIN 
Brucella, Aging and Role of IL-17 in Host 
Defense  
Total: $530,855  
 $259,430 | 2005 | High, Kevin P | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
 $271,425 | 2004 | High, Kevin P | ION TECHNOLOGIES, INC. | WINSTON-






BRUCELLA VACCINE FOR 
BIOTERRORISM  
Total: $1,277,000  
 $288,000 | 2003 | Splitter, Gary A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $288,000 | 2002 | Splitter, Gary A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $413,000 | 2001 | Splitter, Gary A | UNIVERSITY OF WISCONSIN MADISON 
| MADISON, WI  
 $288,000 | 2000 | SPLITTER, GARY A | UNIVERSITY OF WISCONSIN 






Brucella Vaccine for Bioterrorism  
Total: $285,052  
 $285,052 | 2004 | Splitter, Gary A | UNIVERSITY OF WISCONSIN MADISON 






Brucella abortus alters trafficking in 





Total: $95,348  
 $48,928 | 2004 | Bellaire, Bryan H | LOUISIANA STATE UNIV HSC 
SHREVEPORT | SHREVEPORT, LA  
 $46,420 | 2003 | Bellaire, Bryan H | LOUISIANA STATE UNIV HSC 






Virulence regulation in Brucella by LuxR 
quorum sensor  
Total: $78,640  
 $39,722 | 2004 | Garcia, Daniel L | UNIVERSITY OF WISCONSIN MADISON | 
MADISON, WI  
 $38,918 | 2003 | Garcia, Daniel L | UNIVERSITY OF WISCONSIN MADISON | 
MADISON, WI  
11 73 
1R21AI055964-
01 ENNIS, DON 
Attenuation of Brucella Using Dominant 
Repair Mutants  
Total: $470,935  
 $236,163 | 2004 | Ennis, Don G | UNIVERSITY OF LOUISIANA AT 
LAFAYETTE | LAFAYETTE, LA  
 $234,772 | 2003 | Ennis, Don G | UNIVERSITY OF LOUISIANA AT 







Falgellar gene homologues in Brucella 
melitensis  
Total: $83,416  
 $43,016 | 2004 | Sotobonilla, Brenda L | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $40,400 | 2002 | Soto-Bonilla, Brenda L | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
13 58 
1R01AI048499-
01 ROOP, ROY 
BRUCELLA STATIONARY PHASE GENE 
EXPRESSION AND VIRULENCE  
Total: $1,244,197  
 $279,000 | 2003 | Roop, Roy M | EAST CAROLINA UNIVERSITY | 
GREENVILLE, NC  
 $279,000 | 2002 | Roop, Roy M | EAST CAROLINA UNIVERSITY | 
GREENVILLE, NC  
 $379,191 | 2001 | Roop, Roy M | EAST CAROLINA UNIVERSITY | 
GREENVILLE, NC  
 $1,257 | 2000 | ROOP, ROY M | LOUISIANA STATE UNIV HSC SHREVEPORT 
| SHREVEPORT, LA  
 $305,749 | 2000 | ROOP, ROY M | EAST CAROLINA UNIVERSITY | 
GREENVILLE, NC  
14 58 
2R21AI048499-
06 ROOP, ROY 
Brucella Stationary Phase Gene 
Expression and Virulence  
Total: $377,145  
 $377,145 | 2004 | Roop, Roy M | EAST CAROLINA UNIVERSITY | 






Characterization of the Brucella abortus 





Total: $1,218,500  
 $200,000 | 2004 | Tsolis, Renee M | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
 $254,625 | 2004 | Tsolis, Renee M | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
 $254,625 | 2003 | Tsolis, Renee M | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
 $254,625 | 2002 | Tsolis, Renee M | TEXAS A&M UNIVERSITY HEALTH 
SCIENCE CTR | COLLEGE STATION, TX  
 $254,625 | 2001 | Tsolis, Renee M | TEXAS A&M UNIVERSITY HEALTH 






Development and Evaluation of Human 
Brucellosis Vaccines  
Total: $27,834,107  
 $12,024,542 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $11,566,950 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $4,242,615 | 2003 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL BR 






Active and Passive Immunity Against 
Emergent Infectious  
18 44 
1Z01AI000035-
27 INMAN, JOHN 
Design And Synthesis Of 













Sensitive Diagnosis of Biowarfare 
Agents on a Microchip  
Total: $1,154,639  
 $456,719 | 2005 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 
WASHINGTON, DC  
 $455,617 | 2004 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 
WASHINGTON, DC  
 $242,303 | 2003 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY | 






Improved Brucella Vaccine Strains  
Total: $1,222,200 *  
 $363,750 | 2005 | Ficht, Thomas A | TEXAS AGRICULTURAL EXPERIMENT 
STATION | COLLEGE STATION, TX  
 $291,000 | 2003 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 
COLLEGE STATION, TX  
 $276,450 | 2002 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 
COLLEGE STATION, TX  
 $291,000 | 2001 | Ficht, Thomas A | TEXAS A&M UNIVERSITY SYSTEM | 
COLLEGE STATION, TX  
22 29 
1Z01BK003004-
08 GOLDING, H 
Evaluation of new carriers and adjuvants 







09 GOLDING, H 
Evaluation of new carriers/adjuvants for 
HIV-1 vaccines  
24 29 
1Z01BK003004-
10 GOLDING, H 
Evaluation of new carriers and adjuvants 
for HIV-1 vacci  
25 29 
1Z01AI000035-
25 INMAN, JOHN 
DESIGN AND SYNTHESIS OF 




26 INMAN, JOHN 
Design/Synthesis:Immunomodulators 
And Vaccine Constructs  
27 29 
1U01AI049036-
01 PAULSEN, IAN 
COMPLETE GENOME SEQUENCING OF 
BRUCELLA SUIS  
Total: $957,964  
 $957,964 | 2000 | PAULSEN, IAN T | INSTITUTE FOR GENOMIC RESEARCH | 






An Efficient Bacterial Vector-Based 
Tuberculosis Vaccine  
Total: $102,900  
 $102,900 | 2001 | Szumanski, Maria B | VETERINARY TECHNOLOGIES 






B.abortus-based vaccine against viral 
hemorrhagic fevers  
Total: $532,000  
 $266,000 | 2004 | Vemulapalli, Ramesh | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $266,000 | 2003 | Vemulapalli, Ramesh | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
30 15 
1R21AI063324-
01 JAFFE, EILEEN 
Hexameric PBGS as a Bioterrorism 
Defense  
Total: $338,500  
 $338,500 | 2005 | Jaffe, Eileen K | INSTITUTE FOR CANCER RESEARCH | 
PHILADELPHIA, PA  
 
Burkholderia mallei 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Betaproteobacteria, Order 






1. Fritz, D. L., P. Vogel, D. R. Brown, D. Deshazer, and D. M. Waag. 2000. Mouse 
model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei). Vet Pathol 
37:626-36. 
 This paper reports the establishment of a mouse model for glanders, and reports the 
pathology associated with the disease. 
2. Katz, J., R. Dewald, and J. Nicholson. 2000. Procedurally similar competitive 
immunoassay systems for the serodiagnosis of Babesia equi, Babesia caballi, 
Trypanosoma equiperdum, and Burkholderia mallei infection in horses. J Vet Diagn 
Invest 12:46-50. 
 This paper reports the establishment of a competitive ELISA for the serodiagnosis of 
Burkholderia mallei. 
3. DeShazer, D., D. M. Waag, D. L. Fritz, and D. E. Woods. 2001. Identification of a 
Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and 
demonstration that the encoded capsule is an essential virulence determinant. Microb 
Pathog 30:253-69. 
 This paper describes the identification of virulence factors of Burkholderia mallei. 
4. Heine, H. S., M. J. England, D. M. Waag, and W. R. Byrne. 2001. In vitro antibiotic 
susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth 
microdilution and E-test. Antimicrob Agents Chemother 45:2119-21. 
 This paper reports the antibiotic resistence profile of several strains of Burkholderia 
mallei. 
5. Amemiya, K., G. V. Bush, D. DeShazer, and D. M. Waag. 2002. Nonviable 
Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c 
mice. Infect Immun 70:2319-25. 
 This paper reports the evaluation of nonviable cell preparations of Burkholderia mallei as 
potential vaccine candidates in a BALB/c murine model (incl. heat-killed preparation, an 
irradiation-inactivated preparation, and a preparation of a capsule-negative mutant strain 
which had been irradiation inactivated).  
6. Woods, D. E., J. A. Jeddeloh, D. L. Fritz, and D. DeShazer. 2002. Burkholderia 
thailandensis E125 harbors a temperate bacteriophage specific for Burkholderia mallei. J 
Bacteriol 184:4003-17. 
 This paper reports the identification of a bacteriophage in an agent related to Burkholderia 
mallei, which can form plaques on Burkholderia mallei but not on any other bacterial 
species tested. 
7. Gee, J. E., C. T. Sacchi, M. B. Glass, B. K. De, R. S. Weyant, P. N. Levett, A. M. 
Whitney, A. R. Hoffmaster, and T. Popovic. 2003. Use of 16S rRNA gene sequencing 
for rapid identification and differentiation of Burkholderia pseudomallei and B. mallei. J 
Clin Microbiol 41:4647-54. 
This paper reports the evaluation of the use of 16S rRNA gene sequencing to rapidly 
identify these two bacterial species and differentiate them from each other as well as from 
closely related species and genera. 
8. Lopez, J., J. Copps, C. Wilhelmsen, R. Moore, J. Kubay, M. St-Jacques, S. Halayko, 
C. Kranendonk, S. Toback, D. DeShazer, D. L. Fritz, M. Tom, and D. E. Woods. 





 This paper reports the findings of horses infected with the bacterium. 
9. Moore, R. A., S. Reckseidler-Zenteno, H. Kim, W. Nierman, Y. Yu, A. Tuanyok, J. 
Warawa, D. DeShazer, and D. E. Woods. 2004. Contribution of gene loss to the 
pathogenic evolution of Burkholderia pseudomallei and Burkholderia mallei. Infect 
Immun 72:4172-87. 
 This paper reports that the ability to metabolize arabinose reduces the virulence of B. 
pseudomallei and that the genes encoding arabinose assimilation may be considered 
antivirulence genes.  
10. Nierman, W. C., D. DeShazer, H. S. Kim, H. Tettelin, K. E. Nelson, T. Feldblyum, R. 
L. Ulrich, C. M. Ronning, L. M. Brinkac, S. C. Daugherty, T. D. Davidsen, R. T. 
Deboy, G. Dimitrov, R. J. Dodson, A. S. Durkin, M. L. Gwinn, D. H. Haft, H. 
Khouri, J. F. Kolonay, R. Madupu, Y. Mohammoud, W. C. Nelson, D. Radune, C. 
M. Romero, S. Sarria, J. Selengut, C. Shamblin, S. A. Sullivan, O. White, Y. Yu, N. 
Zafar, L. Zhou, and C. M. Fraser. 2004. Structural flexibility in the Burkholderia mallei 
genome. Proc Natl Acad Sci U S A 101:14246-51. 
 This paper reports the analysis of a complete genome of the bacterium. 
11. Ulrich, R. L., and D. DeShazer. 2004. Type III secretion: a virulence factor delivery 
system essential for the pathogenicity of Burkholderia mallei. Infect Immun 72:1150-4. 
This paper reports that a functional type III secretion system is required for the full 
pathogenicity of the bacterium in the BALB/c mouse and Syrian hamster models of 
infection. 
12. Ulrich, R. L., D. Deshazer, H. B. Hines, and J. A. Jeddeloh. 2004. Quorum sensing: a 
transcriptional regulatory system involved in the pathogenicity of Burkholderia mallei. 
Infect Immun 72:6589-96. 
This paper reports that individual cells of the bacterium communicate via quorum sensing, 
and that the bacterium carries multiple luxIR homologues that either directly or indirectly 
regulate the biosynthesis of an essential virulence factors that contributes to the 
pathogenicity in vivo. 
13. Glass, M. B., and T. Popovic. 2005. Preliminary evaluation of the API 20NE and RapID 
NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J 
Clin Microbiol 43:479-83. 
 This paper evaluates commercially available diagnostic systems for its use in diagnosing 
both bacteria. 
14. Harvey, S. P., and J. M. Minter. 2005. Ribotyping of Burkholderia mallei isolates. 
FEMS Immunol Med Microbiol 44:91-7. 
This paper reports the attempt to the subspecies differentiation of 25 isolates of 
Burkholderia mallei based on their ribotype polymorphisms.  
15. Smith, M. J., and J. A. Jeddeloh. 2005. DNA methylation in lysogens of pathogenic 
Burkholderia spp. requires prophage induction and is restricted to excised phage DNA. J 
Bacteriol 187:1196-200. 
 This paper reports that upon induction of a phage of the bacterium, cytosine methylation 










01 STEWART, DONALD 
Antibodies to Burkholderia type III 
secretion system  
Total: $992,819  
 $330,684 | 2005 | Stewart, Donald I | CANGENE CORPORATION | CANADA - 
MISSISSAUGA  
 $415,395 | 2004 | Stewart, Donald I | CANGENE CORPORATION | CANADA - 
MISSISSAUGA  




01 NIERMAN, WILLIAM 
Regulation of Burkholderia mallei 
virulence genes  
Total: $1,131,955  
$454,064 | 2005 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH | 
ROCKVILLE, MD  
$446,178 | 2004 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH | 
ROCKVILLE, MD  
$231,713 | 2003 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH | 
ROCKVILLE, MD  
3 67 
1U01AI049037-
01 NIERMAN, WILLIAM 
SEQUENCING THE GENOME 
BURKHOLDERIA MALLEI  
Total: $2,087,240  
$984,990 | 2001 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH | 
ROCKVILLE, MD  
$1,102,250 | 2000 | NIERMAN, WILLIAM C | INSTITUTE FOR GENOMIC RESEARCH 






Vaccine discovery for Burkholderia 
via protection screen  
Total: $500,000  
 $500,000 | 2003 | Sykes, Kathryn F | MACROGENICS, INC. | DALLAS, TX  
5 63 
1R03AI054411-
01 LIPUMA, JOHN 
Burkholderia sp: Identification of 
major clonal lineages  
Total: $152,750  
 $76,500 | 2004 | Lipuma, John J | UNIVERSITY OF MICHIGAN AT ANN ARBOR 
| ANN ARBOR, MI  
 $76,250 | 2003 | Lipuma, John J | UNIVERSITY OF MICHIGAN AT ANN ARBOR 
| ANN ARBOR, MI  
6 63 
1R01AI050565-
01 NIERMAN, WILLIAM 
Microarray Expression Analysis of 
Burkholderia Mallei  
Total: $877,268  
 $277,234 | 2003 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH 
| ROCKVILLE, MD  
 $200,621 | 2002 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH 
| ROCKVILLE, MD  
 $399,413 | 2001 | Nierman, William C | INSTITUTE FOR GENOMIC RESEARCH 










Type IV Pilins as Vaccines against 
Bioterrorism Threats  
Total: $148,500  
 $74,250 | 2004 | Donnenberg, Michael S | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $74,250 | 2003 | Donnenberg, Michael S | UNIVERSITY OF MARYLAND BALT 






Non-antiobiotic resistance markers 
for bacteria  
Total: $179,725  
 $179,725 | 2005 | Schweizer, Herbert P | COLORADO STATE UNIVERSITY-




Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Betaproteobacteria, Order 
Burkholderiales, Family Burkholderiaceae. 
Publications: 
1. O'Quinn, A. L., E. M. Wiegand, and J. A. Jeddeloh. 2001. Burkholderia pseudomallei 
kills the nematode Caenorhabditis elegans using an endotoxin-mediated paralysis. Cell 
Microbiol 3:381-93. 
This paper reports that Burkholderia pseudomallei is able to cause 'disease-like' symptoms 
and kill the nematode Caenorhabditis elegans, and recommends that a C. elegans model 
might be useful for the identification of vertebrate animal virulence factors in 
Burkholderia pseudomallei. 
2. Reckseidler, S. L., D. DeShazer, P. A. Sokol, and D. E. Woods. 2001. Detection of 
bacterial virulence genes by subtractive hybridization: identification of capsular 
polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect 
Immun 69:34-44. 
 This paper reports the development of a new system for the detection of virulence factors 
of pathogenic bacteria. 
3. DeShazer, D. 2004. Genomic diversity of Burkholderia pseudomallei clinical isolates: 
subtractive hybridization reveals a Burkholderia mallei-specific prophage in B. 
pseudomallei 1026b. J Bacteriol 186:3938-50. 
This paper describes the discovery of a bacterial virus within Burkholderia pseudomallei 
strains. 
4. Moore, R. A., S. Reckseidler-Zenteno, H. Kim, W. Nierman, Y. Yu, A. Tuanyok, J. 





pathogenic evolution of Burkholderia pseudomallei and Burkholderia mallei. Infect 
Immun 72:4172-87. 
 This paper reports that the ability to metabolize arabinose reduces the virulence of B. 
pseudomallei and that the genes encoding arabinose assimilation may be considered 
antivirulence genes.  
5. Glass, M. B., and T. Popovic. 2005. Preliminary evaluation of the API 20NE and RapID 
NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J 
Clin Microbiol 43:479-83. 








Burkholderia type III 
secretion system  
Total: $992,819  
 $330,684 | 2005 | Stewart, Donald I | CANGENE 
CORPORATION | CANADA - MISSISSAUGA  
 $415,395 | 2004 | Stewart, Donald I | CANGENE 
CORPORATION | CANADA - MISSISSAUGA  
 $246,740 | 2003 | Stewart, Donald I | CANGENE 
CORPORATION | CANADA - MISSISSAUGA  
2 67 1R21AI061602-01 CROSA, JORGE 




Total: $302,000  
 $302,000 | 2004 | Crosa, Jorge H | OREGON 
HEALTH & SCIENCE UNIVERSITY | PORTLAND, OR  
3 31 1U01AI061363-01 FELGNER, PHILIP 
Scanning B. pseudomallei 
proteome for vaccine 
antigens  
Total: $1,566,070  
 $1,566,070 | 2004 | Felgner, Philip L | UNIVERSITY OF 
CALIFORNIA IRVINE | IRVINE, CA  
4 16 1U54AI057141-010002 
MANOIL, 
COLIN 
Bacterial Essential and 
Virulence Gene  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF 
WASHINGTON | SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF 
WASHINGTON | SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF 







01 HASSETT, DANIEL 
B.pseudomallei bioterrorism 
and quorum sensing  
Total: $153,500  
 $76,750 | 2003 | Hassett, Daniel J | UNIVERSITY OF CINCINNATI | 
CINCINNATI, OH  
 $76,750 | 2002 | Hassett, Daniel J | UNIVERSITY OF CINCINNATI | 
CINCINNATI, OH  
6 47 
1U54AI057160-
010013 MAJERUS, PHILIP 
The Role of Inositol 
Phosphate in B. 
Pseudomallei Pathogenesis  
Total: $18,865,686  
 $7,627,721 | 2005 | Stanley, Samuel L | ORION GENOMICS, LLC | ST. 
LOUIS, MO  
 $7,894,128 | 2004 | Stanley, Samuel L | JACOBS FACILITIES, INC. | ST 
LOUIS, MO  
 $3,343,837 | 2003 | Stanley, Samuel L | MISSOURI WESTERN STATE 
COLLEGE | ST. JOSEPH, MO  
7 47 
1R43AI056644-
01 MOIR, DONALD 
Discovery of B. pseudomallei 
Therapeutics for Biodefense  
Total: $349,543  
 $349,543 | 2004 | Moir, Donald T | MICROBIOTIX, INC. | WORCESTER, 
MA  




markers for bacteria  
Total: $179,725  
 $179,725 | 2005 | Schweizer, Herbert P | COLORADO STATE 
UNIVERSITY-FORT COLLINS | FORT COLLINS, CO  
 
Camelpoxvirus 
Taxonomy: Family Poxviridae, Subfamily Chordopoxvirinae, Genus Orthopoxvirus, Species 
Camelpox virus. Virus: Camelpox virus. 
Publications: 
1. Vladimir N. Loparev, Robert F. Massung, Joseph J. Esposito, and Hermann Meyer. 
2001. Detection and Differentiation of Old World Orthopoxviruses: Restriction Fragment 
Length Polymorphism of the crmB Gene Region. J Clin Microbiol 39:94-100. 
This paper describes the development of a restriction fragment length polymorphism 






2. Smee, D. F., Bray, M., and Huggins, J. W. 2001. Antiviral activity and mode of action 
studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem 
Chemother 12:327-35. 
This paper describes the testing of various antiviral against Camelpox and Monkeypox 
virus.  
3. C. L. Afonso, E. R. Tulman, Z. Lu, L. Zsak, N. T. Sandybaev, U. Z. Kerembekova, 
V. L. Zaitsev, G. F. Kutish and D. L. Rock. 2002. The Genome of Camelpox Virus. 
Virology 295:1-9. 
This paper describes the determination of the sequence of a Camelpox virus strain.  
4. M. Sofi Ibrahim, David A. Kulesh, Sharron S. Saleh, Inger K. Damon, Joseph J. 
Esposito, Alan L. Schmaljohn, and Peter B. Jahrling. 2003. Real-Time PCR Assay To 
Detect Smallpox Virus. J Clin Microbiol 41:3835-39. 
This paper describes the development of a real-time 5' nuclease PCR assay (also known as 
the TaqMan assay) for the rapid diagnosis of Variola virus. 48 different strains of Variola 
virus were used. Controls included Camelpox virus, and Monkeypox virus.  
5. Baker Robert O., Mike Bray, and John W. Huggins. 2003. Potential antiviral 
therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 
57:13-23. 
This paper describes the evaluation of 24 different potential antivirals for their activity 
against Variola virus (35 strains), Monkeypox virus, Camelpox virus, and Cowpox virus. 
Several active compounds were isolated. 
6. Olson, Victoria A., Thomas Laue, Miriam T. Laker, Igor V. Babkin, Christian 
Drosten, Sergei N. Shchelkunov, Matthias Niedrig, Inger K. Damon, and Hermann 
Meyer. 2004. Real-Time PCR System for Detection of Orthopoxviruses and 
Simultaneous Identification of Smallpox Virus. J Clin Microbiol 42:1940-6. 
This paper describes the development of a real-time PCR system for various 
orthopoxviruses including Variola virus, Monkeypox virus, Camelpox virus, and Cowpox 
virus. Several active compounds were isolated. 
 
NIH grants: None identified. 
 
“Candidatus Liberobacter africanus” 
Taxonomy: Domain Bacteria, final status undetermined. 
Publications: None identified. 






“Candidatus Liberobacter asiaticus” 
Taxonomy: Domain Bacteria, final status undetermined. 
Publications: None identified. 
NIH Grants: None identified. 
 
Cercopithecine herpesvirus 1 
Taxonomy: Family Herpesviridae, Subfamily: Alphaherpesvirinae, Genus Simplexvirus, Species 
Cercopithecus herpesvirus 1. Virus: Cercopithecus herpesvirus 1, B-virus, Herpesvirus simiae. 
Publications: 
1. Makoto Hirano, Shin Nakamura, Fusako Mitsunaga, Maki Okada, Keiko Shimizu, 
Masahiro Ueda, Alice Bennett, and Richard Eberle. 2002. Efficacy of a B virus gD 
DNA vaccine for induction of humoral and cellular immune responses in Japanese 
macaques. Vaccine 20:2523-32. 
This paper describes the development and evaluation of a vaccine candidate against 
Cercopithecine herpesvirus 1. 
2. Ludmila Perelygina, Holley Zurkuhlen, Irina Patrusheva, and Julia K. Hilliard. 2002. 
Identification of a Herpes B Virus Specific Glycoprotein D Immunodominant Epitope 
Recognized by Natural and Foreign Hosts. J Infect Dis 186:453-61. 
This paper describes the determination of immunogenic epitopes of the glycoprotein of 
Cercopithecine herpesvirus 1. 
3. L. Perelygina, I. Patrusheva, H. Zurkuhlen, J. K. Hilliard. 2002. Characterization of B 
virus glycoprotein antibodies induced by DNA immunization. Arch Virol 147:2057-73. 
This paper describes the creation o f polyclonal antibodies to glycoproteins of 
Cercopithecine herpesvirus 1 by DNA immunization. 
4. J. L. Huff, R. Eberle, J. Capitanio, S. S. Zhou, and P. A. Barry. 2003. Differential 
detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol 84:83-
92. 
This paper describes the development of a real-time PCR assay to quantify Cercopithecine 
herpesvirus type 1 DNA in mucosal fluids of rhesus macaques. 
5. Ludmila Perelygina, Irina Patrusheva, Nina Manes, Martin J. Wildes, Peter Krug, 
and Julia K. Hilliard. 2003. Quantitative real-time PCR for detection of monkey B virus 
(Cercopithecine herpesvirus 1) in clinical samples. J Virol Methods 109:245-51. 
This paper describes the development of a TaqMan-based real-time PCR assay for rapid 





6. K. Ohsawa, D. H. Black, H. Sato, K. Rogers, and R. Eberle. 2003. Sequence and 
genetic arrangement of the UL region of the monkey B virus (Cercopithecine herpesvirus 
1) genome and comparison with the UL region of other primate herpesviruses. Arch Virol 
148:989-97. 
This paper reports the DNA sequence of the unique long region of Cercopithecine 
herpesvirus 1. 
7. Ludmila Perelygina, Li Zhu, Holley Zurkuhlen, Ryan Mills, Mark Borodovsky, and 
Julia K. Hilliard. 2003. Complete Sequence and Comparative Analysis of the Genome of 
Herpes B Virus (Cercopithecine Herpesvirus 1) from a Rhesus Monkey. J Virol 77:6167-
77. 
This paper reports the complete DNA sequence of a Cercopithecine herpesvirus 1 isolate. 
8. Ritchey, J. W., M. E. Payton, and R. Eberle. 2005. Clinicopathological characterization 
of monkey B virus (cercopithecine herpesvirus 1) infection in mice. J Comp Pathol 
132:202-17. 
This paper describes the establishment of a murine model for cercopithecine herpesvirus 1 
infection. 
 






HERPES B VIRUS--A NATIONAL RESOURCE 
LABORATORY  
Total: $3,274,545  
 $318,968 | 2005 | Hilliard, Julia K | GEORGIA STATE UNIVERSITY | ATLANTA, 
GA  
 $623,999 | 2004 | Hilliard, Julia K | GEORGIA STATE UNIVERSITY | ATLANTA, 
GA  
 $605,824 | 2003 | Hilliard, Julia K | GEORGIA STATE UNIVERSITY | ATLANTA, 
GA  
 $591,667 | 2002 | Hilliard, Julia K | GEORGIA STATE UNIVERSITY | ATLANTA, 
GA  
 $574,434 | 2001 | Hilliard, Julia K | GEORGIA STATE UNIVERSITY | ATLANTA, 
GA  
 $559,653 | 2000 | HILLIARD, JULIA K | GEORGIA STATE UNIVERSITY | 
ATLANTA, GA  
 
Classical swine fever virus 
Taxonomy: Family Flaviviridae, Genus Pestivirus, Species: Classical swine fever virus. Virus: 






1. Risatti, G. R., J. D. Callahan, W. M. Nelson, and M. V. Borca. 2003. Rapid detection 
of classical swine fever virus by a portable real-time reverse transcriptase PCR assay. J 
Clin Microbiol 41:500-5. 
 This paper describes the development of a a fluorogenic-probe hydrolysis TaqMan reverse 
transcriptase PCR assay for the detection of the virus.  
2. Risatti, G., L. Holinka, Z. Lu, G. Kutish, J. D. Callahan, W. M. Nelson, E. Brea Tio, 
and M. V. Borca. 2005. Diagnostic evaluation of a real-time reverse transcriptase PCR 
assay for detection of classical swine fever virus. J Clin Microbiol 43:468-71. 
 This paper describes the evaluation of a fluorogenic-probe hydrolysis TaqMan-reverse 
transcriptase PCR assay for the detection of the virus 
3. Risatti, G. R., M. V. Borca, G. F. Kutish, Z. Lu, L. G. Holinka, R. A. French, E. R. 
Tulman, and D. L. Rock. 2005. The E2 glycoprotein of classical swine fever virus is a 
virulence determinant in swine. J Virol 79:3787-96. 
This paper demonstrates that the E2 surface protein of the virus alone is responsible for 
virulence differences in different virus strains. 
 
NIH grants: None identified. 
 
 
Clostridium botulinum (neurotoxin-producing) 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Clostridia, Order Clostridiales, Family 
Clostridiaceae. 
Publications: 
1. Chea, F. P., Y. Chen, T. J. Montville, and D. W. Schaffner. 2000. Modeling the 
germination kinetics of clostridium botulinum 56A spores as affected by temperature, pH, 
and sodium chloride. J Food Prot 63:1071-9. 
 This paper reports the effects of temperature and pH on germination of spores of the 
bacterium. 
2. Dineen, S. S., M. Bradshaw, and E. A. Johnson. 2000. Cloning, nucleotide sequence, 
and expression of the gene encoding the bacteriocin boticin B from Clostridium 
botulinum strain 213B. Appl Environ Microbiol 66:5480-3. 
 This paper reports the characterization of a gene of the bacterium. 
3. Lawlor, K. A., M. D. Pierson, C. R. Hackney, J. R. Claus, and J. E. Marcy. 2000. 
Nonproteolytic Clostridium botulinum toxigenesis in cooked turkey stored under 
modified atmospheres. J Food Prot 63:1511-6. 





4. Peleg, M., and M. B. Cole. 2000. Estimating the survival of Clostridium botulinum 
spores during heat treatments. J Food Prot 63:190-5. 
 This paper reports survival characteristics of spores of the bacterium. 
5. Skinner, G. E., S. M. Gendel, G. A. Fingerhut, H. A. Solomon, and J. Ulaszek. 2000. 
Differentiation between types and strains of Clostridium botulinum by riboprinting. J 
Food Prot 63:1347-52. 
 This paper reports the evaluation of a diagnostic system. 
6. Cai, S., and B. R. Singh. 2001. Role of the disulfide cleavage induced molten globule 
state of type a botulinum neurotoxin in its endopeptidase activity. Biochemistry 
40:15327-33. 
 This paper reports the effect of disulfide cleavage on a toxin of the bacterium. 
7. Prabakaran, S., W. Tepp, and B. R. DasGupta. 2001. Botulinum neurotoxin types B 
and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and 
comparison of their identified cleaved sites relative to the three-dimensional structure of 
type A neurotoxin. Toxicon 39:1515-31. 
 This paper reports the characterization of specific cleavage sites of toxins of the 
bacterium. 
8. Craven, K. E., J. L. Ferreira, M. A. Harrison, and P. Edmonds. 2002. Specific 
detection of Clostridium botulinum types A, B, E, and F using the polymerase chain 
reaction. J AOAC Int 85:1025-8. 
 This paper reports a detection system. 
9. Peterson, M. E., R. N. Paranjpye, F. T. Poysky, G. A. Pelroy, and M. W. Eklund. 
2002. Control of nonproteolytic Clostridium botulinum types B and E in crab analogs by 
combinations of heat pasteurization and water phase salt. J Food Prot 65:130-9. 
 This paper reports the effect of certain inactivating methods on strains of the bacterium in 
imitation crab meat. 
10. Zhao, L., T. J. Montville, and D. W. Schaffner. 2002. Time-to-detection, percent-
growth-positive and maximum growth rate models for Clostridium botulinum 56A at 
multiple temperatures. Int J Food Microbiol 77:187-97. 
 This paper reports growth characteristics of the bacterium. 
11. Dineen, S. S., M. Bradshaw, and E. A. Johnson. 2003. Neurotoxin gene clusters in 
Clostridium botulinum type A strains: sequence comparison and evolutionary 
implications. Curr Microbiol 46:345-52. 
 This paper reports the phylogenetic relationships of the toxin genes of different strains of 
the bacterium. 
12. Ferreira, J. L., S. Maslanka, E. Johnson, and M. Goodnough. 2003. Detection of 
botulinal neurotoxins A, B, E, and F by amplified enzyme-linked immunosorbent assay: 
collaborative study. J AOAC Int 86:314-31. 
 This paper reports the evaluation of a detection system. 
13. Lim, Y. H., M. K. Hamdy, and R. T. Toledo. 2003. Combined effects of ionizing-
irradiation and different environments on Clostridium botulinum type E spores. Int J Food 
Microbiol 89:251-63. 





14. Reddy, N. R., H. M. Solomon, R. C. Tetzloff, and E. J. Rhodehamel. 2003. 
Inactivation of Clostridium botulinum type A spores by high-pressure processing at 
elevated temperatures. J Food Prot 66:1402-7. 
 This paper reports the evaluation of an inactivation method for spores of the bacterium. 
15. Sharma, S. K., M. A. Ramzan, and B. R. Singh. 2003. Separation of the components of 
type A botulinum neurotoxin complex by electrophoresis. Toxicon 41:321-31. 
 This paper reports the separation of toxin components of the bacterium. 
16. Zhang, L., W. J. Lin, S. Li, and K. R. Aoki. 2003. Complete DNA sequences of the 
botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. 
Gene 315:21-32. 
 This paper reports the sequence of toxin-encoding genes of a strain of the bacterium. 
17. Barash, J. R., and S. S. Arnon. 2004. Dual toxin-producing strain of Clostridium 
botulinum type Bf isolated from a California patient with infant botulism. J Clin 
Microbiol 42:1713-5. 
 This paper reports the identification of a novel strain of the bacterium. 
18. Dineen, S. S., M. Bradshaw, C. E. Karasek, and E. A. Johnson. 2004. Nucleotide 
sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in 
Clostridium botulinum. FEMS Microbiol Lett 235:9-16. 
 This paper reports the sequence of toxin-encoding genes of a strain of the bacterium. 
19. Eklund, M. W., F. T. Poysky, M. E. Peterson, R. N. Paranjpye, and G. A. Pelroy. 
2004. Competitive inhibition between different Clostridium botulinum types and strains. J 
Food Prot 67:2682-7. 
 This paper reports the effect of different strains of the bacterium on each other. 
20. Glass, K. A., and E. A. Johnson. 2004. Antibotulinal activity of process cheese 
ingredients. J Food Prot 67:1765-9. 
 This paper reports the inhibitory effects of cheese on the bacterium. 
21. Kirma, N., J. L. Ferreira, and B. R. Baumstark. 2004. Characterization of six type A 
strains of Clostridium botulinum that contain type B toxin gene sequences. FEMS 
Microbiol Lett 231:159-64. 
 This paper reports the characterization of several strains of the bacterium. 
22. Sharma, S. K., and B. R. Singh. 2004. Enhancement of the endopeptidase activity of 
purified botulinum neurotoxins A and E by an isolated component of the native 
neurotoxin associated proteins. Biochemistry 43:4791-8. 
 This paper reports a toxin-associated protein of the bacterium that enhances the activity of 
the toxin. 
23. Simpson, L. L., A. B. Maksymowych, J. B. Park, and R. S. Bora. 2004. The role of the 
interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J 
Pharmacol Exp Ther 308:857-64. 
 This paper reports structural requirements for toxic activity of a toxin of the bacterium. 
24. Zhou, Y., and B. R. Singh. 2004. Cloning, high-level expression, single-step 
purification, and binding activity of His6-tagged recombinant type B botulinum 
neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 34:8-16. 





25. Johnson, E. A., W. H. Tepp, M. Bradshaw, R. J. Gilbert, P. E. Cook, and E. D. 
McIntosh. 2005. Characterization of Clostridium botulinum strains associated with an 
infant botulism case in the United Kingdom. J Clin Microbiol 43:2602-7. 
 This paper reports the characterization of novel strains of the bacterium. 
26. Sharma, S. K., B. S. Eblen, R. L. Bull, D. H. Burr, and R. C. Whiting. 2005. 
Evaluation of lateral-flow Clostridium botulinum neurotoxin detection kits for food 
analysis. Appl Environ Microbiol 71:3935-41. 





019004 JOHNSON, ERIC 
Core--Clostridium botulinum and 
neurotoxin facility  
Total: $20,734,800 * 
 $8,532,653 | 2005 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | CHICAGO, 
IL  
 $8,543,253 | 2004 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | CHICAGO, 
IL  
 $3,658,894 | 2003 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | CHICAGO, 
IL  
2 37 1R21AI059125-01 JOHNSON, ERIC 
Development of Genetic Tools for 
Clostridium botulinum  
Total: $502,375  
 $245,500 | 2005 | Johnson, Eric A | UNIVERSITY OF WISCONSIN MADISON | 
MADISON, WI  
 $256,875 | 2004 | Johnson, Eric A | UNIVERSITY OF WISCONSIN MADISON | 






SERUM & MILK IDENTIFICATION OF 
CLOSTRIDIUM BOTULINUM  
Total: $6,706,649  
 $1,446,875 | 2004 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-LAWRNC 
LVRMR NAT LAB | LIVERMORE, CA  
 $1,276,355 | 2003 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-LAWRNC 
LVRMR NAT LAB | LIVERMORE, CA  
 $1,257,387 | 2002 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-LAWRNC 
LVRMR NAT LAB | LIVERMORE, CA  
 $1,311,794 | 2001 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-LAWRNC 
LVRMR NAT LAB | LIVERMORE, CA  
 $1,414,238 | 2000 | TURTELTAUB, KENNETH W | UNIVERSITY OF CALIF-






Automated, portable, concurrent, WMD 
detection system  
Total: $994,832  
 $500,000 | 2005 | Schoen, Christian | CONCURRENT ANALYTICAL, INC. | 
Kailua, HI  





Kailua, HI  
5 12 1U01AI054374-01 
HENRICKSON, 
KELLY 
Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN | 
MILWAUKEE, WI  
 $391,730 | 2004 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN | 
MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN | 
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Taxonomy: Empira: Eukarya, Kingdom: Fungi, Phylum: Ascomycota, Class: Eurotiomycetes, 
Order: Onygenales, Family Onygenaceae. 
Publications: 
1. Fierer, J., L. Walls, and T. N. Kirkland. 2000. Genetic evidence for the role of the Lv 
locus in early susceptibility but not IL-10 synthesis in experimental coccidioidomycosis in 
C57BL mice. J Infect Dis 181:681-5. 
 This paper reports the discovery that different mouse strains have different susceptibilities 
to the infection with the fungus; and that this difference can be pinpointed to a specific 
location on chromosome 4. 
2. Fisher, M. C., G. Koenig, T. J. White, and J. W. Taylor. 2000. A test for concordance 
between the multilocus genealogies of genes and microsatellites in the pathogenic fungus 
Coccidioides immitis. Mol Biol Evol 17:1164-74. 
 This paper describes the sequencing of seven microsatellites of strains of C. immitis and 





3. Gromadzki, S. G., and V. Chaturvedi. 2000. Limitation of the AccuProbe Coccidioides 
immitis culture identification test: false-negative results with formaldehyde-killed 
cultures. J Clin Microbiol 38:2427-8. 
 This paper warns that the AccuProbe Coccidioides immitis culture identification test is not 
reliable when formaldehyde-inactivated spores of the fungus are used. 
4. Guevara-Olvera, L., C. Y. Hung, J. J. Yu, and G. T. Cole. 2000. Sequence, expression 
and functional analysis of the Coccidioides immitis ODC (ornithine decarboxylase) gene. 
Gene 242:437-48. 
 This paper reports the sequencing and expression of a gene of the fungus. 
5. Hung, C. Y., N. M. Ampel, L. Christian, K. R. Seshan, and G. T. Cole. 2000. A major 
cell surface antigen of Coccidioides immitis which elicits both humoral and cellular 
immune responses. Infect Immun 68:584-93. 
 This paper describes the identification of a cell surface antigen of the fungus. 
6. Li, R. K., M. A. Ciblak, N. Nordoff, L. Pasarell, D. W. Warnock, and M. R. 
McGinnis. 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B 
against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. 
Antimicrob Agents Chemother 44:1734-6. 
 This paper reports the evaluation of different antifungal compounds for their efficacies 
against the fungus. 
7. Reichard, U., C. Y. Hung, P. W. Thomas, and G. T. Cole. 2000. Disruption of the gene 
which encodes a serodiagnostic antigen and chitinase of the human fungal pathogen 
Coccidioides immitis. Infect Immun 68:5830-8. 
 This paper describes the disruption of a gene of the fungus.  
8. Sorensen, K. N., R. A. Sobel, K. V. Clemons, L. Calderon, K. J. Howell, P. R. Irani, 
D. Pappagianis, P. L. Williams, and D. A. Stevens. 2000. Comparative efficacies of 
terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a 
rabbit model. Antimicrob Agents Chemother 44:3087-91. 
 This paper reports the evaluation of different antifungal compounds for their efficacies 
against the fungus in vivo. 
9 Sorensen, K. N., R. A. Sobel, K. V. Clemons, D. Pappagianis, D. A. Stevens, and P. L. 
Williams. 2000. Comparison of fluconazole and itraconazole in a rabbit model of 
coccidioidal meningitis. Antimicrob Agents Chemother 44:1512-7. 
 This paper reports the evaluation of different antifungal compounds for their efficacies 
against the fungus in vivo. 
10. Gonzalez, G. M., R. Tijerina, L. K. Najvar, R. Bocanegra, M. Luther, M. G. Rinaldi, 
and J. R. Graybill. 2001. Correlation between antifungal susceptibilities of Coccidioides 
immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob 
Agents Chemother 45:1854-9. 
 This paper evaluates an antifungal in vitro and in vivo. 
11. Hung, C. Y., J. J. Yu, P. F. Lehmann, and G. T. Cole. 2001. Cloning and expression of 
the gene which encodes a tube precipitin antigen and wall-associated beta-glucosidase of 
Coccidioides immitis. Infect Immun 69:2211-22. 
This paper reports the structure and expression and of the Coccidioides immitis BGL2 





12. Li, K., J. J. Yu, C. Y. Hung, P. F. Lehmann, and G. T. Cole. 2001. Recombinant 
urease and urease DNA of Coccidioides immitis elicit an immunoprotective response 
against coccidioidomycosis in mice. Infect Immun 69:2878-87. 
 This paper describes the development of novel vaccine candidates. 
13. Clemons, K. V., R. A. Sobel, P. L. Williams, D. Pappagianis, and D. A. Stevens. 2002. 
Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal 
meningitis in rabbits. Antimicrob Agents Chemother 46:2420-6. 
 This paper reports the evaluation of an antibiotic. 
14. Gonzalez, G. M., R. Tijerina, L. K. Najvar, R. Bocanegra, M. Rinaldi, D. 
Loebenberg, and J. R. Graybill. 2002. In vitro and in vivo activities of posaconazole 
against Coccidioides immitis. Antimicrob Agents Chemother 46:1352-6. 
This paper reports the evaluation of an antimycotic. 
15. Gonzalez, G. M., R. Tijerina, D. A. Sutton, J. R. Graybill, and M. G. Rinaldi. 2002. 
In vitro activities of free and lipid formulations of amphotericin B and nystatin against 
clinical isolates of Coccidioides immitis at various saprobic stages. Antimicrob Agents 
Chemother 46:1583-5. 
This paper reports the evaluation of antimycotics. 
16. Hung, C. Y., J. J. Yu, K. R. Seshan, U. Reichard, and G. T. Cole. 2002. A parasitic 
phase-specific adhesin of Coccidioides immitis contributes to the virulence of this 
respiratory Fungal pathogen. Infect Immun 70:3443-56. 
 This paper reports the identification of a virulence factor of the fungus. 
17. Jiang, C., D. M. Magee, F. D. Ivey, and R. A. Cox. 2002. Role of signal sequence in 
vaccine-induced protection against experimental coccidioidomycosis. Infect Immun 
70:3539-45. 
 This paper evaluates a vaccine candidate. 
18. Mirbod, F., R. A. Schaller, and G. T. Cole. 2002. Purification and characterization of 
urease isolated from the pathogenic fungus Coccidioides immitis. Med Mycol 40:35-44. 
 This paper reports the purification and characterization of urease isolated from 
Coccidioides immitis 
19. Peng, T., L. Shubitz, J. Simons, R. Perrill, K. I. Orsborn, and J. N. Galgiani. 2002. 
Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against 
infection with Coccidioides immitis in mice. Infect Immun 70:3330-5. 
 This paper reports the identification and localization of a protective antigen of the fungus. 
20. Shubitz, L., T. Peng, R. Perrill, J. Simons, K. Orsborn, and J. N. Galgiani. 2002. 
Protection of mice against Coccidioides immitis intranasal infection by vaccination with 
recombinant antigen 2/PRA. Infect Immun 70:3287-9. 
 This paper reports the evaluation of a vaccine candidate. 
21. Ivey, F. D., D. M. Magee, M. D. Woitaske, S. A. Johnston, and R. A. Cox. 2003. 
Identification of a protective antigen of Coccidioides immitis by expression library 
immunization. Vaccine 21:4359-67. 
 This paper reports the identification and localization of a protective antigen of the fungus. 
22. Kamberi, P., R. A. Sobel, K. V. Clemons, D. A. Stevens, D. Pappagianis, and P. L. 
Williams. 2003. A murine model of coccidioidal meningitis. J Infect Dis 187:453-60. 





23. Johannesson, H., P. Vidal, J. Guarro, R. A. Herr, G. T. Cole, and J. W. Taylor. 2004. 
Positive directional selection in the proline-rich antigen (PRA) gene among the human 
pathogenic fungi Coccidioides immitis, C. posadasii and their closest relatives. Mol Biol 
Evol 21:1134-45. 
This paper reports the possibility of selection acting on the proline-rich antigen gene in 
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Coccidioides posadasii (formerly non-California Coccidioides immitis) 
Taxonomy: Empira: Eukarya, Kingdom: Fungi, Phylum: Ascomycota, Class: Eurotiomycetes, 
Order: Onygenales, Family Onygenaceae. 
Publications: 
1. Clemons, K. V., and D. A. Stevens. 2000. Efficacies of sordarin derivatives GM193663, 
GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. p6. 
Antimicrob Agents Chemother 44:1874-7. 
 This paper evaluates the efficacy of sordarin derivatives as antifungal compounds in a 
murine model for coccidiomycosis. 
2. Fisher, M. C., G. Koenig, T. J. White, and J. W. Taylor. 2000. A test for concordance 
between the multilocus genealogies of genes and microsatellites in the pathogenic fungus 
Coccidioides immitis. Mol Biol Evol 17:1164-74. 
 This paper describes the sequencing of seven microsatellites of strains of C. immitis and 
C. posadasii and the establishment of a phylogenetic tree of these isolates. 
3. Hung, C. Y., N. M. Ampel, L. Christian, K. R. Seshan, and G. T. Cole. 2000. A major 
cell surface antigen of Coccidioides immitis which elicits both humoral and cellular 
immune responses. Infect Immun 68:584-93. 
 This paper describes the identification of a cell surface antigen of the fungus. 
4. Sorensen, K. N., R. A. Sobel, K. V. Clemons, L. Calderon, K. J. Howell, P. R. Irani, 
D. Pappagianis, P. L. Williams, and D. A. Stevens. 2000. Comparative efficacies of 
terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a 
rabbit model. Antimicrob Agents Chemother 44:3087-91. 
 This paper reports the evaluation of different antifungal compounds for their efficacies 
against the fungus in vivo. 
5. Sorensen, K. N., R. A. Sobel, K. V. Clemons, D. Pappagianis, D. A. Stevens, and P. L. 
Williams. 2000. Comparison of fluconazole and itraconazole in a rabbit model of 
coccidioidal meningitis. Antimicrob Agents Chemother 44:1512-7. 
 This paper reports the evaluation of different antifungal compounds for their efficacies 
against the fungus in vivo. 
6. Delgado, N., J. Xue, J. J. Yu, C. Y. Hung, and G. T. Cole. 2003. A recombinant beta-
1,3-glucanosyltransferase homolog of Coccidioides posadasii protects mice against 
coccidioidomycosis. Infect Immun 71:3010-9. 
 This paper reports the evaluation of a vaccine candidate. 
7. Awasthi, S., D. M. Magee, and J. J. Coalson. 2004. Coccidioides posadasii infection 
alters the expression of pulmonary surfactant proteins (SP)-A and SP-D. Respir Res 5:28. 
8. Delgado, N., C. Y. Hung, E. Tarcha, M. J. Gardner, and G. T. Cole. 2004. Profiling 
gene expression in Coccidioides posadasii. Med Mycol 42:59-71. 
 This paper reports  
9. Johannesson, H., P. Vidal, J. Guarro, R. A. Herr, G. T. Cole, and J. W. Taylor. 2004. 





pathogenic fungi Coccidioides immitis, C. posadasii and their closest relatives. Mol Biol 
Evol 21:1134-45. 
This paper reports the possibility of selection acting on the proline-rich antigen gene in 
natural populations of the two fungi. 
19. Kellner, E. M., K. I. Orsborn, E. M. Siegel, M. A. Mandel, M. J. Orbach, and J. N. 
Galgiani. 2005. Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene 
that appears to be essential for growth. Eukaryot Cell 4:111-20. 
This paper reports the identification of an enzyme that is essential for replication of the 
fungus.  
20. Viriyakosol, S., J. Fierer, G. D. Brown, and T. N. Kirkland. 2005. Innate immunity to 
the pathogenic fungus Coccidioides posadasii is dependent on Toll-like receptor 2 and 
Dectin-1. Infect Immun 73:1553-60. 
This paper reports the identification of key factor in the immune response to infection 
with the fungus. 
 
NIH Grants: None identified. 
 
Coxiella burnetii 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Gammaproteobacteria, Order 
Legionellales, Family Coxiellaceae. 
Publications: 
1. Howe, D., and L. P. Mallavia. 2000. Coxiella burnetii exhibits morphological change 
and delays phagolysosomal fusion after internalization by J774A.1 cells. Infect Immun 
68:3815-21. 
 This paper reports on the function of a protein that seems to be involved in letting the 
bacterium switch between morphological forms, both of which are important for its 
survival in the environment of the inside of host cells. 
2. Sinai, A. P., S. Paul, M. Rabinovitch, G. Kaplan, and K. A. Joiner. 2000. Coinfection 
of fibroblasts with Coxiella burnetti and Toxoplasma gondii: to each their own. Microbes 
Infect 2:727-36. 
 This paper reports the coinfection of cells with the bacterium and a protozoan at the same 
time, and demonstrates that the two pathogens basically do not interact with each others. 
3. Wilhelmsen, C. L., and D. M. Waag. 2000. Guinea pig abscess/hypersensitivity model 






This paper reports a model of abscess hypersensitivity in Hartley guinea pigs to assess the 
likelihood that Q fever vaccines would induce adverse vaccination reactions in previously 
sensitized individuals. 
4. Seshadri, R., and J. E. Samuel. 2001. Characterization of a stress-induced alternate 
sigma factor, RpoS, of Coxiella burnetii and its expression during the development cycle. 
Infect Immun 69:4874-83. 
 This paper reports the cloning and characterization of the major sigma factor of the 
bacterium, encoded by an rpoD homologue, and the stress response sigma factor, encoded 
by an rpoS homologue. 
5. Ghigo, E., C. Capo, C. H. Tung, D. Raoult, J. P. Gorvel, and J. L. Mege. 2002. 
Coxiella burnetii survival in THP-1 monocytes involves the impairment of phagosome 
maturation: IFN-gamma mediates its restoration and bacterial killing. J Immunol 
169:4488-95. 
 This paper identifies factors that allow the bacterium to survive in macrophages. 
6. Howe, D., L. F. Barrows, N. M. Lindstrom, and R. A. Heinzen. 2002. Nitric oxide 
inhibits Coxiella burnetii replication and parasitophorous vacuole maturation. Infect 
Immun 70:5140-7. 
 This paper reports the effects of nitric oxide in the bacterium. 
7. Miller, J. D., and H. A. Thompson. 2002. Permeability of Coxiella burnetii to 
ribonucleosides. Microbiology 148:2393-403. 
 This paper reports the ability of the bacterium to uptake nucleotides. 
8. Varghees, S., K. Kiss, G. Frans, O. Braha, and J. E. Samuel. 2002. Cloning and porin 
activity of the major outer membrane protein P1 from Coxiella burnetii. Infect Immun 
70:6741-50. 
 This paper reports the cloning and characterization of a protein of the bacterium. 
9. Brennan, R. E., and J. E. Samuel. 2003. Evaluation of Coxiella burnetii antibiotic 
susceptibilities by real-time PCR assay. J Clin Microbiol 41:1869-74. 
 This paper reports the antibiotic resistance profile of the bacterium. 
10. Capo, C., A. Moynault, Y. Collette, D. Olive, E. J. Brown, D. Raoult, and J. L. Mege. 
2003. Coxiella burnetii avoids macrophage phagocytosis by interfering with spatial 
distribution of complement receptor 3. J Immunol 170:4217-25. 
 This paper reports the involvement of a host factor in the bacterium’s ability to evade 
phagocytosis. 
11. Howe, D., J. Melnicakova, I. Barak, and R. A. Heinzen. 2003. Fusogenicity of the 
Coxiella burnetii parasitophorous vacuole. Ann N Y Acad Sci 990:556-62. 
 This paper reports on the function of the bacterium’s parasitophorous vacuole, and 
suggests that sustained C. burnetii protein synthesis is required for vacuole fusion with 
other vacuoles of the endocytic pathway. 
12. Howe, D., J. Melnicakova, I. Barak, and R. A. Heinzen. 2003. Maturation of the 
Coxiella burnetii parasitophorous vacuole requires bacterial protein synthesis but not 
replication. Cell Microbiol 5:469-80. 
 This paper reports on the function of the bacterium’s parasitophorous vacuole, and that 
sustained C. burnetii protein synthesis is required for vacuole fusion with other vacuoles 





13. Melnicakova, J., M. Lukacova, D. Howe, R. A. Heinzen, and I. Barak. 2003. 
Identification of Coxiella burnetii RpoS-dependent promoters. Ann N Y Acad Sci 
990:591-5. 
 This paper describes the identification of promoters for a gene important in morphological 
switching of the bacterium. 
14. Ren, Q., S. J. Robertson, D. Howe, L. F. Barrows, and R. A. Heinzen. 2003. 
Comparative DNA microarray analysis of host cell transcriptional responses to infection 
by Coxiella burnetii or Chlamydia trachomatis. Ann N Y Acad Sci 990:701-13 
 This paper reports the transcriptional response of host cells to infection with the 
bacterium. 
15. Seshadri, R., I. T. Paulsen, J. A. Eisen, T. D. Read, K. E. Nelson, W. C. Nelson, N. L. 
Ward, H. Tettelin, T. M. Davidsen, M. J. Beanan, R. T. Deboy, S. C. Daugherty, L. 
M. Brinkac, R. Madupu, R. J. Dodson, H. M. Khouri, K. H. Lee, H. A. Carty, D. 
Scanlan, R. A. Heinzen, H. A. Thompson, J. E. Samuel, C. M. Fraser, and J. F. 
Heidelberg. 2003. Complete genome sequence of the Q-fever pathogen Coxiella burnetii. 
Proc Natl Acad Sci U S A 100:5455-60. 
 This paper reports the complete genomic sequence of the bacterium. 
16. Zamboni, D. S., S. McGrath, M. Rabinovitch, and C. R. Roy. 2003. Coxiella burnetii 
express type IV secretion system proteins that function similarly to components of the 
Legionella pneumophila Dot/Icm system. Mol Microbiol 49:965-76. 
 This paper reports the identification of type IV secretion systems in the bacterium. 
17. Zhang, G. Q., and J. E. Samuel. 2003. Identification and cloning potentially protective 
antigens of Coxiella burnetii using sera from mice experimentally infected with Nine Mile 
phase I. Ann N Y Acad Sci 990:510-20. 
 This paper reports the identification of protective antigens for the prevention of infection 
with the bacterium. 
18. Brennan, R. E., K. Russell, G. Zhang, and J. E. Samuel. 2004. Both inducible nitric 
oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella 
burnetii infections. Infect Immun 72:6666-75. 
 This paper identifies two host proteins that control the bacterium after infection. 
19. Coleman, S. A., E. R. Fischer, D. Howe, D. J. Mead, and R. A. Heinzen. 2004. 
Temporal analysis of Coxiella burnetii morphological differentiation. J Bacteriol 
186:7344-52. 
 This paper describes the morphology of the bacterium. 
20. Miller, J. D., A. T. Curns, and H. A. Thompson. 2004. A growth study of Coxiella 
burnetii Nine Mile Phase I and Phase II in fibroblasts. FEMS Immunol Med Microbiol 
42:291-7. 
 This paper reports growth characteristics of a avirulent strain of the bacterium. 
21. Shaw, E. I., H. Moura, A. R. Woolfitt, M. Ospina, H. A. Thompson, and J. R. Barr. 
2004. Identification of biomarkers of whole Coxiella burnetii phase I by MALDI-TOF 
mass spectrometry. Anal Chem 76:4017-22. 
 This paper reports the identification of biomarkers of the bacterium. 
22. Zamboni, D. S., M. A. Campos, A. C. Torrecilhas, K. Kiss, J. E. Samuel, D. T. 





Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage 
production of pro-inflammatory cytokines and resistance to infection. J Biol Chem 
279:54405-15. 
 This paper identifies a key factor if the innate immune response to infection with the 
bacterium. 
23. Zhang, G., K. Kiss, R. Seshadri, L. R. Hendrix, and J. E. Samuel. 2004. Identification 
and cloning of immunodominant antigens of Coxiella burnetii. Infect Immun 72:844-52. 
 This paper reports the identification of protective antigens for the prevention of infection 
with the bacterium. 
24. Zhang, G., H. To, K. E. Russell, L. R. Hendrix, T. Yamaguchi, H. Fukushi, K. Hirai, 
and J. E. Samuel. 2005. Identification and characterization of an immunodominant 28-
kilodalton Coxiella burnetii outer membrane protein specific to isolates associated with 
acute disease. Infect Immun 73:1561-7. 
 This paper reports the identification of a protective antigen for the prevention of infection 
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Eastern equine encephalitis virus 
Taxonomy: Family Togaviridae, Genus Alphavirus, Species Eastern equine encephalitis virus, 
Virus: Eastern equine encephalitis virus 
Publications: 
1. Cooper, L. A., B. J. Sina, M. J. Turell, and T. W. Scott. 2000. Effects of initial dose on 
eastern equine encephalomyelitis virus dependent mortality in intrathoracically inoculated 
Culiseta melanura (Diptera: Culicidae). J Med Entomol 37:815-9. 
 This paper the effects of the infecting dose of the virus on the survival of intrathoracically 
inoculated mosquitoes.  
2. Brown, T. M., C. J. Mitchell, R. S. Nasci, G. C. Smith, and J. T. Roehrig. 2001. 
Detection of eastern equine encephalitis virus in infected mosquitoes using a monoclonal 
antibody-based antigen-capture enzyme-linked immunosorbent assay. Am J Trop Med 
Hyg 65:208-13. 
 This paper describes the development of an ELISA system for the detection of the virus. 
3. Cooper, L. A., and T. W. Scott. 2001. Differential evolution of eastern equine 
encephalitis virus populations in response to host cell type. Genetics 157:1403-12. 
 This paper describes how repeatedly transferred strains of the virus through either 
mosquito or avian cells or in alternating passages between these two cell types leads to the 
evolution of new strains. 
4. Schoepp, R. J., J. F. Smith, and M. D. Parker. 2002. Recombinant chimeric western 
and eastern equine encephalitis viruses as potential vaccine candidates. Virology 302:299-
309. 
 This paper reports the construction of attenuated vaccine-candidate chimeric viruses 
constructed of parts from Western and Eastern encephalitis viruses. 
5. Lambert, A. J., D. A. Martin, and R. S. Lanciotti. 2003. Detection of North American 
eastern and western equine encephalitis viruses by nucleic acid amplification assays. J 
Clin Microbiol 41:379-85. 
 This paper reports the developed of a nucleic acid sequence-based amplification, standard 
reverse transcription PCR, and TaqMan nucleic acid amplification assays for the rapid 
detection of Eastern equine encephalitis viral RNAs from samples collected in the field 
and clinical samples. 
6. Nasci, R. S., K. L. Gottfried, K. L. Burkhalter, J. R. Ryan, E. Emmerich, and K. 
Dave. 2003. Sensitivity of the VecTest antigen assay for eastern equine encephalitis and 





 This paper reports the evaluation of a diagnostic assay for the virus. 
7. Ryan, J., K. Dave, E. Emmerich, B. Fernandez, M. Turell, J. Johnson, K. Gottfried, 
K. Burkhalter, A. Kerst, A. Hunt, R. Wirtz, and R. Nasci. 2003. Wicking assays for 
the rapid detection of West Nile and St. Louis encephalitis viral antigens in mosquitoes 
(Diptera: Culicidae). J Med Entomol 40:95-9. 
 This paper reports the development of a new diagnostic assay for the virus. 
8. O'Guinn, M. L., J. S. Lee, J. P. Kondig, R. Fernandez, and F. Carbajal. 2004. Field 
detection of eastern equine encephalitis virus in the Amazon Basin region of Peru using 
reverse transcription-polymerase chain reaction adapted for field identification of 
arthropod-borne pathogens. Am J Trop Med Hyg 70:164-71. 
 This paper reports the development of a PCR-based diagnostic assay for the detection of 
the virus in the field. 
9. Paessler, S., P. Aguilar, M. Anishchenko, H. Q. Wang, J. Aronson, G. Campbell, A. 
S. Cararra, and S. C. Weaver. 2004. The hamster as an animal model for eastern equine 
encephalitis--and its use in studies of virus entrance into the brain. J Infect Dis 189:2072-
6. 
 This paper reports the development of a hamster model for the disease caused by the 
virus. 
10. Vogel, P., W. M. Kell, D. L. Fritz, M. D. Parker, and R. J. Schoepp. 2005. Early 
events in the pathogenesis of eastern equine encephalitis virus in mice. Am J Pathol 
166:159-71. 
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Ehrlichia ruminantium (formerly known as Cowdria ruminantium) 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Alphaproteobacteria, Order 






1. Bell-Sakyi, L., E. A. Paxton, U. G. Munderloh, and K. J. Sumption. 2000. Growth of 
Cowdria ruminantium, the causative agent of heartwater, in a tick cell line. J Clin 
Microbiol 38:1238-40. 
 This paper describes a tick-derived cell line that supports growth of the bacterium. 
2. Byrom, B., A. F. Barbet, M. Obwolo, and S. M. Mahan. 2000. CD8(+) T cell knockout 
mice are less susceptible to Cowdria ruminantium infection than athymic, CD4(+) T cell 
knockout, and normal C57BL/6 mice. Vet Parasitol 93:159-72. 
 This paper reports the different susceptibilities of certain mice strains to the bacterium, 
and that immunity to the agent is mediated by both CD4 and CD8 cells. 
3. de Villiers, E. P., K. A. Brayton, E. Zweygarth, and B. A. Allsopp. 2000. Genome size 
and genetic map of Cowdria ruminantium. Microbiology 146 (Pt 10):2627-34. 
 This paper presents a complete physical map and a preliminary genetic map for the 
bacterium 
4. Peter, T. F., A. F. Barbet, A. R. Alleman, B. H. Simbi, M. J. Burridge, and S. M. 
Mahan. 2000. Detection of the agent of heartwater, Cowdria ruminantium, in 
Amblyomma ticks by PCR: validation and application of the assay to field ticks. J Clin 
Microbiol 38:1539-44. 
 This paper reports the valuation of a PCR assay used to detect the bacterium in ticks in the 
field. 
5. Peter, T. F., M. J. Burridge, and S. M. Mahan. 2000. Competence of the African 
tortoise tick, Amblyomma marmoreum (Acari: Ixodidae), as a vector of the agent of 
heartwater (Cowdria ruminantium). J Parasitol 86:438-41. 
 This paper reports the ability of a certain tick species to support replication of the 
bacterium. 
6. Shompole, S., F. R. Rurangirwa, A. Wambugu, J. Sitienei, D. M. Mwangi, A. J. 
Musoke, S. Mahan, C. W. Wells, and T. C. McGuire. 2000. Monoclonal antibody 
binding to a surface-exposed epitope on Cowdria ruminantium that is conserved among 
eight strains. Clin Diagn Lab Immunol 7:983-6. 
 This paper reports the isolation of an antibody that detects eight strains of the bacterium. 
7. Van Kleef, M., N. J. Gunter, H. Macmillan, B. A. Allsopp, V. Shkap, and W. C. 
Brown. 2000. Identification of Cowdria ruminantium antigens that stimulate proliferation 
of lymphocytes from cattle immunized by infection and treatment or with inactivated 
organisms. Infect Immun 68:603-14. 
 This paper reports the identification of several antigens of the bacterium that could be 
used for vaccine development. 
8. Barbet, A. F., W. M. Whitmire, S. M. Kamper, B. H. Simbi, R. R. Ganta, A. L. 
Moreland, D. M. Mwangi, T. C. McGuire, and S. M. Mahan. 2001. A subset of 
Cowdria ruminantium genes important for immune recognition and protection. Gene 
275:287-98. 
 This paper reports the identification and sequencing of a subset of recombinant genes 
encoding antigens recognized by antibody and peripheral blood mononuclear cells from 





9. Peter, T. F., S. M. Mahan, and M. J. Burridge. 2001. Resistance of leopard tortoises 
and helmeted guineafowl to Cowdria ruminantium infection (heartwater). Vet Parasitol 
98:299-307. 
 This paper reports that leopard tortoises and helmeted guineafowl is resistant to the agent. 
10. Semu, S. M., T. F. Peter, D. Mukwedeya, A. F. Barbet, F. Jongejan, and S. M. 
Mahan. 2001. Antibody responses to MAP 1B and other Cowdria ruminantium antigens 
are down regulated in cattle challenged with tick-transmitted heartwater. Clin Diagn Lab 
Immunol 8:388-96. 
 This paper reports that cattle antibody responses to certain antigens of the bacterium are 
downregulated in infected animals. 
11. Mwangi, D. M., D. J. McKeever, J. K. Nyanjui, A. F. Barbet, and S. M. Mahan. 
2002. Immunisation of cattle against heartwater by infection with Cowdria ruminantium 
elicits T lymphocytes that recognise major antigenic proteins 1 and 2 of the agent. Vet 
Immunol Immunopathol 85:23-32. 
This paper reports the examination T cell responses against recombinant analogues of 
surface-exposed Ehrlichia ruminantium antigens in cattle immunised by infection and 
treatment. 
12. Nyika, A., A. F. Barbet, M. J. Burridge, and S. M. Mahan. 2002. DNA vaccination 
with map1 gene followed by protein boost augments protection against challenge with 
Cowdria ruminantium, the agent of heartwater. Vaccine 20:1215-25. 
 This paper reports the results of a DNA vaccination approach. 
13. Pretorius, A., F. Van Strijp, K. A. Brayton, N. E. Collins, and B. A. Allsopp. 2002. 
Genetic immunization with Ehrlichia ruminantium GroEL and GroES homologues. Ann 
N Y Acad Sci 969:151-4. 
 This paper reports the results of a DNA vaccination approach. 
14. van Heerden, H., N. E. Collins, K. A. Brayton, C. Rademeyer, and B. A. Allsopp. 
2004. Characterization of a major outer membrane protein multigene family in Ehrlichia 
ruminantium. Gene 330:159-68. 
 This paper reports the discovery of an outer membrane protein family in the bacterium. 
15. Collins, N. E., J. Liebenberg, E. P. de Villiers, K. A. Brayton, E. Louw, A. Pretorius, 
F. E. Faber, H. van Heerden, A. Josemans, M. van Kleef, H. C. Steyn, M. F. van 
Strijp, E. Zweygarth, F. Jongejan, J. C. Maillard, D. Berthier, M. Botha, F. Joubert, 
C. H. Corton, N. R. Thomson, M. T. Allsopp, and B. A. Allsopp. 2005. The genome of 
the heartwater agent Ehrlichia ruminantium contains multiple tandem repeats of actively 
variable copy number. Proc Natl Acad Sci U S A 102:838-43. 
 This paper reports the sequence of the genome of the bacterium. 
 







Foot and mouth disease virus 
Taxonomy: Family Picornaviridae, Genus Aphthovirus, Species Foot and mouth disease virus, 
Virus: Foot and mouth disease virus. 
Publications: 
1. Beard, C. W., and P. W. Mason. 2000. Genetic determinants of altered virulence of 
Taiwanese foot-and-mouth disease virus. J Virol 74:987-91. 
 This paper describes molecular virulence determinants of the virus. 
2. Brown, C. C., J. Chinsangaram, and M. J. Grubman. 2000. Type I interferon 
production in cattle infected with 2 strains of foot-and-mouth disease virus, as determined 
by in situ hybridization. Can J Vet Res 64:130-3. 
 This paper reports the interferon reponse of cattle infected with the virus. 
3. Burrage, T., E. Kramer, and F. Brown. 2000. Structural differences between foot-and-
mouth disease and poliomyelitis viruses influence their inactivation by aziridines. Vaccine 
18:2454-61. 
 This paper reports the susceptibility of the virus to a potential antiviral agent. 
4. Jackson, T., D. Sheppard, M. Denyer, W. Blakemore, and A. M. King. 2000. The 
epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol 
74:4949-56. 
 This paper reports the identification of a receptor for the virus. 
5. Konet, D. S., J. M. Mezencio, G. Babcock, and F. Brown. 2000. Inhibitors of RT-PCR 
in serum. J Virol Methods 84:95-8. 
 This paper reports problems with amplifying the genome of the virus. 
6. Neff, S., P. W. Mason, and B. Baxt. 2000. High-efficiency utilization of the bovine 
integrin alpha(v)beta(3) as a receptor for foot-and-mouth disease virus is dependent on the 
bovine beta(3) subunit. J Virol 74:7298-306. 
 This paper reports specifics of the interaction of the virus with one of its receptors. 
7. Chinsangaram, J., M. Koster, and M. J. Grubman. 2001. Inhibition of L-deleted foot-
and-mouth disease virus replication by alpha/beta interferon involves double-stranded 
RNA-dependent protein kinase. J Virol 75:5498-503. 
 This paper reports the specifics of the interferon-response to infection with the virus. 
8. Knowles, N. J., P. R. Davies, T. Henry, V. O'Donnell, J. M. Pacheco, and P. W. 
Mason. 2001. Emergence in Asia of foot-and-mouth disease viruses with altered host 
range: characterization of alterations in the 3A protein. J Virol 75:1551-6. 
 This paper reports the molecular characterization of novel strains of the virus. 
9. Mayr, G. A., V. O'Donnell, J. Chinsangaram, P. W. Mason, and M. J. Grubman. 
2001. Immune responses and protection against foot-and-mouth disease virus (FMDV) 
challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19:2152-62. 





10. Miller, L. C., W. Blakemore, D. Sheppard, A. Atakilit, A. M. King, and T. Jackson. 
2001. Role of the cytoplasmic domain of the beta-subunit of integrin alpha(v)beta6 in 
infection by foot-and-mouth disease virus. J Virol 75:4158-64. 
 This paper reports specifics of the interaction of the virus with one of its receptors. 
11. Neff, S., and B. Baxt. 2001. The ability of integrin alpha(v)beta(3) To function as a 
receptor for foot-and-mouth disease virus is not dependent on the presence of complete 
subunit cytoplasmic domains. J Virol 75:527-32. 
 This paper reports specifics of the interaction of the virus with one of its receptors. 
12. O'Donnell, V. K., J. M. Pacheco, T. M. Henry, and P. W. Mason. 2001. Subcellular 
distribution of the foot-and-mouth disease virus 3A protein in cells infected with viruses 
encoding wild-type and bovine-attenuated forms of 3A. Virology 287:151-62. 
 This paper reports the intracellular distribution of a protein of the virus. 
13. Wang, C. Y., T. Y. Chang, A. M. Walfield, J. Ye, M. Shen, M. L. Zhang, J. Lubroth, 
S. P. Chen, M. C. Li, Y. L. Lin, M. H. Jong, P. C. Yang, N. Chyr, E. Kramer, and F. 
Brown. 2001. Synthetic peptide-based vaccine and diagnostic system for effective control 
of FMD. Biologicals 29:221-8. 
 This paper reports the evaluation of a vaccine candidate. 
14. Callahan, J. D., F. Brown, F. A. Osorio, J. H. Sur, E. Kramer, G. W. Long, J. 
Lubroth, S. J. Ellis, K. S. Shoulars, K. L. Gaffney, D. L. Rock, and W. M. Nelson. 
2002. Use of a portable real-time reverse transcriptase-polymerase chain reaction assay 
for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220:1636-42. 
 This paper reports the evaluation of a detection system. 
15. Capozzo, A. V., D. J. Burke, J. W. Fox, I. E. Bergmann, J. L. La Torre, and P. R. 
Grigera. 2002. Expression of foot and mouth disease virus non-structural polypeptide 
3ABC induces histone H3 cleavage in BHK21 cells. Virus Res 90:91-9. 
 This paper reports the functional characterization of a protein of the virus. 
16. Jackson, T., A. P. Mould, D. Sheppard, and A. M. King. 2002. Integrin alphavbeta1 is 
a receptor for foot-and-mouth disease virus. J Virol 76:935-41. 
 This paper reports the identification of a receptor for the virus. 
17. Lazo, A., J. Tassello, V. Jayarama, A. Ohagen, V. Gibaja, E. Kramer, A. 
Marmorato, D. Billia-Shaveet, A. Purmal, F. Brown, and J. Chapman. 2002. Broad-
spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. 
Vox Sang 83:313-23. 
 This paper reports the evaluation of a virus-inactivating substance. 
18. Mason, P. W., S. V. Bezborodova, and T. M. Henry. 2002. Identification and 
characterization of a cis-acting replication element (cre) adjacent to the internal ribosome 
entry site of foot-and-mouth disease virus. J Virol 76:9686-94. 
 This paper reports the identification of a gene-regulating sequence in the genome of the 
virus. 
19. Moraes, M. P., G. A. Mayr, P. W. Mason, and M. J. Grubman. 2002. Early protection 
against homologous challenge after a single dose of replication-defective human 
adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) 
strain A24. Vaccine 20:1631-9. 





20. Van Rensburg, H. G., and P. W. Mason. 2002. Construction and evaluation of a 
recombinant foot-and-mouth disease virus: implications for inactivated vaccine 
production. Ann N Y Acad Sci 969:83-7. 
 This paper reports the development of a vaccine candidate. 
21. Wang, C. Y., T. Y. Chang, A. M. Walfield, J. Ye, M. Shen, S. P. Chen, M. C. Li, Y. L. 
Lin, M. H. Jong, P. C. Yang, N. Chyr, E. Kramer, and F. Brown. 2002. Effective 
synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20:2603-10. 
 This paper reports the development of a vaccine candidate. 
22. Amass, S. F., J. M. Pacheco, P. W. Mason, J. L. Schneider, R. M. Alvarez, L. K. 
Clark, and D. Ragland. 2003. Procedures for preventing the transmission of foot-and-
mouth disease virus to pigs and sheep by personnel in contact with infected pigs. Vet Rec 
153:137-40. 
 This paper reports methods for prevening the transmission of the virus.  
23. Bautista, E. M., G. S. Ferman, and W. T. Golde. 2003. Induction of lymphopenia and 
inhibition of T cell function during acute infection of swine with foot and mouth disease 
virus (FMDV). Vet Immunol Immunopathol 92:61-73. 
 This paper reports the immunopathology of swine after infection with the virus. 
24. Chinsangaram, J., M. P. Moraes, M. Koster, and M. J. Grubman. 2003. Novel viral 
disease control strategy: adenovirus expressing alpha interferon rapidly protects swine 
from foot-and-mouth disease. J Virol 77:1621-5. 
 This paper reports the development of a vaccine candidate. 
25. Duque, H., and B. Baxt. 2003. Foot-and-mouth disease virus receptors: comparison of 
bovine alpha(V) integrin utilization by type A and O viruses. J Virol 77:2500-11. 
 This paper reports the comparison of receptors used by different strains of the virus. 
26. Fischer, D., D. Rood, R. W. Barrette, A. Zuwallack, E. Kramer, F. Brown, and L. K. 
Silbart. 2003. Intranasal immunization of guinea pigs with an immunodominant foot-and-
mouth disease virus peptide conjugate induces mucosal and humoral antibodies and 
protection against challenge. J Virol 77:7486-91. 
 This paper reports the evaluation of a vaccine candidate. 
27. Kweon, C. H., Y. J. Ko, W. I. Kim, S. Y. Lee, J. J. Nah, K. N. Lee, H. J. Sohn, K. S. 
Choi, B. H. Hyun, S. W. Kang, Y. S. Joo, and J. Lubroth. 2003. Development of a 
foot-and-mouth disease NSP ELISA and its comparison with differential diagnostic 
methods. Vaccine 21:1409-14. 
 This paper reports the development of a diagnostic system. 
28. Mason, P. W., J. Chinsangaram, M. P. Moraes, G. A. Mayr, and M. J. Grubman. 
2003. Engineering better vaccines for foot-and-mouth disease. Dev Biol (Basel) 114:79-
88. 
 This paper reports the development of new vaccine candidate. 
29. Mason, P. W., J. M. Pacheco, Q. Z. Zhao, and N. J. Knowles. 2003. Comparisons of 
the complete genomes of Asian, African and European isolates of a recent foot-and-mouth 
disease virus type O pandemic strain (PanAsia). J Gen Virol 84:1583-93. 
 This paper reports the genomic comparisons of different strains of the virus. 
30. Moraes, M. P., J. Chinsangaram, M. C. Brum, and M. J. Grubman. 2003. Immediate 





expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 
22:268-79. 
 This paper reports the evaluation of a vaccine candidate. 
31. Pacheco, J. M., T. M. Henry, V. K. O'Donnell, J. B. Gregory, and P. W. Mason. 
2003. Role of nonstructural proteins 3A and 3B in host range and pathogenicity of foot-
and-mouth disease virus. J Virol 77:13017-27. 
 This paper reports that proteins of the virus are determinants of host range and virulence. 
32. Pantarotto, D., C. D. Partidos, J. Hoebeke, F. Brown, E. Kramer, J. P. Briand, S. 
Muller, M. Prato, and A. Bianco. 2003. Immunization with peptide-functionalized 
carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol 
10:961-6. 
 This paper reports the evaluation of a vaccine candidate. 
33. Rodriguez, L. L., J. Barrera, E. Kramer, J. Lubroth, F. Brown, and W. T. Golde. 
2003. A synthetic peptide containing the consensus sequence of the G-H loop region of 
foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces 
peptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine 
21:3751-6. 
 This paper reports the evaluation of a vaccine candidate. 
34. Wu, Q., M. C. Brum, L. Caron, M. Koster, and M. J. Grubman. 2003. Adenovirus-
mediated type I interferon expression delays and reduces disease signs in cattle challenged 
with foot-and-mouth disease virus. J Interferon Cytokine Res 23:359-68. 
 This paper reports the evaluation of a vaccine candidate. 
35. Wu, Q., M. P. Moraes, and M. J. Grubman. 2003. Recombinant adenovirus co-
expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in 
vitro characterization and induction of neutralizing antibodies against FMDV in swine. 
Virus Res 93:211-9. 
 This paper reports the evaluation of a vaccine candidate. 
36. Zhao, Q., J. M. Pacheco, and P. W. Mason. 2003. Evaluation of genetically engineered 
derivatives of a Chinese strain of foot-and-mouth disease virus reveals a novel cell-
binding site which functions in cell culture and in animals. J Virol 77:3269-80. 
 This paper reports the characterization of a novel strain of the virus. 
37. Aarthi, D., K. Ananda Rao, R. Robinson, and V. A. Srinivasan. 2004. Validation of 
binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture 
vaccine. Biologicals 32:153-6. 
 This paper reports the evaluation of a chemical inactivating agent. 
38. Clavijo, A., E. M. Zhou, K. Hole, B. Galic, and P. Kitching. 2004. Development and 
use of a biotinylated 3ABC recombinant protein in a solid-phase competitive ELISA for 
the detection of antibodies against foot-and-mouth disease virus. J Virol Methods 
120:217-27. 
 This paper reports the evaluation of a diagnostic system. 
39. Duque, H., M. LaRocco, W. T. Golde, and B. Baxt. 2004. Interactions of foot-and-
mouth disease virus with soluble bovine alphaVbeta3 and alphaVbeta6 integrins. J Virol 
78:9773-81. 





40. Jackson, T., S. Clark, S. Berryman, A. Burman, S. Cambier, D. Mu, S. Nishimura, 
and A. M. King. 2004. Integrin alphavbeta8 functions as a receptor for foot-and-mouth 
disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J Virol 
78:4533-40. 
 This paper reports the characterization of the interaction of the virus with one of its 
receptors. 
41. van Rensburg, H. G., T. M. Henry, and P. W. Mason. 2004. Studies of genetically 
defined chimeras of a European type A virus and a South African Territories type 2 virus 
reveal growth determinants for foot-and-mouth disease virus. J Gen Virol 85:61-8. 
 This paper reports the characterization of recombinant strains of the virus. 
42. Bautista, E. M., G. S. Ferman, D. Gregg, M. C. Brum, M. J. Grubman, and W. T. 
Golde. 2005. Constitutive expression of alpha interferon by skin dendritic cells confers 
resistance to infection by foot-and-mouth disease virus. J Virol 79:4838-47. 
 This paper reports the molecular basis of resistence of dendritic cells to infection with the 
virus. 
43. Beignon, A. S., F. Brown, P. Eftekhari, E. Kramer, J. P. Briand, S. Muller, and C. D. 
Partidos. 2005. A peptide vaccine administered transcutaneously together with cholera 
toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol 
Immunopathol 104:273-80. 
 This paper reports the evaluation of a vaccine candidate. 
44. Carrillo, C., E. R. Tulman, G. Delhon, Z. Lu, A. Carreno, A. Vagnozzi, G. F. Kutish, 
and D. L. Rock. 2005. Comparative genomics of foot-and-mouth disease virus. J Virol 
79:6487-504. 
 This paper reports the comparison of the genomic sequences of differents strains of the 
virus. 
45. de los Santos, T., Q. Wu, S. de Avila Botton, and M. J. Grubman. 2005. Short hairpin 
RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits 
replication of multiple serotypes of foot-and-mouth disease virus. Virology 335:222-31. 
 This paper reports the development of a potential antiviral. 
46. Dus Santos, M. J., C. Carrillo, F. Ardila, R. D. Rios, P. Franzone, M. E. Piccone, A. 
Wigdorovitz, and M. V. Borca. 2005. Development of transgenic alfalfa plants 
containing the foot and mouth disease virus structural polyprotein gene P1 and its 
utilization as an experimental immunogen. Vaccine 23:1838-43. 
 This paper reports the development of a vaccine candidate. 
47. O'Donnell, V., M. LaRocco, H. Duque, and B. Baxt. 2005. Analysis of foot-and-mouth 
disease virus internalization events in cultured cells. J Virol 79:8506-18. 
 This paper reports characteristics of the cell-entry process of the virus.  
48. Pacheco, J. M., M. C. Brum, M. P. Moraes, W. T. Golde, and M. J. Grubman. 2005. 
Rapid protection of cattle from direct challenge with foot-and-mouth disease virus 
(FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. 
Virology 337:205-209. 






NIH Grants: None identified. 
 
Flexal virus 
Taxonomy: Family Arenaviridae, Genus Arenavirus, Species: Flexal virus. Virus: Flexal virus, 
BeAn 293022 virus. 
Publications: 
1. Christina F. Spiropoulou, Stefan Kunz, Pierre E. Rollin, Kevin P. Campbell, and 
Michael B. A. Oldstone. 2002. New World Arenavirus Clade C, but Not Clade A and B 
Viruses, Utilizes -Dystroglycan as Its Major Receptor. J Virol 76:51406. 
This paper comes to the conclusion that Flexal, Guanaríto, Machupo, and Sabiá viruses do 
not use the Lassa fever virus receptor -Dystroglycan. 
2. Angela M. Archer, and Rebeca Rico-Hesse. 2002. High Genetic Divergence and 
Recombination in Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanaríto, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 
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12. Johansson, A., S. K. Urich, M. C. Chu, A. Sjostedt, and A. Tarnvik. 2002. In vitro 
susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect 
Dis 34:327-30. 
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15. Emanuel, P. A., R. Bell, J. L. Dang, R. McClanahan, J. C. David, R. J. Burgess, J. 
Thompson, L. Collins, and T. Hadfield. 2003. Detection of Francisella tularensis within 
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 The paper reports the comparison of the immunological properties of lipopolysaccharides 
isolated from the bacterium and a close relative. 
18. Versage, J. L., D. D. Severin, M. C. Chu, and J. M. Petersen. 2003. Development of a 
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CANADA | CANADA - OTTAWA  
 $213,750 | 2001 | Conlan, Joseph W | NATIONAL RESEARCH COUNCIL OF 
CANADA | CANADA - OTTAWA  
37 29 
1U54AI057168-
010004 CROSS, ANDREW 
DESIGN OF ATTENUATED 
TULAREMIA VACCINE  
Total: $22,072,698 *  
 $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
38 29 
1P01AI055637-
010001 DAEFLER, SIMON 
Intracellular trafficking of the F. 
tularensis vacuole  
Total: $5,077,589 *  
 $1,751,649 | 2005 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,700,631 | 2004 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,625,309 | 2003 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
39 29 
1U54AI057141-
010005 ERNST, ROBERT 
Bacterial Lipopolysaccharide 
Structure  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
40 29 
1R21AI056059-
01 ESCUYER, VINCENT 
Virulence genes identification in 
Francisella tularensis  
Total: $640,006  
 $321,438 | 2004 | Escuyer, Vincent E | SOUTHERN RESEARCH INSTITUTE 
| BIRMINGHAM, AL  
 $318,568 | 2003 | Escuyer, Vincent E | SOUTHERN RESEARCH INSTITUTE 
| BIRMINGHAM, AL  
41 29 
1P01AI056296-
01 GLIMCHER, LAURIE 
Arming the Immune System 





Total: $11,095,528 *  
 $4,365,288 | 2005 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $4,276,251 | 2004 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $2,453,989 | 2003 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
42 29 
1P01AI056296-
010002 GRUSBY, MICHAEL 
Regulation of the Immune 
Response to Pathogens by Stat4  
Total: $11,095,528 *  
 $4,365,288 | 2005 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $4,276,251 | 2004 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $2,453,989 | 2003 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
43 29 
1U54AI057141-
010003 GUINA, TINA Bacterial Proteome  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
44 29 
1R21EB000985-
01 HEFFRON, FRED 
Rapid Identification of Secreted of 
F tularensis Antigen  
Total: $528,500  
 $226,500 | 2003 | Heffron, Fred L | OREGON HEALTH & SCIENCE 
UNIVERSITY | PORTLAND, OR  
 $302,000 | 2002 | Heffron, Fred L | OREGON HEALTH & SCIENCE 






Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
 $391,730 | 2004 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF 






Genetic susceptibility to F 
tularensis  
Total: $275,600  
 $275,600 | 2004 | Cook, Donald N | DUKE UNIVERSITY | DURHAM, NC  
47 29 
1R21AI059489-








Total: $630,000  
 $315,000 | 2005 | Lewis, Kim A | NORTHEASTERN UNIVERSITY | 
BOSTON, MA  
 $315,000 | 2004 | Lewis, Kim A | NORTHEASTERN UNIVERSITY | 
BOSTON, MA  
48 29 
1P01AI056320-
01 METZGER, DENNIS 
Mucosal Immunopathogenesis of 
Franscisella Tularensis  
Total: $4,819,067 *  
 $1,941,836 | 2005 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $1,890,499 | 2004 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $986,732 | 2003 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
49 29 
1P01AI056320-
010003 METZGER, DENNIS 
Immune Protection Against 
Pneumonic Tularemia  
Total: $4,819,067 *  
 $1,941,836 | 2005 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $1,890,499 | 2004 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $986,732 | 2003 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 






Outer membrane proteins & 
lipoproteins of F. tularensis  
Total: $5,077,589 *  
 $1,751,649 | 2005 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,700,631 | 2004 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,625,309 | 2003 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 






Core--Equipment - Laser Scanning 
Confocal Microscope  
Total: $5,077,589 *  
 $1,751,649 | 2005 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,700,631 | 2004 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,625,309 | 2003 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
52 29 
1U54AI057141-
010001 OLSON, MAYNARD Bacterial Genome Diversity  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  





SEATTLE, WA  
53 29 
1P01AI056296-
010005 PETSKO, GREGORY 
Structural Biology of Immune 
System Modulators  
Total: $11,095,528 *  
 $4,365,288 | 2005 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $4,276,251 | 2004 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $2,453,989 | 2003 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 






Tularemia and Lung Innate 
Immunity  
Total: $1,354,051 *  
 $670,963 | 2004 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
 $683,088 | 2003 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
55 29 
1P01AI056320-
010002 SELLATI, TIMOTHY 
Innate Pattern Recognition of F. 
tularensis  
Total: $4,819,067 *  
 $1,941,836 | 2005 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $1,890,499 | 2004 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $986,732 | 2003 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 






Polyclonal Antibody Libraries for 
Tularemia  
Total: $6,264,376 *  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $1,584,061 | 2003 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
57 29 
1U54AI057141-
010007 SKERRETT, SHAWN Airway Inflammation  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 






Genetics of virulence expression 
by F. tularensis  





MED CTR/DALLAS | DALLAS, TX  
 $1,700,631 | 2004 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,625,309 | 2003 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 






Conjugate Vaccine for the 
Prevention of Tularemia  
Total: $26,169,985  
 $10,173,756 | 2005 | Kasper, Dennis L | HARVARD UNIVERSITY 
(MEDICAL SCHOOL) | BOSTON, MA  
 $11,843,830 | 2004 | Kasper, Dennis L | HARVARD UNIVERSITY 
(MEDICAL SCHOOL) | BOSTON, MA  
 $4,152,399 | 2003 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
60 14 
1P01AI056320-
010004 BANAS, JEFFREY 
Mutant F. tularensis Interactions 
with Macrophages  
Total: $4,819,067 *  
 $1,941,836 | 2005 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $1,890,499 | 2004 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $986,732 | 2003 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
61 14 
1R03AI048492-
01 BENACH, JORGE 
HOST RESPONSES TO THE 
TULAREMIA AGENT  
Total: $225,750  
 $75,250 | 2002 | Benach, Jorge L | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
 $75,250 | 2001 | Benach, Jorge L | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
 $75,250 | 2000 | Benach, Jorge L | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
62 14 
1R01AI056047-
01 COLLINS, GREG 
Sensitive Diagnosis of Biowarfare 
Agents on a Microchip  
Total: $1,154,639  
 $456,719 | 2005 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY 
| WASHINGTON, DC  
 $455,617 | 2004 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY 
| WASHINGTON, DC  
 $242,303 | 2003 | Collins, Greg E | U.S. NAVAL RESEARCH LABORATORY 






Anti-infectives that target 
bacterial ribosomes  
Total: $621,051  
 $621,051 | 2004 | Cunningham, Philip R | WAYNE STATE UNIVERSITY | 
DETROIT, MI  





01 Anti-Endotoxin Agents  
Total: $810,372  
 $271,792 | 2005 | David, Sunil A | UNIVERSITY OF KANSAS LAWRENCE | 
LAWRENCE, KS  
 $267,961 | 2004 | David, Sunil A | UNIVERSITY OF KANSAS LAWRENCE | 
LAWRENCE, KS  
 $270,619 | 2003 | David, Sunil A | UNIVERSITY OF KANSAS LAWRENCE | 
LAWRENCE, KS  
65 14 
1R43AI058326-
01A1 DE GROOT, ANNE 
A GENOME-DERIVED, EPITOPE-
DRIVEN TULAREMIA VACCINE  
Total: $421,437  
 $421,437 | 2004 | Degroot, Anne S | EPIVAX, INC. | PROVIDENCE, RI  
66 14 
1P01AI056320-
010001 DRAKE, JAMES 
Immunobiology of F. tularensis-
Macrophage Interactions  
Total: $4,819,067 *  
 $1,941,836 | 2005 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $1,890,499 | 2004 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
 $986,732 | 2003 | Metzger, Dennis W | ALBANY MEDICAL COLLEGE OF 
UNION UNIV | ALBANY, NY  
67 14 
1U01AI056480-
01 DUNN, JOHN 
Rapid Detection and Identification 
of Zoonotic Pathogens  
Total: $2,387,159  
 $879,674 | 2005 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-
BROOKHAVEN LAB | UPTON, NY  
 $854,379 | 2004 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-
BROOKHAVEN LAB | UPTON, NY  
 $653,106 | 2003 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-
BROOKHAVEN LAB | UPTON, NY  
68 14 
1R01CI000099-
01 ECKER, DAVID 
Automated Simultaneous 







Total: $6,264,376 *  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $1,584,061 | 2003 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
70 14 
1Z01AI000725-
06 FARBER, JOSHUA 




08 FARBER, JOSHUA Activities Of Chemokines In Vivo  
72 14 
1P01AI056296-





Against Pathogens  
Total: $11,095,528 *  
 $4,365,288 | 2005 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $4,276,251 | 2004 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $2,453,989 | 2003 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
73 14 
1P01AI055637-
010002 HANSEN, ERIC 
Identification of F. tularensis gene 
products  
Total: $5,077,589 *  
 $1,751,649 | 2005 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,700,631 | 2004 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
 $1,625,309 | 2003 | Norgard, Michael V | UNIVERSITY OF TEXAS SW 
MED CTR/DALLAS | DALLAS, TX  
74 14 
1R01AI050564-
01 KLOSE, KARL 
An Oral Vaccine Against Multiple 
Biowarfare Agents  
Total: $1,466,918  
 $358,704 | 2004 | Klose, Karl E | UNIVERSITY OF TEXAS SAN ANTONIO | 
SAN ANTONIO, TX  
 $30,791 | 2003 | Klose, Karl E | UNIVERSITY OF TEXAS HLTH SCI CTR 
SAN ANT | SAN ANTONIO, TX  
 $399,948 | 2003 | Klose, Karl E | UNIVERSITY OF TEXAS HLTH SCI CTR 
SAN ANT | SAN ANTONIO, TX  
 $325,125 | 2002 | Klose, Karl E | UNIVERSITY OF TEXAS HLTH SCI CTR 
SAN ANT | SAN ANTONIO, TX  
 $352,350 | 2001 | Klose, Karl E | UNIVERSITY OF TEXAS HLTH SCI CTR 
SAN ANT | SAN ANTONIO, TX  
75 14 
1P01AI056296-
010003 KRAMNIK, IGOR 
Genetic Control of Host Resistance 
to Airborne Pathogens  
Total: $11,095,528 *  
 $4,365,288 | 2005 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $4,276,251 | 2004 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
 $2,453,989 | 2003 | Glimcher, Laurie H | HARVARD UNIVERSITY (SCH OF 
PUBLIC HLTH) | BOSTON, MA  
76 14 
1U56AI057192-
010002 KUSNER, DAVID 
Lung Host Pathogen Interactions 
Research  
Total: $1,477,975 *  
 $1,477,975 | 2003 | Britigan, Bradley E | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
77 14 
1U54AI057168-
01 LEVINE, MYRON 
Defense against Biowarfare and 
Emerging Infection Agents  
Total: $22,072,698 *   $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND 





 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
78 14 
1U54AI057168-
010007 LEVINE, MYRON CAREER DEVELOPMENT PROJECTS  
Total: $22,072,698 *  
 $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
79 14 
1R21AI059483-
01 LEWIS, KIM 
NOVEL METHODS FOR DISCOVERY 
OF ANTI-MICROBIALS  
Total: $628,934  
 $314,200 | 2005 | Lewis, Kim A | NORTHEASTERN UNIVERSITY | 
BOSTON, MA  
 $314,734 | 2004 | Lewis, Kim A | NORTHEASTERN UNIVERSITY | 
BOSTON, MA  
80 14 
1P01AI056295-
01A1 LYONS, C. 
Pulmonary responses to 
Bioweapon Category A Pathogens  
Total: $1,890,737  
 $1,890,737 | 2005 | Lyons, C Rick | UNIVERSITY OF NEW MEXICO 
ALBUQUERQUE | ALBUQUERQUE, NM  
81 14 
1U54AI057141-
010002 MANOIL, COLIN 
Bacterial Essential and Virulence 
Gene  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
82 14 
1U54AI057141-
019008 MANOIL, COLIN CORE--Bacterial Strain  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
83 14 
1U01AI061260-
01 MILLER, MARK 
VSV as a vector for cytokine-
assisted tularemia vaccines  





SCI CTR | MEMPHIS, TN  
84 14 
2P01AI044642-
05 NAUSEEF, WILLIAM 
Innate immune response to 
microbial infection  
Total: $6,572,766  
 $1,364,143 | 2005 | Nauseef, William M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
 $1,327,889 | 2004 | Nauseef, William M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
 $773,147 | 2003 | Nauseef, William M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
 $1,343,563 | 2002 | Nauseef, William M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
 $894,121 | 2001 | Nauseef, William M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
 $869,903 | 2000 | NAUSEEF, WILLIAM M | UNIVERSITY OF IOWA | IOWA 
CITY, IA  
85 14 
1R41AI052921-
01A1 PAPISOV, MIKHAIL 
SYSTEMIC LYMPH NODE SPECIFIC 
AGENTS  
Total: $100,000  
 $100,000 | 2003 | Papisov, Mikhail I | NANOPHARMA, CORPORATION | 
BOSTON, MA  
86 14 
1R21AI053394-
01A1 PIERINI, LYNDA 
Screening for Inhibitors of F. 
tularensis Virulence  
Total: $498,220  
 $252,000 | 2004 | Pierini, Lynda M | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $246,220 | 2003 | Pierini, Lynda M | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
87 14 
1P01AI063302-
01 PORTNOY, DANIEL 
Intracellular Pathogens and 
Innate Immunity  
Total: $2,714,524  
 $2,014,030 | 2005 | Portnoy, Daniel A | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
 $700,494 | 2004 | Portnoy, Daniel A | UNIVERSITY OF CALIFORNIA 
BERKELEY | BERKELEY, CA  
88 14 
1R43AI052898-
01 PRUDENT, JAMES 
Rapid Turn-around Testing for 
Bioterrorism Agents  
Total: $105,250  
 $105,250 | 2002 | Prudent, James R | ERAGEN BIOSCIENCES, INC. | 
MADISON, WI  
89 14 
2R44AI052898-
02 PRUDENT, JAMES 
Rapid Turn-arround Multiplex 
Testing: Bioweapon Agents  
Total: $938,550  
 $389,796 | 2004 | Prudent, James R | ERAGEN BIOSCIENCES, INC. | 
MADISON, WI  











Small Molecule Inhibitors of 
Bacterial Cell Division  
Total: $212,199  
 $212,199 | 2004 | Raychaudhuri, Debabrata | TUFTS UNIVERSITY 
BOSTON | BOSTON, MA  
91 14 
1U54AI057141-
010004 SALAMA, NINA Virulence Factors in the Airway  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
92 14 
1U54AI057141-
019006 SALAMA, NINA CORE--DNA Microarray  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 








Bioterrorism Agents  
Total: $1,354,051 *  
 $670,963 | 2004 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
 $683,088 | 2003 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 








Total: $1,354,051 *  
 $670,963 | 2004 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 
TWIN CITIES | MINNEAPOLIS, MN  
 $683,088 | 2003 | Schlievert, Patrick M | UNIVERSITY OF MINNESOTA 







markers for bacteria  
Total: $179,725  
 $179,725 | 2005 | Schweizer, Herbert P | COLORADO STATE 
UNIVERSITY-FORT COLLINS | FORT COLLINS, CO  
96 14 
1U19AI056543-





Total: $6,264,376 *  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $1,584,061 | 2003 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
97 14 
1U19AI056543-
019002 SHAPIRO, DANIEL Bacteriology/Immunology  
Total: $6,264,376 *  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $1,584,061 | 2003 | Rice, Peter A | BOSTON MEDICAL CENTER | 
BOSTON, MA  
98 14 
1UC1AI067203-
01 SIGAL, GEORGE 
A Multiplexed Point-of-Care 
Diagnostic System for Bio-T*  
99 14 
1R01AI057831-
01 TAYLOR, GREGORY 
Regulation of IFN-g-induced 
Innate Immunity by LRG-47  
Total: $755,096  
 $385,000 | 2005 | Taylor, Gregory A | DUKE UNIVERSITY | DURHAM, NC  
 $370,096 | 2004 | Taylor, Gregory A | DUKE UNIVERSITY | DURHAM, NC  
100 14 
2R01HL062608-
11 VASIL, MICHAEL 
Novel Class of Phospholipases-
Molecular Pathogenesis  
Total: $1,930,954  
 $423,679 | 2004 | Vasil, Michael L | UNIVERSITY OF COLORADO 
DENVER/HSC AURORA | AURORA, CO  
 $451,032 | 2003 | Vasil, Michael L | UNIVERSITY OF COLORADO HLTH 
SCIENCES CTR | AURORA, CO  
 $361,368 | 2002 | Vasil, Michael L | UNIVERSITY OF COLORADO HLTH 
SCIENCES CTR | DENVER, CO  
 $352,492 | 2001 | Vasil, Michael L | UNIVERSITY OF COLORADO HLTH 
SCIENCES CTR | DENVER, CO  
 $342,383 | 2000 | VASIL, MICHAEL L | UNIVERSITY OF COLORADO HLTH 
SCIENCES CTR | DENVER, CO  
101 14 
1R21AI060953-
01 WHITE, STEPHEN 
Development of DHPS as a 
Bioterrorism Therapeutic Target  
Total: $264,000  
 $264,000 | 2004 | White, Stephen W | ST. JUDE CHILDREN'S RESEARCH 
HOSPITAL | MEMPHIS, TN  
102 14 
1R21AI059225-
01A1 ZENG, MINGTAO 









Taxonomy: Family Poxviridae, Subfamily Chordopoxvirinae, Genus Capripoxvirus, Species: 
Goatpox virus. Virus: Goatpox virus. 
Publications: 
1. Tulman, E. R., C. L. Afonso, Z. Lu, L. Zsak, J.-H. Sur, N. T. Sandybaev, U. Z. 
Kerembekova, V. L. Zaitsev, G. F. Kutish, and D. L. Rock. 2002. The Genomes of 
Sheeppox and Goatpox Viruses. J Virol 76:6054-61. 
This paper describes the sequencing and characterization, and comparison of Sheeppox 
and Goatpox virus. 
 
NIH Grants: None 
 
Hendra virus  
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Henipavirus, Species: Hendra virus, Virus: Hendra virus 
Publications: 
1. Tamin, A., B. H. Harcourt, T. G. Ksiazek, P. E. Rollin, W. J. Bellini, and P. A. Rota. 
2002. Functional Properties of the Fusion and Attachment Glycoproteins of Nipah Virus. 
Virology 296:190-200. 
This paper describes the characterization of the immunogenic and functional properties of 
the fusion and attachment proteins of Hendra and Nipah virus after vaccination of mice 
with recombinant vaccinia viruses. 
2. Bossart, K. N., G. Crameri, A. S. Dimitrov, B. A. Mungall, Y. R. Feng, J. R. Patch, 
A. Choudhary, L. F. Wang, B. T. Eaton, and C. C. broder. 2005. Receptor binding, 
fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G 
glycoprotein of Hendra virus. J Virol 79: 6690-6702. 
This paper reports the properties of the surface protein of henipaviruses, and sheds light 
on the cell-entry mechanism.  
3. Bonaparte, M. I., A. S. Dimitrov, K. N. Bossart, G. Crameri, B. A. Mungall, K. A. 
Bishop, V. Choudry, D. S. Dimitrov, L. F. Wang, B. T. Eaton, C. C. Broder. 2005. 
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl 
Acad Med Sci U S A 







1 100 1R21AI063052-01 DUTCH, REBECCA 
Proteolytic cleavage of the Hendra 
virus fusion protein  
Total: $294,600  
 $294,600 | 2005 | Dutch, Rebecca E | UNIVERSITY OF KENTUCKY | LEXINGTON, 
KY  
2 100 1R21AI056185-01 MOSCONA, ANNE 
Fusion triggering by Hendra virus F 
protein: role of G  
Total: $678,000  
 $339,000 | 2004 | Moscona, Anne | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
 $339,000 | 2003 | Moscona, Anne | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
3 67 1R21AI065597-01 
BRODER, 
CHRISTOPHER 
Nipah Virus and Hendra Virus Subunit 
Vaccines  
4 50 1U01AI056423-01 
BRODER, 
CHRISTOPHER 
Nipah virus and Hendra virus Peptide 
Therapeutics  
Total: $1,560,796  
 $625,455 | 2005 | Broder, Christopher C | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $607,239 | 2004 | Broder, Christopher C | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $328,102 | 2003 | Broder, Christopher C | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
5 50 1F31AI061829-01 CRAFT, WILLIE 
Expression and Cleavage of the Hendra 
Virus F Protein  
Total: $24,361  
 $24,361 | 2004 | Craft, Willie W | UNIVERSITY OF KENTUCKY | LEXINGTON, KY  
6 50 
1R01AI055733-
01A1 HORVATH, CURT 
Host Defense Evasion by Fatal 
Emerging Paramyxoviruses  
Total: $539,476  
 $266,000 | 2005 | Horvath, Curt M | EVANSTON NORTHWESTERN HEALTHCARE 
| EVANSTON, IL  
 $201,066 | 2004 | Horvath, Curt M | EVANSTON NORTHWESTERN HEALTHCARE 
| EVANSTON, IL  
 $72,410 | 2004 | Horvath, Curt M | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
7 17 1R01AI051517-01 DUTCH, REBECCA 
SV5 and Hendra virus F protein 
promoted membrane fusion  
Total: $1,013,600  
 $253,400 | 2005 | Dutch, Rebecca E | UNIVERSITY OF KENTUCKY | LEXINGTON, 
KY  






 $253,400 | 2003 | Dutch, Rebecca E | UNIVERSITY OF KENTUCKY | LEXINGTON, 
KY  
 $253,400 | 2002 | Dutch, Rebecca E | UNIVERSITY OF KENTUCKY | LEXINGTON, 
KY  
 
Human enterovirus B (strain Human coxsackievirus B5 (formerly Swine vesicular disease 
virus)) 
Taxonomy: Family Picornaviridae, Genus Enterovirus, Species Human enterovirus B, Virus: 
Human enterovirus B. 
Publications: 
1. Martino, T. A., M. Petric, H. Weingartl, J. M. Bergelson, M. A. Opavsky, C. D. 
Richardson, J. F. Modlin, R. W. Finberg, K. C. Kain, N. Willis, C. J. Gauntt, and P. 
P. Liu. 2000. The coxsackie-adenovirus receptor (CAR) is used by reference strains and 
clinical isolates representing all six serotypes of coxsackievirus group B and by swine 
vesicular disease virus. Virology 271:99-108. 





01 CHAPMAN, NORA Enterovirus persistence in myocarditis  
Total: $147,000  
 $73,500 | 2003 | Chapman, Nora M | UNIVERSITY OF NEBRASKA MEDICAL 
CENTER | OMAHA, NE  
 $73,500 | 2002 | Chapman, Nora M | UNIVERSITY OF NEBRASKA MEDICAL 
CENTER | OMAHA, NE  
 
Influenza A virus (avian highly pathogenic strains H5 and H7) 
Taxonomy: Family Orthomyxoviridae, Genus Influenzavirus A, Species Influenza A virus, Virus: 






1. Cauthen, A. N., D. E. Swayne, S. Schultz-Cherry, M. L. Perdue, and D. L. Suarez. 
2000. Continued circulation in China of highly pathogenic avian influenza viruses 
encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and 
humans. J Virol 74:6592-9. 
 This article reports the circulation of avian influenzavirus strains in China. 
2. Dybing, J. K., S. Schultz-Cherry, D. E. Swayne, D. L. Suarez, and M. L. Perdue. 
2000. Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that 
of other highly pathogenic H5 avian influenza viruses. J Virol 74:1443-50. 
 This paper reports the pathogenesis of an avian influenzavirus in mice and compares it to 
that of related strains. 
3. Katz, J. M., X. Lu, A. M. Frace, T. Morken, S. R. Zaki, and T. M. Tumpey. 2000. 
Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 
54:178-87. 
 This paper reports the pathogenesis of an avian influenza virus. 
4. Kodihalli, S., D. L. Kobasa, and R. G. Webster. 2000. Strategies for inducing 
protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 
18:2592-9. 
 This paper reports a vaccine candidate. 
5. O'Neill, E., S. L. Krauss, J. M. Riberdy, R. G. Webster, and D. L. Woodland. 2000. 
Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus 
infection in C57BL/6 mice. J Gen Virol 81:2689-96. 
 This paper reports a successful vaccine strategy. 
6. Schultz-Cherry, S., J. K. Dybing, N. L. Davis, C. Williamson, D. L. Suarez, R. 
Johnston, and M. L. Perdue. 2000. Influenza virus (A/HK/156/97) hemagglutinin 
expressed by an alphavirus replicon system protects chickens against lethal infection with 
Hong Kong-origin H5N1 viruses. Virology 278:55-9. 
 This paper reports a successful vaccine strategy. 
7. Swayne, D. E., J. R. Beck, and N. Kinney. 2000. Failure of a recombinant fowl poxvirus 
vaccine containing an avian influenza hemagglutinin gene to provide consistent protection 
against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis 44:132-7. 
 This paper reports an unsuccessful vaccine candidate. 
8. Swayne, D. E., M. Garcia, J. R. Beck, N. Kinney, and D. L. Suarez. 2000. Protection 
against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with 
a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene 
insert. Vaccine 18:1088-95. 
 This paper reports a vaccine candidate 
9. Swayne, D. E., M. L. Perdue, J. R. Beck, M. Garcia, and D. L. Suarez. 2000. Vaccines 
protect chickens against H5 highly pathogenic avian influenza in the face of genetic 
changes in field viruses over multiple years. Vet Microbiol 74:165-72. 
 This paper reports successful vaccine candidates. 
10. Donatelli, I., L. Campitelli, L. Di Trani, S. Puzelli, L. Selli, A. Fioretti, D. J. 
Alexander, M. Tollis, S. Krauss, and R. G. Webster. 2001. Characterization of H5N2 
influenza viruses from Italian poultry. J Gen Virol 82:623-30. 





11. Sambhara, S., A. Kurichh, R. Miranda, T. Tumpey, T. Rowe, M. Renshaw, R. 
Arpino, A. Tamane, A. Kandil, O. James, B. Underdown, M. Klein, J. Katz, and D. 
Burt. 2001. Heterosubtypic immunity against human influenza A viruses, including 
recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice 
requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211:143-
53. 
 This paper reports the evaluation of a vaccine candidate. 
12. Swayne, D. E., J. R. Beck, M. L. Perdue, and C. W. Beard. 2001. Efficacy of vaccines 
in chickens against highly pathogenic Hong Kong H5N1 avian influenza. Avian Dis 
45:355-65. 
 This paper reports the evaluation of vaccine candidates. 
13. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery 
of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection 
against lethal influenza A H5N1 virus infection. J Virol 75:5141-50. 
 This paper reports the immune response to a vaccine candidate. 
14. Berinstein, A., B. S. Seal, and D. L. Suarez. 2002. Heteroduplex mobility assay for 
detection of new avian influenza virus variants. Avian Dis 46:393-400. 
This paper reports the development of a diagnostic assay for the differentiation of 
different strains of the virus. 
15. Kaverin, N. V., I. A. Rudneva, N. A. Ilyushina, N. L. Varich, A. S. Lipatov, Y. A. 
Smirnov, E. A. Govorkova, A. K. Gitelman, D. K. Lvov, and R. G. Webster. 2002. 
Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus 
and phenotypic variation of escape mutants. J Gen Virol 83:2497-505. 
 This paper reports the molecular basis of escape mutants of the virus. 
16. Panigrahy, B., D. A. Senne, and J. C. Pedersen. 2002. Avian influenza virus subtypes 
inside and outside the live bird markets, 1993-2000: a spatial and temporal relationship. 
Avian Dis 46:298-307. 
 This paper reports the identification of different strains of the virus. 
17. Spackman, E., D. A. Senne, T. J. Myers, L. L. Bulaga, L. P. Garber, M. L. Perdue, 
K. Lohman, L. T. Daum, and D. L. Suarez. 2002. Development of a real-time reverse 
transcriptase PCR assay for type A influenza virus and the avian H5 and H7 
hemagglutinin subtypes. J Clin Microbiol 40:3256-60. 
 This paper reports the development of a PCR-based diagnostic assay for the detection of 
the virus.  
18. Tumpey, T. M., D. L. Suarez, L. E. Perkins, D. A. Senne, J. G. Lee, Y. J. Lee, I. P. 
Mo, H. W. Sung, and D. E. Swayne. 2002. Characterization of a highly pathogenic 
H5N1 avian influenza A virus isolated from duck meat. J Virol 76:6344-55. 
 This paper reports the characterization of a strain of the virus. 
19. Bright, R. A., T. M. Ross, K. Subbarao, H. L. Robinson, and J. M. Katz. 2003. Impact 
of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. 
Virology 308:270-8. 






20. Liu, M., J. M. Wood, T. Ellis, S. Krauss, P. Seiler, C. Johnson, E. Hoffmann, J. 
Humberd, D. Hulse, Y. Zhang, R. G. Webster, and D. R. Perez. 2003. Preparation of a 
standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 
314:580-90. 
 This paper reports the development of a vaccine candidate. 
21. Lu, X. H., D. Cho, H. Hall, T. Rowe, I. P. Mo, H. W. Sung, W. J. Kim, C. Kang, N. 
Cox, A. Klimov, and J. M. Katz. 2003. Pathogenesis of and immunity to a new influenza 
A (H5N1) virus isolated from duck meat. Avian Dis 47:1135-40. 
 This paper reports the pathogenesis of a novel strain of the virus. 
22. Spackman, E., D. A. Senne, L. L. Bulaga, T. J. Myers, M. L. Perdue, L. P. Garber, 
K. Lohman, L. T. Daum, and D. L. Suarez. 2003. Development of real-time RT-PCR 
for the detection of avian influenza virus. Avian Dis 47:1079-82. 
H7 hemagglutinin subtypes. J Clin Microbiol 40:3256-60. 
 This paper reports the development of a PCR-based diagnostic assay for the detection of 
the virus.  
23. Spackman, E., D. A. Senne, L. L. Bulaga, S. Trock, and D. L. Suarez. 2003. 
Development of multiplex real-time RT-PCR as a diagnostic tool for avian influenza. 
Avian Dis 47:1087-90. 
H7 hemagglutinin subtypes. J Clin Microbiol 40:3256-60. 
 This paper reports the development of a PCR-based diagnostic assay for the detection of 
the virus.  
24. Swayne, D. E., D. L. Suarez, S. Schultz-Cherry, T. M. Tumpey, D. J. King, T. 
Nakaya, P. Palese, and A. Garcia-Sastre. 2003. Recombinant paramyxovirus type 1-
avian influenza-H7 virus as a vaccine for protection of chickens against influenza and 
Newcastle disease. Avian Dis 47:1047-50. 
 This paper reports a vaccine candidate. 
25. Hulse, D. J., R. G. Webster, R. J. Russell, and D. R. Perez. 2004. Molecular 
determinants within the surface proteins involved in the pathogenicity of H5N1 influenza 
viruses in chickens. J Virol 78:9954-64. 
 This paper reports the identification of amino acid residues important for the 
pathogenicity of certain strains of the virus. 
26. Jones, Y. L., and D. E. Swayne. 2004. Comparative pathobiology of low and high 
pathogenicity H7N3 Chilean avian influenza viruses in chickens. Avian Dis 48:119-28. 
 This paper compares the pathological effects of different strains of the virus. 
27. Kessler, N., O. Ferraris, K. Palmer, W. Marsh, and A. Steel. 2004. Use of the DNA 
flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses. 
J Clin Microbiol 42:2173-85. 
 This paper reports a DNA chip that can differentiate certain strains of the virus. 
28. Lee, C. W., D. A. Senne, J. A. Linares, P. R. Woolcock, D. E. Stallknecht, E. 
Spackman, D. E. Swayne, and D. L. Suarez. 2004. Characterization of recent H5 
subtype avian influenza viruses from US poultry. Avian Pathol 33:288-97. 
 This paper reports the characterization of a strain of the virus. 
29. Lee, C. W., D. A. Senne, and D. L. Suarez. 2004. Generation of reassortant influenza 





from Vaccinated Animals) strategy for the control of avian influenza. Vaccine 22:3175-
81. 
 This paper reports the development of vaccine candidates. 
30. Lee, C. W., and D. L. Suarez. 2004. Application of real-time RT-PCR for the 
quantitation and competitive replication study of H5 and H7 subtype avian influenza 
virus. J Virol Methods 119:151-8. 
 This paper reports the development of a PCR-based diagnostic system. 
31. Russell, R. J., S. J. Gamblin, L. F. Haire, D. J. Stevens, B. Xiao, Y. Ha, and J. J. 
Skehel. 2004. H1 and H7 influenza haemagglutinin structures extend a structural 
classification of haemagglutinin subtypes. Virology 325:287-96. 
 This paper reports the structure of the surface proteins of strains of the virus. 
32. Tompkins, S. M., C. Y. Lo, T. M. Tumpey, and S. L. Epstein. 2004. Protection against 
lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 
101:8682-6. 
 This paper reports the evaluation of an antiviral. 
33. Lipatov, A. S., R. J. Webby, E. A. Govorkova, S. Krauss, and R. G. Webster. 2005. 
Efficacy of h5 influenza vaccines produced by reverse genetics in a lethal mouse model. J 
Infect Dis 191:1216-20. 
 This paper reports the evaluation of a vaccine candidate. 
34. Mase, M., K. Tsukamoto, T. Imada, K. Imai, N. Tanimura, K. Nakamura, Y. 
Yamamoto, T. Hitomi, T. Kira, T. Nakai, M. Kiso, T. Horimoto, Y. Kawaoka, and S. 
Yamaguchi. 2005. Characterization of H5N1 influenza A viruses isolated during the 
2003-2004 influenza outbreaks in Japan. Virology 332:167-76. 
 This paper describes the characterization of different strains of the virus. 
35. Stephenson, I., R. Bugarini, K. G. Nicholson, A. Podda, J. M. Wood, M. C. Zambon, 
and J. M. Katz. 2005. Cross-Reactivity to Highly Pathogenic Avian Influenza H5N1 
Viruses after Vaccination with Nonadjuvanted and MF59-Adjuvanted Influenza 
A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy. J Infect Dis 
191:1210-5. 
 This paper reports a vaccination strategy. 
36. Swayne, D. E., and J. R. Beck. 2005. Experimental study to determine if low-
pathogenicity and high-pathogenicity avian influenza viruses can be present in chicken 
breast and thigh meat following intranasal virus inoculation. Avian Dis 49:81-5. 






01 RAFFERTY, DANIEL 
AN INACTIVATED AVIAN 
INFLUENZA VACCINE FOR 
PANDEMIC USE  





PHARMACEUTICALS, MI  
2 41 
1R01AI059374-
01A1 MITTAL, SURESH 
Adenoviral Vector-based Pandemic 
Influenza Vaccine  
3 41 
1RC1AI048872-
01 TRENT, DENNIS 
DNA BASED GENERATION OF AVIAN 
INFLUENZA VIRUS VACCINES  
Total: $26,000  
 $26,000 | 2000 | TRENT, DENNIS W | INC. | SWIFTWATER, AVENTIS 
PASTEUR, PA  
4 41 
1UC1AI049519-
01 TRENT, DENNIS 
DNA Based Generation of Avian 
Influenza virus Vaccines  
Total: $1,400,000  
 $1,400,000 | 2000 | TRENT, DENNIS W | INC. | SWIFTWATER, AVENTIS 
PASTEUR, PA  
5 31 
1R21AI059214-
01 GRAY, GREGORY 
Population-based Surveillance for 
Zoonotic Influenza A  
Total: $295,000  






Host range restriction of human 
influenza viruses  
7 31 
1U01AI061252-
01 PEKOSZ, ANDREW 
M2 peptide based vaccines against 
influenza  
Total: $1,110,886  
 $552,548 | 2005 | Pekosz, Andrew S | ORION GENOMICS, LLC | ST. LOUIS, 
MO  
 $558,338 | 2004 | Pekosz, Andrew S | JACOBS FACILITIES, INC. | ST 
LOUIS, MO  
8 31 
1UC1AI049509-
01 POTASH, LOUIS 
Production of Non-Egg grown 
Influenza Vaccines  
Total: $848,254  
 $848,254 | 2000 | POTASH, LOUIS | INC. | ROCKVILLE, NOVAVAX, MD  
9 21 
2R44AI046876-
02 HILLEGAS, WILLIAM 
Microcarrier / CEF / Media SYSTEM 
to make Viral Vaccines  
Total: $791,992  
 $396,090 | 2002 | Hillegas, William J | SOLOHILL ENGINEERING, INC. | ANN 
ARBOR, MI  
 $395,902 | 2001 | Hillegas, William J | SOLOHILL ENGINEERING, INC. | ANN 
ARBOR, MI  
10 21 
1Z01BK002026-
01 LEVANDOWSKI, R Influenza Virus Vaccines  
11 21 
1R43AI063638-
01 LI, SHENGQIANG 
Improved Genetically Modified 





Total: $256,640  
 $256,640 | 2005 | Li, Shengqiang | SCIOGEN, INC. | LOS ALTOS, CA  
12 21 
1Z01AI000933-
01 SUBBARAO, KANTA Vaccines for Pandemic Influenza  
13 21 
1F32AI060292-
01A1 TURPIN, ELIZABETH 
Regulation of TGF-b by influenza 
Virus Neuraminidase  
Total: $48,296  
 $48,296 | 2005 | Turpin, Elizabeth A | UNIVERSITY OF WISCONSIN 






New Influenza A Neuraminidase 
Inhibitors for Biodefense  
Total: $305,100  
 $305,100 | 2005 | Brouillette, Wayne J | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
15 10 
1R21AI056214-
01 KATZE, MICHAEL 
Proteomic Analysis of the Innate 
Antiviral Response  
Total: $516,278  
 $251,689 | 2004 | Katze, Michael G | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $264,589 | 2003 | Katze, Michael G | UNIVERSITY OF WASHINGTON | 






Molecular Mechanisms of Influenza 
Pandemics  
Total: $2,342,539  
 $546,123 | 2005 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $526,358 | 2004 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $319,200 | 2003 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $310,036 | 2002 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $301,138 | 2001 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
 $339,684 | 2000 | KAWAOKA, YOSHIHIRO | UNIVERSITY OF WISCONSIN 
MADISON | MADISON, WI  
17 10 
1RC1AI048908-
01 LI, SHENGQIANG 
LIVE ATTENUATED VACCINES FOR 
PANDEMIC PREPAREDNESS  
Total: $26,000  
 $26,000 | 2000 | LI, SHENGQIANG | AVIRON | MOUNTAIN VIEW, CA  
18 10 
1UC1AI049507-
01 LI, SHENGQIANG 
Live attenuated vaccines for 
pandemic preparedness  
Total: $2,680,016  
 $2,680,016 | 2000 | LI, SHENGQIANG | AVIRON | MOUNTAIN VIEW, CA  
19 10 
1R01AI052155-






Total: $773,000  
 $297,000 | 2005 | Perez, Daniel R | UNIVERSITY OF MARYLAND COLLEGE 
PK CAMPUS | COLLEGE PARK, MD  
 $377,000 | 2004 | Perez, Daniel R | UNIVERSITY OF MARYLAND COLLEGE 
PK CAMPUS | COLLEGE PARK, MD  
 $99,000 | 2003 | Perez, Daniel R | UNIVERSITY OF MARYLAND COLLEGE PK 






Lethality of H5N1 Influenza Virus is 
Linked to TGF-beta  
Total: $245,175  
 $245,175 | 2005 | Schultzcherry, Stacey L | UNIVERSITY OF WISCONSIN 






Discovery of a Novel Promoter in 
Pathogenic Influenza  
Total: $586,702  
 $297,205 | 2005 | Wentworth, David E | WADSWORTH CENTER | ALBANY, 
NY  
 $289,497 | 2004 | Wentworth, David E | WADSWORTH CENTER | ALBANY, 
NY  
 
Japanese encephalitis virus 
Taxonomy: Family Flaviviridae, Genus Flavivirus, Species Japanese encephalitis virus, Virus: 
Japanese encephalitis virus, JaOArS982. 
Publications:  
1. Bhatt, T. R., M. B. Crabtree, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2000. 
Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, 
ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and 
Aedes aegypti mosquitoes. Am J Trop Med Hyg 62:480-4. 
 This paper reports the growth characteristics of a vaccine candidate of the virus in 
different mosquitoes. 
2. Chang, G. J., A. R. Hunt, and B. Davis. 2000. A single intramuscular injection of 
recombinant plasmid DNA induces protective immunity and prevents Japanese 
encephalitis in mice. J Virol 74:4244-52. 
 This paper reports the evaluation of a DNA vaccine strategy. 
3. Kanesa-thasan, N., J. J. Smucny, C. H. Hoke, D. H. Marks, E. Konishi, I. Kurane, D. 
B. Tang, D. W. Vaughn, P. W. Mason, and R. E. Shope. 2000. Safety and 
immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese 
encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune 





 This paper reports the evaluation of a DNA vaccine strategy and vaccine candidate. 
4. Konishi, E., M. Yamaoka, I. Kurane, and P. W. Mason. 2000. Japanese encephalitis 
DNA vaccine candidates expressing premembrane and envelope genes induce virus-
specific memory B cells and long-lasting antibodies in swine. Virology 268:49-55. 
 This paper reports the evaluation of a DNA candidate. 
5. Monath, T. P., I. Levenbook, K. Soike, Z. X. Zhang, M. Ratterree, K. Draper, A. D. 
Barrett, R. Nichols, R. Weltzin, J. Arroyo, and F. Guirakhoo. 2000. Chimeric yellow 
fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and 
extended safety testing in rhesus monkeys. J Virol 74:1742-51. 
 This paper reports the evaluation of a DNA candidate. 
6. Arroyo, J., F. Guirakhoo, S. Fenner, Z. X. Zhang, T. P. Monath, and T. J. 
Chambers. 2001. Molecular basis for attenuation of neurovirulence of a yellow fever 
Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75:934-42. 
 This paper reports the characterization of a vaccine candidate. 
7. Chia, S. C., P. S. Leung, C. P. Liao, J. H. Huang, and S. T. Lee. 2001. Fragment of 
Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice 
from virus challenge. Microb Pathog 31:9-19. 
 This paper reports a vaccine candidate. 
8. Hunt, A. R., C. B. Cropp, and G. J. Chang. 2001. A recombinant particulate antigen of 
Japanese encephalitis virus produced in stably-transformed cells is an effective 
noninfectious antigen and subunit immunogen. J Virol Methods 97:133-49. 
 This paper reports a vaccine candidate. 
9. Konishi, E., A. Fujii, and P. W. Mason. 2001. Generation and characterization of a 
mammalian cell line continuously expressing Japanese encephalitis virus subviral 
particles. J Virol 75:2204-12. 
 This paper reports the generation of a cell line that releases subviral particles 
10. Mishin, V. P., F. Cominelli, and V. F. Yamshchikov. 2001. A 'minimal' approach in 
design of flavivirus infectious DNA. Virus Res 81:113-23. 
 This paper reports a vaccine candidate. 
11. Srivastava, A. K., J. R. Putnak, S. H. Lee, S. P. Hong, S. B. Moon, D. A. Barvir, B. 
Zhao, R. A. Olson, S. O. Kim, W. D. Yoo, A. C. Towle, D. W. Vaughn, B. L. Innis, 
and K. H. Eckels. 2001. A purified inactivated Japanese encephalitis virus vaccine made 
in Vero cells. Vaccine 19:4557-65. 
 This paper reports the evaluation of a vaccine candidate. 
12. Lin, Y. L., H. Y. Lei, Y. S. Lin, T. M. Yeh, S. H. Chen, and H. S. Liu. 2002. Heparin 
inhibits dengue-2 virus infection of five human liver cell lines. Antiviral Res 56:93-6. 
 This paper reports that heparin can inhibit the virus. 
13. Monath, T. P., J. Arroyo, I. Levenbook, Z. X. Zhang, J. Catalan, K. Draper, and F. 
Guirakhoo. 2002. Single mutation in the flavivirus envelope protein hinge region 
increases neurovirulence for mice and monkeys but decreases viscerotropism for 
monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol 
76:1932-43. 
 This paper reports the importance of a single amino acid residue in the envelope protein of 





14. Tesh, R. B., A. P. Travassos da Rosa, H. Guzman, T. P. Araujo, and S. Y. Xiao. 2002. 
Immunization with heterologous flaviviruses protective against fatal West Nile 
encephalitis. Emerg Infect Dis 8:245-51. 
 This paper reports the evaluation of the virus as a vaccine for West Nile fever. 
15. Chang, G. J., A. R. Hunt, D. A. Holmes, T. Springfield, T. S. Chiueh, J. T. Roehrig, 
and D. J. Gubler. 2003. Enhancing biosynthesis and secretion of premembrane and 
envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese 
encephalitis virus. Virology 306:170-80. 
 This paper reports the evaluation of a vaccine candidate. 
16. Konishi, E., N. Ajiro, C. Nukuzuma, P. W. Mason, and I. Kurane. 2003. Comparison 
of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins 
that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21:3675-
83. 
 This paper reports the comparison of different vaccine candidates. 
17. Solomon, T., H. Ni, D. W. Beasley, M. Ekkelenkamp, M. J. Cardosa, and A. D. 
Barrett. 2003. Origin and evolution of Japanese encephalitis virus in southeast Asia. J 
Virol 77:3091-8. 
 This paper reports the sequence of a strain of the virus. 
18. Yun, S. I., S. Y. Kim, C. M. Rice, and Y. M. Lee. 2003. Development and application of 
a reverse genetics system for Japanese encephalitis virus. J Virol 77:6450-65. 
 This paper reports the development of a cDNA clone of the virus. 
19. Beasley, D. W., L. Li, M. T. Suderman, F. Guirakhoo, D. W. Trent, T. P. Monath, R. 
E. Shope, and A. D. Barrett. 2004. Protection against Japanese encephalitis virus strains 
representing four genotypes by passive transfer of sera raised against ChimeriVax-JE 
experimental vaccine. Vaccine 22:3722-6. 








Flaviviruses: Yin-yang of Heterologous 
Immunity  
Total: $8,201,872  
 $3,211,928 | 2005 | Ennis, Francis A | UNIV OF MASSACHUSETTS MED 
SCH WORCESTER | WORCESTER, MA  
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Encephalitis vaccine  
Total: $1,914,095  
 $1,914,095 | 2005 | Nagy, Eszter | INTERCELL AG | AUSTRIA - VIENNA  
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Structure-function of alpha- and 
flavivirus proteins  
Total: $8,127,036 *  
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Lumpy skin disease virus 
Taxonomy: Family Poxviridae, Subfamily Chordopoxvirinae, Genus Capripoxvirus, Species 
Lumpy skin disease virus. Virus: Lumpy skin disease virus. 
Publications: 
1. Tulman, E. R., C. L. Afonso, Z. Lu, L. Zsak, G. F. Kutish, and D. L. Rock. 2001. 
Genome of Lumpy Skin Disease Virus. J Virol 75:7122-30. 
This paper describes the sequencing and characterization of Lumpy skin disease virus. 
2. Kara, P. D., C. L. Afonso, D. B. Wallace, G. F. Kutish, C. Abolnik, Z. Lu, F. T. 
Vreede, L. C. F. Taljaard, A. Zsak, G. J. Viljoen, D. L. Rock. 2003. Comparative 
sequence analysis of the South African vaccine strain and two virulent field isolates of 
Lumpy skin disease virus. Arch Virol 148:1335-56. 
This paper describes the sequencing and comparison of various virulent and attenuated 
strains of Lumpy skin disease virus. 
 







Taxonomy: Order: Mononegavirales, Family Paramyxoviridae, Subfamily Paramyxovirinae, 
Genus Rubulavirus, Species Menangle virus. Virus: Menangle virus. 
Publications: None identified. 
NIH grants: None 
 
Monkeypox virus 
Taxonomy: Family Poxviridae, Subfamily Chordopoxvirinae, Genus Orthopoxvirus, Species: 
Monkeypox virus, Virus: Monkeypox virus. 
Publications: 
1. Loparev, V. N., R. F. Massung, J. J. Esposito, and H. Meyer. 2001. Detection and 
differentiation of old world orthopoxviruses: restriction fragment length polymorphism of 
the crmB gene region. J Clin Microbiol 39:94-100. 
This paper describes the development of a restriction fragment length polymorphism 
assay to differentiate various poxviruses including Camelpoxvirus, Monkeypox virus, and 
Variola virus. 
2. Shchelkunov, S. N., A. V. Totmenin, I. V. Babkin, P. F. Safronov, O. I. Ryazankina, 
N. A. Petrov, V. V. Gutorov, E. A. Uvarova, M. V. Mikheev, J. R. Sisler, J. J. 
Esposito, P. B. Jahrling, B. Moss, and L. S. Sandakhchiev. 2001. Human monkeypox 
and smallpox viruses: genomic comparison. FEBS Lett 509:66-70. 
This paper describes the cloning and sequencing of individual genomics fragments of a 
strain of Monkeypox virus, and the final determination of its full sequence. The sequence 
is then compared to that of Variola virus. 
3. Smee, D. F., M. Bray, and J. W. Huggins. 2001. Antiviral activity and mode of action 
studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem 
Chemother 12:327-35. 
This paper describes the testing of various antiviral against Camelpox and Monkeypox 
virus.  
4. Espy, M. J., I. F. Cockerill, R. F. Meyer, M. D. Bowen, G. A. Poland, T. L. Hadfield, 
and T. F. Smith. 2002. Detection of smallpox virus DNA by LightCycler PCR. J Clin 
Microbiol 40:1985-8. 
This paper describes the development of a rapid real-time LightCycler PCR assay for 






5. Shchelkunov, S. N., A. V. Totmenin, P. F. Safronov, M. V. Mikheev, V. V. Gutorov, 
O. I. Ryazankina, N. A. Petrov, I. V. Babkin, E. A. Uvarova, L. S. Sandakhchiev, J. 
R. Sisler, J. J. Esposito, I. K. Damon, P. B. Jahrling, and B. Moss. 2002. Analysis of 
the monkeypox virus genome. Virology 297:172-94. 
This paper describes the cloning and sequencing of individual genomics fragments of a 
strain of Monkeypox virus, and the final determination of its full sequence. The sequence 
is then compared to that of Variola virus. 
6. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for 
smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57:13-23. 
This paper describes the evaluation of 24 different potential antivirals for their activity 
against Variola virus (35 strains), Monkeypox virus, and Camelpox virus. Several active 
compounds were isolated. 
7. Chu, C. K., Y. H. Jin, R. O. Baker, and J. Huggins. 2003. Antiviral activity of 
cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox). 
Bioorg Med Chem Lett 13:9-12. 
This paper describes the synthesis and testing of novel antivirals for antiviral activity 
against Variola virus and Monkeypox virus. Several active compounds are described. 
8. Jin, Y. H., P. Liu, J. Wang, U. Das, R. Baker, J. Huggins, and C. K. Chu. 2003. 
Practical synthesis of D- and l-2-cyclopentenone and their utility for the synthesis of 
carbocyclic antiviral nucleosides against orthopox viruses (smallpox, monkeypox, and 
cowpox virus). J Org Chem 68:9012-8. 
This paper describes the synthesis and testing of novel antivirals for antiviral activity 
against Variola virus and Monkeypox virus. Several active compounds are described. 
9. Laassri, M., V. Chizhikov, M. Mikheev, S. Shchelkunov, and K. Chumakov. 2003. 
Detection and discrimination of orthopoxviruses using microarrays of immobilized 
oligonucleotides. J Virol Methods 112:67-78. 
This paper describes the creation of a novel diagnostic microarray system that can identify 
and differentiate Variola virus and Monkeypox virus. 
10. Sofi Ibrahim, M., D. A. Kulesh, S. S. Saleh, I. K. Damon, J. J. Esposito, A. L. 
Schmaljohn, and P. B. Jahrling. 2003. Real-time PCR assay to detect smallpox virus. J 
Clin Microbiol 41:3835-9. 
This paper describes the development of a real-time 5' nuclease PCR assay (also known as 
the TaqMan assay) for the rapid diagnosis of Variola virus. 48 different strains of Variola 
virus were used. Controls included Camelpox virus, and Monkeypox virus. 
11. Olson, V. A., T. Laue, M. T. Laker, I. V. Babkin, C. Drosten, S. N. Shchelkunov, M. 
Niedrig, I. K. Damon, and H. Meyer. 2004. Real-time PCR system for detection of 
orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol 
42:1940-6. 
This paper describes the development of a real-time PCR system for various 
orthopoxviruses including Variola virus, Monkeypox virus, Camelpox virus, and Cowpox 










01 BULLER, R Study of monkeypox virus in rodents 
Total: $294,000  




01 RELMAN, DAVID 
Host responses to smallpox and 
monkeypox  
Total: $952,661  
 $315,035 | 2005 | Relman, David A | STANFORD UNIVERSITY | STANFORD, 
CA  
 $315,054 | 2004 | Relman, David A | STANFORD UNIVERSITY | STANFORD, 
CA  
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smallpox vaccine in humans  
Total: $412,295  
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DNA Microarray Evaluation of 
Vaccine Safety  
6 17 
1R21AI064615-
01 HOSTETLER, KARL Lung-Targeted Poxivirus Antivirals  
Total: $288,800  
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Total: $1,754,505  
 $379,746 | 2004 | Burton, Dennis R | SCRIPPS RESEARCH INSTITUTE | LA 
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Mycoplasma capricolum capripneumoniae (formerly known as Mycoplasma F38) 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Mollicutes, Order Mycoplasmatales, 
Family Mycoplasmataceae. 
Publications: 
1. Gasparich, G. E., R. F. Whitcomb, D. Dodge, F. E. French, J. Glass, and D. L. 
Williamson. 2004. The genus Spiroplasma and its non-helical descendants: phylogenetic 
classification, correlation with phenotype and roots of the Mycoplasma mycoides clade. 
Int J Syst Evol Microbiol 54:893-918. 








Novel Integrative Genetic Elements of 
Mycoplasmas  
Total: $543,750  
 $181,250 | 2003 | Calcutt, Michael J | UNIVERSITY OF MISSOURI | 
COLUMBIA, MO  
 $181,250 | 2002 | Calcutt, Michael J | UNIVERSITY OF MISSOURI COLUMBIA 
| COLUMBIA, MO  
 $181,250 | 2001 | Calcutt, Michael J | UNIVERSITY OF MISSOURI COLUMBIA 






Mycoplasma mycoides capri 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Mollicutes, Order Mycoplasmatales, 
Family Mycoplasmataceae. 
Publications: None identified. 
NIH Grants: None identified. 
 
Mycoplasma mycoides mycoides 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Mollicutes, Order Mycoplasmatales, 
Family Mycoplasmataceae. 
Publications: 
1. Rurangirwa, F. R., P. S. Shompole, A. N. Wambugu, and T. C. McGuire. 2000. 
Monoclonal antibody differentiation of Mycoplasma mycoides subsp. mycoides small-
colony strains causing contagious bovine pleuropneumonia from less important large-
colony strains. Clin Diagn Lab Immunol 7:519-21. 
 This paper reports the identification of an antibody capable of differentiating different 
morphovariants of the bacterium. 
2. Gasparich, G. E., R. F. Whitcomb, D. Dodge, F. E. French, J. Glass, and D. L. 
Williamson. 2004. The genus Spiroplasma and its non-helical descendants: phylogenetic 
classification, correlation with phenotype and roots of the Mycoplasma mycoides clade. 
Int J Syst Evol Microbiol 54:893-918. 
 This paper reports the phylogenetic relationship of the bacterium to other mollicutes. 
3. Nicolas, M. M., I. H. Stalis, T. L. Clippinger, M. Busch, R. Nordhausen, G. Maalouf, 
and M. D. Schrenzel. 2005. Systemic disease in Vaal rhebok (Pelea capreolus) caused by 
mycoplasmas in the mycoides cluster. J Clin Microbiol 43:1330-40. 
 This paper reports the isolation and molecular characterization of a new strain of the 
bacterium from a sick Vaal rhebok. 
 







Newcastle disease virus 
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Avulavirus, Species Newcastle disease virus, Virus: Newcastle disease virus, Australia-
Victoria isolate, Ulster 2C, D26, Beaudette C. 
Publications: 
1. Azimi, N., K. M. Shiramizu, Y. Tagaya, J. Mariner, and T. A. Waldmann. 2000. 
Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in 
the IL-15 promoter region. J Virol 74:7338-48. 
 This paper reports that the virus can activate the production of a cytokine in the infected 
cell. 
2. Li, Y. C., D. R. Ledoux, A. J. Bermudez, K. L. Fritsche, and G. E. Rottinghaus. 2000. 
The individual and combined effects of fumonisin B1 and moniliformin on performance 
and selected immune parameters in turkey poults. Poult Sci 79:871-8. 
 This paper reports the effect on the immune system of two antibiotics on turkey poults. 
3. Li, Y. C., D. R. Ledoux, A. J. Bermudez, K. L. Fritsche, and G. E. Rottinghaust. 
2000. Effects of moniliformin on performance and immune function of broiler chicks. 
Poult Sci 79:26-32. 
 This paper reports the effect on the immune system of two antibiotics on broiler chicks. 
4. Reynolds, D. L., and A. D. Maraqa. 2000. Protective immunity against Newcastle 
disease: the role of antibodies specific to Newcastle disease virus polypeptides. Avian Dis 
44:138-44. 
 This paper reports the evaluation of vaccine candidates. 
5. Reynolds, D. L., and A. D. Maraqa. 2000. Protective immunity against Newcastle 
disease: the role of cell-mediated immunity. Avian Dis 44:145-54. 
 This paper reports the evaluation of vaccine candidates. 
6. Seal, B. S., D. J. King, and R. J. Meinersmann. 2000. Molecular evolution of the 
Newcastle disease virus matrix protein gene and phylogenetic relationships among the 
paramyxoviridae. Virus Res 66:1-11. 
 This paper reports phylogenetic relationships of strains of the virus and other 
paramyxoviruses. 
7. Takimoto, T., G. L. Taylor, S. J. Crennell, R. A. Scroggs, and A. Portner. 2000. 
Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein. 
Virology 270:208-14. 
 This paper reports the crystal structure of a surface protein of the virus. 
8. Trigiante, G., and W. H. Huestis. 2000. Selective virus-mediated intracellular delivery 
of membrane-impermeant compounds by means of plasma membrane vesicles. Antiviral 
Res 45:211-21. 






9. Ward, M. D., F. J. Fuller, Y. Mehrotra, and E. V. De Buysscher. 2000. Nucleotide 
sequence and vaccinia expression of the nucleoprotein of a highly virulent, neurotropic 
strain of Newcastle disease virus. Avian Dis 44:34-44. 
 This paper reports the sequence of the nucleoprotein of a strain of the virus. 
10. Barnes, B. J., P. A. Moore, and P. M. Pitha. 2001. Virus-specific activation of a novel 
interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha 
genes. J Biol Chem 276:23382-90. 
 This paper reports the activation of an interferon-regulatory factor by the virus. 
11. Berinstein, A., H. S. Sellers, D. J. King, and B. S. Seal. 2001. Use of a heteroduplex 
mobility assay to detect differences in the fusion protein cleavage site coding sequence 
among Newcastle disease virus isolates. J Clin Microbiol 39:3171-8. 
 This paper reports the development of a diagnostic system to differentiate between 
different strains of the virus. 
12. El Tayeb, A. B., and R. P. Hanson. 2001. The interaction between Newcastle disease 
virus and Escherichia coli endotoxin in chickens. Avian Dis 45:313-20. 
 This paper reports the effect of endotoxins on the susceptibility of chickens to infections 
with the virus. 
13. Graves, I. L. 2001. Agglutination-separation reactions of red blood cells sensitized with 
Newcastle disease virus: quantities, agglutination characteristics, and serology of altered 
virus and HN spikes released following neuraminidase reactivation. Vet Res 32:475-89. 
 This paper reports the development of an assay to differentiate between different strains of 
the virus. 
14. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2001. High-level expression 
of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease 
virus. J Gen Virol 82:1729-36. 
 This paper reports the expression of a foreign gene from a recombinant strain of the virus. 
15. Iwamura, T., M. Yoneyama, N. Koizumi, Y. Okabe, H. Namiki, C. E. Samuel, and T. 
Fujita. 2001. PACT, a double-stranded RNA binding protein acts as a positive regulator 
for type I interferon gene induced by Newcastle disease virus. Biochem Biophys Res 
Commun 282:515-23. 
 This paper reports the identification of a protein mediating the interferon response 
induced by the virus. 
16. King, D. J. 2001. Selection of thermostable Newcastle disease virus progeny from 
reference and vaccine strains. Avian Dis 45:512-6. 
 This paper reports the isolation of a novel strain of the virus. 
17. Kommers, G. D., D. J. King, B. S. Seal, and C. C. Brown. 2001. Virulence of pigeon-
origin Newcastle disease virus isolates for domestic chickens. Avian Dis 45:906-21. 
 This paper reports the virulence of a novel strain of the virus. 
18. Marcus, P. I., and M. J. Sekellick. 2001. Combined sequential treatment with interferon 
and dsRNA abrogates virus resistance to interferon action. J Interferon Cytokine Res 
21:423-9. 





19. Nakaya, T., J. Cros, M. S. Park, Y. Nakaya, H. Zheng, A. Sagrera, E. Villar, A. 
Garcia-Sastre, and P. Palese. 2001. Recombinant Newcastle disease virus as a vaccine 
vector. J Virol 75:11868-73. 
 This paper reports the development of a vaccine candidate. 
20. Phuangsab, A., R. M. Lorence, K. W. Reichard, M. E. Peeples, and R. J. Walter. 
2001. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of 
local or systemic administration. Cancer Lett 172:27-36. 
 This paper reports the anti-tumor effect of the virus after infection of mice. 
21. Sagrera, A., C. Cobaleda, J. M. Gonzalez De Buitrago, A. Garcia-Sastre, and E. 
Villar. 2001. Membrane glycoproteins of Newcastle disease virus: nucleotide sequence of 
the hemagglutinin-neuraminidase cloned gene and structure/function relationship of 
predicted amino acid sequence. Glycoconj J 18:283-9. 
 This paper reports the sequence of a surface protein-encoding gene of different strains of 
the virus. 
22. Alfaro, J. C., V. M. Petrone, T. Fehervari, G. Nava, M. Kogut, D. Nisbet, and G. 
Tellez. 2002. Resistance to velogenic Newcastle disease virus in leghorn chickens by use 
of prophylactic lymphokines. Avian Dis 46:525-34. 
 This paper reports the use of cytokines to prevent infection with the virus. 
23. Bai, L., J. Koopmann, C. Fiola, P. Fournier, and V. Schirrmacher. 2002. Dendritic 
cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer 
patients. Int J Oncol 21:685-94. 
 This paper reports an ex vivo stimulation protocol for cancer reactive memory T cells 
based on autologous dendritic cells using lysates from from tumor cells infected with th 
virus. 
24. Barnes, B. J., M. J. Kellum, A. E. Field, and P. M. Pitha. 2002. Multiple regulatory 
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 This paper reports the interaction of a bacterium and the virus in chickens. 
27. Fair, J. M., and R. E. Ricklefs. 2002. Physiological, growth, and immune responses of 
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 This paper reports the pathogenesis of pigeons infected with the virus. 
29. McGinnes, L. W., K. Gravel, and T. G. Morrison. 2002. Newcastle disease virus HN 
protein alters the conformation of the F protein at cell surfaces. J Virol 76:12622-33. 
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 This paper reports the development of a PCR-based diagnostic assay for detection of the 
virus. 
31. Saif, Y. M., and K. E. Nestor. 2002. Increased mortality in turkeys selected for increased 
body weight following vaccination with a live Newcastle disease virus vaccine. Avian Dis 
46:505-8. 
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Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
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paramyxovirus. Science 288:1432-5. 
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2. Harcourt, B. H., A. Tamin, T. G. Ksiazek, P. E. Rollin, L. J. Anderson, W. J. Bellini, 
and P. A. Rota. 2000. Molecular characterization of Nipah virus, a newly emergent 
paramyxovirus. Virology 271:334-49. 
This paper describes the cloning, sequencing and characterization of individual genes of 
Nipah virus. 
3. Chua, K. B., S. K. Lam, K. J. Goh, P. S. Hooi, T. G. Ksiazek, A. Kamarulzaman, J. 
Olson, and C. T. Tan. 2001. The presence of Nipah virus in respiratory secretions and 
urine of patients during an outbreak of Nipah virus encephalitis in Malaysia. J Infect 
42:40-3. 
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4. Harcourt, B. H., A. Tamin, K. Halpin, T. G. Ksiazek, P. E. Rollin, W. J. Bellini, and 
P. A. Rota. 2001. Molecular characterization of the polymerase gene and genomic termini 
of Nipah virus. Virology 287:192-201. 
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and the genomic termini of Nipah virus and compares the sequences with those of Hendra 
virus. 
5. Tamin, A., B. H. Harcourt, T. G. Ksiazek, P. E. Rollin, W. J. Bellini, and P. A. Rota. 
2002. Functional properties of the fusion and attachment glycoproteins of Nipah virus. 
Virology 296:190-200. 
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the fusion and attachment proteins of Hendra and Nipah virus after vaccination of mice 
with recombinant vaccinia viruses.  
6. Goldsmith, C. S., T. Whistler, P. E. Rollin, T. G. Ksiazek, P. A. Rota, W. J. Bellini, P. 
Daszak, K. T. Wong, W. J. Shieh, and S. R. Zaki. 2003. Elucidation of Nipah virus 
morphogenesis and replication using ultrastructural and molecular approaches. Virus Res 
92:89-98. 
This paper describes the study of the morphologic features of Nipah virus in infected Vero 
E6 cells and human brain by electron microscopy and ultrastructural in situ hybridization. 
7. Halpin, K., B. Bankamp, B. H. Harcourt, W. J. Bellini, and P. A. 2004. Nipah virus 
conforms to the rule of six in a minigenome replication assay. J Gen Virol 85:701-7. 
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8. Bossart, K. N., G. Crameri, A. S. Dimitrov, B. A. Mungall, Y. R. Feng, J. R. Patch, 
A. Choudhary, L. F. Wang, B. T. Eaton, and C. C. broder. 2005. Receptor binding, 
fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G 
glycoprotein of Hendra virus. J Virol 79: 6690-6702. 
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on the cell-entry mechanism.  
9. Bonaparte, M. I., A. S. Dimitrov, K. N. Bossart, G. Crameri, B. A. Mungall, K. A. 
Bishop, V. Choudry, D. S. Dimitrov, L. F. Wang, B. T. Eaton, C. C. Broder. 2005. 
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl 
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Peste-des-petits-ruminants virus 
Taxonomy: Order: Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Morbillivirus, Species Peste-des-petits-ruminants virus. Virus: Peste-des-petits-ruminants 
virus. 
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Yesus, B. Egziabher, M. Diop, J. Sarr, and P. Verardi. 2003. Inexpensive vaccines and 
rapid diagnostic kits tailor-made for the global eradication of rinderpest, and technology 
transfer to Africa and Asia. Dev Biol 114:99-111. 
This paper reports the construction of a improved recombinant vaccinia virus vaccines 
expressing proteins of Rinderpest virus/Peste-des-petits-ruminants virus, and the 
following evaluation of the vaccine using live cattle. 
 
NIH Grants: None identified. 
 
Phakopsora pachyrhizi 
Taxonomy: Empire: Eukarya, Kingdom: Fungi, Phylum: Basidiomycota, Class: Urediniomycetes, 
Order: Uredinales, Family: Melampsoraceae. 
Publications: None identified. 






Plum pox virus 
Taxonomy: Family Potyviridae, Genus Potyvirus, Species Plum pox virus. Virus: Plum pox virus. 
Publications: 
1. Scorza, R., A. Callahan, L. Levy, V. Damsteegt, K. Webb, and M. Ravelonandro. 
2001. Post-transcriptional gene silencing in plum pox virus resistant transgenic European 
plum containing the plum pox potyvirus coat protein gene. Transgenic Res 10:201-9. 
This paper reports the resistance and its mechanism of transgenic plants to PPV infection. 
 
NIH Grants: None identified. 
 
Ralstonia solanacearum (race 3 biovar 2) 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Betaproteobacteria, Order 
Burkholderiales, Family Ralstoniaceae. 
Publications: None reported 
NIH Grants: None identified. 
 
Rickettsia prowazekii 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Alphaproteobacteria, Order 
Rickettsiales, Family Rickettsiaceae. 
Publications: 
1. Ives, T. J., E. L. Marston, R. L. Regnery, J. D. Butts, and T. C. Majerus. 2000. In 
vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as 
determined by immunofluorescent antibody analysis of infected vero cell monolayers. J 
Antimicrob Chemother 45:305-10. 
 This paper reports the testing of Rickettsia prowazekii and Rickettsia rickettsii to different 





2. Moron, C. G., D. H. Bouyer, X. J. Yu, L. D. Foil, P. Crocquet-Valdes, and D. H. 
Walker. 2000. Phylogenetic analysis of the rompB genes of Rickettsia felis and 
Rickettsia prowazekii European-human and North American flying-squirrel strains. Am J 
Trop Med Hyg 62:598-603. 
 This paper reports a phylogenetic analysis of different strains of the bacterium. 
3. Van Kirk, L. S., S. F. Hayes, and R. A. Heinzen. 2000. Ultrastructure of Rickettsia 
rickettsii actin tails and localization of cytoskeletal proteins. Infect Immun 68:4706-13. 
 This paper reports the ultrastructure of a part of different rickettsiae. 
4. Walker, D. H., H. M. Feng, and V. L. Popov. 2001. Rickettsial phospholipase A2 as a 
pathogenic mechanism in a model of cell injury by typhus and spotted fever group 
rickettsiae. Am J Trop Med Hyg 65:936-42. 
 This paper identifies an enzyme of the bacterium as a key factor of pathogenesis. 
5. Gaywee, J., S. Radulovic, J. A. Higgins, and A. F. Azad. 2002. Transcriptional analysis 
of Rickettsia prowazekii invasion gene homolog (invA) during host cell infection. Infect 
Immun 70:6346-54. 
 This paper reports the analysis of the function of a gene of the bacterium that is important 
for infection. 
6. Gaywee, J., W. Xu, S. Radulovic, M. J. Bessman, and A. F. Azad. 2002. The 
Rickettsia prowazekii invasion gene homolog (invA) encodes a Nudix hydrolase active on 
adenosine (5')-pentaphospho-(5')-adenosine. Mol Cell Proteomics 1:179-85. 
 This paper reports the analysis of the function of a gene of the bacterium that is important 
for infection. 
7. Coker, C., M. Majid, and S. Radulovic. 2003. Development of Rickettsia prowazekii 
DNA vaccine: cloning strategies. Ann N Y Acad Sci 990:757-64. 
 This paper reports the development of a DNA vaccine to defend against infection with the 
bacterium. 
8. Gaywee, J., J. B. Sacci, Jr., S. Radulovic, M. S. Beier, and A. F. Azad. 2003. 
Subcellular localization of rickettsial invasion protein, InvA. Am J Trop Med Hyg 68:92-
6. 
 This paper reports the location of a protein important for infection within the bacterial 
cell. 
9. Ge, H., Y. Y. Chuang, S. Zhao, J. J. Temenak, and W. M. Ching. 2003. Genomic 
studies of Rickettsia prowazekii virulent and avirulent strains. Ann N Y Acad Sci 
990:671-7. 
 This paper reports genomic sequences of different strains of the bacterium. 
10. Tucker, A. M., H. H. Winkler, L. O. Driskell, and D. O. Wood. 2003. S-
adenosylmethionine transport in Rickettsia prowazekii. J Bacteriol 185:3031-5. 
 This paper reports the transports of a metabolic intermediate in the bacterium. 
11. Chao, C. C., D. Chelius, T. Zhang, L. Daggle, and W. M. Ching. 2004. Proteome 
analysis of Madrid E strain of Rickettsia prowazekii. Proteomics 4:1280-92. 
 This paper reports the analysis of the proteome of the bacterium. 
12. Ge, H., Y. Y. Chuang, S. Zhao, M. Tong, M. H. Tsai, J. J. Temenak, A. L. Richards, 
and W. M. Ching. 2004. Comparative genomics of Rickettsia prowazekii Madrid E and 
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Rickettsia rickettsii 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Alphaproteobacteria, Order 
Rickettsiales, Family Rickettsiaceae. 
Publications: 
1. Ives, T. J., E. L. Marston, R. L. Regnery, J. D. Butts, and T. C. Majerus. 2000. In 
vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as 
determined by immunofluorescent antibody analysis of infected vero cell monolayers. J 
Antimicrob Chemother 45:305-10. 
 This paper reports the testing of Rickettsia prowazekii and Rickettsia rickettsii to different 
concentrations of an antibiotic. 
2 Van Kirk, L. S., S. F. Hayes, and R. A. Heinzen. 2000. Ultrastructure of Rickettsia 
rickettsii actin tails and localization of cytoskeletal proteins. Infect Immun 68:4706-13. 
 This paper reports the ultrastructure of a part of different rickettsiae. 
3. Shi, R. J., P. J. Simpson-Haidaris, V. J. Marder, D. J. Silverman, and L. A. Sporn. 
2000. Post-transcriptional regulation of endothelial cell plasminogen activator inhibitor-1 
expression during R. rickettsii infection. Microb Pathog 28:127-33. 
 This paper reports the regulation of a blood coagulation-control protein upon infection 
with the bacterium.  
4. Eremeeva, M. E., G. A. Dasch, and D. J. Silverman. 2001. Quantitative analyses of 
variations in the injury of endothelial cells elicited by 11 isolates of Rickettsia rickettsii. 
Clin Diagn Lab Immunol 8:788-96. 
 This paper reports the effect of different strains of the bacterium on endothelial cells. 
5. Temenak, J. J., B. E. Anderson, and G. A. McDonald. 2001. Molecular cloning, 
sequence and characterization of cjsT, a putative protease from Rickettsia rickettsii. 
Microb Pathog 30:221-8. 
 This paper reports the cloning of a protease of the bacterium. 
6. Rydkina, E., A. Sahni, D. J. Silverman, and S. K. Sahni. 2002. Rickettsia rickettsii 
infection of cultured human endothelial cells induces heme oxygenase 1 expression. Infect 
Immun 70:4045-52. 
 This paper reports the induction of a host-cell gene by the bacterium. 
7. Eremeeva, M. E., G. A. Dasch, and D. J. Silverman. 2003. Evaluation of a PCR assay 
for quantitation of Rickettsia rickettsii and closely related spotted fever group rickettsiae. 
J Clin Microbiol 41:5466-72. 






8. Eremeeva, M. E., R. M. Klemt, L. A. Santucci-Domotor, D. J. Silverman, and G. A. 
Dasch. 2003. Genetic analysis of isolates of Rickettsia rickettsii that differ in virulence. 
Ann N Y Acad Sci 990:717-22. 
This paper reports the sequencing of parts of the genomes of different strains of the 
bacterium. 
9. Eremeeva, M. E., Z. Liang, C. Paddock, S. Zaki, J. G. Vandenbergh, G. A. Dasch, 
and D. J. Silverman. 2003. Rickettsia rickettsii infection in the pine vole, Microtus 
pinetorum: kinetics of infection and quantitation of antioxidant enzyme gene expression 
by RT-PCR. Ann N Y Acad Sci 990:468-73. 
 This paper characterizes the infection of the pine vole with the bacterium. 
10. Harlander, R. S., M. Way, Q. Ren, D. Howe, S. S. Grieshaber, and R. A. Heinzen. 
2003. Effects of ectopically expressed neuronal Wiskott-Aldrich syndrome protein 
domains on Rickettsia rickettsii actin-based motility. Infect Immun 71:1551-6. 
 This paper reports the effect of a protein on the intracellular motility of the bacterium. 
11. Heinzen, R. A. 2003. Rickettsial actin-based motility: behavior and involvement of 
cytoskeletal regulators. Ann N Y Acad Sci 990:535-47. 
 This paper sheds light on the mechanism of intracellular motility of the bacterium. 
12. Joshi, S. G., C. W. Francis, D. J. Silverman, and S. K. Sahni. 2003. Nuclear factor 
kappa B protects against host cell apoptosis during Rickettsia rickettsii infection by 
inhibiting activation of apical and effector caspases and maintaining mitochondrial 
integrity. Infect Immun 71:4127-36. 
 This paper reports the identification of a protein that protects against cell death induced by 
the bacterium. 
13. Lee, K. N., I. Padmalayam, B. Baumstark, S. L. Baker, and R. F. Massung. 2003. 
Characterization of the ftsZ gene from Ehrlichia chaffeensis, Anaplasma 
phagocytophilum, and Rickettsia rickettsii, and use as a differential PCR target. DNA Cell 
Biol 22:179-86. 
 This paper reports the characterization of a gene of the bacterium. 
14. Rahman, M. S., J. A. Simser, K. R. Macaluso, and A. F. Azad. 2003. Molecular and 
functional analysis of the lepB gene, encoding a type I signal peptidase from Rickettsia 
rickettsii and Rickettsia typhi. J Bacteriol 185:4578-84. 
 This protein reports the analysis of a gene of the bacterium. 
15. Sahni, S. K., E. Rydkina, S. G. Joshi, L. A. Sporn, and D. J. Silverman. 2003. 
Interactions of Rickettsia rickettsii with endothelial nuclear factor-kappaB in a "cell-free" 
system. Ann N Y Acad Sci 990:635-41. 
 This paper reports the interaction of the bacterium with a cellular protein. 
16. Baldridge, G. D., N. Y. Burkhardt, J. A. Simser, T. J. Kurtti, and U. G. Munderloh. 
2004. Sequence and expression analysis of the ompA gene of Rickettsia peacockii, an 
endosymbiont of the Rocky Mountain wood tick, Dermacentor andersoni. Appl Environ 
Microbiol 70:6628-36. 
 This paper reports the sequence and expression of a gene of an agent related to the 





17. Jeng, R. L., E. D. Goley, J. A. D'Alessio, O. Y. Chaga, T. M. Svitkina, G. G. Borisy, 
R. A. Heinzen, and M. D. Welch. 2004. A Rickettsia WASP-like protein activates the 
Arp2/3 complex and mediates actin-based motility. Cell Microbiol 6:761-9. 
 This paper reports the effect of a protein of the bacterium on its intracellular motility. 
18. Joshi, S. G., C. W. Francis, D. J. Silverman, and S. K. Sahni. 2004. NF-kappaB 
activation suppresses host cell apoptosis during Rickettsia rickettsii infection via 
regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic 
proteins. FEMS Microbiol Lett 234:333-41. 
 This paper reports that a host-cell protein is able to suppress cell death even after infection 
with the bacterium 
19. Labruna, M. B., T. Whitworth, M. C. Horta, D. H. Bouyer, J. W. McBride, A. 
Pinter, V. Popov, S. M. Gennari, and D. H. Walker. 2004. Rickettsia species infecting 
Amblyomma cooperi ticks from an area in the state of Sao Paulo, Brazil, where Brazilian 
spotted fever is endemic. J Clin Microbiol 42:90-8. 
 This paper reports the isolation of the bacterium from a tick species. 
20. Clifton, D. R., E. Rydkina, R. S. Freeman, and S. K. Sahni. 2005. NF-kappaB 
activation during Rickettsia rickettsii infection of endothelial cells involves the activation 
of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of 
the inhibitor protein IkappaBalpha. Infect Immun 73:155-65. 
 This paper reports specifics of the activation of a host-cell protein upon infection with 
bacterium. 
21. Rahman, M. S., J. A. Simser, K. R. Macaluso, and A. F. Azad. 2005. Functional 
analysis of secA homologues from rickettsiae. Microbiology 151:589-96. 
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Rift Valley fever virus 
Taxonomy: Family Bunyaviridae, Genus Phlebovirus, Species Rift Valley fever virus, Virus: Rift 
Valley fever virus, ZH548, MM12, Belterra virus, Icoaraci virus 
Publications: 
1. Dohm, D. J., E. D. Rowton, P. G. Lawyer, M. O'Guinn, and M. J. Turell. 2000. 
Laboratory transmission of Rift Valley fever virus by Phlebotomus duboscqi, 
Phlebotomus papatasi, Phlebotomus sergenti, and Sergentomyia schwetzi (Diptera: 
Psychodidae). J Med Entomol 37:435-8. 
 This paper reports the ability of certain mosquitoes to transmit the virus. 
2. Gora, D., T. Yaya, T. Jocelyn, F. Didier, D. Maoulouth, S. Amadou, T. D. Ruel, and 
J. P. Gonzalez. 2000. The potential role of rodents in the enzootic cycle of Rift Valley 
fever virus in Senegal. Microbes Infect 2:343-6. 
This paper describes the screening of rodents for antibodies to RFVF. Two rodent species 
with high high antibody prevalence were identified. Artificial infection of these species 
with RVFV demonstrated their ability to replicate the virus. 
3. Gerrard, S. R., P. E. Rollin, and S. T. Nichol. 2002. Bidirectional infection and release 
of Rift Valley fever virus in polarized epithelial cells. Virology 301:226-35. 
This paper describes the characterization of RVFV entry and egress in polarized epithelial 
cells. 
4. Miller, B. R., M. S. Godsey, M. B. Crabtree, H. M. Savage, Y. Al-Mazrao, M. H. Al-
Jeffri, A. M. Abdoon, S. M. Al-Seghayer, A. M. Al-Shahrani, and T. G. Ksiazek. 
2002. Isolation and genetic characterization of Rift Valley fever virus from Aedes vexans 
arabiensis, Kingdom of Saudi Arabia. Emerg Infect Dis 8:1492-4. 
This paper describes the isolation and genetic characterization of an Arabic RVFV isolate 





5. Shoemaker, T., C. Boulianne, M. J. Vincent, L. Pezzanite, M. M. Al-Qahtani, Y. Al-
Mazrou, A. S. Khan, P. E. Rollin, R. Swanepoel, T. G. Ksiazek, and S. T. Nichol. 
2002. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi 
Arabia and Yemen, 2000-01. Emerg Infect Dis 8:1415-20. 
This paper describes the genetic characterization of an Arabic RVFV isolate. 
6. Morrill, J. C., and C. J. Peters. 2003. Pathogenicity and neurovirulence of a mutagen-
attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21:2994-3002. 
This paper describes the evaluation of an attenuated RVFV strain as a potential vaccine 
candidate. 
7. Paweska, J. T., F. J. Burt, F. Anthony, S. J. Smith, A. A. Grobbelaar, J. E. Croft, T. 
G. Ksiazek, and R. Swanepoel. 2003. IgG-sandwich and IgM-capture enzyme-linked 
immunosorbent assay for the detection of antibody to Rift Valley fever virus in domestic 
ruminants. J Virol Methods 113:103-12. 
This paper describes the development and evaluation of sandwich and capture ELISAs for 
the detection of IgG and IgM antibodies to RVFV in bovine, caprine and ovine sera. 
8. Aitichou, M., S. S. Saleh, A. K. McElroy, C. Schmaljohn, and M. S. Ibrahim. 2005. 
Identification of Dobrava, Hantaan, Seoul, and Puumala viruses by one-step real-time RT-
PCR. J Virol Methods 124:21-6. 
 This paper reports th development of a diagnostic system for hantaviruses and the use of 
the virus as a control. 
9. Ikegami, T., C. J. Peters, and S. Makino. 2005. Rift valley fever virus nonstructural 
protein NSs promotes viral RNA replication and transcription in a minigenome system. J 
Virol 79:5606-15. 
This paper reports the identification of a protein of the virus that is important for both 
replication and transcription. 
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 $372,974 | 2005 | Compans, Richard W | EMORY UNIVERSITY | ATLANTA, 
GA  
 $363,996 | 2004 | Compans, Richard W | EMORY UNIVERSITY | ATLANTA, 
GA  
 $179,552 | 2003 | Compans, Richard W | EMORY UNIVERSITY | ATLANTA, 
GA  





Fever Virus Vaccine  
4 33 1R01AI053135-01 FROLOV, ILYA 
A Sindbis virus-based Vaccine 
Against RVFV Infection  
Total: $906,000  
 $302,000 | 2005 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $302,000 | 2004 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $302,000 | 2003 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
5 33 1R41AI058353-01 OLIVO, PAUL 
Molecular tools for Bunyavirus 
antiviral screening  
Total: $741,038  
 $413,699 | 2005 | Olivo, Paul D | ORION GENOMICS, LLC | ST. LOUIS, MO 
 $327,339 | 2004 | Olivo, Paul D | JACOBS FACILITIES, INC. | ST LOUIS, 
MO  
6 33 1R21AI053551-01 
WATOWICH, 
STANLEY 
Novel Countermeasures to 
Hemorrhagic Fever Viruses  
Total: $447,000  
 $223,500 | 2003 | Watowich, Stanley J | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $223,500 | 2002 | Watowich, Stanley J | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
7 16 1UC1AI062579-01 BARANY, FRANCIS 
Multiplexed Detection of Bioterror 
Agents  
Total: $4,448,762  
 $4,448,762 | 2004 | Barany, Francis | WEILL MEDICAL COLLEGE OF 






Hemorrhagic Fever  
Total: $22,072,698  
 $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
9 16 1R43AI056525-01 COLLETT, MARC 
Antiviral Drugs Against 
Hemorrhagic Fever Viruses  
Total: $909,502  
 $909,502 | 2003 | Collett, Marc S | VIROPHARMA, INC. | EXTON, PA  
10 16 1U01AI054374-01 
HENRICKSON, 
KELLY 
Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  





WISCONSIN | MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
 
Rinderpest virus 
Taxonomy: Order: Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Morbillivirus, Species Rinderpest virus, Virus: Rinderpest virus. 
Publications: 
1. Verardi, P. H., Fatema H. Aziz, Shabbir Ahmad, and Leslie A. Jones, Berhanu 
Beyene, Rosemary N. Ngotho, Henry M. Wamwayi, Mebratu G. Yesus, Berhe G. 
Egziabher, and Tilahun D. Yilma. 2002. Long-Term Sterilizing Immunity to Rinderpest 
in Cattle Vaccinated with a Recombinant Vaccinia Virus Expressing High Levels of the 
Fusion and Hemagglutinin Glycoproteins. J Virol 76:484-91. 
This paper reports the construction of a recombinant vaccinia virus vaccine expressing 
proteins of Rinderpest virus, and the following evaluation of the vaccine using live cattle. 
2. Pahar, B., B. Sharma B, and A. C. Goel. 2002. Effect of immunization with plasmid 
DNA encoding for rinderpest virus matrix protein on systemic rinderpest virus infection in 
rabbits. Vet Res Commun 26:227-37. 
This paper reports the evaluation of a DNA vaccine candidate against Rinderpest virus in 
rabbits. 
3. Yilma, T., F. Aziz, S. Ahmad, L. Jones, R. Ngotho, H. Wamwayi, B. Beyene, M. 
Yesus, B. Egziabher, M. Diop, J. Sarr, and P. Verardi. 2003. Inexpensive vaccines and 
rapid diagnostic kits tailor-made for the global eradication of rinderpest, and technology 
transfer to Africa and Asia. Dev Biol 114:99-111. 
This paper reports the construction of a improved recombinant vaccinia virus vaccines 
expressing proteins of Rinderpest virus/Peste-des-petits-ruminants virus, and the 
following evaluation of the vaccine using live cattle. 
 
NIH Grants: None identified. 
 
Sabiá virus 







1. Spiropoulou, C. F., Stefan Kunz, Pierre E. Rollin, Kevin P. Campbell, and Michael 
B. A. Oldstone. 2002. New World Arenavirus Clade C, but Not Clade A and B Viruses, 
Utilizes -Dystroglycan as Its Major Receptor. J Virol 76:5140-5146. 
This paper comes to the conclusion that Flexal, Guanaríto, Machupo, and Sabiá viruses do 
not use the Lassa fever virus receptor dystroglycan. 
2. Archer, A. M., and Rebeca Rico-Hesse. 2002. High Genetic Divergence and 
Recombination in Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanaríto, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 
and functional relationships. 
 
NIH Grants: None identified. 
 
Sclerophthora rayssiae (var. zeae) 
Taxonomy: Empire: Eukaryota, Kingdom: Chromista, Phylum: Bigyra, Class Oomycetes, Order 
Peronosporales, Family Peronosporaceae. 
Publications: None identified. 
NIH grants: None identified. 
 
Sheeppox virus 
Taxonomy: Family Poxviridae, Subfamily Chordopoxvirinae, Genus Capripoxvirus, Species 
Sheeppox virus, Virus: Sheeppox virus. 
Publications: 
1. Tulman, E. R., C. L. Afonso, Z. Lu, L. Zsak, J.-H. Sur, N. T. Sandybaev, U. Z. 
Kerembekova, V. L. Zaitsev, G. F. Kutish, and D. L. Rock. 2002. The Genomes of 
Sheeppox and Goatpox Viruses. J Virol 76:6054-61. 
This paper describes the sequencing and characterization, and comparison of Sheeppox 






NIH grants: None identified. 
 
Synchytrium endobioticum 
Taxonomy: Empire: Eukaryota, Kingdom: Fungi, Phylum: Archemycota, Class: 
Chytridiomycetes, Order: Chytridiales, Family: Synchytriaceae. 
Publications: None identified. 
NIH grants: None identified. 
 
Venezuelan equine encephalitis virus 
Taxonomy: Family Togaviridae, Genus Alphavirus, Species Venezuelan equine encephalitis 
virus, Virus: Venezuelan equine encephalitis virus. 
Publications: 
1. Aronson, J. F., F. B. Grieder, N. L. Davis, P. C. Charles, T. Knott, K. Brown, and R. 
E. Johnston. 2000. A single-site mutant and revertants arising in vivo define early steps 
in the pathogenesis of Venezuelan equine encephalitis virus. Virology 270:111-23. 
 This paper reports the pathological comparison of a virulent and an avirulent strain of the 
virus in order to determine when and where during infection the avirlen strain is blocked. 
2. Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 
glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, 
low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. 
 This paper reports the identigy of amino acid residues in the envelope protein of the virus 
that are important for binding to heparin sulfate and low virlence. 
3. Hart, M. K., K. Caswell-Stephan, R. Bakken, R. Tammariello, W. Pratt, N. Davis, R. 
E. Johnston, J. Smith, and K. Steele. 2000. Improved mucosal protection against 
Venezuelan equine encephalitis virus is induced by the molecularly defined, live-
attenuated V3526 vaccine candidate. Vaccine 18:3067-75. 
 This paper evaluated a novel vaccine candidate. 
4. Linssen, B., R. M. Kinney, P. Aguilar, K. L. Russell, D. M. Watts, O. R. Kaaden, and 
M. Pfeffer. 2000. Development of reverse transcription-PCR assays specific for detection 
of equine encephalitis viruses. J Clin Microbiol 38:1527-35. 
 This paper reports the development of a novel PCR-based diagnostic assay for the 





5. MacDonald, G. H., and R. E. Johnston. 2000. Role of dendritic cell targeting in 
Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914-22. 
 This paper identified dendritic cells as early targets of the virus. 
6. Powers, A. M., A. C. Brault, R. M. Kinney, and S. C. Weaver. 2000. The use of 
chimeric Venezuelan equine encephalitis viruses as an approach for the molecular 
identification of natural virulence determinants. J Virol 74:4258-63. 
 This paper reports the employment of chimeric Venezuelan equine encephalitis viruses for 
the identification of areas of its genome that are important for virulence. 
7. Schoneboom, B. A., K. M. Catlin, A. M. Marty, and F. B. Grieder. 2000. 
Inflammation is a component of neurodegeneration in response to Venezuelan equine 
encephalitis virus infection in mice. J Neuroimmunol 109:132-46. 
 This paper reports the neuropathology of mice infected with the virus. 
8. Schoneboom, B. A., J. S. Lee, and F. B. Grieder. 2000. Early expression of IFN-
alpha/beta and iNOS in the brains of Venezuelan equine encephalitis virus-infected mice. 
J Interferon Cytokine Res 20:205-15. 
 This paper reports the detection of interferons and certain enzymes in the brains of mice 
infected with the virus. 
9. Turell, M. J., J. W. Jones, M. R. Sardelis, D. J. Dohm, R. E. Coleman, D. M. Watts, 
R. Fernandez, C. Calampa, and T. A. Klein. 2000. Vector competence of Peruvian 
mosquitoes (Diptera: Culicidae) for epizootic and enzootic strains of Venezuelan equine 
encephalomyelitis virus. J Med Entomol 37:835-9. 
 This paper reports the evaluation of different mosquitoes for their competence to replicate 
different strains of the virus. 
10. Brault, A. C., A. M. Powers, G. Medina, E. Wang, W. Kang, R. A. Salas, J. De Siger, 
and S. C. Weaver. 2001. Potential sources of the 1995 Venezuelan equine encephalitis 
subtype IC epidemic. J Virol 75:5823-32. 
 This paper attempts to pinpoint the origin of a strain of the virus. 
11. Charles, P. C., J. Trgovcich, N. L. Davis, and R. E. Johnston. 2001. 
Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-
induced disease in the mouse. Virology 284:190-202. 
 This paper reports the immune response of mice infected with the virus. 
12. Hart, M. K., C. Lind, R. Bakken, M. Robertson, R. Tammariello, and G. V. Ludwig. 
2001. Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan 
equine encephalitis virus in vaccinated mice. Vaccine 20:616-22. 
 This paper evaluates a vaccine candidate in mice. 
13. Ludwig, G. V., M. J. Turell, P. Vogel, J. P. Kondig, W. K. Kell, J. F. Smith, and W. 
D. Pratt. 2001. Comparative neurovirulence of attenuated and non-attenuated strains of 
Venezuelan equine encephalitis virus in mice. Am J Trop Med Hyg 64:49-55. 
 This paper compares the neuropathology of mice infected with different strains of the 
virus. 
14. Moncayo, A. C., G. M. Medina, Z. Kalvatchev, A. C. Brault, R. Barrera, J. Boshell, 
C. Ferro, J. E. Freier, J. C. Navarro, R. Salas, J. De Siger, C. Vasquez, R. Walder, 





encephalitis virus field isolates from Colombia and Venezuela. Am J Trop Med Hyg 
65:738-46. 
 This paper reports the phylogenetic relationships of different strains of the virus. 
15. Paredes, A., K. Alwell-Warda, S. C. Weaver, W. Chiu, and S. J. Watowich. 2001. 
Venezuelan equine encephalomyelitis virus structure and its divergence from old world 
alphaviruses. J Virol 75:9532-7. 
 This paper reports the comparison of the structure of the virus with that of other 
alphaviruses. 
16. Powers, A. M., A. C. Brault, Y. Shirako, E. G. Strauss, W. Kang, J. H. Strauss, and 
S. C. Weaver. 2001. Evolutionary relationships and systematics of the alphaviruses. J 
Virol 75:10118-31. 
 This paper reports the phylogenetic relationships of different strains of the virus. 
17. Wang, E., R. A. Bowen, G. Medina, A. M. Powers, W. Kang, L. M. Chandler, R. E. 
Shope, and S. C. Weaver. 2001. Virulence and viremia characteristics of 1992 epizootic 
subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype 
ID strains. Am J Trop Med Hyg 65:64-9. 
 This paper reports the characterization of a strain of the virus. 
18. White, L. J., J. G. Wang, N. L. Davis, and R. E. Johnston. 2001. Role of alpha/beta 
interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating 
mutation in the 5' untranslated region. J Virol 75:3706-18. 
 This paper reports the interferon response of mice infected with wild-type and attenuated 
strains of the virus. 
19. Brault, A. C., A. M. Powers, E. C. Holmes, C. H. Woelk, and S. C. Weaver. 2002. 
Positively charged amino acid substitutions in the e2 envelope glycoprotein are associated 
with the emergence of venezuelan equine encephalitis virus. J Virol 76:1718-30. 
 This paper reports the comparison of genomic sequences of different strains of the virus. 
20. Brault, A. C., A. M. Powers, and S. C. Weaver. 2002. Vector infection determinants of 
Venezuelan equine encephalitis virus reside within the E2 envelope glycoprotein. J Virol 
76:6387-92. 
 This paper reports the comparison of genomic sequences of different strains of the virus. 
21. O'Guinn, M. L., and M. J. Turell. 2002. Effect of triethylamine on the recovery of 
selected South American alphaviruses, flaviviruses, and bunyaviruses from mosquito 
(Diptera: Culicidae) pools. J Med Entomol 39:806-8. 
 This paper reports the effect of a chemical on the isolation of the virus from mosquitoes. 
22. Fernandez, Z., A. C. Moncayo, A. S. Carrara, O. P. Forattini, and S. C. Weaver. 
2003. Vector competence of rural and urban strains of Aedes (Stegomyia) albopictus 
(Diptera: Culicidae) from Sao Paulo State, Brazil for IC, ID, and IF subtypes of 
Venezuelan equine encephalitis virus. J Med Entomol 40:522-7. 
 This paper reports the competence of different mosquitoes to replicate different strains of 
the virus. 
23. Gonzalez-Salazar, D., J. G. Estrada-Franco, A. S. Carrara, J. F. Aronson, and S. C. 
Weaver. 2003. Equine amplification and virulence of subtype IE Venezuelan equine 






 This paper reports the inoculation of horses with a strain of the virus to determine the 
horses’ ability to amplify it. 
24. Paessler, S., R. Z. Fayzulin, M. Anishchenko, I. P. Greene, S. C. Weaver, and I. 
Frolov. 2003. Recombinant sindbis/Venezuelan equine encephalitis virus is highly 
attenuated and immunogenic. J Virol 77:9278-86. 
 This paper reports the development of a vaccine candidate. 
25. Paredes, A., K. Alwell-Warda, S. C. Weaver, W. Chiu, and S. J. Watowich. 2003. 
Structure of isolated nucleocapsids from venezuelan equine encephalitis virus and 
implications for assembly and disassembly of enveloped virus. J Virol 77:659-64. 
 This paper reports the structure of the nucleocapsid of the virus. 
26. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. Tang, 
Q. Bin, T. W. Dubensky, Jr., M. Vajdy, G. R. Otten, and J. M. Polo. 2003. An 
alphavirus replicon particle chimera derived from venezuelan equine encephalitis and 
sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77:10394-403. 
 This paper reports a vaccine candidate. 
27. Pratt, W. D., N. L. Davis, R. E. Johnston, and J. F. Smith. 2003. Genetically 
engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal 
models. Vaccine 21:3854-62. 
 This paper reports the evaluation of a vaccine candidate. 
28. Riemenschneider, J., A. Garrison, J. Geisbert, P. Jahrling, M. Hevey, D. Negley, A. 
Schmaljohn, J. Lee, M. K. Hart, L. Vanderzanden, D. Custer, M. Bray, A. Ruff, B. 
Ivins, A. Bassett, C. Rossi, and C. Schmaljohn. 2003. Comparison of individual and 
combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan 
equine encephalitis virus. Vaccine 21:4071-80. 
 This paper reports the evaluation of a vaccine candidate. 
29. Sahu, S. P., D. D. Pedersen, A. L. Jenny, B. J. Schmitt, and A. D. Alstad. 2003. 
Pathogenicity of a Venezuelan equine encephalomyelitis serotype IE virus isolate for 
ponies. Am J Trop Med Hyg 68:485-94. 
 This paper reports the virulence of a strain of the virus. 
30. Seth, P., M. M. Husain, P. Gupta, A. Schoneboom, B. F. Grieder, H. Mani, and R. K. 
Maheshwari. 2003. Early onset of virus infection and up-regulation of cytokines in mice 
treated with cadmium and manganese. Biometals 16:359-68. 
 This paper reports the effects of metals on the susceptibility of mice for infection with the 
virus 
31. Turell, M. J., M. L. O'Guinn, R. Navarro, G. Romero, and J. G. Estrada-Franco. 
2003. Vector competence of Mexican and Honduran mosquitoes (Diptera: Culicidae) for 
enzootic (IE) and epizootic (IC) strains of Venezuelan equine encephalomyelitis virus. J 
Med Entomol 40:306-10. 
 This paper reports the susceptibility of certain mosquitoes to the virus. 
32. Wang, E., A. C. Brault, A. M. Powers, W. Kang, and S. C. Weaver. 2003. 
Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus 
isolates. J Virol 77:1204-10. 





33. Aguilar, P. V., I. P. Greene, L. L. Coffey, G. Medina, A. C. Moncayo, M. 
Anishchenko, G. V. Ludwig, M. J. Turell, M. L. O'Guinn, J. Lee, R. B. Tesh, D. M. 
Watts, K. L. Russell, C. Hice, S. Yanoviak, A. C. Morrison, T. A. Klein, D. J. Dohm, 
H. Guzman, A. P. Travassos da Rosa, C. Guevara, T. Kochel, J. Olson, C. Cabezas, 
and S. C. Weaver. 2004. Endemic Venezuelan equine encephalitis in northern Peru. 
Emerg Infect Dis 10:880-8. 
 This paper describes a strain of the virus. 
34. Anishchenko, M., S. Paessler, I. P. Greene, P. V. Aguilar, A. S. Carrara, and S. C. 
Weaver. 2004. Generation and characterization of closely related epizootic and enzootic 
infectious cDNA clones for studying interferon sensitivity and emergence mechanisms of 
Venezuelan equine encephalitis virus. J Virol 78:1-8. 
 This paper reports the creation of infectious cDNA clones of different strains of the virus. 
35. Brault, A. C., A. M. Powers, D. Ortiz, J. G. Estrada-Franco, R. Navarro-Lopez, and 
S. C. Weaver. 2004. Venezuelan equine encephalitis emergence: enhanced vector 
infection from a single amino acid substitution in the envelope glycoprotein. Proc Natl 
Acad Sci U S A 101:11344-9. 
 This paper reports a vaccine candidate. 
36. Estrada-Franco, J. G., R. Navarro-Lopez, J. E. Freier, D. Cordova, T. Clements, A. 
Moncayo, W. Kang, C. Gomez-Hernandez, G. Rodriguez-Dominguez, G. V. Ludwig, 
and S. C. Weaver. 2004. Venezuelan equine encephalitis virus, southern Mexico. Emerg 
Infect Dis 10:2113-21. 
 This paper reports the characterization of a strain of the virus. 
37. Ortiz, D. I., and S. C. Weaver. 2004. Susceptibility of Ochlerotatus taeniorhynchus 
(Diptera: Culicidae) to infection with epizootic (subtype IC) and enzootic (subtype ID) 
Venezuelan equine encephalitis viruses: evidence for epizootic strain adaptation. J Med 
Entomol 41:987-93. 
 This paper reports the susceptibility of different mosquitoes for certain strains of the virus. 
38. Romoser, W. S., L. P. Wasieloski, Jr., P. Pushko, J. P. Kondig, K. Lerdthusnee, M. 
Neira, and G. V. Ludwig. 2004. Evidence for arbovirus dissemination conduits from the 
mosquito (Diptera: Culicidae) midgut. J Med Entomol 41:467-75. 
 This paper sheds light on the transmission of the virus from the mosquito midgut. 
39. Greene, I. P., S. Paessler, M. Anishchenko, D. R. Smith, A. C. Brault, I. Frolov, and 
S. C. Weaver. 2005. Venezuelan equine encephalitis virus in the guinea pig model: 
evidence for epizootic virulence determinants outside the E2 envelope glycoprotein gene. 
Am J Trop Med Hyg 72:330-8. 
 This paper reports the creation of a guinea pig model of VEE; and that the adaptation is 
not solely dependent on the envelope protein of the virus. 
 
NIH Grants: 
1 42 1R01AI048807-01 WEAVER, SCOTT 
ECOLOGY AND GENETICS OF 





Total: $1,902,463  
 $388,437 | 2005 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $415,595 | 2004 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $27,488 | 2003 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $412,798 | 2003 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $319,602 | 2002 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $338,543 | 2001 | Weaver, Scott C | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
2 33 1UC1AI062538-01 FINE, DONALD 
Phase 2 Trial for Venezuelan Equine 
Encephalitis V3526  
Total: $9,996,228  
 $9,996,228 | 2004 | Fine, Donald L | DYNPORT VACCINE COMPANY, LLC | 
FREDERICK, MD  
3 28 
1R01AI050537-
01A2 FROLOV, ILYA 
Interaction of Sindbis Virus with 
Cellular Processes  
Total: $720,166  
 $298,000 | 2005 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $298,000 | 2004 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $124,166 | 2003 | Frolov, Ilya V | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
4 28 1R43AI062185-01 OLIVO, PAUL 
Replicon-based screening for 
inhibitors of alphaviruses  
Total: $958,581  
 $475,049 | 2005 | Olivo, Paul D | ORION GENOMICS, LLC | ST. LOUIS, MO 
 $483,532 | 2004 | Olivo, Paul D | JACOBS FACILITIES, INC. | ST LOUIS, 
MO  
5 28 1U01AI056438-01 
SMITH, 
JONATHAN 
Alphavirus Replicon Vaccines to 
Encephalitis Viruses  
Total: $6,081,763  
 $3,373,441 | 2005 | Smith, Jonathan | ALPHAVAX HUMAN VACCINES, 
INC. | RESEARCH TRIANGLE PARK, NC  
 $1,867,474 | 2004 | Smith, Jonathan | ICORIA, INC. | RESEARCH 
TRIANGLE PARK, NC  
 $840,848 | 2003 | Smith, Jonathan | ALPHAVAX HUMAN VACCINES, INC. | 
RESEARCH TRIANGLE PARK, NC  
6 28 
1U54AI057156-
010003 WEAVER, SCOTT Alphavirus Vaccines for Biodefense  
Total: $27,834,107 *  
 $12,024,542 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $11,566,950 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  





BR GALVESTON | GALVESTON, TX  
7 25 1R01AI063233-01 
MACDONALD, 
MARGARET 
Host factors in the alphavirus 
replication complex  
Total: $337,583  
 $337,583 | 2005 | Macdonald, Margaret R | ROCKEFELLER UNIVERSITY | 
NEW YORK, NY  
8 22 1R01AI056351-01 BARIC, RALPH 
Susceptibility and Protective 
Immunity to Noroviruses  
Total: $890,300  
 $376,502 | 2005 | Baric, Ralph S | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $384,133 | 2004 | Baric, Ralph S | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $129,665 | 2003 | Baric, Ralph S | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
9 22 1R21AI055746-01 BRAUN, WERNER 
Interacting motifs of alphavirus 
envelope proteins.  
Total: $598,039  
 $300,325 | 2004 | Braun, Werner A | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $297,714 | 2003 | Braun, Werner A | UNIVERSITY OF TEXAS MEDICAL BR 






HIV-1 gp140 Oligomers as Vaccine 
Immunogens  
Total: $4,594,198 *  
 $1,570,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | ROCKVILLE, MD  
 $1,452,497 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
 $1,571,351 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
11 22 1R21AI053737-01 CHIU, WAH 
High throughput icosahedral particle 
reconstruction  
Total: $451,500  
 $225,750 | 2003 | Chiu, Wah | BAYLOR COLLEGE OF MEDICINE | 
HOUSTON, TX  
 $225,750 | 2002 | Chiu, Wah | BAYLOR COLLEGE OF MEDICINE | 
HOUSTON, TX  
12 22 
2P01AI050246-
020002 ERON, JOSEPH Phase I/II study of a VRP vaccine  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  





CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
13 22 1R43AI060060-01 ESCH, ROBERT 
Ab Alphavirus Replicon Vaccine 
against Cytomegalovirus  
Total: $600,000  
 $300,000 | 2005 | Esch, Robert E | GREER LABORATORIES, INC. | 
LENOIR, NC  
 $300,000 | 2004 | Esch, Robert E | GREER LABORATORIES, INC. | 
LENOIR, NC  
14 22 
1U54AI057157-
010001 FEINBERG, MARK Orthopoxvirus Vaccine Development  
Total: $24,284,241  
 $10,247,734 | 2005 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, 
NC  
 $9,829,455 | 2004 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
 $4,207,052 | 2003 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
15 22 1P01AI050246-01 
JOHNSTON, 
ROBERT 
Therapeutic Vaccination for HIV 
Using VEE Vectors  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
16 22 2P01AI050246-02 
JOHNSTON, 
ROBERT 
Therapeutic Vaccination for HIV 
Using VEE Vectors  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 






First and second generation HIV-VRP 
vaccines  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  





CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
18 22 
2P01AI050246-
020005 KEITH, PAULA 
GMP production of clinical trial 
material  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
19 22 1Z01BP005026-01 NAKHASI, HIRA 
Molecular Mechanism and Diagnosis 
of Leishmaniasis  
20 22 1K08AI059491-01 
PAESSLER, 
SLOBODAN 
VEE PATHOGENESIS AND VACCINE 
DEVELOPMENT  
Total: $211,787  
 $112,619 | 2005 | Paessler, Slobodan | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $99,168 | 2004 | Paessler, Slobodan | UNIVERSITY OF TEXAS MEDICAL 






Broad Neutralizing Response to 
HIVenv/VEE Replicons  
Total: $4,594,198 *  
 $1,570,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | ROCKVILLE, MD  
 $1,452,497 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
 $1,571,351 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 






ENHANCING A BREAST CANCER 
VACCINE  
Total: $13,287,066  
 $110,721 | 2004 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $2,670,618 | 2004 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $3,022,773 | 2003 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $350,606 | 2003 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  





CHAPEL HILL | CHAPEL HILL, NC  
 $2,779,247 | 2001 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $11,600 | 2001 | Earp, H Shelton | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,000,000 | 2000 | EARP, H. S | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
23 22 1U01AI053876-01 
SMITH, 
JONATHAN 
Alphavirus Replicon Vaccines against 
Marburg Virus  
Total: $5,882,478  
 $1,843,827 | 2004 | Smith, Jonathan | ICORIA, INC. | RESEARCH 
TRIANGLE PARK, NC  
 $2,906,025 | 2003 | Smith, Jonathan | ALPHAVAX HUMAN VACCINES, 
INC. | RESEARCH TRIANGLE PARK, NC  
 $1,132,626 | 2002 | Smith, Jonathan F | ALPHAVAX HUMAN VACCINES, 
INC. | RESEARCH TRIANGLE PARK, NC  
24 22 1UC1AI062582-01 
SMITH, 
JONATHAN 
Development of Alphavirus Replicon 
Vaccine Against SARS  
Total: $4,839,367  
 $4,839,367 | 2004 | Smith, Jonathan | ICORIA, INC. | RESEARCH 
TRIANGLE PARK, NC  
25 22 1R21AI051638-01 TISCH, ROLAND 
The Use of VEE Replicons Encoding 
GAD65 to Treat IDDM  
Total: $291,000  
 $145,500 | 2002 | Tisch, Roland M | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $145,500 | 2001 | Tisch, Roland M. | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
26 22 1R21AI050430-01 VAJDY, MICHAEL 
Alphavirus Replicons for Mucosal 
HIV Vaccines  
Total: $584,179  
 $272,907 | 2002 | Vajdy, Michael | CHIRON CORPORATION | EMERYVILLE, 
CA  
 $311,272 | 2001 | Vajdy, Michael | CITY OF HOPE TOTAL AWARDS: $ 
276,381 | DUARTE, CA  
27 22 1F06TW002348-01 WEAVER, SCOTT 
ADAPTATION OF ALPHAVIRUSES TO 
GLYCOSAMINOGLYCAN BINDING  
Total: $15,400  
 $15,400 | 2000 | WEAVER, SCOTT C | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
28 22 1F32AI049680-01 WHITE, LAURA Mechanism of VEE Attenuation  
Total: $108,362  
 $18,218 | 2003 | White, Laura J | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $48,148 | 2002 | White, Laura J | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  





CHAPEL HILL | CHAPEL HILL, NC  
29 22 1U01AI047985-01 WRIGHT, PETER HIV VACCINE CLINICAL TRIALS UNIT 
Total: $9,436,864  
 $1,932,451 | 2004 | Wright, Peter F | VANDERBILT UNIVERSITY | 
NASHVILLE, TN  
 $1,876,165 | 2003 | Wright, Peter F | VANDERBILT UNIVERSITY | 
Nashville, TN  
 $1,821,839 | 2002 | Wright, Peter F | VANDERBILT UNIVERSITY | 
NASHVILLE, TN  
 $1,774,800 | 2001 | Wright, Peter F | VANDERBILT UNIVERSITY | 
NASHVILLE, TN  
 $2,031,609 | 2000 | WRIGHT, PETER F | VANDERBILT UNIVERSITY | 
NASHVILLE, TN  
30 22 
1P01AI048280-
01A10003 YU, XIAO-FANG 
Cellular Immune Responses to DNA 
and Recombinant VEE  
Total: $4,594,198 *  
 $1,570,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | ROCKVILLE, MD  
 $1,452,497 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
 $1,571,351 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
31 22 
1P01AI048280-
01A19002 ZHANG, PENG 
Core--Virus Production and 
Neutralization Facility  
Total: $4,594,198 *  
 $1,570,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | ROCKVILLE, MD  
 $1,452,497 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
 $1,571,351 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
32 12 
2R01NS018596-
21A1 GRIFFIN, DIANE ACUTE ALPHAVIRUAL ENCEPHALITIS 
Total: $1,937,286  
 $378,094 | 2004 | Griffin, Diane E | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
 $403,865 | 2003 | Griffin, Diane E | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
 $394,024 | 2002 | Griffin, Diane E | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
 $384,961 | 2001 | Griffin, Diane E | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
 $376,342 | 2000 | GRIFFIN, DIANE E | JOHNS HOPKINS UNIVERSITY | 
BALTIMORE, MD  
33 12 2R01GM052929-09 
KIELIAN, 
MARGARET 
Molecular Analysis of Alphavirus 
Membrane Fusion Protein  
Total: $1,801,954  
 $415,357 | 2004 | Kielian, Margaret C | YESHIVA UNIVERSITY | NEW 
YORK, NY  





YORK, NY  
 $318,954 | 2002 | Kielian, Margaret C | YESHIVA UNIVERSITY | NEW 
YORK, NY  
 $309,821 | 2001 | Kielian, Margaret C | YESHIVA UNIVERSITY | NEW 
YORK, NY  
 $312,770 | 2000 | KIELIAN, MARGARET C | YESHIVA UNIVERSITY | NEW 
YORK, NY  
34 12 
1P01AI055672-
010003 KUHN, RICHARD 
Molecular analyses of alpha- and 
flavivirus replication  
Total: $8,127,036 *  
 $41,733 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $3,082,404 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,994,435 | 2004 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,008,464 | 2003 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
35 12 
1P01AI055672-
019001 KUHN, RICHARD 
CORE--Shared structural virology 
facilities  
Total: $8,127,036 *  
 $41,733 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $3,082,404 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,994,435 | 2004 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,008,464 | 2003 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
36 12 
1U54AI057153-
010006 KUHN, RICHARD 
Development of Antiviral Strategies 
for Enveloped Virus  
Total: $20,734,800  
 $8,532,653 | 2005 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $8,543,253 | 2004 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $3,658,894 | 2003 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 






Studies on ZAP, a broad-spectrum 
alphavirus inhibitor  
Total: $379,875  
 $379,875 | 2005 | Macdonald, Margaret R | ROCKEFELLER UNIVERSITY | 
NEW YORK, NY  
38 12 1Z01BK007013-01 MARKOFF, L 
Infectious DNAs to derive mutant 
flavi- and alphaviruses  
39 12 
1P01AI055672-
010006 STRAUSS, JAMES 
Structure-function of alpha- and 





Total: $8,127,036 *  
 $41,733 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $3,082,404 | 2005 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,994,435 | 2004 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
 $2,008,464 | 2003 | Kuhn, Richard J | PURDUE UNIVERSITY WEST 
LAFAYETTE | WEST LAFAYETTE, IN  
40 11 
1U54AI057156-
010010 BASEMAN, JOEL Developmental Research  
Total: $27,834,107 *  
 $12,024,542 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $11,566,950 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $4,242,615 | 2003 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
41 11 1K02AI050432-01 
BURKHARD, 
MARY 
Cell-FIV: Mucosal transmission and 
intervention  
Total: $381,306  
 $103,113 | 2004 | Burkhard, Mary J | OHIO STATE UNIVERSITY | 
COLUMBUS, OH  
 $93,458 | 2003 | Burkhard, Mary J | NORTH CAROLINA STATE 
UNIVERSITY RALEIGH | RALEIGH, NC  
 $93,458 | 2002 | Burkhard, Maryjo J | NORTH CAROLINA STATE 
UNIVERSITY RALEIGH | RALEIGH, NC  
 $91,277 | 2001 | Burkhard, Maryjo J | NORTH CAROLINA STATE 
UNIVERSITY RALEIGH | RALEIGH, NC  
42 11 1U01AI057286-01 CHULAY, JEFFREY 
Alphavirus Replicon Vaccines against 
Botulinum Neurotox*  
Total: $6,721,271  
 $1,799,459 | 2005 | Chulay, Jeffrey | ALPHAVAX HUMAN VACCINES, INC. 
| RESEARCH TRIANGLE PARK, NC  
 $3,577,242 | 2004 | Chulay, Jeffrey | ICORIA, INC. | RESEARCH 
TRIANGLE PARK, NC  
 $1,344,570 | 2003 | Chulay, Jeffrey | ALPHAVAX HUMAN VACCINES, INC. 
| RESEARCH TRIANGLE PARK, NC  
43 11 1UC1AI062632-01 CHULAY, JEFFREY 
Alphavirus Replicon Vaccines against 
Influenza  
Total: $6,490,848  
 $6,490,848 | 2005 | Chulay, Jeffrey | ALPHAVAX HUMAN VACCINES, INC. 
| RESEARCH TRIANGLE PARK, NC  
44 11 1Z01BP005021-01 
DUNCAN, 
ROBERT 
Pathogen Chip for Detection of 
Bioterrorism Agents in Bl  
45 11 1R21AI055609-01 EBEL, GREGORY 
Arbovirus quasispecies-impact of 
arthropod transmission  











VRP IMMUNOGENICITY FOR A 
SECOND GENERATION VACCINE  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 






Cell-free VEE assembly system and 
alphavirus drug screen  
48 11 1R01AI049764-01 MADDON, PAUL 
HIV Vaccine Design and 
Development Team  
Total: $4,064,764  
 $2,090,481 | 2001 | Maddon, Paul J | PROGENICS PHARMACEUTICALS, 
INC. | TARRYTOWN, NY  
 $1,974,283 | 2000 | MADDON, PAUL J | INC. | TARRYTOWN, PROGENICS 
PHARMACEUTICALS, NY  
49 11 2R01AI025850-16 
MONTELARO, 
RONALD 
EIAV Envelope Variation and Vaccine 
Efficacy  
Total: $2,421,622  
 $608,093 | 2005 | Montelaro, Ronald C | UNIVERSITY OF PITTSBURGH AT 
PITTSBURGH | PITTSBURGH, PA  
 $616,652 | 2004 | Montelaro, Ronald C | UNIVERSITY OF PITTSBURGH | 
PITTSBURGH, PA  
 $309,211 | 2003 | Montelaro, Ronald C | UNIVERSITY OF PITTSBURGH | 
PITTSBURGH, PA  
 $449,659 | 2001 | Montelaro, Ronald C | UNIVERSITY OF PITTSBURGH | 
PITTSBURGH, PA  
 $438,007 | 2000 | MONTELARO, RONALD C | UNIVERSITY OF 







NEUTRALIZATION AND CTL AGAINST 
HIV 1  
Total: $4,594,198 *  
 $1,570,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | ROCKVILLE, MD  
 $1,452,497 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
 $1,571,351 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR 
THE ADV MIL/MED | BETHESDA, MD  
51 11 
2R01AI037438-





GERALD HIV-1  
Total: $1,296,750  
 $259,350 | 2005 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $259,350 | 2004 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $259,350 | 2003 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | ROCKVILLE, MD  
 $259,350 | 2002 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | BETHESDA, MD  
 $259,350 | 2001 | Quinnan, Gerald V | HENRY M. JACKSON FDN FOR THE 
ADV MIL/MED | BETHESDA, MD  
52 11 1UC1AI067203-01 SIGAL, GEORGE 
A Multiplexed Point-of-Care 
Diagnostic System for Bio-T*  
53 11 
2P01AI050246-
029001 WALKER, BRUCE Core--Human immunology facility  
Total: $4,842,264 *  
 $59,191 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
 $1,413,970 | 2004 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,338,827 | 2003 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $1,390,608 | 2002 | Johnston, Robert E | UNIVERSITY OF NORTH 
CAROLINA CHAPEL HILL | CHAPEL HILL, NC  
 $639,668 | 2001 | Johnston, Robert E | UNIVERSITY OF NORTH CAROLINA 
CHAPEL HILL | CHAPEL HILL, NC  
54 11 1D43TW006590-01 WALKER, DAVID 
Tropical Vector-borne Viral and 
Rickettsial Infections  
Total: $450,000  
 $150,000 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $150,000 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 $150,000 | 2003 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
55 11 1U54AI057156-01 WALKER, DAVID 
Region VI Center for Biodefence and 
Emerging Infections  
Total: $27,834,107 *  
 $12,024,542 | 2005 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $11,566,950 | 2004 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
 $4,242,615 | 2003 | Walker, David H | UNIVERSITY OF TEXAS MEDICAL 
BR GALVESTON | GALVESTON, TX  
56 11 1R21AI063061-01 WHITE, LAURA 
A VEE Replicon-Based Vaccine for 
Dengue Virus  





CHAPEL HILL | CHAPEL HILL, NC  
 
Vesicular stomatitis Alagoas/Indiana virus (exotic) 
Taxonomy: Order Mononegavirales, Family Rhabdoviridae, Genus Vesiculovirus, Species 
Vesicular stomatitis Alagoas/Indiana, Virus: Vesicular stomatitis Alagoas/Indiana virus, exotic 






1 27 1Z01NS002997-01 
SCHUBERT, 
MANFRED 
Viral Vectors For The Nervous System  
2 21 
1R01CA095924-
01A2 BARBER, GLEN Mechanisms of VSV-mediated Oncolysis  
Total: $606,758  
 $303,379 | 2004 | Barber, Glen N | UNIVERSITY OF MIAMI-MEDICAL | CORAL 
GABLES, FL  
 $303,379 | 2003 | Barber, Glen N | UNIVERSITY OF MIAMI-MEDICAL | Coral 
Gables, FL  
3 21 1R41CA103255-01 WHITT, MICHAEL 
Targeted Oncolytic VSV as a Prostate 
Cancer Therapy  
Total: $130,741  
 $130,741 | 2003 | Whitt, Michael A | GTX, INC. | MEMPHIS, TN  
4 21 
1U19AI048216-
010002 WHITT, MICHAEL 
Surrogate HCV to study virus/cell 
interactions  
Total: $3,736,332  
 $809,587 | 2004 | Riely, Caroline A | UNIVERSITY OF TENNESSEE HEALTH SCI 
CTR | MEMPHIS, TN  
 $786,544 | 2003 | Riely, Caroline A | UNIVERSITY OF TENNESSEE HEALTH SCI 
CTR | MEMPHIS, TN  
 $668,404 | 2002 | Riely, Caroline A | UNIVERSITY OF TENNESSEE HEALTH SCI 
CTR | MEMPHIS, TN  
 $738,193 | 2001 | Riely, Caroline A | UNIVERSITY OF TENNESSEE HEALTH SCI 





 $733,604 | 2000 | RIELY, CAROLINE A | UNIVERSITY OF TENNESSEE AT 
MEMPHIS | MEMPHIS, TN  
5 12 
1F32AI051805-
01A1 CONNOR, JOHN 
Protein synthesis control by vesicular 
stomatits virus  
Total: $66,711  
 $20,519 | 2004 | Connor, John H | ION TECHNOLOGIES, INC. | WINSTON-
SALEM, NC  
 $46,192 | 2003 | Connor, John H | KUCERA PHARMACEUTICAL COMPANY | 






NEW MEASLES VACCINE STRATEGY 
USING VSV VECTORS  
Total: $2,166,086  
 $2,166,086 | 2004 | Kousoulas, Konstantin G | LOUISIANA STATE UNIV A&M 






Gene Expression of Negative strand RNA 
Viruses  
Total: $1,969,430  
 $416,685 | 2005 | Banerjee, Amiya K | CLEVELAND CLINIC LERNER COL/MED-
CWRU | CLEVELAND, OH  
 $403,363 | 2003 | Banerjee, Amiya K | CLEVELAND CLINIC FOUNDATION | 
CLEVELAND, OH  
 $393,304 | 2002 | Banerjee, Amiya K | CLEVELAND CLINIC FOUNDATION | 
CLEVELAND, OH  
 $383,537 | 2001 | Banerjee, Amiya K | CLEVELAND CLINIC FOUNDATION | 
CLEVELAND, OH  
 $372,541 | 2000 | Banerjee, Amiya K. | CLEVELAND CLINIC FOUNDATION | 
CLEVELAND, OH  
8 11 
1R01CA104404-
01A1 BERGMAN, IRA 
Targeted Recombinant VSV Virus to 
Treat Breast Cancer  
Total: $277,684  
 $277,684 | 2005 | Bergman, Ira | CHILDREN'S HOSP PITTSBURGH/UPMC HLTH 






Dendritic Cell Subset Regulation of Viral 
Immunity  
Total: $617,372  
 $246,400 | 2005 | Ciavarra, Richard P | EASTERN VIRGINIA MEDICAL SCHOOL 
| NORFOLK, VA  
 $253,025 | 2004 | Ciavarra, Richard P | EASTERN VIRGINIA MEDICAL SCHOOL 
| NORFOLK, VA  
 $117,947 | 2003 | Ciavarra, Richard P | EASTERN VIRGINIA MEDICAL SCHOOL 






Vaccine Platforms  





 $3,970,912 | 2003 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, NY  
11 11 1R01GM071666-01 
DOVICHI, 
NORMAN 
HIGHLY PARALLEL SURVEY OF SINGLE-
CELL PROTEIN EXPRESSION  
Total: $255,417  
 $255,417 | 2004 | Dovichi, Norman J | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
12 11 1R15AI058969-01 
FERRAN, 
MAUREEN 
Interferon Gene Expression in VSV-
Infected Cells  
Total: $206,723  
 $206,723 | 2004 | Ferran, Maureen C | ROCHESTER INSTITUTE OF 
TECHNOLOGY | ROCHESTER, NY  
13 11 1R01AI051560-01 FU, ZHEN 
Developing Avirulent Rabies Virus 
Vaccines  
Total: $837,320  
 $253,400 | 2004 | Fu, Zhen F | UNIVERSITY OF GEORGIA | ATHENS, GA  
 $341,720 | 2003 | Fu, Zhen F | UNIVERSITY OF GEORGIA | ATHENS, GA  






Pathways of Neuronal Damage Involving 
Macrophage-Glia Interactions In Vivo  
Total: $6,320,778  
 $1,487,483 | 2004 | Volsky, David J | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $1,504,124 | 2003 | Volsky, David J | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $1,085,710 | 2002 | Volsky, David J | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $100,000 | 2001 | Volsky, David J | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $1,059,470 | 2001 | Volsky, David J | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $1,033,991 | 2000 | Volsky, David J. | ST. LUKE'S-ROOSEVELT INST FOR HLTH 
SCIS | NEW YORK, NY  
 $50,000 | 2000 | Volsky, David J. | ST. LUKE'S-ROOSEVELT INST FOR HLTH 






Assembly of enveloped viruses  
Total: $1,340,052  
 $287,000 | 2005 | Lyles, Douglas S | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
 $287,500 | 2004 | Lyles, Douglas S | ION TECHNOLOGIES, INC. | WINSTON-
SALEM, NC  
 $262,763 | 2002 | Lyles, Douglas S | WINSTON-SALEM STATE UNIVERSITY | 
WINSTON-SALEM, NC  
 $255,110 | 2001 | Lyles, Douglas S | PPD DEVELOPMENT, INC. | 
WILMINGTON, NC  
 $247,679 | 2000 | LYLES, DOUGLAS S | WAKE FOREST UNIVERSITY | 










Cellular interactions of viral matrix 
protein  
Total: $1,144,780  
 $287,000 | 2005 | Lyles, Douglas S | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
 $287,417 | 2004 | Lyles, Douglas S | ION TECHNOLOGIES, INC. | WINSTON-
SALEM, NC  
 $288,000 | 2003 | Lyles, Douglas S | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
 $282,363 | 2000 | LYLES, DOUGLAS S | WAKE FOREST UNIVERSITY | 






Control of translation by VSV  
Total: $382,667  
 $287,000 | 2005 | Lyles, Douglas S | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
 $95,667 | 2004 | Lyles, Douglas S | ION TECHNOLOGIES, INC. | WINSTON-






Control of translation by VSV  
Total: $287,750  
 $287,750 | 2003 | Lyles, Douglas S | KUCERA PHARMACEUTICAL COMPANY | 
WINSTON-SALEM, NC  
20 11 1P01AI060642-01 MIZEL, STEVEN 
Respiratory Immunity Against Agents of 
Bioterrorism  
Total: $1,818,389  
 $1,818,389 | 2004 | Mizel, Steven B | ION TECHNOLOGIES, INC. | WINSTON-
SALEM, NC  
21 11 
2R01AI014594-
23A1 MOYER, SUE 
TRANSCRIPTION OF NEGATIVE STRAND 
RNA VIRUSES  
Total: $1,727,646  
 $364,708 | 2005 | Moyer, Sue A | UNIVERSITY OF FLORIDA | GAINESVILLE, FL 
 $354,134 | 2004 | Moyer, Sue A | UNIVERSITY OF FLORIDA | GAINESVILLE, FL 
 $343,869 | 2003 | Moyer, Sue A | UNIVERSITY OF FLORIDA | GAINESVILLE, FL 
 $333,903 | 2002 | Moyer, Sue A | UNIVERSITY OF FLORIDA | GAINESVILLE, FL 







SURVIVAL AND EXTINCTION IN RNA 
VIRUS POPULATIONS  
Total: $758,888  
 $257,250 | 2003 | Novella, Isabel S | MEDICAL COLLEGE OF OHIO AT TOLEDO 
| TOLEDO, OH  
 $244,388 | 2002 | Novella, Isabel S | MEDICAL COLLEGE OF OHIO AT TOLEDO 
| TOLEDO, OH  
 $257,250 | 2001 | Novella, Isabel S | MEDICAL COLLEGE OF OHIO AT TOLEDO 
| TOLEDO, OH  






Total: $307,767  
 $307,767 | 2005 | Novella, Isabel S | MEDICAL COLLEGE OF OHIO AT TOLEDO 
| TOLEDO, OH  
24 11 
1P20RR015587-
010002 OTT, TROY 
MX EXPRESSION AND UTERINE 
MUCCOSAL IMMUNITY  
Total: $9,254,978  
 $1,917,030 | 2004 | Bohach, Gregory A | NEZ PERCE TRIBAL EXECUTIVE 
COMMITTEE | LAPWAI, ID  
 $1,905,487 | 2003 | Bohach, Gregory A | UNIVERSITY OF IDAHO | MOSCOW, 
ID  
 $498,384 | 2003 | Bohach, Gregory A | UNIVERSITY OF IDAHO | MOSCOW, ID  
 $1,372,188 | 2002 | Bohach, Gregory A | UNIVERSITY OF IDAHO | MOSCOW, 
ID  
 $1,842,630 | 2001 | Bohach, Gregory A | UNIVERSITY OF IDAHO | MOSCOW, 
ID  
 $1,719,259 | 2000 | BOHACH, GREGORY A | UNIVERSITY OF IDAHO | 
MOSCOW, ID  
25 11 
2R01AI034956-
06A2 PATTNAIK, ASIT VSV RNA Transcription and Replication  
Total: $1,460,808  
 $290,000 | 2005 | Pattnaik, Asit K | UNIVERSITY OF NEBRASKA LINCOLN | 
LINCOLN, NE  
 $290,000 | 2004 | Pattnaik, Asit K | UNIVERSITY OF NEBRASKA LINCOLN | 
LINCOLN, NE  
 $290,000 | 2003 | Pattnaik, Asit K | UNIVERSITY OF NEBRASKA LINCOLN | 
LINCOLN, NE  
 $296,820 | 2002 | Pattnaik, Asit K | UNIVERSITY OF MIAMI | MIAMI, FL  
 $293,988 | 2001 | Pattnaik, Asit K | UNIVERSITY OF MIAMI | MIAMI, FL  
26 11 1R01AI050900-01 
REINHERZ, 
ELLIS 
Thymic vaccination: Manipulating the T 
cell repertoire  
Total: $5,736,415  
 $1,834,795 | 2003 | Reinherz, Ellis L | DANA-FARBER CANCER INSTITUTE | 
BOSTON, MA  
 $1,859,942 | 2002 | Reinherz, Ellis L | DANA-FARBER CANCER INSTITUTE | 
BOSTON, MA  
 $2,041,678 | 2001 | Reinherz, Ellis L | DANA-FARBER CANCER INSTITUTE | 
BOSTON, MA  
27 11 
2R01DC003536-
04A1 REISS, CAROL 
VSV INFECTION OF THE CENTRAL 
NERVOUS SYSTEM  
Total: $1,340,632  
 $269,168 | 2005 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $27,907 | 2004 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $265,723 | 2004 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $262,414 | 2003 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $259,236 | 2002 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $256,184 | 2001 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
28 11 
2R01NS039746-





Total: $1,458,551  
 $352,334 | 2005 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $291,441 | 2003 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $280,886 | 2002 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $17,936 | 2001 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $259,591 | 2001 | Reiss, Carol S | NEW YORK UNIVERSITY | NEW YORK, NY  
 $256,363 | 2000 | REISS, CAROL S | NEW YORK UNIVERSITY | NEW YORK, NY  
29 11 2R01AI045510-05 ROSE, JOHN 
Immune Responses to VSV/HIV/SIV 
Hybrids in Macaques  
Total: $3,315,511  
 $573,574 | 2005 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $623,174 | 2004 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $637,975 | 2003 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $490,129 | 2002 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $501,584 | 2001 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $489,075 | 2000 | ROSE, JOHN K | YALE UNIVERSITY | NEW HAVEN, CT  
30 11 2R37AI040357-08 ROSE, JOHN 
Development of VSV/HIV Recombinants 
as HIV Vaccines  
Total: $817,500  
 $327,000 | 2005 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  
 $327,000 | 2004 | Rose, John K | YALE UNIVERSITY | NEW HAVEN, CT  






Role of Phospholipid Scramblase in 
Interferon Action  
Total: $1,510,763  
 $397,096 | 2004 | Silverman, Robert H | CLEVELAND CLINIC LERNER 
COL/MED-CWRU | CLEVELAND, OH  
 $398,782 | 2003 | Silverman, Robert H | CLEVELAND CLINIC LERNER 
COL/MED-CWRU | CLEVELAND, OH  
 $368,424 | 2002 | Silverman, Robert H | CLEVELAND CLINIC FOUNDATION | 
CLEVELAND, OH  
 $346,461 | 2001 | Silverman, Robert H | CLEVELAND CLINIC FOUNDATION | 






Viral neuropathology neuropeptides and 
epilepsy  
Total: $1,081,220  
 $361,594 | 2005 | Solbrig, Marylou V | UNIVERSITY OF CALIFORNIA IRVINE | 
IRVINE, CA  
 $359,813 | 2004 | Solbrig, Marylou V | UNIVERSITY OF CALIFORNIA IRVINE | 
IRVINE, CA  
 $359,813 | 2003 | Solbrig, Marylou V | UNIVERSITY OF CALIFORNIA IRVINE | 
IRVINE, CA  
33 11 
1R21AI062246-
01A1 THIEL, VOLKER 
Coronavirus-based multigene HIV 
vaccine vectors  
34 11 
1R01AI059371-
01A1 WHELAN, SEAN 
RNA processing in non-segmented 





Total: $339,000  
 $339,000 | 2005 | Whelan, Sean Pj | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
35 11 1R41CA103269-01 WHITT, MICHAEL 
Developing VSV cytolytics against High-
Grade CNS gliomas  
Total: $140,097  
 $140,097 | 2003 | Whitt, Michael A | GTX, INC. | MEMPHIS, TN  
36 11 1R01CA100830-01 WOO, SAVIO 
Oncolytic VSV for Hepatocellular 
Carcinoma  
Total: $1,018,272  
 $339,424 | 2005 | Woo, Savio L | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
 $339,424 | 2004 | Woo, Savio L | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
 $339,424 | 2003 | Woo, Savio Lc | MOUNT SINAI SCHOOL OF MEDICINE OF 






VSV-based Therapeutic Papilloma 
Vaccine  
Total: $971,432  
 $327,409 | 2005 | Brandsma, Janet L | YALE UNIVERSITY | NEW HAVEN, CT  
 $327,409 | 2004 | Brandsma, Janet L | YALE UNIVERSITY | NEW HAVEN, CT  
 $316,614 | 2003 | Brandsma, Janet L | YALE UNIVERSITY | NEW HAVEN, CT  
 
Xanthomonas oryzae (pathovar Oryzicola; formerly known as Xanthomonas campestris pathovar 
Oryzicola) 
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Gammaproteobacteria, Order 
Xanthomonadales, Family Xanthomonadaceae. 
Publications: 
1. Zhao, B. Y., E. Ardales, E. Brasset, L. E. Claflin, J. E. Leach, and S. H. Hulbert. 
2004. The Rxo1/ Rba1 locus of maize controls resistance reactions to pathogenic and non-
host bacteria. Theor Appl Genet 109:71-9. 
This paper identifies a plant factor that provides plants with protection from rapid 
hypersensitive reaction upon exposure to the bacterium. 
 






Xylella fastidiosa (citrus variegated chlorosis strain)  
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Gammaproteobacteria, Order 
Xanthomonadales, Family Xanthomonadaceae. 
Publications: 
1. Chen, J., John S. Hartung, Chung-Jan Chang, Anne K. Vidaver. 2002. An 
Evolutionary Perspective of Pierce's Disease of Grapevine, Citrus Variegated Chlorosis, 
and Mulberry Leaf Scorch Diseases. Curr Microbiol 45:423-8. 
This paper describes the evaluation of the phylogenetic relationships of Xylella fastidiosa 
strains from citrus, grapevine, and mulberry through the analyses of random amplified 
polymorphic DNAs and conserved 16S rDNA genes. 
2. Harakava, R., and Dean W. Gabriel. 2003. Genetic Differences between Two Strains of 
Xylella fastidiosa Revealed by Suppression Subtractive Hybridization. Appl Environ 
Microbiol 69:1315-19. 
This paper reports on the success in using suppression subtractive hybridization for the 
differentiation of Xylella fastidiosa citrus variegated chlorosis and Pierce's disease strains. 
  
NIH grants: None identified. 
 
Yersinia pestis  
Taxonomy: Domain Bacteria, Phylum Proteobacteria, Class Gammaproteobacteria, Order 
Enterobacteriales, Family Enterobacteriaceae. 
Publications: 
1. Adair, D. M., P. L. Worsham, K. K. Hill, A. M. Klevytska, P. J. Jackson, A. M. 
Friedlander, and P. Keim. 2000. Diversity in a variable-number tandem repeat from 
Yersinia pestis. J Clin Microbiol 38:1516-9. 
 This paper reports the differentiation of various strains of the bacterium based on 
sequence variation. 
2. Cowan, C., H. A. Jones, Y. H. Kaya, R. D. Perry, and S. C. Straley. 2000. Invasion of 
epithelial cells by Yersinia pestis: evidence for a Y. pestis-specific invasin. Infect Immun 
68:4523-30. 
 This paper reports the identification of a virulence factor of the bacterium. 
3. Day, J. B., I. Guller, and G. V. Plano. 2000. Yersinia pestis YscG protein is a Syc-like 





 This paper reports the functional characterization of a protein of the bacterium. 
4. Day, J. B., and G. V. Plano. 2000. The Yersinia pestis YscY protein directly binds 
YscX, a secreted component of the type III secretion machinery. J Bacteriol 182:1834-43. 
 This paper reports the characterization of a protein of the bacterium. 
5. Dong, X. Q., L. E. Lindler, and M. C. Chu. 2000. Complete DNA sequence and 
analysis of an emerging cryptic plasmid isolated from Yersinia pestis. Plasmid 43:144-8. 
 This paper reports the sequence of a plasmid of the bacterium. 
6. Engelthaler, D. M., and K. L. Gage. 2000. Quantities of Yersinia pestis in fleas 
(Siphonaptera: Pulicidae, Ceratophyllidae, and Hystrichopsyllidae) collected from areas 
of known or suspected plague activity. J Med Entomol 37:422-6. 
 This paper reports the quantities of the bacterium found in fleas. 
7. Engelthaler, D. M., B. J. Hinnebusch, C. M. Rittner, and K. L. Gage. 2000. 
Quantitative competitive PCR as a technique for exploring flea-Yersina pestis dynamics. 
Am J Trop Med Hyg 62:552-60. 
 This paper reports the development of a PCR-based detection system. 
8. Geoffroy, V. A., J. D. Fetherston, and R. D. Perry. 2000. Yersinia pestis YbtU and 
YbtT are involved in synthesis of the siderophore yersiniabactin but have different effects 
on regulation. Infect Immun 68:4452-61. 
 This paper reports the identification of two proteins of the bacterium that are involved in 
the synthesis of a virulence factor. 
9. Hinnebusch, J., P. Cherepanov, Y. Du, A. Rudolph, J. D. Dixon, T. Schwan, and A. 
Forsberg. 2000. Murine toxin of Yersinia pestis shows phospholipase D activity but is 
not required for virulence in mice. Int J Med Microbiol 290:483-7. 
 This paper reports the characterization of a toxin of the bacterium. 
10. Iqbal, S. S., J. P. Chambers, M. T. Goode, J. J. Valdes, and R. R. Brubaker. 2000. 
Detection of Yersinia pestis by pesticin fluorogenic probe-coupled PCR. Mol Cell Probes 
14:109-14. 
 This paper reports the development of a diagnostic system.  
11. Jackson, M. W., and G. V. Plano. 2000. Interactions between type III secretion 
apparatus components from Yersinia pestis detected using the yeast two-hybrid system. 
FEMS Microbiol Lett 186:85-90. 
 This paper reports specifics of the composition of a secretion system of the bacterium. 
12. Wong, J. D., J. R. Barash, R. F. Sandfort, and J. M. Janda. 2000. Susceptibilities of 
Yersinia pestis strains to 12 antimicrobial agents. Antimicrob Agents Chemother 
44:1995-6. 
 This paper reports the antibiotic susceptibility of the bacterium.  
13. Castle, K. T., D. Biggins, L. G. Carter, M. Chu, K. Innes, and J. Wimsatt. 2001. 
Susceptibility of the Siberian polecat to subcutaneous and oral Yersinia pestis exposure. J 
Wildl Dis 37:746-54. 
 This paper reports that the Siberian polecat is susceptible to infection with the bacterium. 
14. Gong, S., S. W. Bearden, V. A. Geoffroy, J. D. Fetherston, and R. D. Perry. 2001. 
Characterization of the Yersinia pestis Yfu ABC inorganic iron transport system. Infect 
Immun 69:2829-37. 





15. Hines, J., E. Skrzypek, A. V. Kajava, and S. C. Straley. 2001. Structure-function 
analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its 
significance in systemic plague and to model YopM's mechanism of binding host 
proteins. Microb Pathog 30:193-209. 
 This paper reports the characterization of a protein of the bacterium that might have an 
important role in pathogenesis. 
16. Klevytska, A. M., L. B. Price, J. M. Schupp, P. L. Worsham, J. Wong, and P. Keim. 
2001. Identification and characterization of variable-number tandem repeats in the 
Yersinia pestis genome. J Clin Microbiol 39:3179-85. 
 This paper reports the identification of specific sequences in the genome of the bacterium 
that could be used for diagnostics. 
17. Le Fleche, P., Y. Hauck, L. Onteniente, A. Prieur, F. Denoeud, V. Ramisse, P. 
Sylvestre, G. Benson, F. Ramisse, and G. Vergnaud. 2001. A tandem repeats database 
for bacterial genomes: application to the genotyping of Yersinia pestis and Bacillus 
anthracis. BMC Microbiol 1:2. 
 This paper reports the identification of specific sequences in the genome of the bacterium 
that could be used for diagnostics. 
18. Lindler, L. E., W. Fan, and N. Jahan. 2001. Detection of ciprofloxacin-resistant 
Yersinia pestis by fluorogenic PCR using the LightCycler. J Clin Microbiol 39:3649-55. 
 This paper reports the isolation of a strain of the bacterium that is resistant to 
ciprofloxacin. 
19. Matson, J. S., and M. L. Nilles. 2001. LcrG-LcrV interaction is required for control of 
Yops secretion in Yersinia pestis. J Bacteriol 183:5082-91. 
 This paper reports the identifiation of a protein-protein interaction necessary for the 
secretion of a virulence factor of the bacterium. 
20. Radnedge, L., S. Gamez-Chin, P. M. McCready, P. L. Worsham, and G. L. 
Andersen. 2001. Identification of nucleotide sequences for the specific and rapid 
detection of Yersinia pestis. Appl Environ Microbiol 67:3759-62. 
 This paper reports the identification of specific sequences in the genome of the bacterium 
that could be used for diagnostics. 
21. Rossi, M. S., J. D. Fetherston, S. Letoffe, E. Carniel, R. D. Perry, and J. M. Ghigo. 
2001. Identification and characterization of the hemophore-dependent heme acquisition 
system of Yersinia pestis. Infect Immun 69:6707-17. 
 This paper reports the identification of a heme acquisition system in the bacterium. 
22. Subrahmanyam, Y. V., S. Yamaga, Y. Prashar, H. H. Lee, N. P. Hoe, Y. Kluger, M. 
Gerstein, J. D. Goguen, P. E. Newburger, and S. M. Weissman. 2001. RNA expression 
patterns change dramatically in human neutrophils exposed to bacteria. Blood 97:2457-
68. 
 This paper reports the RNA response of neutrophils after exposure to the bacterium. 
23. Thulasiraman, V., S. L. McCutchen-Maloney, V. L. Motin, and E. Garcia. 2001. 
Detection and identification of virulence factors in Yersinia pestis using SELDI 
ProteinChip system. Biotechniques 30:428-32. 





24. Watson, R. P., T. W. Blanchard, M. G. Mense, and P. W. Gasper. 2001. 
Histopathology of experimental plague in cats. Vet Pathol 38:165-72. 
 This paper reports the pathology of cats infected with the bacterium. 
25. Bobrov, A. G., V. A. Geoffroy, and R. D. Perry. 2002. Yersiniabactin production 
requires the thioesterase domain of HMWP2 and YbtD, a putative phosphopantetheinylate 
transferase. Infect Immun 70:4204-14. 
 This paper reports the identification of a protein necessary for production of a toxin of the 
bacterium. 
26. Darby, C., J. W. Hsu, N. Ghori, and S. Falkow. 2002. Caenorhabditis elegans: plague 
bacteria biofilm blocks food intake. Nature 417:243-4. 
 This paper reports that the bacterium can produce a biofilm.  
27. Deng, W., V. Burland, G. Plunkett, 3rd, A. Boutin, G. F. Mayhew, P. Liss, N. T. 
Perna, D. J. Rose, B. Mau, S. Zhou, D. C. Schwartz, J. D. Fetherston, L. E. Lindler, 
R. R. Brubaker, G. V. Plano, S. C. Straley, K. A. McDonough, M. L. Nilles, J. S. 
Matson, F. R. Blattner, and R. D. Perry. 2002. Genome sequence of Yersinia pestis 
KIM. J Bacteriol 184:4601-11. 
 This paper reports the genomic sequence of the bacterium. 
28. Gonzalez, M. D., C. A. Lichtensteiger, R. Caughlan, and E. R. Vimr. 2002. Conserved 
filamentous prophage in Escherichia coli O18:K1:H7 and Yersinia pestis biovar orientalis. 
J Bacteriol 184:6050-5. 
 This paper reports the identification of a virus that infects the bacterium. 
29. Hinnebusch, B. J., M. L. Rosso, T. G. Schwan, and E. Carniel. 2002. High-frequency 
conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut. 
Mol Microbiol 46:349-54. 
 This paper reports the transfer of antibiotic resistence genes between cells of the 
bacterium within fleas. 
30. Hinnebusch, B. J., A. E. Rudolph, P. Cherepanov, J. E. Dixon, T. G. Schwan, and A. 
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 $262,189 | 2002 | Motin, Vladimir L | UNIVERSITY OF CALIF-LAWRNC 
LVRMR NAT LAB | LIVERMORE, CA  
18 51 
1Z01AI000796-
05 HINNEBUSCH, B 
Transmission Of The Plague Bacillus 
Yersinia Pestis By F  
19 51 
1Z01AI000796-
06 HINNEBUSCH, B 
Transmission Of Yersinia Pestis By 
Fleas: Molecular Mech  
20 51 
1Z01AI000796-
07 HINNEBUSCH, B 
Transmission Of Yersinia Pestis By 
Fleas: Molecular Mech  
21 51 
1Z01AI000796-
08 HINNEBUSCH, B 
Transmission Of Yersinia Pestis By 






TRANSMISSION OF THE PLAGUE 
BACILLUS YERSINIA PESTIS BY 






Chaperone/Usher Pathways in 
Plague  
Total: $18,865,686 *   $7,627,721 | 2005 | Stanley, Samuel L | ORION GENOMICS, LLC | ST. 





 $7,894,128 | 2004 | Stanley, Samuel L | JACOBS FACILITIES, INC. | ST 
LOUIS, MO  
 $3,343,837 | 2003 | Stanley, Samuel L | MISSOURI WESTERN STATE 






Biohazard Detection Using Metal-
Enhanced Fluorescence  
Total: $445,500  
 $222,750 | 2003 | Lakowicz, Joseph R | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $222,750 | 2002 | Lakowicz, Joseph R | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
25 51 
1R43AI063616-
01 LING, LOSEE 
Developing Novel Antibiotics Against 
Yersinia pestis  
Total: $537,798  
 $304,709 | 2005 | Ling, Losee Lucy | NOVOBIOTIC PHARMACEUTICALS, 
LLC | CAMBRIDGE, MA  
 $233,089 | 2004 | Ling, Losee Lucy | NOVOBIOTIC PHARMACEUTICALS, 
LLC | CAMBRIDGE, MA  
26 51 
1R21AI064313-
01 MILLER, VIRGINIA 
Autotransporter proteins and 
virulence of Y. pestis  
Total: $306,000  







CD4+ T cell protection against 
pneumonic plague  
Total: $48,296  
 $48,296 | 2005 | Parent, Michelle A | TRUDEAU INSTITUTE, INC. | 
SARANAC LAKE, NY  
28 51 
2R01AI033481-
10 PERRY, ROBERT 
Iron Transport and Regulation in 
Yersinia Pestis  
Total: $1,426,243  
 $294,600 | 2005 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $294,450 | 2004 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $293,500 | 2003 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $301,625 | 2001 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $242,068 | 2000 | PERRY, ROBERT D | UNIVERSITY OF KENTUCKY | 






Function and immunogenicity of 
Yersinia pestis fimbriae  
Total: $634,000  
 $317,000 | 2005 | Schifferli, Dieter M | UNIVERSITY OF PENNSYLVANIA | 
PHILADELPHIA, PA  











Mediators and Inhibitors of 
Immunity to Yersinia pestis  
Total: $26,169,985  
 $10,173,756 | 2005 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $11,843,830 | 2004 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $4,152,399 | 2003 | Kasper, Dennis L | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
31 51 
1U54AI057157-
010004 STRALEY, SUSAN 
Pathogenesis and Vaccine 
Development for Plague  
Total: $24,284,241 *  
 $10,247,734 | 2005 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, 
NC  
 $9,829,455 | 2004 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
 $4,207,052 | 2003 | Haynes, Barton F | DUKE UNIVERSITY | DURHAM, NC  
32 51 
1Z01BC010342-
01 WAUGH, DAVID 
STRUCTURAL BIOLOGY OF 
VIRULENCE IN BIOTERRORISM  
33 51 
1Z01BC010342-
02 WAUGH, DAVID 
Structural Genomics of the Yersinia 
Yop Virulon  
34 51 
1Z01BC010342-
03 WAUGH, DAVID 
Structural Proteomics of the 
Yersinia Yop Virulon  
35 51 
1Z01BC010342-
04 WAUGH, DAVID 
Structural Proteomics of the 
Yersinia Yop Virulon  
36 51 
1Z01BC010342-
05 WAUGH, DAVID 
Structural Proteomics of the 
Yersinia Yop Virulon  
37 40 
1R43AI052902-
01 GLASS, JOHN 
A Rapid Immunoassay for Detection 
of Yersinia Pathogens  
Total: $143,157  
 $143,157 | 2002 | Glass, John D | BIOPEPTIDES, INC. | STONY BROOK, NY 
38 40 
1R21AI053809-
01 SILVERMAN, NEAL 
Genetic and molecular analysis of 
Yersinia YopJ  
Total: $477,000  
 $238,500 | 2003 | Silverman, Neal S | UNIV OF MASSACHUSETTS MED 
SCH WORCESTER | WORCESTER, MA  
 $238,500 | 2002 | Silverman, Neal S | UNIV OF MASSACHUSETTS MED 
SCH WORCESTER | WORCESTER, MA  
39 40 
1R21AI058123-
01 VUORI, KRISTIINA 
Mechanism of anti-phagocytosis by 
Yersinia pestis  
Total: $764,000  
 $382,000 | 2005 | Vuori, Kristiina | BURNHAM INSTITUTE | LA JOLLA, CA  







01 AUSTIN, DAVID 
Rapid Identification of Drug Targets 
in Yersinia pestis  
Total: $458,404  
 $228,849 | 2003 | Austin, David J | YALE UNIVERSITY | NEW HAVEN, CT  
 $229,555 | 2002 | Austin, David J | YALE UNIVERSITY | NEW HAVEN, CT  
41 38 
1R03AI054435-
01 BARBIERI, JOSEPH 
Molecular properties of Yersinia 
YopT  
Total: $150,000  
 $75,000 | 2004 | Barbieri, Joseph T | MEDICAL COLLEGE OF WISCONSIN | 
MILWAUKEE, WI  
 $75,000 | 2003 | Barbieri, Joseph T | MEDICAL COLLEGE OF WISCONSIN | 
MILWAUKEE, WI  
42 38 
1Z01BC006198-
15 BURKE, TERRENCE 
Inhibitors of Tyrosine Kinase-
Dependent Signalling as An  
43 38 
1R43AI056706-
01 CLARKE, JEAN 
Polymer-Based Yersinia Pestis 
Point-of-Case Diagnostics  
Total: $1,000,000  
 $500,000 | 2004 | Clarke, Jean M | NOMADICS, INC. | STILLWATER, OK  
 $500,000 | 2003 | Clarke, Jean M | NOMADICS, INC. | STILLWATER, OK  
44 38 
1R41AI052958-
01 CRAMER, CAROLE 
NASALLY-DELIVERED MUCOSAL 
SUBUNIT VACCINE FOR PLAGUE  
Total: $198,456  
 $198,456 | 2002 | Cramer, Carole L | BIODEFENSE TECHNOLOGIES, INC. | 
BLACKSBURG, VA  
45 38 
1P01AI056293-
010002 CRYSTAL, RONALD 
VECTOR GENE Y PESTIS 
VACCINATION & PASSIVE 
PROTECTION  
Total: $3,474,964 *  
 $1,388,080 | 2005 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $1,344,411 | 2004 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $742,473 | 2003 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF CORNELL 
UNIV | NEW YORK, NY  
46 38 
1R01AI055844-
01 CRYSTAL, RONALD 
Anti-Y. pestis Vaccination and 
Passive Protection  
Total: $1,317,475  
 $539,468 | 2005 | Boyer, Julie L | WEILL MEDICAL COLLEGE OF CORNELL 
UNIV | NEW YORK, NY  
 $523,755 | 2004 | Crystal, Ronald G | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $254,252 | 2003 | Crystal, Ronald G | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
47 38 
1R01AI057885-
01 CURTISS, ROY, III 
Attenuated Live and Recombinant 





Total: $1,121,753  
 $536,769 | 2005 | Curtiss, Royiii Iii | ORION GENOMICS, LLC | ST. LOUIS, 
MO  
 $584,984 | 2004 | Curtiss, Royiii Iii | JACOBS FACILITIES, INC. | ST 
LOUIS, MO  
48 38 
1U01AI056480-
01 DUNN, JOHN 
Rapid Detection and Identification of 
Zoonotic Pathogens  
Total: $2,387,159  
 $879,674 | 2005 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-
BROOKHAVEN LAB | UPTON, NY  
 $854,379 | 2004 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-
BROOKHAVEN LAB | UPTON, NY  
 $653,106 | 2003 | Dunn, John J | BROOKHAVEN SCIENCE ASSOC-






Identifying virulence factors in 
pneumonic plague  
Total: $322,712  
 $183,812 | 2003 | Fetherston, Jacqueline D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $138,900 | 2002 | Fetherston, Jacqueline D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
50 38 
1R43AI055120-
01 GULNIK, SERGEI 
Broadly active inhibitors of high 
priority pathogens  
Total: $802,627  
 $310,030 | 2004 | Gulnik, Sergei | SEQUOIA PHARMACEUTICALS, INC. | 
GAITHERSBURG, MD  
 $492,597 | 2003 | Gulnik, Sergei | SEQUOIA PHARMACEUTICALS, INC. | 
GAITHERSBURG, MD  
51 38 
1U54AI057141-
010006 HOVDE, CAROLYN Vaccine Development  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
52 38 
1R01AI066506-
01 KNAP, ANIA 
Broad Spectrum Agents Against Cat 
A Bacterial Pathogens  
Total: $1,450,688  






Lung Injury and Shock Pathogenesis 
in Y. pestis Sepsis  
54 38 
1R01AI057588-
01 LIEN, EGIL 
The Role of LPS and Toll-like 
Receptors in Plague  
Total: $756,060   $373,900 | 2005 | Lien, Egil | UNIV OF MASSACHUSETTS MED SCH 





 $382,160 | 2004 | Lien, Egil | UNIV OF MASSACHUSETTS MED SCH 
WORCESTER | WORCESTER, MA  
55 38 
1Z01BP005026-
01 NAKHASI, HIRA 
Molecular Mechanism and Diagnosis 
of Leishmaniasis  
56 38 
1R01AI056286-
01A1 PASCUAL, DAVID Mucosal Vaccines for Plague  
Total: $592,717  
 $592,717 | 2004 | Pascual, David W | MONTANA STATE UNIVERSITY 
(BOZEMAN) | BOZEMAN, MT  
57 38 
2R01AI025098-
15 PERRY, ROBERT 
Characterization of the Hms 
phenotype of Yersinia pestis  
Total: $969,547  
 $257,775 | 2005 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $257,556 | 2004 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $85,750 | 2003 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $186,993 | 2001 | Perry, Robert D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $181,473 | 2000 | PERRY, ROBERT D | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
58 38 
2R01AI039575-
06 PLANO, GREGORY 
Control of virulence protein export 
in Yersinia pestis  
Total: $1,411,029  
 $303,000 | 2005 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
CORAL GABLES, FL  
 $303,000 | 2004 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
CORAL GABLES, FL  
 $26,000 | 2003 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
Coral Gables, FL  
 $265,125 | 2003 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
Coral Gables, FL  
 $265,125 | 2002 | Plano, Gregory V | UNIVERSITY OF MIAMI | MIAMI, FL  
 $248,779 | 2001 | Plano, Gregory V | UNIVERSITY OF MIAMI | MIAMI, FL  
59 38 
1R01AI050552-
01 PLANO, GREGORY 
Structure of the Yersinia pestis type 
III export complex  
Total: $902,799  
 $227,250 | 2004 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
CORAL GABLES, FL  
 $227,250 | 2003 | Plano, Gregory V | UNIVERSITY OF MIAMI-MEDICAL | 
Coral Gables, FL  
 $193,163 | 2002 | Plano, Gregory V | UNIVERSITY OF MIAMI | MIAMI, FL  
 $255,136 | 2001 | Plano, Gregory V | UNIVERSITY OF MIAMI | MIAMI, FL  
60 38 
1P01AI056293-
010004 QUADRI, LUIS 
NOVEL M. TUBERCULOSIS AND Y. 
PESTIS GROWTH INHIBITORS  





CORNELL UNIV | NEW YORK, NY  
 $1,344,411 | 2004 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  
 $742,473 | 2003 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF CORNELL 
UNIV | NEW YORK, NY  
61 38 
1R43AI052872-
01A1 REPPY, MARY 
New Materials for Plague Antigen 
and Antibody Detection  
Total: $98,530  
 $98,530 | 2003 | Reppy, Mary A | ANALYTICAL BIOLOGICAL SERVICES, 
INC. | WILMINGTON, DE  
62 38 
1U54AI057141-
010004 SALAMA, NINA Virulence Factors in the Airway  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
63 38 
1R01AI061577-
01 SMILEY, STEPHEN 
Cell-mediated protection against 
pneumonic plague  
Total: $737,759  
 $359,214 | 2005 | Smiley, Stephen T | TRUDEAU INSTITUTE, INC. | 
SARANAC LAKE, NY  
 $378,545 | 2004 | Smiley, Stephen T | TRUDEAU INSTITUTE, INC. | 
SARANAC LAKE, NY  
64 38 
2R44AI052926-
02 STORHOFF, JAMES 
Nanoparticle Probe Assay for 
Biological Threat Agents  
Total: $374,900  




01 STRALEY, SUSAN Early Events in Pneumonic Plague  
Total: $760,492  
 $253,400 | 2002 | Straley, Susan C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $253,400 | 2001 | Straley, Susan C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
 $253,692 | 2000 | STRALEY, SUSAN C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  
66 38 
1R21AI061432-
01 STRALEY, SUSAN 
Surface proteins in pneumonic 
plague  
Total: $294,600  
 $294,600 | 2004 | Straley, Susan C | UNIVERSITY OF KENTUCKY | 
LEXINGTON, KY  





01 Yersinia pestis EF-Tu  
Total: $998,864  
 $499,432 | 2004 | Totrov, Maxim | MOLSOFT, LLC | LA JOLLA, CA  
 $499,432 | 2003 | Totrov, Maxim | MOLSOFT, LLC | LA JOLLA, CA  
68 27 
1R01AI043389-
01A2 BLISKA, JAMES 
MODULATION OF HOST SIGNALING 
FUNCTIONS BY YERSINIA YOPS  
Total: $1,759,478  
 $343,969 | 2005 | Bliska, James B | STATE UNIVERSITY NEW YORK STONY 
BROOK | STONY BROOK, NY  
 $300,159 | 2004 | Bliska, James B | STATE UNIVERSITY NEW YORK STONY 
BROOK | STONY BROOK, NY  
 $291,416 | 2003 | Bliska, James B | STATE UNIVERSITY NEW YORK STONY 
BROOK | STONY BROOK, NY  
 $282,928 | 2002 | Bliska, James B | STATE UNIVERSITY NEW YORK STONY 
BROOK | STONY BROOK, NY  
 $274,688 | 2001 | Bliska, James B | STATE UNIVERSITY NEW YORK STONY 
BROOK | STONY BROOK, NY  
 $266,318 | 2000 | BLISKA, JAMES B | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
69 27 
1F32AI065081-
01 BRODSKY, IGOR 
Interaction of Yersinia with 
dendritic cells  
Total: $43,976  
 $43,976 | 2005 | Brodsky, Igor E | YALE UNIVERSITY | NEW HAVEN, CT  
70 27 
1R01AI052148-
01A1 DARWIN, ANDREW 
The Psp response of Yersinia 
enterocolitica  
Total: $878,400  
 $338,000 | 2005 | Darwin, Andrew J | NEW YORK UNIVERSITY SCHOOL OF 
MEDICINE | NEW YORK, NY  
 $270,400 | 2004 | Darwin, Andrew J | NEW YORK UNIVERSITY SCHOOL OF 
MEDICINE | NEW YORK, NY  
 $270,000 | 2003 | Darwin, Andrew J | NEW YORK UNIVERSITY SCHOOL OF 
MEDICINE | NEW YORK, NY  
71 27 
1U01AI056487-
01 DOW, STEVEN 
Antigen Presentation and Pulmonary 
Immunity to Plague  
Total: $1,128,430  
 $441,176 | 2005 | Dow, Steven W | COLORADO STATE UNIVERSITY-FORT 
COLLINS | FORT COLLINS, CO  
 $428,327 | 2004 | Dow, Steven W | COLORADO STATE UNIVERSITY-FORT 
COLLINS | FORT COLLINS, CO  
 $258,927 | 2003 | Dow, Steven W | COLORADO STATE UNIVERSITY-FORT 
COLLINS | FORT COLLINS, CO  
72 27 
1K08AI052176-
01 LESSER, CAMMIE 
The role of Yersinia YopM in 
pathogenesis  
Total: $367,993  
 $124,070 | 2004 | Lesser, Cammie F | MASSACHUSETTS GENERAL 
HOSPITAL | BOSTON, MA  
 $124,070 | 2003 | Lesser, Cammie F | MASSACHUSETTS GENERAL 
HOSPITAL | BOSTON, MA  











Host signaling pathways targeted by 
a Yersinia effector  
Total: $133,882  
 $38,534 | 2005 | Mcdonald, Christine L | UNIVERSITY OF MICHIGAN AT 
ANN ARBOR | ANN ARBOR, MI  
 $48,928 | 2004 | Mcdonald, Christine L | UNIVERSITY OF MICHIGAN AT 
ANN ARBOR | ANN ARBOR, MI  
 $46,420 | 2003 | Mcdonald, Christine L | UNIVERSITY OF MICHIGAN AT 
ANN ARBOR | ANN ARBOR, MI  
74 27 
1R01AI056068-
01 MECSAS, JOAN 
Yersinia Yops in an Animal Infection 
Model  
Total: $990,625  
 $396,250 | 2005 | Mecsas, Joan C | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $396,250 | 2004 | Mecsas, Joan C | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $198,125 | 2003 | Mecsas, Joan C | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
75 27 
1R01AI056404-
01 ORTH, KIMBERLY 
Biochemical Characterization of 
Yersinia Effector YopJ  
Total: $636,999  
 $273,000 | 2005 | Orth, Kimberly A | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $273,000 | 2004 | Orth, Kimberly A | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $90,999 | 2003 | Orth, Kim A | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
76 27 
1U19AI056572-
010003 STAATS, HERMAN 
Anti-TLR Antibodies as Select Agent 
Vaccine Adjuvants  
Total: $2,635,165  
 $964,605 | 2005 | Gunn, Michael D | DUKE UNIVERSITY | DURHAM, NC  
 $936,517 | 2004 | Gunn, Michael D | DUKE UNIVERSITY | DURHAM, NC  
 $734,043 | 2003 | Gunn, Michael D | DUKE UNIVERSITY | DURHAM, NC  
77 27 
1F32AI060301-
01 SWEET, CHARLES 
Suppression of innate immune 
signaling by Yersinia YopJ  
Total: $97,224  
 $49,928 | 2005 | Sweet, Charles R | UNIV OF MASSACHUSETTS MED SCH 
WORCESTER | WORCESTER, MA  
 $47,296 | 2004 | Sweet, Charles R | UNIV OF MASSACHUSETTS MED SCH 
WORCESTER | WORCESTER, MA  
78 27 
1R43AI055073-
01 U'REN, JACK 
Bacterial Pathogen Amplification & 
Real-Time Detection  
Total: $99,915  







01A1 AFONINA, IRINA 
MGB Eclipse Probe Detection of 
Category A Organisms  
Total: $100,000  
 $100,000 | 2003 | Afonina, Irina A | EPOCH BIOSCIENCES, INC. | 
BOTHELL, WA  
80 26 
1P01AI055621-
01A1 BENACH, JORGE 
Agents of Bioterrorism: 
Pathogenesis and host defense  
Total: $5,601,602  
 $2,531,248 | 2005 | Benach, Jorge L | STATE UNIVERSITY NEW YORK 
STONY BROOK | STONY BROOK, NY  
 $3,070,354 | 2004 | Benach, Jorge L | STATE UNIVERSITY NEW YORK 






HALOGENATION IN PEPTIDE 
ANTIBIOTIC BIOSYNTHESIS  
Total: $109,960  
 $44,212 | 2002 | Burkart, Michael D | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $34,832 | 2001 | Burkart, Michael D | HARVARD UNIVERSITY (MEDICAL 
SCHOOL) | BOSTON, MA  
 $30,916 | 2000 | BURKART, MICHAEL D | RAZZAQUE A OCULAR 
PEMPHIGOID--MECHANISM OF PATHOGENESIS | 5 R01EY008379-11 
AHMED, MA  
82 26 
1Z01BC006198-
13 BURKE, TERRENCE 
Inhibitors of Tyrosine Kinase-
Dependent Signalling as An  
83 26 
1Z01BC006198-
14 BURKE, TERRENCE 
Inhibitors of Tyrosine Kinase-






B cell related prophylaxis and 
therapeutics  
Total: $21,685,329 *  
 $8,996,537 | 2005 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  
 $8,717,880 | 2004 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  




01 CLEMENTS, JOHN 
Combinatorial vaccines against 
anthrax and plague  
Total: $610,500  
 $313,500 | 2004 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $297,000 | 2003 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
86 26 
1U54AI057158-
010002 CRYSTAL, RONALD Vaccine Platforms  
Total: $21,685,329 *  
 $8,996,537 | 2005 | Lipkin, Walter Ian | WADSWORTH CENTER | ALBANY, 
NY  














diagnostics with rSBH system  
Total: $2,305,894  
 $725,838 | 2005 | Drmanac, Radoje | CALLIDA GENOMICS, INC. | 
SUNNYVALE, CA  
 $903,169 | 2004 | Drmanac, Radoje | CALLIDA GENOMICS, INC. | 
SUNNYVALE, CA  




01 DUNCAN, ROBERT 
Pathogen Chip for Detection of 
Bioterrorism Agents in Bl  
90 26 
1U54AI057141-
010005 ERNST, ROBERT 
Bacterial Lipopolysaccharide 
Structure  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
91 26 
1U01AI056513-
01 GRANDI, GUIDO 
Novel vaccine candidates for Y. 
pestis from genomics  
Total: $1,909,381  
 $1,209,134 | 2004 | Grandi, Guido | CHIRON S.P.A. | ITALY - SIENA  
 $700,247 | 2003 | Grandi, Guido | CHIRON S.P.A. | ITALY - SIENA  
92 26 
1U54AI057141-
010003 GUINA, TINA Bacterial Proteome  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 






Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 
| MILWAUKEE, WI  
 $391,730 | 2004 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 
| MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF WISCONSIN 







01 HINNEBUSCH, B 
Rodent Models To Study 
Pathogenesis Of Bubonic And Septi  
95 26 
1Z01AI000919-
02 HINNEBUSCH, B 
Rodent Models To Study 






Rodent Models Of Bubonic And 
Septicemic Plague  
97 26 
1U01AI056422-
01 KIMMEL, BRUCE 
Antibodies for BioDefense using 
Directed Evolution  
Total: $3,176,307  
 $1,025,983 | 2005 | Wall, Mark A | DIVERSA CORPORATION | SAN DIEGO, 
CA  
 $1,264,136 | 2004 | Kimmel, Bruce E | DIVERSA CORPORATION | SAN 
DIEGO, CA  
 $886,188 | 2003 | Kimmel, Bruce E | DIVERSA CORPORATION | SAN 
DIEGO, CA  
98 26 
1UC1AI062567-
01 LOWELL, GEORGE 
Development of ProtollinTM Plague 
Vaccine  
Total: $7,992,403  
 $7,992,403 | 2004 | Lowell, George H | ID BIOMEDICAL CORPORATION OF 






Engineered alkaline phosphatases as 
biosensors  
Total: $532,000  
 $266,000 | 2004 | Matsumura, Ichiro | EMORY UNIVERSITY | ATLANTA, GA 
 $266,000 | 2003 | Matsumura, Ichiro | EMORY UNIVERSITY | ATLANTA, GA 
100 26 
1R01AI051520-
01A1 NILLES, MATTHEW 
Protein Interactions in Type III 
Secretion in Y. pestis  
Total: $1,004,483  
 $245,350 | 2005 | Nilles, Matthew L | UNIVERSITY OF NORTH DAKOTA | 
GRAND FORKS, ND  
 $245,350 | 2004 | Nilles, Matthew L | UNIVERSITY OF NORTH DAKOTA | 
GRAND FORKS, ND  
 $513,783 | 2003 | Nilles, Matthew L | UNIVERSITY OF NORTH DAKOTA | 
GRAND FORKS, ND  
101 26 
1U54AI057141-
010001 OLSON, MAYNARD Bacterial Genome Diversity  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
102 26 
1R41AI052921-
01A1 PAPISOV, MIKHAIL 






Total: $100,000  
 $100,000 | 2003 | Papisov, Mikhail I | NANOPHARMA, CORPORATION | 






QUANTITATIVE ANALYSIS OF 
YERSINIA PESTIS ORF38 PROTEIN  
Total: $6,706,649  
 $1,446,875 | 2004 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-
LAWRNC LVRMR NAT LAB | LIVERMORE, CA  
 $1,276,355 | 2003 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-
LAWRNC LVRMR NAT LAB | LIVERMORE, CA  
 $1,257,387 | 2002 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-
LAWRNC LVRMR NAT LAB | LIVERMORE, CA  
 $1,311,794 | 2001 | Turteltaub, Kenneth W | UNIVERSITY OF CALIF-
LAWRNC LVRMR NAT LAB | LIVERMORE, CA  
 $1,414,238 | 2000 | TURTELTAUB, KENNETH W | UNIVERSITY OF CALIF-






Automated, portable, concurrent, 
WMD detection system  
Total: $994,832  
 $500,000 | 2005 | Schoen, Christian | CONCURRENT ANALYTICAL, INC. | 
Kailua, HI  
 $494,832 | 2004 | Schoen, Christian | CONCURRENT ANALYTICAL, INC. | 
Kailua, HI  
105 26 
1U19AI056543-
010003 SHAPIRO, DANIEL Diagnostics  
Total: $6,264,376  
 $2,310,008 | 2005 | Murphy, John R | BOSTON MEDICAL CENTER | 
BOSTON, MA  
 $2,370,307 | 2004 | Rice, Peter A | BOSTON MEDICAL CENTER | BOSTON, 
MA  







Airway Inflammation  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
107 26 
1R21AI054595-
01 SMILEY, STEPHEN 
Priming CD4+ T cells to protect 
against pneumonic plague  
Total: $692,000  
 $346,000 | 2004 | Smiley, Stephen T | TRUDEAU INSTITUTE, INC. | 
SARANAC LAKE, NY  
 $346,000 | 2003 | Smiley, Stephen T | TRUDEAU INSTITUTE, INC. | 







01 STEBBINS, C 
Novel Plague Antibacterials Through 
Phage Display  
Total: $501,000  
 $250,500 | 2003 | Stebbins, C Erec | ROCKEFELLER UNIVERSITY | NEW 
YORK, NY  
 $250,500 | 2002 | Stebbins, C E | ROCKEFELLER UNIVERSITY | NEW 






Genetic clustering and virulence of 
Y. pestis strains  
Total: $284,875  
 $284,875 | 2004 | Sulakvelidze, Alexander | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
110 26 
1R43AI058410-
01 SURBER, MARK 
Antibacterial Therapy by Pathogen 
Osmolality Disruption  
Total: $265,985  
 $265,985 | 2004 | Surber, Mark W | MPEX PHARMACEUTICALS, INC. | SAN 
DIEGO, CA  
111 26 
1R43AI052953-
01 SYKES, KATHRYN 
Plague vaccine candidates by a 
functional genomic screen  
Total: $133,750  
 $133,750 | 2002 | Sykes, Kathryn F | ELIANCE BIOTECHNOLOGY, INC. | 
DALLAS, TX  
112 26 
1R01AI066505-
01 TALTON, JAMES 
Inhaled Aminoglycoside Formulafor 
Plague and Tularemia  
Total: $603,030  
 $603,030 | 2005 | Talton, James David | NANOTHERAPEUTICS, INC. | 






Novel Therapeutics for Biodefense  
Total: $1,684,306  
 $854,748 | 2005 | Alekshun, Michael N | PARATEK PHARMACEUTICALS | 
BOSTON, MA  
 $829,558 | 2004 | Alekshun, Michael N | PARATEK PHARMACEUTICALS | 







Molecular Detection System  
Total: $380,520  
 $380,520 | 2005 | Bogomolova, Anastasia | FRACTAL SYSTEMS, INC. | 






Development Research Projects  
Total: $1,477,975  
 $1,477,975 | 2003 | Britigan, Bradley E | UNIVERSITY OF IOWA | IOWA 







01 CLEMENTS, JOHN 
Novel adjuvants for biodefense 
vaccines  
Total: $1,759,403  
 $270,779 | 2005 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $460,814 | 2004 | Clements, John D | TULANE UNIVERSITY OF LOUISIANA 
| NEW ORLEANS, LA  
 $1,027,810 | 2003 | Clements, John D | TULANE UNIVERSITY OF 






DISCOVERY AND DEVELOPMENT OF 






Anti-infectives that target bacterial 
ribosomes  
Total: $621,051  
 $621,051 | 2004 | Cunningham, Philip R | WAYNE STATE UNIVERSITY | 
DETROIT, MI  
119 13 
1R01AI060662-
01 DIXON, JACK 
Molecular Mechanism of 
Pathogenesis  
Total: $749,634  
 $374,642 | 2005 | Dixon, Jack E | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
 $374,992 | 2004 | Dixon, Jack E | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
120 13 
1R21AI064614-
01 DIXON, JACK YopT: A Yersinia Virulence Factor  
Total: $307,750  
 $307,750 | 2005 | Dixon, Jack E | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
121 13 
1U01AI056395-
01 DZIARSKI, ROMAN 
Antibacterial peptidoglycan 
recognition proteins  
Total: $940,625  
 $376,250 | 2005 | Dziarski, Roman | INDIANA UNIV-PURDUE UNIV AT 
INDIANAPOLIS | INDIANAPOLIS, IN  
 $376,250 | 2004 | Dziarski, Roman | INDIANA UNIV-PURDUE UNIV AT 
INDIANAPOLIS | INDIANAPOLIS, IN  
 $188,125 | 2003 | Dziarski, Roman | INDIANA UNIV-PURDUE UNIV AT 
INDIANAPOLIS | INDIANAPOLIS, IN  
122 13 
1R01CI000099-
01 ECKER, DAVID 
Automated Simultaneous Detection 
of Bioterrorism Agents  
123 13 
1R03AI064312-
01 GHOSH, PARTHO 
Structure of the multidrug efflux 
protein AcrA  
Total: $70,340  
 $70,340 | 2005 | Ghosh, Partho | UNIVERSITY OF CALIFORNIA SAN DIEGO 






Device for Rapid Gene Detection of 





Total: $721,300  
 $360,650 | 2005 | Henkens, Robert L | ALDERON BIOSCIENCES, INC. | 
DURHAM, NC  
 $360,650 | 2004 | Henkens, Robert L | ALDERON BIOSCIENCES, INC. | 
DURHAM, NC  
125 13 
2R37AI023538-
14 ISBERG, RALPH 
MOLECULAR BASIS OF 
YERSINIA/HOST CELL INTERACTION 
Total: $1,883,891  
 $367,875 | 2005 | Isberg, Ralph R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $321,478 | 2004 | Isberg, Ralph R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $312,115 | 2003 | Isberg, Ralph R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $303,025 | 2002 | Isberg, Ralph R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $294,197 | 2001 | Isberg, Ralph R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $285,201 | 2000 | ISBERG, RALPH R | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
126 13 
1U01AI054815-
01 KIMMEL, BRUCE 
Characterization of Proteomes of 
Category A Pathogens  
Total: $3,671,636  
 $1,421,269 | 2005 | Green, Brian | DIVERSA CORPORATION | SAN DIEGO, 
CA  
 $1,309,441 | 2004 | Kimmel, Bruce E | DIVERSA CORPORATION | SAN 
DIEGO, CA  
 $940,926 | 2003 | Kimmel, Bruce E | DIVERSA CORPORATION | SAN 






Identification of rovA Regulators in 
Y.Enterocolitica  
Total: $48,296  




19 LEVY, STUART 
The multiple antibiotic resistance 
(MAR)regulon  
Total: $1,424,361  
 $480,650 | 2005 | Levy, Stuart B | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $468,681 | 2004 | Levy, Stuart B | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
 $475,030 | 2003 | Levy, Stuart B | TUFTS UNIVERSITY BOSTON | 
BOSTON, MA  
129 13 
1U01AI056536-
01 LU, SHAN 
Multi-gene plague vaccine with 
expanded protection  
Total: $1,089,169  
 $538,990 | 2004 | Lu, Shan | UNIV OF MASSACHUSETTS MED SCH 
WORCESTER | WORCESTER, MA  





WORCESTER | WORCESTER, MA  
130 13 
1U19AI057234-
010002 LYONS, C. 
Dendritic Cell Response to Class A 
Biothreats  
Total: $8,032,229  
 $3,124,596 | 2005 | Banchereau, Jacques F | BAYLOR RESEARCH 
INSTITUTE | DALLAS, TX  
 $3,164,316 | 2004 | Banchereau, Jacques F | BAYLOR RESEARCH 
INSTITUTE | DALLAS, TX  
 $1,743,317 | 2003 | Banchereau, Jacques F | BAYLOR RESEARCH 
INSTITUTE | DALLAS, TX  
131 13 
1U54AI057141-
010002 MANOIL, COLIN 
Bacterial Essential and Virulence 
Gene  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
132 13 
1U54AI057141-
019008 MANOIL, COLIN CORE--Bacterial Strain  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
133 13 
1U54AI057141-
010008 MARTIN, THOMAS 
Variation in Human Innate 
Immunity  
Total: $27,022,275 *  
 $10,904,836 | 2005 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $11,677,224 | 2004 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
 $4,440,215 | 2003 | Miller, Samuel I | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
134 13 
1P01AI060642-
01 MIZEL, STEVEN 
Respiratory Immunity Against 
Agents of Bioterrorism  
Total: $1,818,389  
 $1,818,389 | 2004 | Mizel, Steven B | ION TECHNOLOGIES, INC. | 
WINSTON-SALEM, NC  
135 13 
1P01AI056293-
01 NATHAN, CARL 
MACROPHAGES, DENDRITIC CELLS 
AND PATHOGENS  
Total: $3,474,964 *  
 $1,388,080 | 2005 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF 
CORNELL UNIV | NEW YORK, NY  





CORNELL UNIV | NEW YORK, NY  
 $742,473 | 2003 | Nathan, Carl F | WEILL MEDICAL COLLEGE OF CORNELL 






Evaluation of Prime-Boost 
Responses  
Total: $4,457,410 *  
 $1,930,417 | 2005 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $1,881,608 | 2004 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
 $645,385 | 2003 | Nataro, James P | UNIVERSITY OF MARYLAND BALT 
PROF SCHOOL | BALTIMORE, MD  
137 13 
1R43AI052898-
01 PRUDENT, JAMES 
Rapid Turn-around Testing for 
Bioterrorism Agents  
Total: $105,250  
 $105,250 | 2002 | Prudent, James R | ERAGEN BIOSCIENCES, INC. | 
MADISON, WI  
138 13 
2R44AI052898-
02 PRUDENT, JAMES 
Rapid Turn-arround Multiplex 
Testing: Bioweapon Agents  
Total: $938,550  
 $389,796 | 2004 | Prudent, James R | ERAGEN BIOSCIENCES, INC. | 
MADISON, WI  
 $548,754 | 2003 | Prudent, James R | ERAGEN BIOSCIENCES, INC. | 
MADISON, WI  
139 13 
1R21AI063384-
01A1 QUADRI, LUIS 
Virulence-conferring siderophore 
biosynthesis inhibitors  
Total: $210,000  
 $210,000 | 2005 | Quadri, Luis E | WEILL MEDICAL COLLEGE OF CORNELL 






Novel Strategies for Y pestis 
Immunotherapy  
Total: $501,000  
 $250,500 | 2003 | Ravetch, Jeffrey V | ROCKEFELLER UNIVERSITY | NEW 
YORK, NY  
 $250,500 | 2002 | Ravetch, Jeffrey V | ROCKEFELLER UNIVERSITY | NEW 






Non-antiobiotic resistance markers 
for bacteria  
Total: $179,725  
 $179,725 | 2005 | Schweizer, Herbert P | COLORADO STATE UNIVERSITY-
FORT COLLINS | FORT COLLINS, CO  
142 13 
1UC1AI067203-
01 SIGAL, GEORGE 
A Multiplexed Point-of-Care 
Diagnostic System for Bio-T*  
143 13 
1R43AI052950-





Bioterrorism Agents  
Total: $101,052  




02 U'REN, JACK 
Bacterial Pathogen Amplification & 
Real-Time Detection  
Total: $362,019  







Novel Adjuvants/Delivery Systems 
for Biodefense Vaccines  
Total: $4,680,300  
 $1,624,853 | 2005 | Valiante, Nicholas M | CHIRON CORPORATION | 
EMERYVILLE, CA  
 $2,035,822 | 2004 | Valiante, Nicholas M | CHIRON CORPORATION | 
EMERYVILLE, CA  
 $1,019,625 | 2003 | Valiante, Nicholas M | CHIRON CORPORATION | 
EMERYVILLE, CA  
146 13 
1R21AI060953-
01 WHITE, STEPHEN 
Development of DHPS as a 
Bioterrorism Therapeutic Target  
Total: $264,000  
 $264,000 | 2004 | White, Stephen W | ST. JUDE CHILDREN'S RESEARCH 







BIOLOGY OF PCRV  
Total: $1,643,042  
 $313,175 | 2004 | Wienerkronish, Jeanine P | UNIVERSITY OF CALIFORNIA 
SAN FRANCISCO | SAN FRANCISCO, CA  
 $314,600 | 2003 | Wienerkronish, Jeanine P | UNIVERSITY OF CALIFORNIA 
SAN FRANCISCO | SAN FRANCISCO, CA  
 $38,591 | 2002 | Wiener-Kronish, Jeanine P | UNIVERSITY OF CALIFORNIA 
SAN FRANCISCO | SAN FRANCISCO, CA  
 $327,526 | 2002 | Wiener-Kronish, Jeanine P | UNIVERSITY OF 
CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA  
 $317,925 | 2001 | Wiener-Kronish, Jeanine P | UNIVERSITY OF 
CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA  
 $331,225 | 2000 | WIENER-KRONISH, JEANINE P | UNIVERSITY OF 






2 Increasing virulence of non-listed agent 
Autographa californica multiple nucleopolyhedrovirus 
Taxonomy: Family Baculoviridae, Genus Nucleopolyhedrovirus, Species Autographa californica 
multiple nucleopolyhedrovirus, Virus: Autographa californica multiple nucleopolyhedrovirus. 
Publications: 
1. Regev, A., H. Rivkin, B. Inceoglu, E. Gershburg, B. D. Hammock, M. Gurevitz, and 
N. Chejanovsky. 2003. Further enhancement of baculovirus insecticidal efficacy with 
scorpion toxins that interact cooperatively. FEBS Lett 537:106-10. 
This paper describes the insertion of scorpio toxins into an insect virus, and the resulting 











4 Powder or aerosol production of non-listed agent/5 Powder or aerosol 






6 De novo synthesis of non-listed agent 
Enterobacteria phage φX174  
1. Smith, H. O., C. A. Hutchison, 3rd, C. Pfannkoch, and J. C. Venter. 2003. Generating 
a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic 
oligonucleotides. Proc Natl Acad Sci U S A 100:15440-5. 
 This paper reports the synthesis of the full genome of the phage from synthetic 
oligonucleotides, and the rescue of complete phage particles after transfection of the 











MODERATELY DANGEROUS ACTIVITIES (MDA) 
1 Increasing virulence of listed agent or related agent 
Influenza B virus 
Taxonomy: Family Orthomyxoviridae, Genus Influenzavirus B, Species Influenza B virus, Virus: 
Influenza B virus. 
Publications: 
1. McCullers, J. A., E. Hoffmann, V. C. Huber, and A. D. Nickerson. 2005. A single 
amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus 
confers mouse adaptation and virulence. Virology 336:318-26. 
This paper describes the adaptation of influenza B virus to mice, and reports the 
identification of the amino acid residue that is responsible for increased virulence in mice. 
 
Newcastle disease virus 
Publications: 
1. Shengqing, Y., N. Kishida, H. Ito, H. Kida, K. Otsuki, Y. Kawaoka, and T. Ito. 2002. 
Generation of velogenic Newcastle disease viruses from a nonpathogenic waterfowl 
isolate by passaging in chickens. Virology 301:206-11. 




Taxonomy: Family Arenaviridae, Genus Arenavirus, Species Pichinde virus, Virus: Pichinde 
virus. 
Publications: 
1. Zhang, L., K. A. Marriott, D. G. Harnish, and J. F. Aronson. 2001. Reassortant 




This paper describes the generation of reassortent Pichinde viruses by switching 




2 Insertion of host genes into listed agent or related agent 




3 Increasing transmissibility or environmental stability of listed agent or 
related agent 




4 Powder or aerosol production of listed agent or related agent/5 Powder or 
aerosol dispersal of listed agent or related agent 
Alcelaphine herpesvirus 1,2 
Publications: 
1. Li, H., N. S. Taus, G. S. Lewis, O. Kim, D. L. Traul, and T. B. Crawford. 2004. 
Shedding of ovine herpesvirus 2 in sheep nasal secretions: the predominant mode for 
transmission. J Clin Microbiol 42:5558-64. 
 This paper reports the detection of ovine herpesvirus 2 in nasal secretions of infected 
sheep at various time points of infection; and demonstrates that aerosolized nasal 
secretions are infectious. 
2. Taus, N. S., D. L. Traul, J. L. Oaks, T. B. Crawford, G. S. Lewis, and H. Li. 2005. 
Experimental infection of sheep with ovine herpesvirus 2 via aerosolization of nasal 
secretions. J Gen Virol 86:575-9. 
 This paper reports on the aerosolization of nasal secretions of infected sheep. 
 
Andes virus 
Taxonomy: Family Bunyaviridae, Genus Hantavirus, Species: Andes virus, Virus: Andes virus. 
Publications: 
1. McElroy, A. K., M. Bray, D. S. Reed, and C. S. Schmaljohn. 2002. Andes virus 
infection of cynomolgus macaques. J Infect Dis 186:1706-12. 




1. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. 
Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit 
model of inhalational anthrax. Vaccine 19:4768-73. 
 This paper reports the identification of serum factors conferring immunity to the bacillus. 
2. Weis, C. P., A. J. Intrepido, A. K. Miller, P. G. Cowin, M. A. Durno, J. S. Gebhardt, 
and R. Bull. 2002. Secondary aerosolization of viable Bacillus anthracis spores in a 




 This paper reports the sampling of the bacillus from surfaces and the aerosolization of 
these samples to estimate secondary aerosolization under natural conditions. 
3. McBride, M. T., D. Masquelier, B. J. Hindson, A. J. Makarewicz, S. Brown, K. 
Burris, T. Metz, R. G. Langlois, K. W. Tsang, R. Bryan, D. A. Anderson, K. S. 
Venkateswaran, F. P. Milanovich, and B. W. Colston, Jr. 2003. Autonomous detection 
of aerosolized Bacillus anthracis and Yersinia pestis. Anal Chem 75:5293-9. 
 This paper reports a method for detection of aerosolized bacillus/yersinia. 
4. Vasconcelos, D., R. Barnewall, M. Babin, R. Hunt, J. Estep, C. Nielsen, R. Carnes, 
and J. Carney. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca 
fascicularis). Lab Invest 83:1201-9. 
 This paper reports the pathology of inhalational anthrax in a monkey model. 
5. Hermanson, G., V. Whitlow, S. Parker, K. Tonsky, D. Rusalov, M. Ferrari, P. Lalor, 
M. Komai, R. Mere, M. Bell, K. Brenneman, A. Mateczun, T. Evans, D. Kaslow, D. 
Galloway, and P. Hobart. 2004. A cationic lipid-formulated plasmid DNA vaccine 
confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc 
Natl Acad Sci U S A 101:13601-6. 
 This paper reports the evaluation of a vaccine candidate for the prevention of aerosolized 
infection with the bacillus. 
6. Mohamed, N., M. Clagett, J. Li, S. Jones, S. Pincus, G. D'Alia, L. Nardone, M. 
Babin, G. Spitalny, and L. Casey. 2005. A high-affinity monoclonal antibody to anthrax 
protective antigen passively protects rabbits before and after aerosolized Bacillus 
anthracis spore challenge. Infect Immun 73:795-802. 
 This paper reports the efficacy of a vaccine candidate in aerosol studies. 
7. Hindson, B. J., M. T. McBride, A. J. Makarewicz, B. D. Henderer, U. S. Setlur, S. M. 
Smith, D. M. Gutierrez, T. R. Metz, S. L. Nasarabadi, K. S. Venkateswaran, S. W. 
Farrow, B. W. Colston, Jr., and J. M. Dzenitis. 2005. Autonomous detection of 
aerosolized biological agents by multiplexed immunoassay with polymerase chain 
reaction confirmation. Anal Chem 77:284-9. 
 This paper reports the development of a detection system. 
 
Bacillus atrophaeus 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Bacilli, Order Bacillales, Family 
Bacillaceae. 
Publications: 
1. Fergenson, D. P., M. E. Pitesky, H. J. Tobias, P. T. Steele, G. A. Czerwieniec, S. C. 
Russell, C. B. Lebrilla, J. M. Horn, K. R. Coffee, A. Srivastava, S. P. Pillai, M. T. 




Hadley, M. Frank, and E. E. Gard. 2004. Reagentless detection and classification of 
individual bioaerosol particles in seconds. Anal Chem 76:373-8. 
This paper describes a mass spectrometry-based analytical technique for the real-time 




Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Bacilli, Order Bacillales, Family 
Bacillaceae. 
Publications: 
1. Clark Burton, N., A. Adhikari, S. A. Grinshpun, R. Hornung, and T. Reponen. 2005. 
The effect of filter material on bioaerosol collection of Bacillus subtilis spores used as a 
Bacillus anthracis simulant. J Environ Monit 7:475-80. 
 This paper reports characteristics of filter material used in detection systems for bacilli. 
2. Hindson, B. J., M. T. McBride, A. J. Makarewicz, B. D. Henderer, U. S. Setlur, S. M. 
Smith, D. M. Gutierrez, T. R. Metz, S. L. Nasarabadi, K. S. Venkateswaran, S. W. 
Farrow, B. W. Colston, Jr., and J. M. Dzenitis. 2005. Autonomous detection of 
aerosolized biological agents by multiplexed immunoassay with polymerase chain 
reaction confirmation. Anal Chem 77:284-9. 
 This paper reports the development of a detection system. 
 
Bacillus thuringiensis 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Bacilli, Order Bacillales, Family 
Bacillaceae. 
Publications: 
1. Fergenson, D. P., M. E. Pitesky, H. J. Tobias, P. T. Steele, G. A. Czerwieniec, S. C. 
Russell, C. B. Lebrilla, J. M. Horn, K. R. Coffee, A. Srivastava, S. P. Pillai, M. T. 
Shih, H. L. Hall, A. J. Ramponi, J. T. Chang, R. G. Langlois, P. L. Estacio, R. T. 
Hadley, M. Frank, and E. E. Gard. 2004. Reagentless detection and classification of 
individual bioaerosol particles in seconds. Anal Chem 76:373-8. 
This paper describes a mass spectrometry-based analytical technique for the real-time 







1. Mense, M. G., R. H. Borschel, C. L. Wilhelmsen, M. L. Pitt, and D. L. Hoover. 2004. 
Pathologic changes associated with brucellosis experimentally induced by aerosol 
exposure in rhesus macaques (Macaca mulatta). Am J Vet Res 65:644-52. 




1. Ulrich, R. L., K. Amemiya, D. M. Waag, C. J. Roy, and D. DeShazer. 2005. Aerogenic 
vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated 
glanders in mice. Vaccine 23:1986-92. 





1. Jeddeloh, J. A., D. L. Fritz, D. M. Waag, J. M. Hartings, and G. P. Andrews. 2003. 
Biodefense-driven murine model of pneumonic melioidosis. Infect Immun 71:584-7. 
 This paper reports the developmend of a mouse model of Bukholderia pseudomallei 
infection by aerosol. 
 
Classical swine fever virus 
Publications: 
1. Gonzalez, C., C. Pijoan, A. Ciprian, P. Correa, and S. Mendoza. 2001. The effect of 
vaccination with the PAV-250 strain classical swine fever (CSF) virus on the airborne 
transmission of CSF virus. J Vet Med Sci 63:991-6. 
This paper describes the vaccination of pigs with the virus and the study of aerosol 
transmission from infected to non-infected pigs, and the vaccination of pigs and the 







Taxonomy: Family Poxviridae, Subfamily: Chordopoxvirinae, Genus Orthopoxvirus, Species 
Cowpox virus, Virus: Cowpox virus. 
Publications: 
1. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 
2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. 
J Infect Dis 181:10-9. 
This paper reports the successful protection of mice against cowpox infection by aerosol 
using an antiviral. 
2. Martinez, M. J., M. P. Bray, and J. W. Huggins. 2000. A mouse model of aerosol-
transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted 
orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med 
124:362-77. 
 This paper describes a mouse model for aerosolized cowpox virus infection. 
3. Bray, M., M. Martinez, D. Kefauver, M. West, and C. Roy. 2002. Treatment of 
aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 
54:129-42. 
This paper reports the successful treatment of mice infected with cowpox virus by aerosol. 
   
Coxiella burnetii 
Publications: 
1. Waag, D. M., M. J. England, R. F. Tammariello, W. R. Byrne, P. Gibbs, C. M. 
Banfield, and M. L. Pitt. 2002. Comparative efficacy and immunogenicity of Q fever 
chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in 
cynomolgus monkeys challenged by aerosol. Vaccine 20:2623-34. 
This paper reports the evaluation of a vaccine against aerosol infection with the bacterium. 
 
Human respiratory syncytial virus 
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Pneumovirinae, 






1. Tumas, D. B., B. Chan, W. Werther, T. Wrin, J. Vennari, N. Desjardin, R. L. 
Shields, and P. Jardieu. 2001. Anti-IgE efficacy in murine asthma models is dependent 
on the method of allergen sensitization. J Allergy Clin Immunol 107:1025-33. 
This paper evaluates whether the mode of allergen sensitization influences the role of IgE 
in allergen-induced pulmonary eosinophilic inflammation, using HRSV as a control. 
 
Human Rhinovirus 
Taxonomy: Family Picornaviridae, Genus Enterovirus, Species Rhinovirus, Virus: Human 
rhinovirus. 
Publications: 
1. Myatt, T. A., S. L. Johnston, S. Rudnick, and D. K. Milton. 2003. Airborne rhinovirus 
detection and effect of ultraviolet irradiation on detection by a semi-nested RT-PCR 
assay. BMC Public Health 3:5. 
This paper describes the aerosolization of a rhinovirus in a small aerosol chamber, using 
different concentrations, to determine the effect of UV irradiation on detection of 
rhinoviral aerosols.  
 
Measles virus 
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Morbillivirus, Species Measles virus, Virus: Measles virus. 
Publications: 
1. Sepulveda-Amor, J., J. L. Valdespino-Gomez, L. Garcia-Garcia Mde, J. Bennett, R. 
Islas-Romero, G. Echaniz-Aviles, and J. F. de Castro. 2002. A randomized trial 
demonstrating successful boosting responses following simultaneous aerosols of measles 
and rubella (MR) vaccines in school age children. Vaccine 20:2790-5. 










1. Zaucha, G. M., P. B. Jahrling, T. W. Geisbert, J. R. Swearengen, and L. Hensley. 
2001. The pathology of experimental aerosolized monkeypox virus infection in 
cynomolgus monkeys (Macaca fascicularis). Lab Invest 81:1581-1600. 
This paper reports the exposure of monkeys to a fine-particle aerosol (lethal dose) of 
Monkeypox virus, and the following characterization of the pathology of monkeypox by 
conducting necropsies of the deceased animals. 
 
Mycoplasma gallisepticum 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Mollicutes, Order Mycoplasmatales, 
Family Mycoplasmataceae. 
Publications: 
1. Branton, S. L., W. B. Roush, B. D. Lott, J. D. Evans, W. A. Dozier, 3rd, S. D. Collier, 
S. M. Bearson, B. L. Bearson, and G. T. Pharr. 2005. A self-propelled, constant-speed 
spray vaccinator for commercial layer chickens. Avian Dis 49:147-51. 
This paper reports the construction of a battery-powered, self-propelled, constant-speed 
vaccinator for the vaccination against Mycoplasma gallisepticum. 
 
Mycoplasma synoviae 
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Mollicutes, Order Mycoplasmatales, 
Family Mycoplasmataceae. 
Publications: 
1. Kleven, S. H., G. N. Rowland, and M. C. Kumar. 2001. Poor serologic response to 
upper respiratory infection with Mycoplasma synoviae in turkeys. Avian Dis 45:719-23. 









Taxonomy: Family Togaviridae, Genus Rubivirus, Species Rubella virus, Virus: Rubella virus. 
Publications: 
1. Sepulveda-Amor, J., J. L. Valdespino-Gomez, L. Garcia-Garcia Mde, J. Bennett, R. 
Islas-Romero, G. Echaniz-Aviles, and J. F. de Castro. 2002. A randomized trial 
demonstrating successful boosting responses following simultaneous aerosols of measles 
and rubella (MR) vaccines in school age children. Vaccine 20:2790-5. 




1. Jahrling, P. B., L. E. Hensley, M. J. Martinez, J. W. Leduc, K. H. Rubins, D. A. 
Relman, and J. W. Huggins. 2004. Exploring the potential of variola virus infection of 
cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A 
101:15196-200. 
 This paper describes the development of a monkey model for smallpox. Cynomolgus 
macaques were exposed to several variola strains through aerosol and/or i.v. routes. Two 
strains, Harper and India 7124, produced uniform acute lethality when inoculated i.v. in 
high doses. Lower doses resulted in less fulminant, systemic disease and lower mortality. 
The pathology of the infected monkeys is described. 
 
Venezuelan equine encephalitis virus 
Publications: 
1. Shoemaker, M. O., R. Tammariello, B. Crise, S. S. Bouhaouala, G. B. Knudson, W. 
E. Jackson, 3rd, G. V. Ludwig, and J. F. Smith. 2001. Combined effects of Venezuelan 
equine encephalitis IIIA virus and gamma irradiation in mice. Mil Med 166:88-9. 
 This paper reports the combined effects of of injury from exposure to ionizing radiation 
and aerosol infection of mice with the virus. 
2. Reed, D. S., C. M. Lind, M. G. Lackemeyer, L. J. Sullivan, W. D. Pratt, and M. D. 
Parker. 2005. Genetically engineered, live, attenuated vaccines protect nonhuman 
primates against aerosol challenge with a virulent IE strain of Venezuelan equine 
encephalitis virus. Vaccine 23:3139-47. 
 This paper reports the efficacy of a vaccine candidate in primates challenged with the 






1. McBride, M. T., D. Masquelier, B. J. Hindson, A. J. Makarewicz, S. Brown, K. 
Burris, T. Metz, R. G. Langlois, K. W. Tsang, R. Bryan, D. A. Anderson, K. S. 
Venkateswaran, F. P. Milanovich, and B. W. Colston, Jr. 2003. Autonomous detection 
of aerosolized Bacillus anthracis and Yersinia pestis. Anal Chem 75:5293-9. 
 This paper reports a method for detection of aerosolized bacillus/yersinia. 
2. Worsham, P. L., and C. Roy. 2003. Pestoides F, a Yersinia pestis strain lacking 
plasminogen activator, is virulent by the aerosol route. Adv Exp Med Biol 529:129-31. 
 This paper reports a mutant of the bacterium that is transmissible by aerosol. 
3. Hindson, B. J., M. T. McBride, A. J. Makarewicz, B. D. Henderer, U. S. Setlur, S. M. 
Smith, D. M. Gutierrez, T. R. Metz, S. L. Nasarabadi, K. S. Venkateswaran, S. W. 
Farrow, B. W. Colston, Jr., and J. M. Dzenitis. 2005. Autonomous detection of 
aerosolized biological agents by multiplexed immunoassay with polymerase chain 
reaction confirmation. Anal Chem 77:284-9. 




6 De novo synthesis of listed agent of related agent 
Poliovirus  
Taxonomy: Family Picornaviridae, Genus Enterovirus, Species Poliovirus, Virus: Human 
poliovirus 1,2,3. 
Publications: 
1. Cello, J., A. V. Paul, and E. Wimmer. 2002. Chemical synthesis of poliovirus cDNA: 
generation of infectious virus in the absence of natural template. Science 297:1016-8. 
 This paper reports the synthesis of the full genome of the virus from synthetic 





7 Construction of antibiotic- or vaccine-resistant related agent 
Bacillus subtilis  
Taxonomy: Domain Bacteria, Phylum Firmicutes, Class Bacilli, Order Bacillales, Family 
Bacillaceae. 
Publications: 
1. Novikova, S. I., A. M. Bushueva, L. A. Trachuk, G. E. Konstantinova, A. V. Serkina, 
C. Hoischen, J. Gumpert, G. G. Chestukhina, A. Mankin, and A. B. Shevelev. 2000. 
Introduction of a mini-gene encoding a five-amino acid peptide confers erythromycin 
resistance on Bacillus subtilis and provides temporary erythromycin protection in Proteus 
mirabilis. FEMS Microbiol Lett 182:213-8. 




8 Genome transfer, genome replacement, or cellular reconstitution of listed 
agent or related agent 




EXTREMELY DANGEROUS ACTIVITIES (EDA) 
1 Work with eradicated agent 
“1918 Influenza A virus” (Derivatives of the “1918 Influenza A virus”, and chimeric 
influenza viruses with at least one gene from the “1918 Influenza A virus”) 
Taxonomy: Family Orthomyxoviridae, Genus Influenzavirus A, Species Influenza A virus, Virus: 
“1918 Influenza virus”. 
Publications: 
1. Basler, C. F., A. H. Reid, J. K. Dybing, T. A. Janczewski, T. G. Fanning, H. Zheng, 
M. Salvatore, M. L. Perdue, D. E. Swayne, A. Garcia-Sastre, P. Palese, and J. K. 
Taubenberger. 2001. Sequence of the 1918 pandemic influenza virus nonstructural gene 
(NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. 
Proc Natl Acad Sci U S A 98:2746-51. 
This paper reports the determination of the nonstructural (NS) segment of a 1918 
Influenza A virus, and its introduction into a mouse-adapted Influenza A/WSN/33 (H1N1) 
virus, which was shown to attenuate the virus. 
2. Tumpey, T. M., A. Garcia-Sastre, A. Mikulasova, J. K. Taubenberger, D. E. Swayne, 
P. Palese, and C. F. Basler. 2002. Existing antivirals are effective against influenza 
viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 99:13849-
54. 
This paper reports the generation of recombinant influenza viruses bearing the “1918 
Influenza A virus” HA, NA, or M segments. Recombinant viruses possessing both the 
1918 HA and 1918 NA were virulent in mice. The recombinant viruses were tested for 
their sensitivity to antiinfluenza virus drugs in vitro and in vivo. Zanamivir, oseltamivir, 
amantadine, and rimantadine were shown to be effective antivirals.  
3. Kash, J. C., C. F. Basler, A. Garcia-Sastre, V. Carter, R. Billharz, D. E. Swayne, R. 
M. Przygodzki, J. K. Taubenberger, M. G. Katze, and T. M. Tumpey. 2004. Global 
host immune response: pathogenesis and transcriptional profiling of type A influenza 
viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic 
virus. J Virol 78:9499-511. 
This paper reports the use of recombinant influenza viruses bearing the “1918 Influenza A 
virus” HA and NA segments in a mouse model to elucidate the role of the encoded 
proteins in pathogenesis. 
4. Kobasa, D., A. Takada, K. Shinya, M. Hatta, P. Halfmann, S. Theriault, H. Suzuki, 




Watanabe, M. Suresh, T. Suzuki, Y. Suzuki, H. Feldmann, and Y. Kawaoka. 2004. 
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic 
virus. Nature 431:703-7. 
This paper reports the generation of recombinant influenza viruses containing the HA and 
NA genes of the “1918 Influenza A virus”, and the demonstratation that HA confers 
enhanced pathogenicity in mice to recent human viruses that are otherwise non-
pathogenic in this host.  
5. Tumpey, T. M., A. Garcia-Sastre, J. K. Taubenberger, P. Palese, D. E. Swayne, and 
C. F. Basler. 2004. Pathogenicity and immunogenicity of influenza viruses with genes 
from the 1918 pandemic virus. Proc Natl Acad Sci U S A 101:3166-71. 
This paper reports the generation of recombinant influenzaviruses carrying two to five 
genes of the “1918 Influenza A virus”; the demonstration that these viruses are highly 
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CHARACTERIZATION OF SPANISH 
FLU  
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Variola virus 
Taxonomy: Family Poxviridae, Subfamily: Chordopoxvirinae, Genus Orthopoxvirus, Species 





1. Shchelkunov, S. N., A. V. Totmenin, V. N. Loparev, P. F. Safronov, V. V. Gutorov, 
V. E. Chizhikov, J. C. Knight, J. M. Parsons, R. F. Massung, and J. J. Esposito. 2000. 
Alastrim smallpox variola minor virus genome DNA sequences. Virology 266:361-86. 
This paper describes the cloning and sequencing of individual genomics fragments of a 
strain of Alastrim-causing Variola virus, and the final determination of the almost 
complete sequence. 
2. Loparev, V. N., R. F. Massung, J. J. Esposito, and H. Meyer. 2001. Detection and 
differentiation of old world orthopoxviruses: restriction fragment length polymorphism of 
the crmB gene region. J Clin Microbiol 39:94-100. 
This paper describes the development of a restriction fragment length polymorphism 
assay to differentiate various poxviruses including Camelpoxvirus, Monkeypox virus, and 
Variola virus. 
3. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for 
smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57:13-23. 
This paper describes the evaluation of 24 different potential antivirals for their activity 
against Variola virus (35 strains), Monkeypox virus, and Camelpox virus. Several active 
compounds were isolated. 
4. Chu, C. K., Y. H. Jin, R. O. Baker, and J. Huggins. 2003. Antiviral activity of 
cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox). 
Bioorg Med Chem Lett 13:9-12. 
This paper describes the synthesis and testing of novel antivirals for antiviral activity 
against Variola virus and Monkeypox virus. Several active compounds are described. 
5. Jin, Y. H., P. Liu, J. Wang, U. Das, R. Baker, J. Huggins, and C. K. Chu. 2003. 
Practical synthesis of D- and l-2-cyclopentenone and their utility for the synthesis of 
carbocyclic antiviral nucleosides against orthopox viruses (smallpox, monkeypox, and 
cowpox virus). J Org Chem 68:9012-8. 
This paper describes the synthesis and testing of novel antivirals for antiviral activity 
against Variola virus and Monkeypox virus. Several active compounds are described. 
6. Laassri, M., V. Chizhikov, M. Mikheev, S. Shchelkunov, and K. Chumakov. 2003. 
Detection and discrimination of orthopoxviruses using microarrays of immobilized 
oligonucleotides. J Virol Methods 112:67-78. 
This paper describes the creation of a novel diagnostic microarray system that can identify 
and differentiate Variola virus and Monkeypox virus. 
7. Sofi Ibrahim, M., D. A. Kulesh, S. S. Saleh, I. K. Damon, J. J. Esposito, A. L. 
Schmaljohn, and P. B. Jahrling. 2003. Real-time PCR assay to detect smallpox virus. J 
Clin Microbiol 41:3835-9. 
This paper describes the development of a real-time 5' nuclease PCR assay (also known as 
the TaqMan assay) for the rapid diagnosis of Variola virus. 48 different strains of Variola 
virus were used. Controls included Camelpox virus, and Monkeypox virus. 
8. Jahrling, P. B., L. E. Hensley, M. J. Martinez, J. W. Leduc, K. H. Rubins, D. A. 
Relman, and J. W. Huggins. 2004. Exploring the potential of variola virus infection of 





 This paper describes the development of a monkey model for smallpox. Cynomolgus 
macaques were exposed to several variola strains through aerosol and/or i.v. routes. Two 
strains, Harper and India 7124, produced uniform acute lethality when inoculated i.v. in 
high doses. Lower doses resulted in less fulminant, systemic disease and lower mortality. 
The pathology of the infected monkeys is described. 
9. Olson, V. A., T. Laue, M. T. Laker, I. V. Babkin, C. Drosten, S. N. Shchelkunov, M. 
Niedrig, I. K. Damon, and H. Meyer. 2004. Real-time PCR system for detection of 
orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol 
42:1940-6. 
This paper describes the development of a real-time PCR system for various 
orthopoxviruses including Variola virus, Monkeypox virus, Camelpox virus, and Cowpox 
virus. Several active compounds were isolated. 
10. Rubins, K. H., L. E. Hensley, P. B. Jahrling, A. R. Whitney, T. W. Geisbert, J. W. 
Huggins, A. Owen, J. W. Leduc, P. O. Brown, and D. A. Relman. 2004. The host 
response to smallpox: analysis of the gene expression program in peripheral blood cells in 
a nonhuman primate model. Proc Natl Acad Sci U S A 101:15190-5. 
 This paper describes the molecular and cellular features of hemorrhagic smallpox in 
cynomolgus macaques, using cDNA microarrays to analyze host gene expression patterns 
in sequential blood samples from infected animals.  
 





2 Work with agent requiring Biosafety Level-4 
Côte d’Ivoire ebolavirus  
Taxonomy: Order Mononegavirales, Family Filoviridae, Genus Ebolavirus, Species: Côte 
d’Ivoire ebolavirus, Virus: Côte d’Ivoire ebolavirus 
Publications: None identified. 
NIH Grants: None identified. 
 
Crimean-Congo hemorrhagic fever virus 
Taxonomy: Family Bunyaviridae, Genus Nairovirus, Species: Crimean-Congo hemorrhagic fever 
virus, Species Crimean-Congo hemorrhagic fever virus, Virus: Crimean-Congo hemorrhagic 
fever virus, Hazara virus, Kodzha virus, Khasan virus. 
Publications: 
1. Sanchez, A. J., M. J. Vincent, and S. T. Nichol. 2002. Characterization of the 
glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol 76:7263-75. 
This paper describes the cloning, sequencing, and characterization of the CCHFV M RNA 
segment, and the analysis of the derived proteins. 
2. Yashina, L., I. Petrova, S. Seregin, O. Vyshemirskii, D. Lvov, V. Aristova, J. Kuhn, 
S. Morzunov, V. Gutorov, I. Kuzina, G. Tyunnikov, S. Netesov, and V. Petrov. 2003. 
Genetic variability of Crimean-Congo haemorrhagic fever virus in Russia and Central 
Asia. J Gen Virol 84:1199-206. 
This paper describes the phylogenetic characterization of S RNA segment fragments of 
CCHFV isolates from Kazakhstan and Uzbekistan. 
3. Yashina, L., O. Vyshemirskii, S. Seregin, I. Petrova, E. Samokhvalov, D. Lvov, V. 
Gutorov, I. Kuzina, G. Tyunnikov, Y. W. Tang, S. Netesov, and V. Petrov. 2003. 
Genetic analysis of Crimean-Congo hemorrhagic fever virus in Russia. J Clin Microbiol 
41:860-2. 
This paper describes the phylogenetic characterization of M RNA segment fragments of 
CCHFV isolates from Russia. 
4. Honig, J. E., J. C. Osborne, and S. T. Nichol. 2004. Crimean-Congo hemorrhagic fever 




 This paper describes the CCHFV L gene and its expression product.  
5. Paragas, J., C. A. Whitehouse, T. P. Endy, and M. Bray. 2004. A simple assay for 
determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral 
Res 62:21-5. 
This paper describes a screening method for discovering new antiviral compounds 
directed against CCHFV using SW-13 cells and an in vitro neutral red uptake assay. 
6. Bertolotti-Ciarlet, A., J. Smith, K. Strecker, J. Paragas, L. A. Altamura, J. M. 
McFalls, N. Frias-Staheli, A. Garcia-Sastre, C. S. Schmaljohn, and R. W. Doms. 
2005. Cellular localization and antigenic characterization of crimean-congo hemorrhagic 
fever virus glycoproteins. J Virol 79:6152-61. 
This paper reports the processing and intracellular localization of the CCHFV 








Crimean congo hemorrhagic fever virus 
glycoproteins  
Total: $311,902  $311,902 | 2005 | Doms, Robert W | UNIVERSITY OF PENNSYLVANIA | PHILADELPHIA, PA  
 
Guanarito virus 
Taxonomy: Family Arenaviridae, Genus Arenavirus, Species Guanarito virus, Virus: Guanarito 
virus, INH-95551 virus. 
Publications: 
1. Weaver, S. C., R. A. Salas, N. de Manzione, C. F. Fulhorst, G. Duno, A. Utrera, J. N. 
Mills, T. G. Ksiazek, D. Tovar, and R. B. Tesh. 2000. Guanarito virus (Arenaviridae) 
isolates from endemic and outlying localities in Venezuela: sequence comparisons among 
and within strains isolated from Venezuelan hemorrhagic fever patients and rodents. 
Virology 266:189-95. 
This paper describes the isolation of GTOV from Venezuelan rodents and humans and 
their phylogenetic characterization. 
2. Archer, A. M., and R. Rico-Hesse. 2002. High genetic divergence and recombination in 
Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanarito, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 




3. Spiropoulou, C. F., S. Kunz, P. E. Rollin, K. P. Campbell, and M. B. Oldstone. 2002. 
New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan 
as its major receptor. J Virol 76:5140-6. 
This paper comes to the conclusion that Flexal, Guanarito, Machupo, and Sabiá viruses do 








Rapid, accurate diagnostics for 
arenaviral infections  
Total: $447,000  
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Hendra virus (animal experiments, “large” quantities).  
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily: Paramyxovirinae, 
Genus Henipavirus, Species Hendra virus, Virus: Hendra virus. 
Publications: None identified. 
NIH Grants: None identified. 
 
Junín virus 
Taxonomy: Family Arenaviridae, Genus Arenavirus, Species Junín virus, Virus: Junín virus, 





1. Garcia, J. B., S. P. Morzunov, S. Levis, J. Rowe, G. Calderon, D. Enria, M. Sabattini, 
M. J. Buchmeier, M. D. Bowen, and S. C. St Jeor. 2000. Genetic diversity of the Junin 
virus in Argentina: geographic and temporal patterns. Virology 272:127-36. 
This paper describes phylogenetic analysis of various Junín virus isolates. 
2. Archer, A. M., and R. Rico-Hesse. 2002. High genetic divergence and recombination in 
Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanarito, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 
and functional relationships. 
3. York, J., V. Romanowski, M. Lu, and J. H. Nunberg. 2004. The signal peptide of the 
Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of 
the mature G1-G2 complex. J Virol 78:10783-92. 
This paper reports the assembly and function of the Junín virus envelope glycoproteins 






01 NUNBERG, JACK 
Structure-function of Junin virus 
envelope glycoproteins  
Total: $491,313  
$246,313 | 2005 | Nunberg, Jack H | UNIVERSITY OF MONTANA | MISSOULA, MT  






Rapid, accurate diagnostics for 
arenaviral infections  
Total: $447,000  
$223,500 | 2003 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
$223,500 | 2002 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
3 18 
1R21AI055720-
01 CANNON, PAULA 
ENTRY PATHWAY OF NEW WORLD 
CLADE B ARENAVIRUSES  
Total: $446,400  
 $223,200 | 2004 | Cannon, Paula M | CHILDREN'S HOSPITAL LOS ANGELES | 
LOS ANGELES, CA  
 $223,200 | 2003 | Cannon, Paula M | CHILDREN'S HOSPITAL LOS ANGELES | 








Kyasanur Forest disease virus 
Taxonomy: Family Flaviviridae, Genus Flavivirus, Species: Kyasanur Forest disease virus, 
Virus: Kyasanur Forest disease virus, Alkhumra virus (formerly knowns as Alkhurma virus or 
Fakeeh virus). 
Publications: None identified. 
NIH Grants: None identified. 
 
Lake Victoria marburgvirus  
Taxonomy: Order Mononegavirales, Family Filoviridae, Genus Marburgvirus, Species Lake 
Victoria marburgvirus, Virus: Lake Victoria marburgvirus 
Publications: 
1. Geisbert, T. W., L. E. Hensley, T. R. Gibb, K. E. Steele, N. K. Jaax, and P. B. 
Jahrling. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and 
Marburg viruses. Lab Invest 80:171-86. 
 This paper reports the detection of apoptotic processes in tissues of nonhuman primates 
infected with Zaire ebolavirus and Lake Victoria marburgvirus 
2. Chan, S. Y., C. J. Empig, F. J. Welte, R. F. Speck, A. Schmaljohn, J. F. Kreisberg, 
and M. A. Goldsmith. 2001. Folate receptor-alpha is a cofactor for cellular entry by 
Marburg and Ebola viruses. Cell 106:117-26. 
 This paper describes the identification of a surface molecule as a potential receptor for 
both Zaire ebolavirus and Lake Victoria marburgvirus. 
3. Gibb, T. R., D. A. Norwood, Jr., N. Woollen, and E. A. Henchal. 2001. Development 
and evaluation of a fluorogenic 5'-nuclease assay to identify Marburg virus. Mol Cell 
Probes 15:259-66. 
 This paper describes the development of a diagnostic assay for the identification of Lake 
Victoria marburgvirus 
4. Hevey, M., D. Negley, L. VanderZanden, R. F. Tammariello, J. Geisbert, C. 
Schmaljohn, J. F. Smith, P. B. Jahrling, and A. L. Schmaljohn. 2001. Marburg virus 
vaccines: comparing classical and new approaches. Vaccine 20:586-93. 
 This paper describes the outcome of different vaccination strategies for the prevention of 
marburgvirus disease 
5. Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. 




microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg 
viruses. J Exp Med 195:593-602. 
 This paper reports that both Lake Victoria marburgvirus and Zaire ebolavirus exit cells via 
lipid rafts. 
6. Kachko, A. V., A. V. Sorokin, E. F. Belanov, A. V. Ivanova, A. A. Bukreyev, P. 
Collins, and S. V. Netesov. 2002. The study of transcription and replication of the 
Marburg virus using a minireplicon system constructed on the basis of viral genome. Dokl 
Biochem Biophys 383:108-12. 
 This paper reports the establishment of a minireplicon system for the study of replication 
and transcription of Lake Victoria marburgvirus 
7. Bosio, C. M., M. J. Aman, C. Grogan, R. Hogan, G. Ruthel, D. Negley, M. 
Mohamadzadeh, S. Bavari, and A. Schmaljohn. 2003. Ebola and Marburg viruses 
replicate in monocyte-derived dendritic cells without inducing the production of cytokines 
and full maturation. J Infect Dis 188:1630-8. 
 This paper describes the successful infection of dendritic cells with Lake Victoria 
marburgvirus and Zaire ebolavirus; and shows that infection of these cells leads to 
irregular maturation with defunct cytokine responses. 
8. Hevey, M., D. Negley, and A. Schmaljohn. 2003. Characterization of monoclonal 
antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two 
protective epitopes. Virology 314:350-7. 
 This paper characterizes two novel antibodies that react with the Lake Victoria 
marburgvirus glycoprotein. 
9. Warfield, K. L., D. L. Swenson, D. L. Negley, A. L. Schmaljohn, M. J. Aman, and S. 
Bavari. 2004. Marburg virus-like particles protect guinea pigs from lethal Marburg virus 
infection. Vaccine 22:3495-502. 
 This paper reports that Lake Victoria marburgvirus-like particles can protect against 
infection with virus. 
10. Swenson, D. L., K. L. Warfield, D. L. Negley, A. Schmaljohn, M. J. Aman, and S. 
Bavari. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both 
Ebola and Marburg viral infections. Vaccine 23:3033-42. 
 This paper reports that filovirus-like particles can protect against both Lake Victoria 
marburgvirus and Zaire ebolavirus. 
 
NIH Grants: 
1 80 1U01AI053876-01 SMITH, JONATHAN 
Alphavirus Replicon Vaccines 
against Marburg Virus  
Total: $5,882,478  
 $1,843,827 | 2004 | Smith, Jonathan | ICORIA, INC. | RESEARCH 
TRIANGLE PARK, NC  
 $2,906,025 | 2003 | Smith, Jonathan | ALPHAVAX HUMAN VACCINES, INC. 
| RESEARCH TRIANGLE PARK, NC  




INC. | RESEARCH TRIANGLE PARK, NC  
2 79 1Z01AI000834-06 GARBOCZI, DAVID 
Expression And Crystallization Of 






Hemorrhagic Fever  
Total: $22,072,698 *  
 $8,961,586 | 2005 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $9,124,674 | 2004 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
 $3,986,438 | 2003 | Levine, Myron Max | UNIVERSITY OF MARYLAND 
BALT PROF SCHOOL | BALTIMORE, MD  
4 47 1Z01AI000834-05 GARBOCZI, DAVID 
Expression And Crystallization Of 
Membrane Proteins  
5 47 1R21AI054495-01 HOPE, THOMAS Cell Biology of Filovirus Entry  
Total: $545,546  
 $272,773 | 2004 | Hope, Thomas J | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
 $272,773 | 2003 | Hope, Thomas J | UNIVERSITY OF ILLINOIS AT 
CHICAGO | CHICAGO, IL  
6 47 1R21AI053302-01 MORROW, CASEY 
Disruption of Conserved RNA Stem-
Loops in Filovirus RNA  
Total: $430,500  
 $215,250 | 2003 | Morrow, Casey D | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
 $215,250 | 2002 | Morrow, Casey D | UNIVERSITY OF ALABAMA AT 
BIRMINGHAM | BIRMINGHAM, AL  
7 40 1R43AI052917-01 OLIVO, PAUL 
Indicator cells for antiviral 
screening for filoviruses  
Total: $100,000  
 $100,000 | 2002 | Olivo, Paul D | VIRRX, INC. | ST. LOUIS, MO  
8 33 1Z01AI000834-04 GARBOCZI, DAVID 
Expression And Crystallization Of 
Membrane Proteins  
9 32 1R21AI056214-01 KATZE, MICHAEL 
Proteomic Analysis of the Innate 
Antiviral Response  
Total: $516,278  
$251,689 | 2004 | Katze, Michael G | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
$264,589 | 2003 | Katze, Michael G | UNIVERSITY OF WASHINGTON | 
SEATTLE, WA  
10 32 
1U19AI056540-
010002 NAIR, VASU 
Nucleoside Therapeutics Against 
Pox and Filo Viruses  
Total: $3,041,586 *   $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 




 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
11 32 2R44AI052917-02 OLIVO, PAUL 
Indicator cells for antiviral 
screening for filoviruses  
Total: $725,891  
$368,309 | 2005 | Olivo, Paul D | ORION GENOMICS, LLC | ST. LOUIS, MO  






Methyltransferase Inhibitors as Pox 
and Filo Antivirals  
Total: $3,041,586 *  
 $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
13 32 1Z01BM002007-01 
WILSON, 
CAROLYN 
Critical Amino Acid Residues on 
Filovirus Glycoproteins  
14 27 1R21AI059270-01 PATHAK, ASHISH 
New Adjuvant Technologies for a 
Marburg Virus Vaccine  
Total: $840,676  
 $419,310 | 2005 | Pathak, Ashish K | SOUTHERN RESEARCH INSTITUTE | 
BIRMINGHAM, AL  
 $421,366 | 2004 | Pathak, Ashish K | SOUTHERN RESEARCH INSTITUTE | 
BIRMINGHAM, AL  
15 16 1R01AI048053-01 BURTON, DENNIS 
THE ANTIVIRAL ACTIVITY OF 
ANTIBODIES TO A FILOVIRUS  
Total: $1,520,348  
 $310,275 | 2004 | Burton, Dennis R | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $310,275 | 2003 | Burton, Dennis R | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $279,248 | 2002 | Burton, Dennis R | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $310,275 | 2001 | Burton, Dennis R | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
 $310,275 | 2000 | BURTON, DENNIS R | SCRIPPS RESEARCH INSTITUTE | 
SAN DIEGO, CA  
16 16 
1U54AI057153-
010007 CHEN, LIAOHAI 
Early Detection of Hemorrhagic 
Fevers-Career Development  
Total: $20,734,800 *  
 $8,532,653 | 2005 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  
 $8,543,253 | 2004 | Schneewind, Olaf | UNIVERSITY OF CHICAGO | 
CHICAGO, IL  




CHICAGO, IL  
17 16 
1U19AI056540-
010003 CHU, DAVID 
Carbocyclic Nucleosides for 
Emerging Viral Diseases  
Total: $3,041,586 *  
$1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT AUBURN | 
AUBURN UNIVERSITY, AL  
$1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT AUBURN | 
AUBURN UNIVERSITY, AL  
$621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT AUBURN | 
AUBURN UNIVERSITY, AL  
18 16 1R43AI056525-01 COLLETT, MARC 
Antiviral Drugs Against Hemorrhagic 
Fever Viruses  
Total: $909,502  
 $909,502 | 2003 | Collett, Marc S | VIROPHARMA, INC. | EXTON, PA  
19 16 1Z01BP005021-01 DUNCAN, ROBERT 
Pathogen Chip for Detection of 
Bioterrorism Agents in Bl  
20 16 1U01AI054374-01 
HENRICKSON, 
KELLY 
Multiplex PCR Detection of CDC 'A' 
Bioterrorism Agents  
Total: $1,346,667  
 $496,873 | 2005 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
 $391,730 | 2004 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
 $458,064 | 2003 | Henrickson, Kelly J | MEDICAL COLLEGE OF 
WISCONSIN | MILWAUKEE, WI  
21 7 1U19AI056540-01 
SCHNELLER, 
STEWART 
Therapeutics for Pox, Filo and Other 
Viral Pathogens  
Total: $3,041,586 *  
 $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 
Lassa virus 
Taxonomy: Family Arenaviridae, Genus Arenavirus, Species: Lassa virus, Virus: Lassa virus, 





1. Bausch, D. G., P. E. Rollin, A. H. Demby, M. Coulibaly, J. Kanu, A. S. Conteh, K. D. 
Wagoner, L. K. McMullan, M. D. Bowen, C. J. Peters, and T. G. Ksiazek. 2000. 
Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked 
immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin 
Microbiol 38:2670-7. 
This paper describes the comparison of ELISA and IFA with virus isolation or reverse 
transcription-PCR (RT-PCR) to determine the best method for the diagnosis of Lassa 
virus infection. 
2. Bowen, M. D., P. E. Rollin, T. G. Ksiazek, H. L. Hustad, D. G. Bausch, A. H. Demby, 
M. D. Bajani, C. J. Peters, and S. T. Nichol. 2000. Genetic diversity among Lassa virus 
strains. J Virol 74:6992-7004. 
This paper describes the amplification and cloning of the Lassa S segment RNA and the 
elaboration of a lassa phylogenetic tree based on the sequences of the NP and glycoprotein 
genes. 
3. Fisher-Hoch, S. P., L. Hutwagner, B. Brown, and J. B. McCormick. 2000. Effective 
vaccine for lassa fever. J Virol 74:6777-83. 
This paper describes the more or less successful vaccination of macaques with vaccinia 
virus-expressed Lassa structural proteins. 
4. Pushko, P., J. Geisbert, M. Parker, P. Jahrling, and J. Smith. 2001. Individual and 
bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with 
Lassa and Ebola viruses. J Virol 75:11677-85. 
This paper describes the evaluation of individual vaccines for Lassa virus and bivalent 
vaccines for Lassa and Zaire ebolavirus that are based on an RNA replicon vector derived 
from an attenuated strain of Venezuelan equine encephalitis virus. 
5. Archer, A. M., and R. Rico-Hesse. 2002. High genetic divergence and recombination in 
Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanaríto, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 
and functional relationships. 
6. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P. E. Rollin, and B. Pulendran. 
2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and 
Lassa viruses. J Immunol 170:2797-801. 
This paper describes that Zaire ebolavirus and Lassa fever virus infect human monocyte-
derived dendritic cells and impair their function. 
7. Kunz, S., J. M. Rojek, M. Perez, C. F. Spiropoulou, and M. B. Oldstone. 2005. 
Characterization of the interaction of Lassa fever virus with its cellular receptor alpha-
dystroglycan. J Virol 79:5979-87. 











Rapid, accurate diagnostics for 
arenaviral infections  
Total: $447,000  
$223,500 | 2003 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
$223,500 | 2002 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 






Lassa and Nipah Virus Interferon-
Antagonists  
Total: $169,500  
$84,750 | 2003 | Basler, Christopher F | MOUNT SINAI SCHOOL OF MEDICINE OF 
NYU | NEW YORK, NY  
$84,750 | 2002 | Basler, Christopher F | MOUNT SINAI SCHOOL OF MEDICINE OF 






Vaccination for LASSA FEVER  
Total: $2,102,214  
 $594,797 | 2005 | Buchmeier, Michael J | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $579,359 | 2004 | Buchmeier, Michael J | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $586,673 | 2003 | Buchmeier, Michael J | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $341,385 | 2002 | Buchmeier, Michael J | SCRIPPS RESEARCH INSTITUTE | 






Molecular Pathogenesis of Lassa virus 
infection  
Total: $582,000  
$291,000 | 2004 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN MADISON | 
MADISON, WI  
$291,000 | 2003 | Kawaoka, Yoshihiro | UNIVERSITY OF WISCONSIN MADISON | 






MOP/LAS chimeric vaccine against 
Lassa fever  
Total: $812,907  
 $381,418 | 2005 | Lukashevich, Igor S | UNIVERSITY OF MD BIOTECHNOLOGY 
INSTITUTE | BALTIMORE, MD  
 $431,489 | 2004 | Lukashevich, Igor S | UNIVERSITY OF MD BIOTECHNOLOGY 






Mopeia/Lassa Virus Reassortants as 
Lassa Fever Vaccines  
Total: $399,055  
 $399,055 | 2002 | Lukashevich, Igor S | UNIVERSITY OF MD BIOTECHNOLOGY 
INSTITUTE | BALTIMORE, MD  
6 78 
1R21AI059247-
01 SALVATO, MARIA 
Dendritic Cell Targeting of Lassa Fever 
Vaccine  




INSTITUTE | BALTIMORE, MD  
7 78 
1U01AI056412-
01 THORPE, PHILIP 
Novel Anti-Viral Agents for Treating 
Lassa Fever  
Total: $933,954  
 $357,889 | 2005 | Thorpe, Philip E | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $379,657 | 2004 | Thorpe, Philip E | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
 $196,408 | 2003 | Thorpe, Philip E | UNIVERSITY OF TEXAS SW MED 
CTR/DALLAS | DALLAS, TX  
8 62 
1R21AI053619-
01 SALVATO, MARIA 
Early Response to Hemorrhagic Fever-
Causing Arenaviruses  
Total: $409,125  
 $198,500 | 2003 | Salvato, Maria S | UNIVERSITY OF MD BIOTECHNOLOGY 
INSTITUTE | BALTIMORE, MD  
 $210,625 | 2002 | Salvato, Maria S | UNIVERSITY OF MD BIOTECHNOLOGY 






Therapeutics to Prevent/Treat Lassa 
Fever Virus  
Total: $782,084  
 $469,250 | 2005 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $312,834 | 2004 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | LA 






Therapeutics to Prevent/Treat Lassa 
Fever Virus  
Total: $469,250  
 $469,250 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | LA 






Chimeric VLP Vaccines for Viral 
Hemorrhagic Fever  
Total: $456,000  
 $228,000 | 2003 | Compans, Richard W | EMORY UNIVERSITY | ATLANTA, GA  







STRUCTURE/FUNCTION STUDIES  
Total: $1,551,375  
 $310,275 | 2004 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $310,275 | 2003 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | LA 
JOLLA, CA  
 $310,275 | 2002 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | SAN 
DIEGO, CA  
 $310,275 | 2001 | Oldstone, Michael B | SCRIPPS RESEARCH INSTITUTE | SAN 
DIEGO, CA  




SAN DIEGO, CA  
 
Machupo virus 
Taxonomy: Family Arenaviridae, Genus Arenavirus, Species: Machupo virus, Virus:: Machupo 
virus, AA288-77 virus 
Publications: 
1. Archer, A. M., and R. Rico-Hesse. 2002. High genetic divergence and recombination in 
Arenaviruses from the Americas. Virology 304:274-81. 
This paper describes the sequencing and characterization of the S RNA segments of 
Flexal, Guanarito, Junín, Lassa fever, Machupo, and Sabiá viruses, and their eolutionary 
and functional relationships. 
2. Spiropoulou, C. F., S. Kunz, P. E. Rollin, K. P. Campbell, and M. B. Oldstone. 2002. 
New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan 
as its major receptor. J Virol 76:5140-6. 
This paper comes to the conclusion that Flexal, Guanarito, Machupo, and Sabiá viruses do 








Rapid, accurate diagnostics for 
arenaviral infections  
Total: $447,000  
$223,500 | 2003 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
$223,500 | 2002 | Fulhorst, Charles F | UNIVERSITY OF TEXAS MEDICAL BR 
GALVESTON | GALVESTON, TX  
 
Nipah virus (animal experiments, “large” quantities).  
Taxonomy: Order Mononegavirales, Family Paramyxoviridae, Subfamily Paramyxovirinae, 
Genus Henipavirus, Virus: Nipah virus 







01 LEE, BENHUR 
A reverse genetic system for the study 
of Nipah Virus  
Total: $609,028  
 $305,485 | 2005 | Lee, Benhur | UNIVERSITY OF CALIFORNIA LOS ANGELES | LOS 
ANGELES, CA  
 $303,543 | 2004 | Lee, Benhur | UNIVERSITY OF CALIFORNIA LOS ANGELES | LOS 






Pathogenesis of Nipah Virus Infection 
in Guinea Pigs  
Total: $187,345  
 $94,897 | 2005 | Torresvelez, Fernando J | UNIVERSITY OF GEORGIA | ATHENS, 
GA  
 $92,448 | 2004 | Torresvelez, Fernando J | UNIVERSITY OF GEORGIA | ATHENS, 
GA  
 
Omsk hemorrhagic fever virus 
Taxonomy: Family Flaviviridae, Genus Flavivirus, Species Omsk hemorrhagic fever virus, 
Virus: Omsk hemorrhagic fever virus 
Publications: 
1. Lin, D., L. Li, D. Dick, R. E. Shope, H. Feldmann, A. D. Barrett, and M. R. 
Holbrook. 2003. Analysis of the complete genome of the tick-borne flavivirus Omsk 
hemorrhagic fever virus. Virology 313:81-90. 
This paper reports the complete sequence of the OHFV genome. 
2. Li, L., P. E. Rollin, S. T. Nichol, R. E. Shope, A. D. Barrett, and M. R. Holbrook. 
2004. Molecular determinants of antigenicity of two subtypes of the tick-borne flavivirus 
Omsk haemorrhagic fever virus. J Gen Virol 85:1619-24. 
 This paper compares the amino acid sequences of the surface proteins of two strains of 
OHFV and determines their antigenic differences. 
3. Holbrook, M. R., J. F. Aronson, G. A. Campbell, S. Jones, H. Feldmann, and A. D. 
Barrett. 2005. An animal model for the tickborne flavivirus-Omsk hemorrhagic fever 
virus. J Infect Dis 191:100-8. 
 This paper reports the establishment of a mouse model of OFHV. 
 






Reston ebolavirus  
Taxonomy: Order Mononegavirales, Family Filoviridae, Genus Ebolavirus, Species Reston 
ebolavirus, Virus: Reston ebolavirus 
Publications: 
1. Hutchinson, K. L., F. Villinger, M. E. Miranda, T. G. Ksiazek, C. J. Peters, and P. E. 
Rollin. 2001. Multiplex analysis of cytokines in the blood of cynomolgus macaques 
naturally infected with Ebola virus (Reston serotype). J Med Virol 65:561-6. 
 This paper describes the cytokine response of monkeys infected with REBOV. 
 
NIH Grants: None identified. 
 
Sudan ebolavirus  
Taxonomy: Order Mononegavirales, Family Filoviridae, Genus Ebolavirus, Species Sudan 
ebolavirus, Virus: Sudan ebolavirus 
Publications: 
1. Gibb, T. R., D. A. Norwood, Jr., N. Woollen, and E. A. Henchal. 2001. Development 
and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola 
virus subtypes Zaire and Sudan. J Clin Microbiol 39:4125-30. 
This paper describes the development of a diagnostic assay for the identification of Sudan 
and Zaire ebolavirues 
2. Sanchez, A., M. Lukwiya, D. Bausch, S. Mahanty, A. J. Sanchez, K. D. Wagoner, 
and P. E. Rollin. 2004. Analysis of human peripheral blood samples from fatal and 
nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and 
nitric oxide levels. J Virol 78:10370-7. 
This paper reports on the patho-clinical changes in sera from naturally SEBOV-infected 
humans. 
3. Towner, J. S., P. E. Rollin, D. G. Bausch, A. Sanchez, S. M. Crary, M. Vincent, W. F. 
Lee, C. F. Spiropoulou, T. G. Ksiazek, M. Lukwiya, F. Kaducu, R. Downing, and S. 
T. Nichol. 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-
PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. 




 This paper reports the evaluation of a PCR-based diagnostic assay during a natural 
outbreak of Sudan ebolavirus. 
 
NIH Grants: None identified. 
 
Tick-borne encephalitis virus (Far Eastern subtype, formerly known as Russian spring-summer 
encephalitis virus; Western European subtype, formerly known as Central European encephalitis 
virus) 
Taxonomy: Family Flaviviridae, Genus Flavivirus, Species: Tick-borne encephalitis virus, Virus: 
Absettarov, Hanzalova, Hypr, Kumlinge, Neudoerfl virus, Sofjin virus. 
Publications: 
1. Pletnev, A. G., G. G. Karganova, T. I. Dzhivanyan, V. A. Lashkevich, and M. Bray. 
2000. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the 
highly virulent strains of tick-borne encephalitis virus. Virology 274:26-31. 
 This paper reports the creation of recombinant dengue viruses encoding Langat virus 
preM and E proteins. In mice, these chimeric viruses protected against challenge with 
tick-borne encephalitis virus. 
2. Pletnev, A. G., M. Bray, K. A. Hanley, J. Speicher, and R. Elkins. 2001. Tick-borne 
Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for 
protection against disease caused by members of the tick-borne encephalitis virus 
complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75:8259-67. 
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Zaire ebolavirus  
Taxonomy: Order Mononegavirales, Family Filoviridae, Genus Ebolavirus, Species Zaire 
ebolavirus, Virus: Zaire ebolavirus 
Publications: 
1. Bray, M., J. Driscoll, and J. W. Huggins. 2000. Treatment of lethal Ebola virus 
infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. 
Antiviral Res 45:135-47. 
 This paper reports the successful treatment of mice infected with mouse-adapted Zaire 
ebolavirus. 
2. Geisbert, T. W., L. E. Hensley, T. R. Gibb, K. E. Steele, N. K. Jaax, and P. B. 
Jahrling. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and 
Marburg viruses. Lab Invest 80:171-86. 
 This paper reports the detection of apoptotic processes in tissues of nonhuman primates 
infected with Zaire ebolavirus and Lake Victoria marburgvirus. 
3. Pushko, P., M. Bray, G. V. Ludwig, M. Parker, A. Schmaljohn, A. Sanchez, P. B. 
Jahrling, and J. F. Smith. 2000. Recombinant RNA replicons derived from attenuated 
Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola 
hemorrhagic fever virus. Vaccine 19:142-53. 
 This paper reports a successful vaccination of guinea pigs against Zaire ebolavirus 
4. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. 
Development of a preventive vaccine for Ebola virus infection in primates. Nature 
408:605-9. 
 This paper reports successful vaccination of nonhuman primates against Zaire ebolavirus. 
5. Wilson, J. A., M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. 
Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 
287:1664-6. 
 This paper reports the development of monoclonal antibodies to Zaire ebolavirus proteins, 
and their protective effects in animal models. 
6. Bray, M. 2001. The role of the Type I interferon response in the resistance of mice to 
filovirus infection. J Gen Virol 82:1365-73. 
 This paper describes the type I interferon response in mice infected with a Zaire 
ebolavirus. 
7. Bray, M., S. Hatfill, L. Hensley, and J. W. Huggins. 2001. Haematological,  
biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a 
mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 125:243-53. 
 This paper describes the pathology of different animals infected with a mouse-adapated 
Zaire ebolavirus. 
8. Chan, S. Y., C. J. Empig, F. J. Welte, R. F. Speck, A. Schmaljohn, J. F. Kreisberg, 
and M. A. Goldsmith. 2001. Folate receptor-alpha is a cofactor for cellular entry by 




 This paper describes the identification of a surface molecule as a potential receptor for 
both Zaire ebolavirus and Lake Victoria marburgvirus. 
9. Gibb, T. R., M. Bray, T. W. Geisbert, K. E. Steele, W. M. Kell, K. J. Davis, and N. K. 
Jaax. 2001. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J 
Comp Pathol 125:233-42. 
 This paper describes the pathology of Zaire ebolavirus in mice. 
10. Gibb, T. R., D. A. Norwood, Jr., N. Woollen, and E. A. Henchal. 2001. Development 
and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola 
virus subtypes Zaire and Sudan. J Clin Microbiol 39:4125-30. 
This paper describes the development of a diagnostic assay for the identification of Sudan 
and Zaire ebolavirues 
11. Gupta, M., S. Mahanty, R. Ahmed, and P. E. Rollin. 2001. Monocyte-derived human 
macrophages and peripheral blood mononuclear cells infected with ebola virus secrete 
MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 
284:20-5. 
 This paper describes the cytokine responses of mononuclear cells after exposure to Zaire 
ebolavirus.  
12. Gupta, M., S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin. 2001. Passive transfer 
of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola 
virus infection without complete inhibition of viral replication. J Virol 75:4649-54. 
 This paper reports that the immunization of mice with antibodies against Zaire ebolavirus 
can protect these animals from infection with this virus. 
13. Pushko, P., J. Geisbert, M. Parker, P. Jahrling, and J. Smith. 2001. Individual and 
bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with 
Lassa and Ebola viruses. J Virol 75:11677-85. 
This paper describes the evaluation of individual vaccines for Lassa virus and bivalent 
vaccines for Lassa and Zaire ebolavirus that are based on an RNA replicon vector derived 
from an attenuated strain of Venezuelan equine encephalitis virus. 
14. Steele, K., B. Crise, A. Kuehne, and W. Kell. 2001. Ebola virus glycoprotein 
demonstrates differential cellular localization in infected cell types of nonhuman primates 
and guinea pigs. Arch Pathol Lab Med 125:625-30. 
 This paper describes the localization of GP and VP40 antigen in ZEBOV-infected guinea 
pigs and nonhuman primates using immunohistochemistry. 
15. Steele, K. E., K. Stabler, and L. VanderZanden. 2001. Cutaneous DNA vaccination 
against Ebola virus by particle bombardment: histopathology and alteration of CD3-
positive dendritic epidermal cells. Vet Pathol 38:203-15. 
 This paper describes the histological changes of guinea pigs and mice after DNA 
vaccination against ZEBOV.  
16. Wilson, J. A., M. Bray, R. Bakken, and M. K. Hart. 2001. Vaccine potential of Ebola 
virus VP24, VP30, VP35, and VP40 proteins. Virology 286:384-90. 
 This paper evaluates the use of different ZEBOV proteins for vaccine development. 
17. Wilson, J. A., and M. K. Hart. 2001. Protection from Ebola virus mediated by cytotoxic 




 This paper reports that C57BL/6 mice vaccinated with Venezuelan equine encephalitis 
virus replicons encoding the ZEBOV nucleoprotein survived lethal challenge with 
ZEBOV. 
18. Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. 
Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman. 2002. Lipid raft 
microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg 
viruses. J Exp Med 195:593-602. 
 This paper reports that both Lake Victoria marburgvirus and Zaire ebolavirus exit cells via 
lipid rafts. 
19. Bray, M., J. L. Raymond, T. Geisbert, and R. O. Baker. 2002. 3-deazaneplanocin A 
induces massively increased interferon-alpha production in Ebola virus-infected mice. 
Antiviral Res 55:151-9. 
 This paper reports the detection of interferon in ZEBOV-infected mice treated with an 
antiviral. 
20. Geisbert, T. W., L. E. Hensley, J. B. Geisbert, and P. B. Jahrling. 2002. Evidence 
against an important role for infectivity-enhancing antibodies in Ebola virus infections. 
Virology 293:15-9. 
 This paper reports that another publisher experiment could not be repeated. 
21. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling. 
2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 
8:503-7. 
 This paper compares different vaccination approaches for the prevention of ZEBOV 
infection. 
22. Gibb, T. R., D. A. Norwood, Jr., N. Woollen, and E. A. Henchal. 2002. Viral 
replication and host gene expression in alveolar macrophages infected with Ebola virus 
(Zaire strain). Clin Diagn Lab Immunol 9:19-27. 
 This paper reports the successful infection of macrophages with ZEBOV and the induced 
gene expression 
23. Hensley, L. E., H. A. Young, P. B. Jahrling, and T. W. Geisbert. 2002. 
Proinflammatory response during Ebola virus infection of primate models: possible 
involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169-79. 
 This paper reports the cytokine responses of primates infected with ZEBOV. 
24. Neumann, G., H. Feldmann, S. Watanabe, I. Lukashevich, and Y. Kawaoka. 2002. 
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein 
is not essential for replication in cell culture. J Virol 76:406-10. 
 This paper describes the establishment of a recombinant ZEBOV based on cDNA. 
25. Parren, P. W., T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton. 2002. 
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive 
transfer of a neutralizing human antibody. J Virol 76:6408-12. 
 This paper describes an approach to prevent Zaire ebolavirus disease using neutralizing 
antibodies. 
26. Rao, M., M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas. 2002. Induction of 




encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 
76:9176-85. 
 This paper describes the immune response of mice to a novel vaccine candidate. 
27. Barrientos, L. G., B. R. O'Keefe, M. Bray, A. Sanchez, A. M. Gronenborn, and M. R. 
Boyd. 2003. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits 
infectivity of Ebola virus. Antiviral Res 58:47-56. 
 This paper reports the discovery of a new-ZEBOV substance. 
28. Basler, C. F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger, M. 
Bray, H. D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus VP35 
protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945-56. 
 This paper reports that the ZEBOV protein VP35 has anti-interferon properties. 
29. Bosio, C. M., M. J. Aman, C. Grogan, R. Hogan, G. Ruthel, D. Negley, M. 
Mohamadzadeh, S. Bavari, and A. Schmaljohn. 2003. Ebola and Marburg viruses 
replicate in monocyte-derived dendritic cells without inducing the production of cytokines 
and full maturation. J Infect Dis 188:1630-8. 
 This paper describes the successful infection of dendritic cells with Lake Victoria 
marburgvirus and Zaire ebolavirus; and shows that infection of these cells leads to 
irregular maturation with defunct cytokine responses. 
30. Chepurnov, A. A., L. F. Bakulina, A. A. Dadaeva, E. N. Ustinova, T. S. Chepurnova, 
and J. R. Baker, Jr. 2003. Inactivation of Ebola virus with a surfactant nanoemulsion. 
Acta Trop 87:315-20. 
 This paper describes the anti-ZEBOV activity of a chemical. 
31. Crary, S. M., J. S. Towner, J. E. Honig, T. R. Shoemaker, and S. T. Nichol. 2003. 
Analysis of the role of predicted RNA secondary structures in Ebola virus replication. 
Virology 306:210-8. 
 This paper describes the effects of mutations in the untranslated regions of ZEBOV on 
replications and transcription. 
32. Geisbert, T. W., L. E. Hensley, P. B. Jahrling, T. Larsen, J. B. Geisbert, J. Paragas, 
H. A. Young, T. M. Fredeking, W. E. Rote, and G. P. Vlasuk. 2003. Treatment of 
Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in 
rhesus monkeys. Lancet 362:1953-8. 
 This paper reports the successful treatment of ZEBOV-infected rhesus monkeys with an 
inhibitor of tissue factor. 
33. Geisbert, T. W., L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed, J. B. Geisbert, D. 
P. Scott, E. Kagan, P. B. Jahrling, and K. J. Davis. 2003. Pathogenesis of Ebola 
hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and 
sustained targets of infection. Am J Pathol 163:2347-70. 
 This paper describes the pathology of ZEBOV-infected macaques; and demonstrates that 
dendritic cells are among the earliest cellular targets of the virus. 
34. Geisbert, T. W., H. A. Young, P. B. Jahrling, K. J. Davis, E. Kagan, and L. E. 
Hensley. 2003. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic 
fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J 




This paper describes the pathology of ZEBOV-infected macaques; and demonstrates that 
macrophages are among the earliest cellular targets of the virus. 
35. Geisbert, T. W., H. A. Young, P. B. Jahrling, K. J. Davis, T. Larsen, E. Kagan, and 
L. E. Hensley. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: 
evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial 
cells. Am J Pathol 163:2371-82. 
This paper describes the pathology of ZEBOV-infected macaques; and demonstrates that 
hemorraghagic manifestations of the disease occur before the vascular endothelium is 
destroyed by the virus. 
36. Han, Z., H. Boshra, J. O. Sunyer, S. H. Zwiers, J. Paragas, and R. N. Harty. 2003. 
Biochemical and functional characterization of the Ebola virus VP24 protein: implications 
for a role in virus assembly and budding. J Virol 77:1793-800. 
 This paper reports that ZEBOV VP24 is a matrix protein and plays important roles in 
virus budding and assembly. 
37. Licata, J. M., M. Simpson-Holley, N. T. Wright, Z. Han, J. Paragas, and R. N. Harty. 
2003. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein 
function independently as late budding domains: involvement of host proteins TSG101 
and VPS-4. J Virol 77:1812-9. 
 This paper demonstrated that two overlapping sequences of the ZEBOV VP40 protein can 
function independently while having the same overall function in virus budding. 
38. Mahanty, S., M. Gupta, J. Paragas, M. Bray, R. Ahmed, and P. E. Rollin. 2003. 
Protection from lethal infection is determined by innate immune responses in a mouse 
model of Ebola virus infection. Virology 312:415-24. 
 This paper demonstrates that mice survival in ZEBOV infection is dependent on the 
innate immune system. 
39. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P. E. Rollin, and B. Pulendran. 
2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and 
Lassa viruses. J Immunol 170:2797-801. 
This paper describes that Zaire ebolavirus and Lassa fever virus infect human monocyte-
derived dendritic cells and impair their function. 
40. Mellquist-Riemenschneider, J. L., A. R. Garrison, J. B. Geisbert, K. U. Saikh, K. D. 
Heidebrink, P. B. Jahrling, R. G. Ulrich, and C. S. Schmaljohn. 2003. Comparison of 
the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA 
virus in guinea pigs. Virus Res 92:187-93. 
 This paper reports the comparison of different vaccine approaches for the prevention of 
Zaire ebolavirus. 
41. Panchal, R. G., G. Ruthel, T. A. Kenny, G. H. Kallstrom, D. Lane, S. S. Badie, L. Li, 
S. Bavari, and M. J. Aman. 2003. In vivo oligomerization and raft localization of Ebola 
virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A 100:15936-41. 
 This paper further describes the interaction of ZEBOV VP40 with lipid rafts and its role in 
virus budding. 
42. Riemenschneider, J., A. Garrison, J. Geisbert, P. Jahrling, M. Hevey, D. Negley, A. 
Schmaljohn, J. Lee, M. K. Hart, L. Vanderzanden, D. Custer, M. Bray, A. Ruff, B. 




combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan 
equine encephalitis virus. Vaccine 21:4071-80. 
 This paper reports the comparison of different vaccine approaches for the prevention of 
Zaire ebolavirus. 
43. Simmons, G., J. D. Reeves, C. C. Grogan, L. H. Vandenberghe, F. Baribaud, J. C. 
Whitbeck, E. Burke, M. J. Buchmeier, E. J. Soilleux, J. L. Riley, R. W. Doms, P. 
Bates, and S. Pohlmann. 2003. DC-SIGN and DC-SIGNR bind ebola glycoproteins and 
enhance infection of macrophages and endothelial cells. Virology 305:115-23. 
 This paper reports that certain surface lectins are ZEBOV attachment factors. 
44. Takada, A., H. Feldmann, T. G. Ksiazek, and Y. Kawaoka. 2003. Antibody-dependent 
enhancement of Ebola virus infection. J Virol 77:7539-44. 
 This paper reports that certain natural antibodies to ZEBOV can enhance, rather than 
abolish infection. 
45. Takada, A., H. Feldmann, U. Stroeher, M. Bray, S. Watanabe, H. Ito, M. McGregor, 
and Y. Kawaoka. 2003. Identification of protective epitopes on ebola virus glycoprotein 
at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 
77:1069-74. 
 This paper reports protective epitopes of ZEBOV GP. 
46. Warfield, K. L., C. M. Bosio, B. C. Welcher, E. M. Deal, M. Mohamadzadeh, A. 
Schmaljohn, M. J. Aman, and S. Bavari. 2003. Ebola virus-like particles protect from 
lethal Ebola virus infection. Proc Natl Acad Sci U S A 100:15889-94. 
 This paper reports that ZEBOV-like particles can be used as a vaccine. 
47. Bosio, C. M., B. D. Moore, K. L. Warfield, G. Ruthel, M. Mohamadzadeh, M. J. 
Aman, and S. Bavari. 2004. Ebola and Marburg virus-like particles activate human 
myeloid dendritic cells. Virology 326:280-7. 
 This paper reports that both Lake Victoria marburgvirus and Zaire ebolavirus can activate 
dendritic cells. 
48. Gupta, M., S. Mahanty, P. Greer, J. S. Towner, W. J. Shieh, S. R. Zaki, R. Ahmed, 
and P. E. Rollin. 2004. Persistent infection with ebola virus under conditions of partial 
immunity. J Virol 78:958-67. 
 This paper reports the peristent infection with ZEBOV of immunocompromised mice. 
49. Reed, D. S., L. E. Hensley, J. B. Geisbert, P. B. Jahrling, and T. W. Geisbert. 2004. 
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola 
hemorrhagic Fever in cynomolgus macaques. Viral Immunol 17:390-400. 
 This paper reports that subfraction of T lymphocytes that gets depleted in the course of 
ZEBOV infection in macaques. 
50. Theriault, S., A. Groseth, G. Neumann, Y. Kawaoka, and H. Feldmann. 2004. Rescue 
of Ebola virus from cDNA using heterologous support proteins. Virus Res 106:43-50. 
 This paper demonstrates that transcription/replication of ZEBOV are neither strictly 
species-specific nor genus-specific. 
51. Warfield, K. L., J. G. Perkins, D. L. Swenson, E. M. Deal, C. M. Bosio, M. J. Aman, 
W. M. Yokoyama, H. A. Young, and S. Bavari. 2004. Role of natural killer cells in 
innate protection against lethal ebola virus infection. J Exp Med 200:169-79. 




52. Chandran, K., N. J. Sullivan, U. Felbor, S. P. Whelan, and J. M. Cunningham. 2005. 
Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection. Science 
308:1643-5. 
 This paper identifies intracellular proteases that are necessary for successful ZEBOV cell-
entry. 
53. Gupta, M., P. Greer, S. Mahanty, W. J. Shieh, S. R. Zaki, R. Ahmed, and P. E. 
Rollin. 2005. CD8-mediated protection against Ebola virus infection is perforin 
dependent. J Immunol 174:4198-202. 
 This paper identified perforin as an important factor in the immune response during 
ZEBOV infection. 
54. Kallstrom, G., K. L. Warfield, D. L. Swenson, S. Mort, R. G. Panchal, G. Ruthel, S. 
Bavari, and M. J. Aman. 2005. Analysis of Ebola virus and VLP release using an 
immunocapture assay. J Virol Methods 127:1-9. 
 This paper reports the use of an analysis system for ZEBOV budding. 
55. Ruthel, G., G. L. Demmin, G. Kallstrom, M. P. Javid, S. S. Badie, A. B. Will, T. 
Nelle, R. Schokman, T. L. Nguyen, J. H. Carra, S. Bavari, and M. J. Aman. 2005. 
Association of ebola virus matrix protein VP40 with microtubules. J Virol 79:4709-19. 
 This paper reports on the interaction of ZEBOV VP40 protein with cellular microtubules. 
56. Swenson, D. L., K. L. Warfield, D. L. Negley, A. Schmaljohn, M. J. Aman, and S. 
Bavari. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both 
Ebola and Marburg viral infections. Vaccine 23:3033-42. 
 This paper reports that filovirus-like particles can protect against both Lake Victoria 
marburgvirus and Zaire ebolavirus. 
57. Towner, J. S., J. Paragas, J. E. Dover, M. Gupta, C. S. Goldsmith, J. W. Huggins, 
and S. T. Nichol. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for 
analysis of early pathogenesis events and high-throughput antiviral drug screening. 
Virology 332:20-7. 
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 $259,875 | 2003 | Garry, Robert F | TULANE 
UNIVERSITY OF LOUISIANA | NEW ORLEANS, LA  




Production Of A 
Multicomponent Ebola 
rAd  











Production Of An Ebola 
DNA Plasmid Vacci  




Production Of An Ebola 
DNA Vaccine  





Vaccine In Adult Volun  
20 71 1Z01AI005049-01 
GRAHAM, 
BARNEY 
A Phase I Clinical Trial to 
Evaluate a Multiple 
Strain E  
21 57 1U01AI061253-01 
ARNTZEN, 
CHARLES 
Development of a 
vaccine for Ebola virus in 
plant system  
Total: $576,398  
 $576,398 | 2005 | Arntzen, Charles J | ARIZONA STATE 
UNIVERSITY | TEMPE, AZ  
22 57 1Z01AI005049-02 GRAHAM, BARNEY 
Evaluation Of A 
Multicomponent Ebola 
Vaccine In Adults  
23 57 1Z01AI005004-01 NABEL, GARY Ebola Vaccine Development  




25 57 1Z01AI005004-03 NABEL, GARY Ebola Vaccine Development  
26 57 1Z01AI005007-01 NABEL, GARY Ebola Virology  
27 57 1Z01AI005007-02 NABEL, GARY Ebola Virology  
28 57 1R01AI066502-01 OLIVO, PAUL Therapeutics for Ebola virus 
Total: $1,350,000  
 $1,350,000 | 2005 | Olivo, Paul D | ORION GENOMICS, LLC | 
ST. LOUIS, MO  
29 42 1R01AI048053-01 
BURTON, 
DENNIS 
THE ANTIVIRAL ACTIVITY OF 
ANTIBODIES TO A FILOVIRUS  
Total: $1,520,348  
 $310,275 | 2004 | Burton, Dennis R | SCRIPPS RESEARCH 
INSTITUTE | LA JOLLA, CA  
 $310,275 | 2003 | Burton, Dennis R | SCRIPPS RESEARCH 
INSTITUTE | LA JOLLA, CA  
 $279,248 | 2002 | Burton, Dennis R | SCRIPPS RESEARCH 
INSTITUTE | SAN DIEGO, CA  
 $310,275 | 2001 | Burton, Dennis R | SCRIPPS RESEARCH 
INSTITUTE | SAN DIEGO, CA  
 $310,275 | 2000 | BURTON, DENNIS R | SCRIPPS RESEARCH 
INSTITUTE | SAN DIEGO, CA  
30 42 
1R21AI054495-
01 HOPE, THOMAS Cell Biology of Filovirus Entry  
Total: $545,546  
 $272,773 | 2004 | Hope, Thomas J | UNIVERSITY OF ILLINOIS AT CHICAGO | 
CHICAGO, IL  
 $272,773 | 2003 | Hope, Thomas J | UNIVERSITY OF ILLINOIS AT CHICAGO | 
CHICAGO, IL  
31 42 
1R21AI055592-
01 KAGAN, ELLIOTT 
Biodefense Against an 
Aerosolized Ebola Threat  
Total: $598,800  
 $299,400 | 2004 | Kagan, Elliott | HENRY M. JACKSON FDN FOR THE ADV 
MIL/MED | ROCKVILLE, MD  
 $299,400 | 2003 | Kagan, Elliott | HENRY M. JACKSON FDN FOR THE ADV 
MIL/MED | ROCKVILLE, MD  
32 42 
1Z01BP004021-
01 KAPLAN, GERARDO 
Development of Biologics 
against Ebola virus  
33 42 
1R21AI053539-




Total: $444,000  
 $222,000 | 2003 | Karp, Christopher L | CHILDREN'S HOSPITAL MED CTR 
(CINCINNATI) | CINCINNATI, OH  
 $222,000 | 2002 | Karp, Christopher L | CHILDREN'S HOSPITAL MED CTR 
(CINCINNATI) | CINCINNATI, OH  
34 42 1Z01AI005007-03 
NABEL, 
GARY 




35 42 1Z01AI005070-01 
NABEL, 
GARY 
Mechanisms in Ebola Glycoprotein Induced 
Cytotoxicity  
36 42 1R43AI052917-01 
OLIVO, 
PAUL 
Indicator cells for antiviral screening for 
filoviruses  
Total: $100,000  
 $100,000 | 2002 | Olivo, Paul D | VIRRX, INC. | ST. LOUIS, MO  
37 28 
1U19AI056540-
010002 NAIR, VASU 
Nucleoside Therapeutics Against Pox and 
Filo Viruses  
Total: $3,041,586 *  
 $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT AUBURN 
| AUBURN UNIVERSITY, AL  
38 28 2R44AI052917-02 OLIVO, PAUL 
Indicator cells for antiviral screening for 
filoviruses  
Total: $725,891  
 $368,309 | 2005 | Olivo, Paul D | ORION GENOMICS, LLC | ST. LOUIS, MO  
 $357,582 | 2004 | Olivo, Paul D | JACOBS FACILITIES, INC. | ST LOUIS, MO  
39 28 1U19AI056540-01 
SCHNELLER, 
STEWART 
Therapeutics for Pox, Filo and Other 
Viral Pathogens  
Total: $3,041,586 *  
 $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
40 28 1U19AI056540-010001 
SCHNELLER, 
STEWART 
Methyltransferase Inhibitors as Pox 
and Filo Antivirals  
Total: $3,041,586 *  
 $1,226,999 | 2005 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $1,192,986 | 2004 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
 $621,601 | 2003 | Schneller, Stewart W | AUBURN UNIVERSITY AT 
AUBURN | AUBURN UNIVERSITY, AL  
41 28 1Z01BM002007-01 
WILSON, 
CAROLYN 
Critical Amino Acid Residues on 
Filovirus Glycoproteins  
42 14 
2P41RR004050-
160052 AMAN, M 
TRACKING OF E BOLA VIRUS 
ASSEMBLY IN LIVE CELLS  
Total: $12,853,059  
 $2,160,714 | 2005 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
 $2,726,690 | 2004 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 




 $2,083,473 | 2003 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | LA JOLLA, CA  
 $2,145,033 | 2002 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | SAN DIEGO, CA  
 $64,643 | 2001 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | SAN DIEGO, CA  
 $383,218 | 2001 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | SAN DIEGO, CA  
 $1,546,132 | 2001 | Ellisman, Mark H | UNIVERSITY OF CALIFORNIA SAN 
DIEGO | SAN DIEGO, CA  
 $1,743,156 | 2000 | ELLISMAN, MARK H. | UNIVERSITY OF CALIFORNIA 
SAN DIEGO | SAN DIEGO, CA  
43 14 
1R01HL075363-
01 MCCRAY, PAUL 
Filovirus enveloped FIV:virus-epithelia 
interactions-CF  
Total: $737,500  
 $368,750 | 2005 | Mccray, Paul B | UNIVERSITY OF IOWA | IOWA CITY, IA  





3 De novo synthesis of eradicated agent/agent requiring Biosafety Level-4 




4 Expanding host range of disease agent to new host (in humans, other animals 
and plants) or changing the tissue range of listed agent 
Plum pox virus 
Publications: 
1. Pilar, S., B. Salvador, C. Simón-Mateo, K. D. Kasschau, J. C. Carrington, and J. A. 
García. 2002. Host-Specific Involvement of the HC Protein in the Long-Distance 
Movement of Potyviruses. J Virol 76:1922-31. 
This paper reports the manipulation of PPV by complementing it with movement proteins 
from a tobacco virus. This complementation resulted in a systemic PPV infection of a 




5 Construction of antibiotic- or vaccine-resistant listed agent 
Bacillus anthracis 
1. Price, L. B., A. Vogler, T. Pearson, J. D. Busch, J. M. Schupp, and P. Keim. 2003. In 
vitro selection and characterization of Bacillus anthracis mutants with high-level 
resistance to ciprofloxacin. Antimicrob Agents Chemother 47:2362-5. 





1. Abuodeh, R. O., M. J. Orbach, M. A. Mandel, A. Das, and J. N. Galgiani. 2000. 
Genetic transformation of Coccidioides immitis facilitated by Agrobacterium tumefaciens. 
J Infect Dis 181:2106-10. 
This paper describes the genetic transformation of the fungus with the help of the 
bacterium Agrobacterium tumefaciens, which was used to transfer a gene cassette 
encoding hygromycin phosphotransferase (hph). The transformed fungus turned out to be 




1. Suhan, M. L., and H. A. Thompson. 2000. Expression of beta-lactamase in Coxiella 
burnetii transformants. FEMS Microbiol Lett 184:303-6. 
 This paper describes the creation of ampicillin-resistant Coxiella burnetii. 
 
Camelpoxvirus 
Taxonomy: Family Poxviridae, Subfamily: Chordopoxvirinae, Genus Orthopoxvirus, Species 





1. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. 
Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, Cowpox, 
Monkeypox, and Vaccinia Viruses. Antimicrob Agents Chemother 46:1329-35. 
This paper describes the creation of Cidofovir-resistant Camelpox and Monkeypox virus 




1. Lauriano, C. M., J. R. Barker, F. E. Nano, B. P. Arulanandam, and K. E. Klose. 
2003. Allelic exchange in Francisella tularensis using PCR products. FEMS Microbiol 
Lett 229:195-202. 
This paper describes a technique for allelic exchange in the bacterium utilizing PCR 
products. Linear PCR fragments containing gene deletions with an erythromycin 
resistance cassette insertion were transformed into the bacterium, resulting in 
erythrombycin-resistant progeny. This technique was used to insert mutations into the 
genome of the bacterium 
2. Kawula, T. H., J. D. Hall, J. R. Fuller, and R. R. Craven. 2004. Use of transposon-
transposase complexes to create stable insertion mutant strains of Francisella tularensis 
LVS. Appl Environ Microbiol 70:6901-4. 
 This paper describes the use of transposome complexes to create insertion mutations in the 





1. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. 
Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, Cowpox, 
Monkeypox, and Vaccinia Viruses. Antimicrob Agents Chemother 46:1329-35. 
This paper describes the creation of Cidofovir-resistant Camelpox and Monkeypox virus 











1. Rachek, L. I., A. Hines, A. M. Tucker, H. H. Winkler, and D. O. Wood. 2000. 
Transformation of Rickettsia prowazekii to erythromycin resistance encoded by the 
Escherichia coli ereB gene. J Bacteriol 182:3289-91. 
 This paper reports the introduction of an erythromycin-resistance gene into the bacterium. 
2. Qin, A., A. M. Tucker, A. Hines, and D. O. Wood. 2004. Transposon mutagenesis of 
the obligate intracellular pathogen Rickettsia prowazekii. Appl Environ Microbiol 
70:2816-22. 





I. US research institutes that would have been affected by the proposed 
oversight system had it existed between the years of 2000 and 2005: 
1. Abbott Laboratories, Abbott Park, Illinois 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Rickettsia prowazekii 2000 
- PDA/1 Rickettsia rickettsii 2000 
- PDA/1 Yersinia pestis 2003 
2. Acambis Inc., Cambridge, Massachusetts 
- PDA/1 Japanese encephalitis virus 2002, 2004 
3. Advanced Biosystems, Inc., Manassas, Virginia 
- PDA/1 Bacillus anthracis 2002, 2003, 2004, 2005 
4. Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 
- PDA/1 Bacillus anthracis 2002 
5. Albany Medical College, Albany, New York 
- PDA/1 Francisella tularensis 2005 
6. Allergan Inc., Irvine, California 
- PDA/1 Clostridium botulinum 2003 
7. AlphaVax, Inc., Research Triangle Park, North Carolina 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2005 
- PDA/1 Venezuelan equine encephalitis virus 2001, 2003 
8. Antibody Systems, Hurst, Texas 
- EDA/2 Zaire ebolavirus 2003 
9. Argonne National Laboratory, Argonne, Illinois 
- PDA/1 Bacillus anthracis 2001, 2004 
10. Armed Forces Institute of Pathology, Washington, D.C. 
- EDA/1 “1918 Influenza virus” 2001, 2002, 2004 
- PDA/1 Bacillus anthracis 2002 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2003 
- PDA/1 Francisella tularensis 2002, 2003 
- PDA/1 Monkeypox virus 2002 
- PDA/1 Yersinia pestis 2001 
11. Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
- PDA/1 Bacillus anthracis 2001, 2002 
- MDA/4/5 Venezuelan equine encephalitis virus 2001 
12. Auburn University, Auburn, Alabama 
- PDA/1 Bacillus anthracis 2004 




- MDA/4/5 Bacillus anthracis 2003, 2005 
- PDA/1 Bacillus anthracis 2003, 2004 
- PDA/1 Francisella tularensis 2000 
14. Bayer Corporation, Clayton, North Carolina 
- PDA/1 Venezuelan equine encephalitis virus 2001 
15. Bayer Corporation, Emeryville, California 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
16. Baylor College of Medicine, Houston, Texas 
- PDA/1 Bacillus anthracis 2003, 2004 
- PDA/1 Venezuelan equine encephalitis virus 2001 
17. BD Technologies, Research Triangle Park, North Carolina 
- PDA/1 Bacillus anthracis 2005 
18. Beam Tech, Inc., San Antonio, Texas 
- PDA/1 Bacillus anthracis 2002 
19. BioSense Consulting, Columbus, Ohio 
- PDA/1 Francisella tularensis 2000 
20. BCR Diagnostics, Inc., Jamestown, Rhode Island 
- PDA/1 Bacillus anthracis 2004 
21. Brigham Young University, Provo, Utah 
- PDA/1 Bacillus anthracis 2002, 2003 
22. Brookhaven National Laboratory, Upton, New York 
- PDA/1 Yersinia pestis 2005 
23. Brooks Air Force Base, San Antonio, Texas 
- PDA/1 Bacillus anthracis 2000, 2002 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Influenza A virus 2002, 2003 
- PDA/1 Yersinia pestis 2003 
24. Brown University, Providence, Rhode Island 
- PDA/1 Bacillus anthracis 2004 
25. California Animal Health and Food Safety Laboratory, Davis, California 
- PDA/1 Newcastle disease virus 2005 
26. California Department of Health Services, Berkeley, California 
- PDA/1 Francisella tularensis 2001 
- PDA/1 Yersinia pestis 2000, 2001 
27. California Department of Health Services, Richmond, California 
- PDA/1 Brucella melitensis 2004 
- PDA/1 Clostridium botulinum 2004 
28. California Institute for Medical Research, San Jose, California 
- PDA/1 Coccidioides immitis 2000, 2002 
- PDA/1 Coccidioides posadasii 2000 
29. California Institute of Technology, Pasadena, California 
- PDA/1 Venezuelan equine encephalitis virus 2001 




- PDA/1 Newcastle disease virus 2002 
31. Center for Biologics Evaluation and Research, Food and Drug Administration, 
Bethesda, Maryland 
- PDA/1 Bacillus anthracis 2004, 2005 
- PDA/1 Brucella melitensis 2001 
- PDA/1 Influenza A virus 2004 
32. Center for Biologics Evaluation and Research, Food and Drug Administration, 
Kensington, Maryland 
- PDA/1 Bacillus anthracis 2004 
33. Center for Biologics Evaluation and Research, Food and Drug Administration, 
Rockville, Maryland 
- EDA/1 Variola virus 2003 
- PDA/1 Francisella tularensis 2000, 2001, 2002, 2003, 2004 
- PDA/1 Monkeypox virus 2003 
34. Centers for Disease Control and Prevention, Atlanta, Georgia 
- EDA/1 Variola virus 2000, 2001, 2003, 2004 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2002, 2004 
- EDA/2 Guanarito virus 2000, 2002 
- EDA/2 Junín virus 2000 
- EDA/2 Lake Victoria marburgvirus 2000 
- EDA/2 Lassa virus 2000, 2003, 2005 
- EDA/2 Machupo virus 2002 
- EDA/2 Omsk hemorrhagic fever virus 2004 
- EDA/2 Sudan ebolavirus 2004 
- EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Bacillus anthracis 2002, 2003, 2004, 2005 
- PDA/1 Brucella melitensis 2004 
- PDA/1 Burkholderia mallei 2002, 2005 
- PDA/1 Burkholderia pseudomallei 2002, 2005 
- PDA/1 Camelpox virus 2001, 2003, 2004 
- PDA/1 Coccidioides immitis 2000 
- PDA/1 Coxiella burnetii 2003, 2004 
- PDA/1 Flexal virus 2002 
- PDA/1 Francisella tularensis 2002 
- PDA/1 Hendra virus 2002 
- PDA/1 Influenza A virus 2000, 2001, 2003 
- PDA/1 Monkeypox virus 2001, 2002, 2003, 204 
- PDA/1 Nipah virus 2000, 2001, 2002, 2004 
- PDA/1 Rickettsia prowazekii 2000 
- PDA/1 Rickettsia rickettsii 2000, 2003 
- PDA/1 Rift Valley fever virus 2002, 2003 
- PDA/1 Sabiá virus 2002 
- PDA/1 Yersinia pestis 2003 




- PDA/1 Eastern equine encephalitis virus 2001, 2003 
- PDA/1 Francisella tularensis 2003, 2004, 2005 
- PDA/1 Japanese encephalitis virus 2000, 2001, 2003 
- PDA/1 Nipah virus 
- PDA/1 Venezuelan equine encephalitis virus 2000 
- PDA/1 Yersinia pestis 2000, 2001, 2002, 2003, 2005 
36. Centers for Disease Control and Prevention, Cincinnati, Ohio 
- MDA/4/5 Bacillus globigii 2005 
37. Centers for Epidemiology and Animal Health, National Animal Health Monitoring 
System, Fort Collins, Colorado 
- PDA/1 Influenza A virus 2002, 2003 
38. Center for Food Safety and Applied Nutrition, Food and Drug Administration, 
College Park, Maryland 
- PDA/1 Bacillus anthracis 2003, 2004 
- PDA/1 Clostridium botulinum 2005 
39. Charles River SPAFAS, Inc., Storrs, Connecticut 
- PDA/1 Newcastle disease virus 2002 
40. Children’s Hospital, Los Angeles, California 
- EDA/2 Junín virus 2003, 2004 
41. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
- PDA/1 Human enterovirus B 2000 
42. Chiron, Emeryville, California 
- PDA/1 Venezuelan equine encephalitis virus 2003 
- PDA/1 Bacillus anthracis 2005 
43. Ciphergen Biosystems, Fremont, California 
- PDA/1 Yersinia pestis 2001 
44. CJ America, Ridgefield Park, New Jersey 
- PDA/1 Japanese encephalitis virus 2001 
45. ClinCyte, LLC, San Diego, California 
- PDA/1 Brucella melitensis 2000 
46. Clinical Research Management, Frederick, Maryland 
- EDA/2 Lake Victoria marburgvirus 2004 
- EDA/2 Zaire ebolavirus 2003, 2004 
- PDA/1 Rift Valley Fever virus 2003, 2005 
47. Clinical Research Management, North Royalton, Ohio 
- PDA/1 Bacillus anthracis 2002, 2003, 2004 
- PDA/1 Yersinia pestis 2002, 2003 
48. Clonetech, Inc., Palo Alto, California 
- PDA/1 Japanese encephalitis virus 2000 
49. Colorado State University, Fort Collins, Colorado 
- PDA/1 Alcelaphine herpesvirus 1,2 2001 
- PDA/1 Venezuelan equine encephalitis virus 2001 
- PDA/1 Yersinia pestis 2001, 2005 




- PDA/1 Bacillus anthracis 2000, 2002 
51. Cook County Hospital, Chicago, Illinois 
- PDA/1 Newcastle disease virus 2001 
52. Cornell University, New York, New York 
- EDA/2 Junín virus 2004 
- PDA/1 Bacillus anthracis 2003, 2004, 2005 
53. Corvas International, San Diego, California 
- EDA/2 Zaire ebolavirus 2003 
54. Critical Response Engineering, Inc., Alexandria, Virginia 
- PDA/1 Bacillus anthracis 2003 
55. Dana Farber Cancer Institute, Massachussetts 
- PDA/1 Human enterovirus B 2000 
56. Dartmouth Medical School, Lebanon, New Hampshire 
- PDA/1 Human enterovirus B 2000 
57. Department of Health, New York City, New York 
- PDA/1 Bacillus anthracis 2003 
58. Department of Health and Senior Services, Trenton, New Jersey 
- PDA/1 Bacillus anthracis 2003 
59. Drexel University, Philadelphia, Pennsylvania 
- PDA/1 Bacillus anthracis 2003, 2004 
60. Duke University, Durham, North Carolina 
- PDA/1 Bacillus anthracis 2000, 2002 
61. East Carolina University, Greenville, Nort Carolina 
- PDA/1 Brucella melitensis 2003, 2004 
- PDA/1 Influenza A virus 2003 
62. Elusys Therapeutics Inc., Pine Brook, New Jersey 
- MDA/4/5 Bacillus anthracis 2005 
63. Emory University, Atlanta, Georgia  
- EDA/2 Lassa virus 2002, 2003 
- EDA/2 Reston ebolavirus 2001 
- EDA/2 Zaire ebolavirus 2001, 2004 
- MDA/4/5 Measles virus 2002 
- MDA/4/5 Rubella virus 2002 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Influenza A virus 2003 
- PDA/1 Yersinia pestis 2003 
64. FBI Academy, Quantico, Virginia 
- PDA/1 Bacillus anthracis 2004 
65. Florida A&M University, Tallahassee, Florida 
- PDA/1 Xylella fastidiosa 2002 
66. Florida Department of Health, State Public Health Laboratory-Miami, Miami, 
Florida 
- MDA/4/5 Bacillus atrophaeus 2004 




67. Focus Technologies, Cypress, California 
- PDA/1 Bacillus anthracis 2003 
68. Focus Technologies, Herndon, Virginia 
- PDA/1 Bacillus anthracis 2003 
69. Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware 
- PDA/1 Bacillus anthracis 2005 
70. Functional Genetics, Inc., Rockville, Maryland 
- EDA/2 Zaire ebolavirus 2003 
71. GeneWorks, Inc., Ann Arbor, Michigan, USA 
- PDA/1 Bacillus anthracis 2004 
72. Genentech, Inc, South San Francisco, California 
- MDA/4/5 Human respiratory syncytial virus 2001 
73. Geo-Centers, Inc., Lanham, Maryland 
- PDA/1 Bacillus anthracis 2001, 2004 
74. Geo-Centers, Newtown, Massachusetts 
- PDA/1 Bacillus anthracis 2004 
75. George Mason University, Fairfax, Virginia 
- PDA/1 Bacillus anthracis 2002, 2003, 2004, 2005 
76. George Washington University, Washington, D.C. 
- PDA/1 Bacillus anthracis 2003, 2004 
77. Georgia Institute of Technology, Atlanta, Georgia 
- PDA/1 Cercopithecine herpesvirus 1 2003 
78. Georgia Southern University, Statesboro, Georgia 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
79. Georgia State University, Atlanta, Georgia 
- PDA/1 Cercopithecine herpesvirus 1 2002, 2003 
- PDA/1 Clostridium botulinum 2004 
80. Gladstone Institute of Virology and Immunology, San Francisco, California 
- EDA/2 Lake Victoria marburgvirus 2001 
- EDA/2 Zaire ebolavirus 2001 
81. Harvard Medical School, Boston, Massachusetts 
- EDA/2 Zaire ebolavirus 2005 
- PDA/1 Bacillus anthracis 2000, 2002, 2003 
- PDA/1 Coxiella burnetii 2002 
- PDA/1 Influenza A virus 2004 
- PDA/1 Yersinia pestis 2005 
82. Harvard School of Public Health, Boston, Massachusetts 
- MDA/4/5 Human Rhinovirus 2003 
83. Heska Corporation, Fort Collins, Colorado 
- PDA/1 Yersinia pestis 2003, 2004 
84. Human Genome Sciences, Inc., Rockville, Maryland 
- PDA/1 Newcastle disease virus 2001 




- PDA/1 Bacillus anthracis 2003 
86. Innovative Biotechnologies International, Inc., Grand Island, New York 
- PDA/1 Bacillus anthracis 2004 
87. Institute for Biological Energy Alternatives, Manassas, Virginia 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
88. Institute for Biological Energy Alternatives, Rockville, Maryland 
- PDA/6 Enterobacteria phage φX174 2003 
89. Institute for Genomic Research, Rockville, Maryland 
- PDA/1 Bacillus anthracis 2002, 2003, 2004, 2005 
- PDA/1 Burkholderia mallei 2004 
- PDA/1 Burkholderia pseudomallei 2004 
- PDA/1 Coxiella burnetii 2003 
90. Indiana University, Indianapolis, Indiana 
- PDA/1 Japanese encephalitis virus 2002 
91. Integrated Genomics, Inc., Chicago, Illinois 
- PDA/1 Brucella melitensis 2002 
92. Intervet, Inc., Dallas Center, Iowa 
- PDA/1 Brucella melitensis 2000 
93. IOMAI, Gaithersburg, Maryland 
- PDA/1 Bacillus anthracis 2004 
94. Iowa State University, Ames, Iowa 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Brucella melitensis 2000, 2001 
- PDA/1 Foot and mouth disease virus 2004 
- PDA/1 Newcastle disease virus 2000 
95. The IT Corporation, Washington, D.C. 
- PDA/1 Bacillus anthracis 2002 
96. James Madison University, Harrisonburg, Virginia 
- PDA/1 Yersinia pestis 2005 
97. Jefferson Medical College, Philadelphia, Pennsylvania 
- PDA/1 Clostridium botulinum 2004 
98. Johns Hopkins University, Baltimore, Maryland 
- EDA/5 Bacillus anthracis 2003, 2004 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Newcastle disease virus 2001, 2002, 2003 
99. Kansas State University, Manhattan, Kansas 
- PDA/1 Xanthomonas oryzae 2004 
100. Kaweah Delta District Hospital, Visalia, California 
- PDA/1 Coccidioides immitis 2002, 2003 
101. Lackland Air Force Base, San Antonio, Texas 
- MDA/4/5 Coxiella burnetii 2002 
102. Lawrence Berkeley National Laboratory, Berkeley, California 




103. Lawrence Livermore National Laboratory, Livermore, California 
- MDA/4/5 Bacillus anthracis 2003, 2005 
- MDA/4/5 Bacillus atrophaeus 2004 
- MDA/4/5 Bacillus globigii 2005 
- MDA/4/5 Bacillus thuringiensis 2004 
- MDA/4/5 Yersinia pestis 2003, 2005 
- PDA/1 Bacillus anthracis 2002, 2003 
- PDA/1 Francisella tularensis 2005 
- PDA/1 Yersinia pestis 2001, 2002, 2003, 2004, 2005 
104. Litton/TASC, San Antonio, Texas 
- PDA/1 Bacillus anthracis 2002 
105. Los Alamos National Laboratory, Los Alamos, New Mexico  
- PDA/1 Bacillus anthracis 2000, 2002, 2003, 2004, 2005 
- PDA/1 Newcastle disease virus 2004 
- PDA/1 Yersinia pestis 2000 
106. Louisiana State University, Baton Rouge, Louisiana 
- PDA/1 Bacillus anthracis 2000, 2001, 2002 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2003 
- PDA/1 Newcastle disease virus 2004 
- PDA/1 Rickettsia prowazekii 2000 
107. Loyola University, Maywood, Illinois 
- PDA/1 Bacillus anthracis 2003, 2004 
108. Lovelace Respiratory Research Institute, Albuquerque, New Mexico 
- PDA/1 Bacillus anthracis 2005 
109. Massachusetts Institute of Technology, Cambridge, Massachusetts 
- PDA/1 Brucella melitensis 2000, 2004 
- PDA/1 Yersinia pestis 2003 
110. Massachusetts Institute of Technology, Lexington, Massachusetts 
- PDA/1 Yersinia pestis 2003 
111. Mayo ClinicFoundation, Rochester, Minnesota 
- PDA/1 Bacillus anthracis 2002 
- PDA/1 Bovine spongiform encephalopathy prion 2002 
- PDA/1 Monkeypox virus 2002 
112. Medical College of Ohio, Toledo, Ohio 
- PDA/1 Coccidioides immitis 2000, 2001, 2002 
- PDA/1 Coccidioides posadasii 2000, 2003 
113. Medical College of Wisconsin, Milwaukee, Wisconsin 
- PDA/1 Francisella tularensis 2004 
114. Merial-Select, Inc., Gainesville, Georgia 
- PDA/1 Influenza A virus 2000 
115. MetriGenix, Inc., Gaithersburg, Maryland 
- PDA/1 Influenza A virus 2004 
116. Michigan State University, East Lansing, Michigan 




117. Mississippi State University, Mississippi State, Mississippi 
- MDA/4/5 Mycoplasma gallisepticum 2005 
118. Montana Department of Fish, Wildlife and Parks, Bozeman, Montana 
- PDA/1 Brucella melitensis 2001 
119. Montana State University, Bozeman, Montana 
- PDA/1 Bacillus anthracis 2002, 2003 
120. Morgan State University, Baltimore, Maryland 
- PDA/1 Bacillus anthracis 2003 
121. Mount Sinai School of Medicine, New York, New York 
- EDA/1 “1918 Influenza virus” 2001, 2002, 2004 
- EDA/2 Lassa virus 2002, 2003 
- EDA/2 Zaire ebolavirus 2003 
- PDA/1 Bacillus anthracis 2001 
- PDA/1 Influenza A virus 2003 
- PDA/1 Newcastle disease virus 2001, 2003, 2004, 2005 
- PDA/1 Yersinia pestis 2001 
122. National Cancer Institute, Frederick, Maryland 
- EDA/2 Zaire ebolavirus 2002, 2003, 2005 
- PDA/1 Bacillus anthracis 2001, 2005 
- PDA/1 Hendra virus 2005 
- PDA/1 Nipah virus 2005 
- PDA/1 Yersinia pestis 2005 
123. National Cancer Institute, Bethesda, Maryland 
- EDA/2 Zaire ebolavirus 2000 
124. National Institutes of Health, Hamilton, Montana 
- PDA/1 Coxiella burnetii 2004 
- PDA/1 Rickettsia prowazekii 2000 
- PDA/1 Rickettsia rickettsii 2000 
- PDA/1 Yersinia pestis 2000, 2002, 2004, 2005 
125. National Institutes of Health, Bethesda, Maryland 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2004 
- EDA/2 Lake Victoriamarburgvirus 2002 
- EDA/2 Tick-borne encephalitis virus 2000 
- EDA/2 Zaire ebolavirus 2000, 2003, 2005 
- MDA/6 Langat virus 2000, 2001 
- PDA/1 Bacillus anthracis 2000, 2001, 2002, 2003, 2004 
- PDA/1 Brucella melitensis 2001 
- PDA/1 Monkeypox virus 2001, 2002 
- PDA/1 Newcastle disease virus 2000, 2004 
126. National Institutes of Health, Gaithersburg, Maryland 
- PDA/1 Rickettsia prowazekii 2003, 2004 
127. Naval Medical Research Center Detachment, NAMRID, Peru 
- PDA/1 Venezuelan equine encephalitis virus 2000, 2004 




- PDA/1 Francisella tularensis 2000 
- PDA/1 Rickettsia rickettsii 2001 
129. Naval Medical Research Center, Rockville, Maryland 
- PDA/1 Bacillus anthracis 2004, 2005 
130. Naval Medical Research Center, Silver Spring, Maryland 
- MDA/4/5 Bacillus anthracis 2002, 2004 
- PDA/1 Bacillus anthracis 2004, 2005 
- PDA/1 Clostridium botulinum 2005 
- PDA/1 Francisella tularensis 2002 
- PDA/1 Rickettsia prowazekii 2003, 2004 
131. Naval Research Laboratory, Center for Bio/Molecular Science and 
Engineering, Washington, D. C. 
- PDA/1 Bacillus anthracis 2002 
- PDA/1 Francisella tularensis 2000 
132. Naval Surface Warfare Center, Dahlgren, Virginia 
- PDA/1 Bacillus anthracis 2005 
133. New Mexico State University, Las Cruces, New Mexico 
- PDA/1 Bacillus anthracis 2004 
134. New York State Department of Health, Albany, New York 
- PDA/1 Coccidioides immitis 2000 
135. New York University, New York, New York 
- PDA/1 Bacillus anthracis 2003, 2004 
- PDA/1 Yersinia pestis 2002 
136. North Carolina State University, Raleigh, North Carolina 
- PDA/1 Newcastle disease virus 2000 
- PDA/1 Rickettsia rickettsii 2003 
137. North-Western University, Chicago, Illinois 
- PDA/1 Rickettsia rickettsii 2004 
138. Northern Arizona University, Flagstaff, Arizona 
- EDA/5 Bacillus anthracis 2003 
- PDA/1 Bacillus anthracis 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Francisella tularensis 2001, 2004 
- PDA/1 Yersinia pestis 2000, 2001, 2004, 2005 
139. Northwestern University, Evanston, Illinois 
- PDA/1 Bacillus anthracis 2001 
140. Novozymes Biotech Inc., Davis, California 
- PDA/1 Bacillus anthracis 2002, 2003 
141. Oak Ridge National Laboratory, Oak Ridge, Tennessee 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Foot and mouth disease virus 2005 
- PDA/1 Yersinia pestis 2004 
142. Oklahoma State Department of Health, Oklahoma City, Oklahoma 
- PDA/1 Francisella tularensis 2001 




- PDA/1 Bacillus anthracis 2004, 2005 
144. Ohio State University, Columbus, Ohio 
- MDA/4/5 Bacillus anthracis 2004 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Newcastle disease virus 2001, 2002 
145. Ohio State University, Wooster, Ohio 
- PDA/1 Newcastle disease virus 2002 
146. Ohio University, Athens, Ohio 
- PDA/1 Venezuelan equine encephalitis virus 2004 
147. Oklahoma State University, Stillwater, Oklahoma 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Cercopithecine herpesvirus 1 2002, 2003, 2005 
148. Oregon State University, Corvallis, Oregon 
- EDA/4 Plum pox virus 2002 
149. Orion Genomics, St. Louis, Missouri 
- PDA/1 Burkholderia mallei 2005 
150. Orovax Inc., Cambridge, Massachusetts 
- PDA/1 Japanese encephalitis virus 2000, 2001 
151. Pfizer, Lincoln, Nebraska 
- PDA/1 Foot and mouth disease virus 2004 
152. Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York 
- PDA/1 African swine fever virus 2000, 2001, 2002, 2004, 2005 
- PDA/1 Camelpox virus 2002 
- PDA/1 Classical swine fever virus 2003, 2005 
- PDA/1 Foot and mouth disease virus 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Goatpox virus 2002 
- PDA/1 Japanese encephalitis virus 2000, 2001, 2003 
- PDA/1 Lumpy skin disease virus 2001, 2003 
- PDA/1 Sheeppox virus 2002 
153. Potomoac Hospital, Woodbridge, Virginia 
- PDA/1 Bacillus anthracis 2005 
154. Procter and Gamble, St. Bernard, Ohio 
- PDA/1 Bacillus anthracis 2004, 2005 
155. Public Health Research Institute, Newark, New Jersey 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Yersinia pestis 2004 
156. Pukkerbush Veterinary Clinic, Bristolville, Ohio 
- PDA/1 Brucella melitensis 2001 
157. Purdue University, West Lafayette, Indiana 
- PDA/1 Bacillus anthracis 2004, 2005 
- PDA/1 Foot and mouth disease virus 2003 
158. Roche Molecular Systems, Alameda, California 




- PDA/1 Coccidioides posadasii 2000 
159. Rockefeller University, New York, New York 
- PDA/1 Bacillus anthracis 2002 
- PDA/1 Coxiella burnetii 2000 
- PDA/1 Japanese encephalitis virus 2003 
160. Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 
- PDA/1 Newcastle disease virus 2001 
161. Rutgers - The State University of New Jersey, New Brunswick, New Jersey 
- PDA/1 Clostridium botulinum 2000, 2002 
162. University Schering-Plough Research Institute, Kenilworth, New Jersey 
- PDA/1 Coccidioides immitis 2002 
163. Schott Glass Technologies Inc., Duryea, Pennsylvania 
- PDA/1 Bacillus anthracis 2002 
164. Scripps Research Institute, La Jolla, California 
- EDA/2 Guanarito virus 2000, 2002 
- EDA/2 Junín virus 2000 
- EDA/2 Lassa virus 2000, 2001, 2002, 2003, 2004, 2005 
- EDA/2 Machupo virus 2002 
- EDA/2 Zaire ebolavirus 2002, 2003 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Bovine spongiform encephalopathy prion 2002 
- PDA/1 Flexal virus 2002 
- PDA/1 Sabiá virus 2002 
- PDA/1 Yersinia pestis 2004 
165. Sierra Biomedical Inc., Sparks, Nevada 
- PDA/1 Japanese encephalitis virus 2000, 2002 
166. Southeast Poultry Research Laboratory, United States Department of 
Agriculture, Athens, Georgia 
- EDA/1 “1918 Influenza virus” 2001, 2002, 2004 
- PDA/1 Influenza A virus 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Newcastle disease virus 2000, 2001, 2002, 2003, 2004, 2005 
167. Southwest Foundation for Biomedical Research, San Antonio, Texas 
- EDA/2 Guanarito virus 2002 
- EDA/2 Junín virus 2002 
- EDA/2 Lassa fever virus 2002 
- EDA/2 Machupo virus 2002 
- PDA/1 Flexal virus 2002 
- PDA/1 Sabiá virus 2002) 
168. Southern Research Institute, Frederick, Maryland 
- PDA/1 Bacillus anthracis 2004 
169. SRI International, Menlo Park, California 
- PDA/1 Francisella tularensis 2005 
170. St. Jude Children's Research Hospital, Memphis, Tennessee 




- PDA/1 Bacillus anthracis 2004 
- PDA/1 Influenza A virus 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Newcastle disease virus 2000, 2002 
171. St. Louis University, St. Louis, Missouri 
- PDA/1 Japanese encephalitis virus 2001 
- PDA/1 Newcastle disease virus 2003 
172. Stanford University, Stanford, California 
- EDA/1 Variola virus 2004 
- PDA/1 Coccidioides immitis 2000, 2002, 2003 
- PDA/1 Coccidioides posadasii 2000 
- PDA/1 Newcastle disease virus 2000 
- PDA/1 Yersinia pestis 2002, 2004 
173. State University of New York at Stony Brook, Stony Brook, New York 
- MDA/6 Poliovirus 2002 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
- PDA/1 Yersinia pestis 2003, 2004 
174. Stony Brook University, Stony Brook, New York 
- PDA/1 Francisella tularensis 2003, 2004, 2005 
- PDA/1 Yersinia pestis 2005 
175. Tetracore Inc., Gaithersburg, Maryland 
- PDA/1 African swine fever virus 2005 
- PDA/1 Classical swine fever virus 2003, 2005 
- PDA/1 Foot and mouth disease virus 2002 
176. Texas A&M University, College Station, Texas  
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2004 
- PDA/1 Coxiella burnetii 2001, 2002, 2003, 2004, 2005 
177. Texas A&M University, Houston, Texas 
- PDA/1 Bacillus anthracis 2004 
178. Texas Veterinary Medical Diagnostic Laboratory, Gonzalez, Texas 
- PDA/1 Influenza A virus 2004 
179. Buck Institute for Age Research, Novato, California 
- PDA/1 Francisella tularensis 2004 
180. Thermo Finnigan, San Jose, California 
- PDA/1 Rickettsia prowazekii 2004 
181. Towson University, Towson, Maryland 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
182. Translational Genomics Research Institute Phoenix, Arizona 
- PDA/1 Bacillus anthracis 2005 
183. Tulane Regional Primate Center, Covington, Louisiana 
- PDA/1 Japanese encephalitis virus 2000 
184. Tulane University, New Orleans, Louisiana 




- EDA/2 Zaire ebolavirus 2003 
- PDA/1 Influenza A virus 2001 
185. Tuskegee University, Tuskegee, Alabama 
- PDA/1 Influenza A virus 2004 
186. Uniformed Services University of the Health Sciences, Bethesda, Maryland 
- EDA/2 Zaire ebolavirus 2003 
- PDA/1 Hendra virus 2005 
- PDA/1 Nipah virus 2005 
- PDA/1 Venezuelan equine encephalitis virus 2000, 2003 
187. United Biomedical, Inc., Hauppauge, New York 
- PDA/1 Foot and mouth disease virus 2001, 2002 
188. United Cancer Research Institute, Alexandria, Virginia 
- PDA/1 Newcastle disease virus 2004 
189. United Postal Service, Washington, D. C.  
- PDA/1 Bacillus anthracis 2002 
190. United States Air Forsce Academy, Colorado Springs, Colorado 
- PDA/1 Yersinia pestis 2003 
191. United States Army Center for Health Promotion and Preventive Medicine, 
Aberdeen Proving Ground, Maryland 
- MDA/4/5 Bacillus anthracis 2002 
192. United States Army Center for Health Promotion and Prevention Medicine-
Pacific, Camp Zama, Japan 
- PDA/1 Eastern equine encephalitis virus 2004 
193. United States Army Dugway Proving Grounds, Dugway, Utah 
- MDA/4/5 Bacillus anthracis 2003, 2005 
- MDA/4/5 Bacillus globigii 2005 
- MDA/4/5 Yersinia pestis 2005 
194. United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland 
- EDA/1 Variola virus 2003, 2004 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2004 
- EDA/2 Lake Victoria marburgvirus 2000, 2001, 2002, 2003 
- EDA/2 Lassa virus 2001 
- EDA/2 Reston ebolavirus 2001 
- EDA/2 Tick-borne encephalitis virus 2000, 2001 
- EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, 2004, 2005 
- EDA/5 Camelpox virus 2002 
- EDA/5 Monkeypox virus 2001, 2002 
- MDA/4/5 Andes virus 2002 
- MDA/4/5 Bacillus anthracis 2001 
- MDA/4/5 Brucella melitensis 2004 
- MDA/4/5 Burkholderia mallei 2005 
- MDA/4/5 Burkholderia pseudomallei 2003 




- MDA/4/5 Coxiella burnetii 2002 
- MDA/4/5 Monkeypox virus 2001 
- MDA/4/5 Venezuelan equine encephalitis virus 2001, 2005 
- MDA/4/5 Yersinia pestis 2003 
- PDA/1 Bacillus anthracis 2001, 2002, 2003, 2004, 2005 
- PDA/1 Burkholderia mallei 2000, 2001, 2002, 2003, 2004, 2005 
- PDA/1 Burkholderia pseudomallei 2001, 2004 
- PDA/1 Camelpox virus 2001, 2002, 2003 
- PDA/1 Coxiella burnetii 2000 
- PDA/1 Eastern equine encephalitis virus 2000, 2002, 2003, 2005 
- PDA/1 Francisella tularensis 2000 
- PDA/1 Monkeypox virus 2001, 2002, 2003 
- PDA/1 Rift Valley Fever virus 2003, 2005 
- PDA/1 Venezuelan equine encephalitis virus 2000, 2001, 2002, 2003, 2004 
- PDA/1 Yersinia pestis 2000, 2001, 2002, 2003, 2004, 2005 
195. United States Department of Agriculture, Bozeman, Montana 
- PDA/1 Brucella melitensis 2001 
196. United States Department of Agriculture, Agricultural Research Service, 
Ames, Iowa 
- MDA/4/5 Mycoplasma gallisepticum 2005 
- PDA/1 Bacillus anthracis 2001, 2002, 2003 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2003, 2004 
- PDA/1 Burkholderia mallei 2000 
- PDA/1 Influenza A virus 2002, 2003 
- PDA/1 Newcastle disease virus 2004 
- PDA/1 Venezuelan equine encephalitis virus 2003 
197. United States Department of Agriculture, Agricultural Research Service, 
Athens, Georgia 
- PDA/1 Newcastle disease virus 2000 
198. United States Department of Agriculture, Agricultural Research Service, 
Beltsville, Maryland 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Brucella melitensis 2001 
- PDA/1 Francisella tularensis 2000 
- PDA/1 Mycoplasma capricolum capripneumoniae 2004 
- PDA/1 Mycoplasma mycoides mycoides 2004 
- PDA/1 Newcastle disease virus 2005 
- PDA/1 Rickettsia prowazekii 2002 
- PDA/1 Plum pox virus 2001 
- PDA/1 Xylella fastidiosa 2002 
199. United States Department of Agriculture, Agricultural Research Service, 
College Station, Texas 




200. United States Department of Agriculture, Agricultural Research Service, Fort 
Detrick, Frederick, Maryland 
- PDA/1 Plum pox virus 2001 
201. United States Department of Agriculture, Agricultural Research Service, 
Kearneysville, West Virginia 
- PDA/1 Plum pox virus 2001 
202. United States Department of Agriculture, Agricultural Research Service, 
Laramie, Wyoming 
- PDA/1 Alcelaphine herpesvirus 1,2 2001 
203. United States Department of Agriculture, Agricultural Research Service, 
Mississippi State, Mississippi 
- MDA/4/5 Mycoplasma gallisepticum 2005 
204. United States Department of Agriculture, Agricultural Research Service, 
Pullman, Washington 
- PDA/1 Alcelaphine herpesvirus 1,2 2000, 2001, 2002, 2003 
- PDA/1 Bovine spongiform encephalopathy prion 2001 
- MDA/4/5 Alcelaphine herpesvirus 1,2 2004, 2005 
205. United States Department of Agriculture, Agricultural Research Service, 
Washington, D.C. 
- PDA/1 Bacillus anthracis 2003 
206. United States Department of Agriculture, Agricultural Research Service, 
Wyndmoor, Pennsylvania 
- PDA/1 Bacillus anthracis 2005 
207. United States Department of Agriculture, Animal and Plant Health Inspection 
Service, Riverdale, Maryland 
- PDA/1 Brucella melitensis 2001 
- PDA/1 Influenza A virus 2002, 2003 
208. United States Department of Agriculture, Animal and Plant Health Inspection 
Service, Robbinsville, New Jersey 
- PDA/1 Influenza A virus 2002, 2003 
- PDA/1 Bluetongue virus 2000, 2001 
209. United States Department of Agriculture Center for Animal Disease 
Information and Analysis, Fort Collins, Colorado  
- PDA/1 Venezuelan equine encephalitis virus 2001 
210. United States Department of Agriculture, Southeast Poultry Research 
Laboratory, Athens, Georgia 
- PDA/1 Bluetongue virus 2000 
211. Unites States Department of Commerce, Seattle, Washington 
- PDA/1 Clostridium botulinum 2002, 2004 
212. United States Department of the Interior, Bozeman, Montana 
- PDA/1 Brucella melitensis 2001 
213. United States Environmental Protection Agency, Cincinnati, Ohio 




214. United States Environmental Protection Agency National Enforcement 
Investigations Center, Denver, Colorado 
- MDA/4/5 Bacillus anthracis 2002 
215. United States Environmental Protection Agency Region 5, Westlake, Ohio 
- MDA/4/5 Bacillus anthracis 2002 
216. United States Food and Drug Administration, Atlanta, Georgia 
- PDA/1 Clostridium botulinum 2002, 2003 
217. United States Food and Drug Administration, Summit-Argo, Illinois 
- PDA/1 Clostridium botulinum 2000, 2003, 2005 
218. United States Geological Survey, Fort Collins, Colorado 
- PDA/1 Yersinia pestis 2001 
219. United States Geological Survey, Madison, Wisconsin 
- PDA/1 Yersinia pestis 2003, 2004 
220. United States Naval Medical Research Center Detachment, Lima, Peru  
- PDA/1 Eastern equine encephalitis virus 2004 
221. United States Public Health Service Center, Denver, Colorado 
- MDA/4/5 Bacillus anthracis 2002 
222. United States Department of Agriculture, Agricultural Research Service, 
Dubois, Idaho 
- PDA/1 Alcelaphine herpesvirus 1,2 2004, 2005 
223. University of Alabama at Birmingham, Birmingham, Alabama 
- PDA/1 Bacillus anthracis 2001, 2003, 2004 
- PDA/1 Yersinia pestis 2004 
224. University of Arizona, Tucson, Arizona 
- EDA/5 Coccidioides immitis 2000 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Coccidioides immitis 2000, 2002 
- PDA/1 Coccidioides posadasii 2000, 2003, 2005 
225. University of California Berkeley, California 
- PDA/1 Coccidioides immitis 2000, 2003 
- PDA/1 Coccidioides posadasii 2000, 2003 
- PDA/1 Rickettsia rickettsii 2004 
226. University of California Davis, Davis, California  
- MDA/4/5 Bacillus athropaeus 2004 
- MDA/4/5 Bacillus thuringiensis 2004 
- PDA/1 Bluetongue virus 2000 
- PDA/1 Brucella melitensis 2003 
- PDA/1 Cercopithecine herepesvirus 1 2003 
- PDA/1 Coccidioides immitis 2000, 2002, 2003 
- PDA/1 Coccidioides posadasii 2000 
- PDA/1 Influenza A virus 2004 
- PDA/1 Japanese encephalitis virus 2001 
- PDA/1 Mycoplasma mycoides mycoides 2005 




- PDA/1 Peste-des-petits-ruminants virus 2003 
- PDA/1 Rinderpest virus 2002, 2003 
- PDA/1 Venezuelan equine encephalitis virus 2004 
- PDA/2 Autographa californica multiple nucleopolyhedrovirus 2003 
227. University of California, Los Angeles, California 
- EDA/2 Nipah virus 2004, 2005 
- EDA/3 Nipah virus 2004, 2005 
- PDA/1 Francisella tularensis 2003 
228. University of California, San Diego, California 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Coccidioides immitis 2000 
229. University of California, San Francisco, California 
- EDA/2 Lake Victoria marburgvirus 2001 
- EDA/2 Zaire ebolavirus 2001 
- PDA/1 Bovine spongiform encephalopathy prion 2002, 2005 
- PDA/1 Coxiella burnetii 2003 
- PDA/1 Foot and mouth disease virus 2000, 2001, 2002, 2004 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Newcastle disease virus 2004 
- PDA/1 Yersinia pestis 2004 
230. University of California at Santa Barbara, Santa Barbara, California 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Newcastle disease virus 2001 
231. University of Cincinnati, Cincinnati, Ohio 
- PDA/1 Francisella tularensis 2004 
232. University of Connecticut, Storrs, Connecticut 
- PDA/1 African swine fever virus 2005 
- PDA/1 Bacillus anthracis 2005 
- PDA/1 Classical swine fever virus 2005 
- PDA/1 Foot and mouth disease virus 2005 
- PDA/1 Newcastle disease virus 2001, 2002 
233. University of Delaware, Newark, Delaware 
- PDA/1 Newcastle disease virus 2003 
234. University of Florida, Gainesville, Florida 
- PDA/1 Ehrlichia ruminantium 2000, 2001, 2002 
- PDA/1 Xylella fastidiosa 2003 
235. University of Georgia, Athens, Georgia 
- EDA/1 Variola virus 2003 
- EDA/2 Nipah virus 2004, 2005 
- MDA/4/5 Mycoplasma synoviae 2001 
- PDA/1 Brucella melitensis 2004 
- PDA/1 Clostridium botulinum 2003 
- PDA/1 Foot and mouth disease virus 2000 




- PDA/1 Monkeypox virus 2003 
- PDA/1 Newcastle disease virus 2003 
236. University of Georgia, Griffin, Georgia 
- PDA/1 Bacillus anthracis 2004, 2005 
- PDA/1 Xylella fastidiosa 2002 
237. University of Illinois at Chicago, Chicago, Illinois 
- EDA/2 Zaire ebolavirus 2003, 2004 
- MDA/7 Bacillis subtilis 2000 
- PDA/1 Bacillus anthracis 2005 
238. University of Illinois at Urbana-Champaign, Urbana, Illinois  
- PDA/1 Yersinia pestis 2002 
239. University of Iowa, Iowa City, Iowa 
- EDA/2 Guanarito virus 2000, 2002 
- EDA/2 Machupo virus 2002 
- PDA/1 Flexal virus 2002 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Sabiá virus 2002 
240. University of Kentucky, Lexington, Kentucky 
- PDA/1 Yersinia pestis 2000, 2001, 2002, 2003, 2004, 2005 
241. University of Louisville, Louisville, Kentucky 
- PDA/1 Bacillus anthracis 2004 
242. University of Maryland, Baltimore, Maryland 
- EDA/2 Lassa virus 2002, 2003, 2004, 2005 
- PDA/1 Bacillus anthracis 2003, 2004, 2005 
- PDA/1 Rickettsia prowazekii 2002, 2003 
- PDA/1 Rickettsia rickettsii 2000, 2001, 2002, 2003, 2004, 2005 
243. University of Maryland, College Park, Maryland 
- PDA/1 Eastern equine encephalitis virus 2000, 2001 
- PDA/1 Newcastle disease virus 2001, 2003, 2004 
- PDA/1 Yersinia pestis 2001 
244. University of Massachusetts, Amherst, Massachusetts 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2003 
- PDA/1 Clostridium botulinum 2000 
245. University of Massachusetts, Worcester, Massachusetts 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Coxiella burnetii 2004 
- PDA/1 Japanese encephalitis virus 2000 
- PDA/1 Newcastle disease virus 2002 
- PDA/1 Yersinia pestis 2001, 2004 
246. University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 
- PDA/1 Clostridium botulinum 2001, 2003, 2004 
247. University of Medicine and Dentistry of New Jersey, Newark, New Jersey  
- PDA/1 Bacillus anthracis 2004 




248. University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 
- PDA/1 Newcastle disease virus 2002 
249. University of Miami, Miami, Florida 
- PDA/1 Yersinia pestis 2000, 2002, 2003, 2004, 2005 
250. University of Michigan, Ann Arbor, Michigan 
- EDA/2 Zaire ebolavirus 2003 
- PDA/1 Bacillus anthracis 2000, 2002, 2003, 2004, 2005 
- PDA/1 Yersinia pestis 2002 
251. University of Minnesota, Minneapolis, Minnesota 
- PDA/1 Bacillus anthracis 2004, 2005 
252. University of Minnesota, St. Paul, Minnesota 
- EDA/5 Coccidoides immitis 2000 
- MDA/4/5 Classical swine fever virus 2001 
- PDA/1 Ehrlichia ruminantium 2000 
- PDA/1 Rickettsia rickettsii 2004 
- PDA/1 Newcastle disease virus 2002, 2004, 2005 
253. University of Mississippi, Jackson, Mississippi 
- PDA/1 Bacillus anthracis 2004 
254. University of Missouri, Columbia, Missouri 
- PDA/1 Newcastle disease virus 2000 
- PDA/1 Rickettsia rickettsii 2001 
255. University of Missouri, Kansas City, Missouri 
- PDA/1 Brucella melitensis 2003 
256. University of Missouri-St. Louis, St. Louis, Missouri 
- PDA/1 Newcastle disease virus 2002 
257. University of Montana, Missoula, Montana 
- EDA/2 Junín virus 2004, 2005 
258. University of Nebraska, Lincoln, Nebraska 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Xylella fastidiosa 2002 
259. University of Nebraska, Omaha, Nebraska 
- PDA/1 Francisella tularensis 2004 
260. University of Nevada at Reno, Reno, Nevada 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2003 
- EDA/2 Junín virus 2000 
- PDA/1 Bacillus anthracis 2004 
261. University of New Mexico, Albuquerque, New Mexico 
- PDA/1 Bacillus anthracis 2004, 2005 
262. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
- EDA/5 Francisella tularensis 2004 
- PDA/1 Influenza A virus 2000 
- PDA/1 Rickettsia prowazekii 2000 
- PDA/1 Rickettsia rickettsii 2000 




263. University of North Dakota, Grand Forks, North Dakota 
- PDA/1 Yersinia pestis 2001, 2002 
264. University of Northern Iowa, Cedar Falls, Iowa 
- PDA/1 Bacillus anthracis 2003 
265. University of Pennsylvania, Philadelphia, Pennsylvania 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2005 
- EDA/2 Zaire ebolavirus 2003 
266. University of Pittsburgh, Pittsburgh, Pennsylvania 
- PDA/1 Bacillus anthracis 2003, 2004 
267. University of Rochester, Rochester, New York 
- PDA/1 Rickettsia rickettsii 2000, 2002, 2003, 2004 
268. University of Scranton, Scranton, Pennsylvania 
- PDA/1 Bacillus anthracis 2001, 2002, 2003, 2004 
- PDA/1 Brucella melitensis 2001, 2002 
269. University of South Alabama, Mobile, Alabama 
- EDA/5 Rickettsia prowazekii 2000, 2004 
- PDA/1 Rickettsia prowazekii 2003 
270. University of South Carolina, Columbia South Carolina 
- PDA/1 Bacillus anthracis 2004 
271. University of South Florida, Tampa, Florida 
- PDA/1 Bacillus anthracis 2003, 2004 
- PDA/1 Rickettsia rickettsii 2001 
272. University of Southern California, Los Angeles, California 
- PDA/1 Newcastle disease virus 2004 
273. University of Tennessee, Memphis, Tennessee 
- PDA/1 Bacillus anthracis 2004 
274. University of Texas, Austin, Texas 
- PDA/1 Yersinia pestis 2003, 2004 
275. University of Texas, Dallas, Texas 
- PDA/1 Bacillus anthracis 2002 
276. University of Texas Medical Branch, Galveston, Texas 
- EDA/2 Guanarito virus 2000, 2002, 2003 
- EDA/2 Junín virus 2002, 2003 
- EDA/2 Lassa virus 2002, 2003 
- EDA/2 Machupo virus 2002, 2003 
- EDA/2 Omsk hemorrhagic fever virus 2003, 2004, 2005 
- MDA/1 Pichinde virus 2001 
- PDA/1 Coccidioides immitis 2000 
- PDA/1 Eastern equine encephalitis virus 2004 
- PDA/1 Japanese encephalitis virus 2000, 2002, 2003 
- PDA/1 Rickettsia prowazekii 2000, 2001 
- PDA/1 Rickettsia rickettsii 2005 
- PDA/1 Rift Valley Fever virus 2003, 2005 




277. University of Texas, Houston, Texas 
- PDA/1 Bacillus anthracis 2000, 2002, 2004, 2005 
278. University of Texas San Antonio, San Antonio, Texas 
- EDA/2 Guanarito virus 2002 
- EDA/2 Junín virus 2002 
- EDA/2 Lassa fever virus 2002 
- EDA/2 Machupo virus 2002 
- EDA/5 Francisella tularensis 2003 
- PDA/1 Bacillus anthracis 2000 
- PDA/1 Coccidioides immitis 2001, 2002, 2003 
- PDA/1 Coccidioides posadasii 2003 
- PDA/1 Flexal virus 2002 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Human enterovirus B 2000 
- PDA/1 Sabiá virus 2002 
- PDA/1 Yersinia pestis 2000 
279. University of Texas SW Med Ctr., Dallas, Texas 
- EDA/2 Lassa virus 2003, 2004, 2005 
- PDA/1 Coccidioides immitis 2003 
280. University of Virginia, Charlottesville, Virginia 
- PDA/1 Bacillus anthracis 2003 
- PDA/1 Foot and mouth disease virus 2002 
- PDA/1 Japanese encephalitis virus 2001 
281. University of Washington, Seattle, Washington 
- EDA/1 “1918 Influenza A virus” 2004 
- PDA/1 Bacillus anthracis 2002, 2004 
- PDA/1 Francisella tularensis 2004 
- PDA/1 Yersinia pestis 2004 
282. University of Wisconsin, Madison, Wisconsin 
- EDA/1 “1918 Influenza A virus” 2004 
- EDA/2 Lassa virus 2003, 2004 
- EDA/2 Zaire ebolavirus 2002, 2003, 2004 
- MDA/1 Newcastle disease virus 2002 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Brucella melitensis 2000, 2002, 2003, 2004, 2005 
- PDA/1 Clostridium botulinum 2000, 2001, 2003, 2004, 2005 
- PDA/1 Influenza A virus 2005 
- PDA/1 Yersinia pestis 2002 
283. University of Wyoming, Laramie, Wyoming 
- PDA/1 Brucella melitensis 2000, 2002 
- PDA/1 Coxiella burnetii 2002, 2003 
- PDA/1 Rickettsia prowazekii 2000 
- PDA/1 Rickettsia rickettsii 2000, 2003 




284. United States Army Edgewood Chemical Biological Center, Aberdeen 
Proving Ground, Maryland 
- PDA/1 Bacillus anthracis 2000, 2004 
- PDA/1 Burkholderia mallei 2005 
- PDA/1 Francisella tularensis 2003 
- PDA/1 Yersinia pestis 2000 
285. USA Cancer Research Institute, College of Medicine, University of South 
Alabama, Mobile, Alabama 
- EDA/2 Zaire ebolavirus 2003 
286. Utah State University, Logan, Utah 
- EDA/5 Camelpox virus 2002 
- EDA/5 Monkeypox virus 2002 
- PDA/1 Brucella melitensis 2002 
287. V. I. Technologies, Inc., Watertown, Massachusetts 
- PDA/1 Foot and mouth disease virus 2002 
288. Van Andel Research Institute, Grand Rapids, Missouri 
- PDA/1 Bacillus anthracis 2001, 2003 
289. Vanderbilt University Medical Center, Nashville, Tennessee 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2003 
290. Veridian, Inc., San Antonio, Texas 
- PDA/1 Bacillus anthracis 2000, 2002 
291. Vaxin Inc., Birmingham, Alabama 
- PDA/1 Bacillus anthracis 2004 
292. Veterans Affairs Medical Center, Houston, Texas 
- PDA/1 Francisella tularensis 2000 
293. Vical Inc., San Diego, California 
- MDA/4/5 Bacillus anthracis 2004 
294. Virginia Polytechnic Institute and State University, Blacksburg, Virginia 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2003 
- PDA/1 Clostridium botulinum 2000 
295. Vital Probes Inc., Mayfield, Philadelphia 
- PDA/1 Bacillus anthracis 2003 
296. Vitruvius Biosciences, The Woodlands, Texas 
- PDA/1 Bacillus anthracis 2004 
297. Wadsworth Center, Albany, New York 
- PDA/1 Yersinia pestis 2002 
298. Walter Reed Army Institute of Research, Forest Glen, Maryland 
- MDA/4/5 Brucella melitensis 2004 
- PDA/1 Brucella melitensis 2000, 2001 
299. Walter Reed Army Institute of Research, Silver Spring, Maryland 
- EDA/2 Crimean-Congo hemorrhagic fever virus 2004 
- PDA/1 Bacillus anthracis 2004 
- PDA/1 Brucella melitensis 2001 




- PDA/1 Francisella tularensis 2001, 2005 
- PDA/1 Japanese encephalitis virus 2000, 2001 
- PDA/1 Rickettsia rickettsii 2001 
- PDA/1 Yersinia pestis 2001, 2002, 2003, 2004 
300. Walter Reed Army Institute of Research, Washington, D. C. 
- MDA/4/5 Brucella melitensis 2004 
- PDA/1 Brucella melitensis 2000, 2001, 2002, 2004 
- PDA/1 Yersinia pestis 2000, 2001, 2002 
301. Walter Reed Army Medical Center, Washington, D.C. 
- EDA/2 Zaire ebolavirus 2004 
- PDA/1 Japanese encephalitis virus 2000 
302. Washington State University, Pullman, Washington 
- PDA/1 Alcelaphine herpesvirus 1,2 2000, 2001, 2003, 2004, 2005 
- PDA/1 Bovine spongiform encephalopathy prion 2001 
- PDA/1 Coxiella burnetii 2000 
- PDA/1 Ehrlichia ruminantium 2000, 2001, 2002, 2004, 2005 
- PDA/1 Mycoplasma mycoides mycoides 2000 
303. Washington University, St. Louis, Missouri 
- EDA/2 Zaire ebolavirus 
- PDA/1 Yersinia pestis 2005 
304. Wayne State University, Detroit, Michigan 
- EDA/2 Zaire ebolavirus 2000 
305. West Virginia University, Morgantown, West Virginia 
- EDA/5 Coxiella burnetii 2000 
- PDA/1 Coxiella burnetii 2002 
306. Wildlife Research Center, Fort Collins, Colorado 
- PDA/1 Brucella melitensis 2000 
307. Wildlife Science Group, University of Washington, Seattle, Washington 
- PDA/1 Yersinia pestis 2004 
308. Wyoming Game and Fish Laboratory, University Station, Laramie, Wyoming 
- PDA/1 Brucella melitensis 2000, 2002 
309. Yale University, New Haven, Connecticut 
- PDA/1 Coxiella burnetii 2000, 2003, 2004 
- PDA/1 Japanese encephalitis virus 2000 
- PDA/1 Rift Valley fever virus 2000 
- PDA/1 Yersinia pestis 2001 
310. Zoological Society of San Diego, San Diego, California 





II. US researchers that would have been affected by the proposed oversight 
system had it existed between the years of 2000 and 2005: 
1. Abney, J., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 2004) 
2. Abrams, M., Northern Arizona University, Flagstaff, Arizona (PDA/1 Francisella 
tularensis 2001) 
3. Abshire, T. G., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2002, 2005) 
4. Abuodeh, R. O., University of Arizona, Tucson, Arizona (EDA/5 Coccidioides immitis 
2000) 
5. Adamovicz, J. J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Yersinia pestis 2004) 
6. Adams, G., Texas A&M University, College Station, Texas (PDA/1 Brucella melitensis 
2002) 
7. Adams, L. G., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2000, 2001) 
8. Adesiyun, A. A., University of California Davis, Davis, California (PDA/1 Brucella 
melitensis 2003) 
9. Adhikari, A., Centers for Disease Control and Prevention, Cincinnati, Ohio (MDA/4/5 
Bacillus globigii 2005) 
10. Afonso, C. L., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2002, 2004, PDA/1 
Camelpox virus 2002, PDA/1 Goatpox virus 2002, PDA/1 Lumpy skin disease virus 
2001, 2003, PDA/1 Sheeppox virus 2002) 
11. Agarwal, S., Emory Vaccine Research Center and Department of Pathology, Emory 
University, Atlanta, Georgia (EDA/2 Lassa virus 2003, EDA/2 Zaire ebolavirus 2003) 
12. Agranovich, I., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Brucella melitensis 2001) 
13. Agron, P. G., Lawrence Livermore National Laboratory, Livermore, California (PDA/1 
Bacillus anthracis 2003, PDA/1 Yersinia pestis 2002) 
14. Aguilar, P., Naval Medical Research Center Detachment, NAMRID, Peru/University of 
Texas Medical Branch, Galveston, Texas (PDA/1 Eastern equine encephalitis virus 2004, 
PDA/1 Venezuelan equine encephalitis virus 2000, 2004) 
15. Ahmad, S., University of California-Davis, Davis, California (PDA/1 Peste-des-petits-
ruminants virus 2003, PDA/1 Rinderpest virus 2002, 2003) 
16. Ahmed, R., Emory University, Atlanta, Georgia (EDA/2 Zaire ebolavirus 2001, 2003, 
2004, 2005) 
17. Aitichou, M., Clinical Research Management, Frederick, Maryland (PDA/1 Rift Valley 
fever virus 2005) 





19. Albert, H., Harvard Medical School, Boston, Massachusetts (PDA/1 Bacillus anthracis 
2002) 
20. Alcantara, R. B., East Carolina University, Greenville, North Carolina (PDA/1 Brucella 
melitensis 2004) 
21. Aldrich, J. L. Tetracore Inc., Gaithersburg, Maryland (PDA/1 Francisella tularensis 
2000)  
22. Aldrich, J., Naval Medical Research Institute, Bethesda, Maryland (PDA/1 Francisella 
tularensis 2000) 
23. Alesi, K., Montana State University, Bozeman, Montana (PDA/1 Bacillus anthracis 2003) 
24. Alibek, D., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus anthracis 
2002) 
25. Alibek, K., Advanced Biosystems, Inc., Manassas, Virginia/George Mason University, 
Fairfax, Virginia (PDA/1 Bacillus anthracis 2002, 2003, 2004, 2005) 
26. al-Khaldi, S., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003) 
27. Alland, D., University of Medicine and Dentistry of New Jersey, Newark, New Jersey 
(PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 
28. Alleman, A. R., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2000) 
29. Allen, C. A., Texas A&M University, College Station, Texas (PDA/1 Brucella melitensis 
2000) 
30. Allen, S. G., Naval Medical Research Institute, Bethesda, Maryland (PDA/1 Francisella 
tularensis 2000) 
31. Allender, C. J., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2005, PDA/1 Yersinia pestis 2004) 
32. Alls, J. L., Veridian, Inc., San Antonio, Texas (PDA/1 Bacillus anthracis 2000, 2002) 
33. Alstad, A. D., United States Department of Agriculture, Agricultural Research Service, 
Ames, Iowa (PDA/1 Venezuelan equine encephalitis virus 2003) 
34. Altamura, L. A., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Crimean-Congo hemorrhagic fever virus 2005) 
35. Alvarez, R., United States Department of Agriculture, Southeast Poultry Research 
Laboratory, Atlanta Georgia (PDA/1 Foot and mouth disease virus 2003, PDA/1 
Newcastle disease virus 2004, 2005) 
36. Alving, C. R., Walter Reed Army Institute of Research, Silver Spring, Maryland (EDA/2 
Zaire ebolavirus 2002) 
37. Alwell-Warda, K., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2001, 2003) 
38. Aman, M. J., United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2002, 2003, 2004, 2005, EDA/2 
Zaire ebolavirus 2002, 2003, 2004, 2005) 





40. Amemiya, K., United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (MDA/4/5 Burkholderia mallei 2005, PDA/1 Burkholderia mallei 
2002) 
41. Ampel, Neil M., University of Arizona, Tucson, Arizona (PDA/1 Coccidioides immitis 
2000, PDA/1 Coccidioides posadasii 2000) 
42. Amuso, P. University of South Florida, Tampa, Florida (PDA/1 Bacillus anthracis 2003) 
43. Anand, S. P., University of Pittsburgh, Pittsburgh, Pennsylvania (PDA/1 Bacillus 
anthracis 2004) 
44. Anantharaman, T. S., New York University, New York, New York/University of 
Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 2002) 
45. Andersen, G. L., Lawrence Berkeley National Laboratory, Berkeley, California (PDA/1 
Bacillus anthracis 2003, PDA/1 Yersinia pestis 2000, 2002) 
46. Anderson, A. O., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2005) 
47. Anderson, B. E., University of South Florida, Tampa, Florida/University of Missouri–
Columbia, Columbia, Missouri/Walter Reed Army Institute of Research, Silver Spring, 
Maryland (PDA/1 Rickettsia rickettsii 2001) 
48. Anderson, D. A., United States Army Dugway Proving Grounds, Dugway, Utah 
(MDA/4/5 Bacillus anthracis 2003, MDA/4/5 Yersinia pestis 2003)  
49. Anderson, G. P., Naval Research Laboratory, Center for Bio/Molecular Science and 
Engineering, Washington, D. C. (PDA/1 Bacillus anthracis 2002, PDA/1 Francisella 
tularensis 2000) 
50. Anderson, I., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella melitensis 
2002) 
51. Anderson, K., United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (EDA/2 Zaire ebolavirus 2002) 
52. Anderson, L. J., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Nipah virus 2000) 
53. Andrews, G. P., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland/University of Wyoming, Laramie, Wyoming (MDA/4/5 
Burkholderia pseudomallei 2003, PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 
2004, 2005) 
54. Anishchenko, M., University of Texas Medical Branch, Galveston, Texas (PDA/1 Eastern 
equine encephalitis virus 2004, PDA/1 Venezuelan equine encephalitis virus 2003, 2004, 
2005) 
55. Antolin, M. F., Northern Arizona University, Flagstaff, Arizona (PDA/1 Yersinia pestis 
2005) 
56. Aoki, K. R., Allergan Inc., Irvine, California (PDA/1 Clostridium botulinum 2003) 
57. Apicella, M. A., University of Iowa, Iowa City, Iowa (PDA/1 Francisella tularensis 
2004) 
58. Arakawa, E. T., Oak Ridge National Laboratory, Oak Ridge, Tennessee (PDA/1 Bacillus 
anthracis 2003) 
59. Arasteh, A., United States Army Edgewood Chemical Biological Center, Aberdeen 




60. Araujo, T. P. University of Texas Medical Branch, Galveston, Texas (PDA/1 Japanese 
encephalitis virus 2002) 
61. Arceneaux, J. E., University of Mississippi, Jackson, Mississippi (PDA/1 Bacillus 
anthracis 2004) 
62. Archer, Angela M., University of Texas San Antonio, San Antonio, Texas (EDA/2 Lassa 
fever virus 2002, EDA/2 Guanarito virus 2002, EDA/2 Junín virus 2002, EDA/2 
Machupo virus 2002, PDA/1 Flexal virus 2002, PDA/1 Sabiá virus 2002) 
63. Arcibal, I. G., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus anthracis 
2003) 
64. Arciniega, J., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
65. Ardakes, E., Kansas State University, Manhattan, Kansas (PDA/1 Xanthomonas oryzae 
2004) 
66. Ardans, A. A., California Animal Health and Food Safety Laboratory, Davis, California 
(PDA/1 Newcastle disease virus 2005) 
67. Arduino, M. J., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2004, 2005, PDA/1 Yersinia pestis 2003) 
68. Arnon, S. S., California Department of Health Services, Richmond, California (PDA/1 
Clostridium botulinum 2004) 
69. Aronson, A. I., Purdue University, West Lafayette, Indiana (PDA/1 Bacillus anthracis 
2004, 2005) 
70. Aronson, J. F., University of Texas Medical Branch, Galveston, Texas/University of 
North Carolina at Chapel Hill, Chapel Hill, North Carolina (EDA/2 Omsk hemorrhagic 
fever virus 2005, MDA/1 Pichinde virus 2001, PDA/1 Eastern equine encephalitis virus 
2004, PDA/1 Venezuelan equine encephalitis virus 2000, 2003) 
71. Arroyo, J., Orovax Inc./ Acambis Inc., Cambridge, Massachusetts (PDA/1 Japanese 
encephalitis virus 2000, 2001, 2002) 
72. Arulanandam, B. P., University of Texas San Antonio, San Antonio, Texas (EDA/5 
Francisella tularensis 2003, PDA/1 Francisella tularensis 2004) 
73. Asay, M., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 Bacillus 
anthracis 2004) 
74. Ashar, H. R., University of Medicine and Dentistry of New Jersey, Piscataway, New 
Jersey (PDA/1 Newcastle disease virus 2002) 
75. Atakilit, A., University of California, San Francisco, California (PDA/1 Foot and mouth 
disease virus 2001) 
76. Atchley, D. H., Brooks Air Force Base, San Antonio, Texas (PDA/1 Francisella 
tularensis 2004) 
77. Aune, K., Montana Department of Fish, Wildlife and Parks, Bozeman, Montana (PDA/1 
Brucella melitensis 2001) 
78. Awasthi, S., University of Texas San Antonio, San Antonio, Texas (PDA/1 Coccidioides 
posadasii 2003) 
79. Azad, A. F., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia prowazekii 




80. Azimi, N., National Institutes of Health, Bethesda, Maryland (PDA/1 Newcastle disease 
virus 2000) 
81. Aziz, Fatema H., University of California-Davis, Davis, California (PDA/1 Peste-des-
petits-ruminants virus 2003, PDA/1 Rinderpest virus 2002, 2003) 
82. Babaoglu, K., St. Jude Children's Research Hospital, Memphis, Tennessee/University of 
Tennessee, Memphis, Tennessee (PDA/1 Bacillus anthracis 2004) 
83. Babcock, G., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2000) 
84. Babin, M., Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2003, 2005) 
85. Backlund, P., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
86. Bacon, R. M., Centers for Disease Control and Prevention, Fort Collins, Colorado (PDA/1 
Francisella tularensis 2004) 
87. Badie, S. S., United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, 2005) 
88. Bae, J. E., Virginia Polytechnic Institute and State University, Blacksburg, Virginia 
(PDA/1 Brucella melitensis 2002) 
89. Baeten, L. A., United States Geological Survey, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2004) 
90. Baeumner, A. J., Cornell University, Ithaca, New York (PDA/1 Bacillus anthracis 2003, 
2004) 
91. Bai, L., Case Western Reserve University, Cleveland, Ohio (PDA/1 Newcastle disease 
virus 2002) 
92. Bailey, C., Advanced Biosystems, Inc., Manassas, Virginia/George Mason University, 
Fairfax, Virginia (PDA/1 Bacillus anthracis 2002, 2004, 2005) 
93. Bailie, L., University of Maryland, Baltimore, Maryland (PDA/1 Bacillus anthracis 2003) 
94. Baillie, L. W., Institute for Genomic Research, Rockville, Maryland/University of 
Maryland, Baltimore, Maryland/George Washington University, Washington D. 
C./United States Navy Medical Research Center, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2003, 2004, 2005) 
95. Bajani, M. D., Centers for Disease Control and Prevention, Atlanta, Georgia (EDA/2 
Lassa virus 2000) 
96. Baker, D. D., University of Northern Iowa, Cedar Falls, Iowa (PDA/1 Bacillus anthracis 
2003) 
97. Baker, Jr., J. R., University of Michigan Medical School, Ann-Arbor, Michigan (EDA/2 
Zaire ebolavirus 2003) 
98. Baker, R. O., United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (EDA/1 Variola virus 2003, EDA/2 Zaire ebolavirus 2002. PDA/1 
Camelpox virus 2003, PDA/1 Monkeypox virus 2003) 
99. Baker, S. L., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Rickettsia rickettsii 2003) 
100. Bakken, R., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2000, 2001, PDA/1 Venezuelan equine 




101. Baldridge, G. D., University of Minnesota, St. Paul, Minnesota (PDA/1 Rickettsia 
rickettsii 2004) 
102. Baldwin, C. L., University of Massachusetts, Amherst, Massachusetts (PDA/1 
Brucella melitensis 2000, 2001, 2002, 2003) 
103. Balinsky, C. A., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2004) 
104. Ball, H., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
105. Balog, R., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 Bacillus 
anthracis 2004) 
106. Baloglu, S., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000) 
107. Banerjee, S. N., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 2003) 
108. Banfield, C. M., Lackland Air Force Base, San Antonio, Texas (MDA/4/5 Coxiella 
burnetii 2002) 
109. Bankamp, B., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Nipah virus 2004) 
110. Barash, J. R., California Department of Health Services, Berkeley, California 
(PDA/1 Clostridium botulinum 2003, PDA/1 Yersinia pestis 2000) 
111. Barathur, R. R., ClinCyte, LLC, San Diego, California (PDA/1 Brucella melitensis 
2000) 
112. Barbet, A. F., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2000, 2001, 2002) 
113. Bardsley, K., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2002) 
114. Baribaud, F., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
115. Barker, J. R., University of Texas San Antonio, San Antonio, Texas (EDA/5 
Francisella tularensis 2003, PDA/1 Francisella tularensis 2004) 
116. Barnes, B. J., Johns Hopkins University, Baltimore, Maryland (PDA/1 Newcastle 
disease virus 2001, 2002, 2003) 
117. Barnes, W. J., Brooks Air Force Base, San Antonio, Texas (PDA/1 Yersinia pestis 
2003) 
118. Barnett, G. A., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
119. Barnewall, R., Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2003, 
PDA/1 Bacillus anthracis 2004) 
120. Barr, J. R., Center fo Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Coxiella burnetii 2004) 
121. Barrera, J., Plum Island Animal Disease Center, United States Department of 




122. Barrett, A. D. T., University of Texas Medical Branch, Galveston, Texas (EDA/2 
Omsk hemorrhagic fever virus 2003, 2004, 2005, PDA/1 Japanese encephalitis virus 
2000, 2003, 2004) 
123. Barrientos, L. G., National Institutes of Health, Bethesda, Maryland (EDA/2 Zaire 
ebolavirus 2003) 
124. Barrow, E. W., Oklahoma State University, Stillwater, Oklahoma (PDA/1 Bacillus 
anthracis 2004) 
125. Barrow, W. W., Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Bacillus anthracis 2004) 
126. Barrows, L. F., University of Wyoming, Laramie, Wyoming (PDA/1 Coxiella 
burnetii 2002, 2003) 
127. Barry, P. A., University of California-Davis, Davis, California (PDA/1 
Cercopithecine herepesvirus 1 2003) 
128. Barth, J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (MDA/4/5 Bacillus anthracis 2001) 
129. Barthel, R.,Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2001) 
130. Barvir, D. A., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Japanese encephalitis virus 2001) 
131. Basler, C. F., Mount Sinai School of Medicine, New York, New York (EDA/1 
“1918 Influenza virus” 2001, 2002, 2004, EDA/2 Lassa virus 2002, 2003, EDA/2 Zaire 
ebolavirus 2002, 2003, PDA/1 Newcastle disease virus 2003) 
132. Bassett, A., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Venezuelan equine 
encephalitis virus 2003) 
133. Baszler, T. V., Washington State University, Pullman, Washington (PDA/1 Bovine 
spongiform encephalopathy prion 2001) 
134. Bates, P., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 Zaire 
ebolavirus 2003) 
135. Baumgartner, J., University of Georgia, Athens, Georgia (PDA/1 Brucella 
melitensis 2004) 
136. Baumstark, B., Centers for Disease Control and Prevention, Atlanta, 
Georgia/Georgia State University, Atlanta, Georgia (PDA/1 Clostridium botulinum 2004, 
PDA/1 Rickettsia rickettsii 2003) 
137. Bausch, Daniel G., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Lassa virus 2000, EDA/2 Sudan ebolavirus 2004) 
138. Bautista, E. M., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2005) 
139. Bavari, S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2002, 2003, 2004, 2005, 
EDA/2 Zaire ebolavirus 2002, 2003, 2004, 2005, PDA/1 Bacillus anthracis 2004, 2005) 





141. Baxt, B. , Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2000, 2001, 
2004, 2005) 
142. Bean, T. J., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2004) 
143. Beanan, M. J. Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Coxiella burnetii 2003) 
144. Beard, C. W., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York/Southeast Poultry Research Laboratory, United States 
Department of Agriculture, Athens, Georgia (PDA/1 Foot and mouth disease virus 2000, 
PDA/1 Influenza A virus 2001) 
145. Bearden, S. W., Centers for Disease Control and Prevention, Fort Collins, 
Colorado/University of Kentucky, Lexington, Kentucky (PDA/1 Francisella tularensis 
2004, PDA/1 Yersinia pestis 2001, 2003) 
146. Bearson, B. L., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (MDA/4/5 Mycoplasma gallisepticum 2005) 
147. Bearson, S. M. D., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (MDA/4/5 Mycoplasma gallisepticum 2005) 
148. Beasley, D. W. C., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Japanese encephalitis virus 2003, 2004) 
149. Bechner, M., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
150. Beck, J. R., Southeast Poultry Research Laboratory, United States Department of 
Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2000, 2001, 2005, PDA/1 
Newcastle disease virus 2004) 
151. Beecher, D. J., FBI Academy, Quantico, Virginia (PDA/1 Bacillus anthracis 2004) 
152. Beier, M. S., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2003) 
153. Bell, C. A., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Bacillus 
anthracis 2002) 
154. Bell, C., Purdue University, West Lafayette, Indiana (PDA/1 Bacillus anthracis 
2005) 
155. Bell, M., Ohio State University, Columbus, Ohio (MDA/4/5 Bacillus anthracis 
2004) 
156. Bell, R., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Francisella tularensis 2003) 
157. Bellaire, B. H., Louisiana State University Health Sciences Center, Shreveport, 
Louisiana (PDA/1 Brucella melitensis 2002, 2003) 
158. Bellini, W. J., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Hendra virus 2002, PDA/1 Nipah virus 2000, 2001, 2002, 2003, 2004) 
159. Belosludtsev, Y. Y., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 
Bacillus anthracis 2004) 
160. Benach, J. L., Stony Brook University, Stony Brook, New York (PDA/1 




161. Benedek, O., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2003) 
162. Bennet, J., Emory University, Atlanta, Georgia (MDA/4/5 Measles virus 2002, 
MDA/4/5 Rubella virus 2002) 
163. Benson, A. K., University of Nebraska, Lincoln, Nebraska (PDA/1 Francisella 
tularensis 2004) 
164. Benson, G., Mount Sinai School of Medicine, New York, New York (PDA/1 
Bacillus anthracis 2001, PDA/1 Yersinia pestis 2001) 
165. Benton, J. L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
166. Bergelson, J. M., Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
(PDA/1 Human enterovirus B 2000) 
167. Bergman, N. H., Institute for Genomic Research, Rockville, Maryland/University 
of Michigan Medical School, Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2004, 
2005) 
168. Berliba, L., University of New Mexico, Albuquerque, New Mexico (PDA/1 
Bacillus anthracis 2004) 
169. Bermudez, A. J., University of Missouri, Columbia, Missouri (PDA/1 Newcastle 
disease virus 2000) 
170. Bernal, A., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
171. Bernard, K. A., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Venezuelan equine encephalitis virus 2000) 
172. Bernardi, J., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002) 
173. Berry, K. J., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003) 
174. Berthold, I., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
175. Bertolotti-Ciarlet, A., University of Pennsylvania, Philadelphia, Pennsylvania 
(EDA/2 Crimean-Congo hemorrhagic fever virus 2005) 
176. Bessman, M. J., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2002) 
177. Beuchat, L. R., University of Georgia, Griffin, Georgia (PDA/1 Bacillus anthracis 
2004, 2005) 
178. Beyene, B., University of California-Davis, Davis, California (PDA/1 Peste-des-
petits-ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
179. Bezborodova, S. V., Plum Island Animal Disease Center, United States 
Department of Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 
2002) 
180. Bhatt, T. R., Clonetech, Inc., Palo Alto, California (PDA/1 Japanese encephalitis 
virus 2000) 
181. Bhattacharjee, A. K., Walter Reed Army Institute of Research, Washington, D.C. 




182. Bhattacharyya, A., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
183. Bi, S., Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004) 
184. Biggins, D., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Yersinia pestis 2001) 
185. Billharz, R., University of Washington, Seattle, Washington (EDA/1 “1918 
Influenza virus” 2004) 
186. Billia-Shaveet, D., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 
Foot and mouth disease virus 2002) 
187. Bin, Q., Chiron, Emeryville, California (PDA/1 Venezuelan equine encephalitis 
virus 2003) 
188. Bishara, J., University of Scranton, Scranton, Pennsylvania/University of Texas, 
Dallas, Texas (PDA/1 Bacillus anthracis 2004) 
189. Bishop, K. A., Uniformed Services University, Bethesda, Maryland (PDA/1 
Hendra virus 2005, PDA/1 Nipah virus 2005) 
190. Black, D. H., Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Cercopithecine herpesvirus 1 2003) 
191. Black, S., Critical Response Engineering, Inc., Alexandria, Virginia (PDA/1 
Bacillus anthracis 2003) 
192. Blair, H., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2004) 
193. Blanchard, D. J., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
194. Blanchard, T. W., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Yersinia pestis 2001) 
195. Blaser, M. J., New York University, New York, New York (PDA/1 Bacillus 
anthracis 2003, 2005) 
196. Blattner, F. R., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
197. Blazar, B. R., University of Minnesota, Minneapolis, Minnesota (PDA/1 Bacillus 
anthracis 2004) 
198. Bliska, J. B., Brookhaven National Laboratory, Upton, New York/State University 
of New York at Stony Brook, Stony Brook, New York (PDA/1 Yersinia pestis 2003, 
2004) 
199. Bliss, K. A., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2004) 
200. Bobrov, A. G., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2002, 2004) 
201. Bocanegra, R., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002) 
202. Bode, E., United States Army Medical Research Institute of Infectious Diseases, 




203. Bodey, B., University of Southern California, Los Angeles, California (PDA/1 
Newcastle disease virus 2004) 
204. Boiarski, A. A., BioSense Consulting, Columbus, Ohio (PDA/1 Francisella 
tularensis 2000) 
205. Bolger, C. E., Stony Brook University, Stony Brook, New York (PDA/1 
Francisella tularensis 2005) 
206. Bolin, C. A., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2001) 
207. Bonaparte, M. I., Uniformed Services University, Bethesda, Maryland (PDA/1 
Hendra virus 2005, PDA/1 Nipah virus 2005) 
208. Bonneau, K. R., University of California-Davis, Davis, California (PDA/1 
Bluetongue virus 2000) 
209. Bookout, J. B., ClinCyte, LLC, San Diego, California (PDA/1 Brucella melitensis 
2000) 
210. Boone, S. A., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 
Bacillus anthracis 2003)  
211. Booth, N. J., Louisiana State University, Baton Rouge, Louisiana (PDA/1 Brucella 
melitensis 2000, 2001, 2002) 
212. Bora, R. S., Jefferson Medical College, Philadelphia, Pennsylvania (PDA/1 
Clostridium botulinum 2004) 
213. Boras, A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002) 
214. Borca, M. V., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2005, PDA/1 
Classical swine fever virus 2003, 2005, PDA/1 Foot and mouth disease virus 2005)  
215. Borisey, G. G., North-Western University, Chicago, Illinois (PDA/1 Rickettsia 
rickettsii 2004) 
216. Borodovsky, M., Georgia Institute of Technology, Atlanta, Georgia (PDA/1 
Cercopithecine herpesvirus 1 2003) 
217. Bortolin, L. T., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
218. Boshra, H., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 Zaire 
ebolavirus 2003) 
219. Bosio, C. M., United States Army Medical Research Institute of Infectious 
Diseases/Clinical Research Management, Frederick, Maryland/Center for Biologics 
Evaluation and Research, Food and Drug Administration, Rockville, Maryland (EDA/2 
Lake Victoria marburgvirus 2002, 2003, 2004, EDA/2 Zaire ebolavirus 2002, 2003, 2004, 
PDA/1 Francisella tularensis 2001) 
220. Bossart, K. N., Uniformed Services University, Bethesda, Maryland (PDA/1 
Hendra virus 2005, PDA/1 Nipah virus 2005) 
221. Bouhaouala, S. S., Armed Forces Radiobiology Research Institute, Bethesda, 
Maryland (MDA/4/5 Venezuelan equine encephalitis virus 2001, PDA/1 Bacillus 




222. Boulianne, C., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rift Valley fever virus 2002) 
223. Bourgogne, A., University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 
2003, 2004) 
224. Bournce, P. C., Oklahoma State University, Stillwater, Oklahoma (PDA/1 Bacillus 
anthracis 2004) 
225. Boutin, A., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
226. Bouvier, N., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2003) 
227. Bouyer, D. H., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia prowazekii 2000, PDA/1 Rickettsia rickettsii 2005) 
228. Bowen, M. D., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Lassa virus 2000, EDA/2 Junín virus 2000, PDA/1 Monkeypox virus 2002) 
229. Bowen, R. A., Colorado State University, Fort Collins, Colorado (PDA/1 
Venezuelan equine encephalitis virus 2001)  
230. Bowerman, D., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 Bacillus 
anthracis 2004) 
231. Bowling, J. M., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
232. Boyaka, P. N., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2003) 
233. Boyd, M. R., Cancer Research Institute, College of Medicine, University of South 
Alabama, Mobile, Alabama (EDA/2 Zaire ebolavirus 2003) 
234. Boyle, S. M., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000, 2001) 
235. Bozue, J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004, 2005) 
236. Bradburne, C., Advanced Biosystems Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2004) 
237. Bradshaw, M., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2000, 2003, 2004, 2005) 
238. Bragg, S. L., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002) 
239. Braha, O., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2002) 
240. Brandt, S., University of Nevada School of Medicine, Reno, Nevada (PDA/1 
Bacillus anthracis 2004) 
241. Branton, S. L., United States Department of Agriculture, Agricultural Research 
Service, Mississippi State, Mississippi (MDA/4/5 Mycoplasma gallisepticum 2005)  





243. Brault, A. C., University of Texas Medical Branch, Galveston, Texas/Centers for 
Disease Control and Prevention, Fort Collins, Colorado (PDA/1 Venezuelan equine 
encephalitis virus 2000, 2001, 2002, 2003, 2004, 2005) 
244. Bray, M., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland/National Institutes of Health, Bethesda, 
Maryland/United States Army Medical Research Institute of Infectious Diseases, Fort 
Detrick, Maryland (EDA/1 Variola virus 2003, EDA/2 Crimean-Congo hemorrhagic fever 
virus 2004, EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, EDA/5 Camelpox virus 
2002, EDA/2 Tick-borne encephalitis virus 2000, 2001, EDA/5 Monkeypox virus 2002, 
MDA/4/5 Andes virus 2002, MDA/4/5 Cowpox virus 2000, 2002, PDA/1 Bacillus 
anthracis 2004, PDA/1 Camelpox virus 2001, 2003, PDA/1 Monkeypox virus 2001, 
2003, PDA/1 Venezuelan equine encephalitis virus 2003) 
245. Brayton, K. A., Washington State University, Pullman, Washington (PDA/1 
Ehrlichia ruminantium 2000, 2002, 2004, 2005) 
246. Breadmore, M. C., University of Virginia, Charlottesville, Virginia (PDA/1 
Bacillus anthracis 2003) 
247. Breeze, R., United States Department of Agriculture, Agricultural Research 
Service, Washington, D.C. (PDA/1 Bacillus anthracis 2003) 
248. Brennan, R. E., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2003, 2004) 
249. Brenneman, K., Ohio State University, Columbus, Ohio (MDA/4/5 Bacillus 
anthracis 2004) 
250. Bresnitz, E., Department of Health and Senior Services, Trenton, New Jersey 
(PDA/1 Bacillus anthracis 2003) 
251. Brettin, T., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2005) 
252. Bricker, B. J., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000, 2001, 2003) 
253. Bridge, D., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
254. Bridges, J. H., United Postal Service, Washington, D. C. (PDA/1 Bacillus 
anthracis 2002) 
255. Brigati, J., Auburn University, Auburn, Alabama (PDA/1 Bacillus anthracis 2004)  
256. Bright, R. A., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Influenza A virus 2003) 
257. Brinkac, L. M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 
pseudomallei 2004, PDA/1 Coxiella burnetii 2003) 
258. Brittingham, J. M., BD Technologies, Research Triangle Park, North Carolina 
(PDA/1 Bacillus anthracis 2005) 
259. Brittingham, K. C., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2005) 
260. Broder, C. C., Uniformed Services University, Bethesda, Maryland (PDA/1 




261. Brook, I., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
(PDA/1 Bacillus anthracis 2001, 2002) 
262. Brown, B., Centers for Disease Control and Prevention, Atlanta, Georgia (EDA/2 
Lassa virus 2000) 
263. Brown, C. C., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia/University of Georgia, Athens, Georgia (PDA/1 Foot and 
mouth disease virus 2000, PDA/1 Newcastle disease virus 2001, 2002, 2003) 
264. Brown, D. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Burkholderia mallei 2000) 
265. Brown, F., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2000, 2001, 
2002, 2003, 2005) 
266. Brown, J. E., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2005) 
267. Brown, K., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Venezuelan equine encephalitis virus 2000) 
268. Brown, P. O., Stanford University, Stanford, Connecticut (EDA/1 Variola virus 
2004) 
269. Brown, P., Bethesda, Maryland (PDA/1 Bovine spongiform encephalopathy prion 
2005) 
270. Brown, S., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus anthracis 2003, MDA/4/5 Yersinia pestis 2003) 
271. Brown, T. D., East Carolina University, Greenville, North Carolina (PDA/1 
Brucella melitensis 2004) 
272. Brown, T. M., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Eastern equine encephalitis virus 2001) 
273. Brown, W. C., Washington State University, Pullman, Washington (PDA/1 
Ehrlichia ruminantium 2000) 
274. Brubaker, R. R., Michigan State University, East Lansing, Michigan (PDA/1 
Yersinia pestis 2000, 2002, 2004) 
275. Brum, M. C., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2005) 
276. Brumlik, M. J., University of Scranton, Scranton, Pennsylvania (PDA/1 Bacillus 
anthracis 2001, 2004) 
277. Bruno, J. G., University of Texas, San Antonio, Texas (PDA/1 Bacillus anthracis 
2000) 
278. Bryan, R., United States Army Dugway Proving Grounds, Dugway, Utah 
(MDA/4/5 Bacillus anthracis 2003, MDA/4/5 Yersinia pestis 2003) 
279. Buccolo, L. S., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000) 
280. Buchmeier, M. J., Scripps Research Institute, La Jolla, California (EDA/2 Junín 
virus 2000, EDA/2 Lassa virus 2002, 2003, 2004, 2005, EDA/2 Zaire ebolavirus 2003) 
281. Budhavarapu, V. N., University of Texas San Antonio, San Antonio, Texas 




282. Buhr, T. L., Naval Surface Warfare Center, Dahlgren, Virginia (PDA/1 Bacillus 
anthracis 2005) 
283. Buitenhuis, A. J., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 
2001) 
284. Bukofzer, S., Abbott Laboratories, Chicago, Illinois (PDA/1 Bacillus anthracis 
2003, PDA/1 Yersinia pestis 2003) 
285. Bulaga, L. L., United States Department of Agriculture, Animal and Plant Health 
Inspection Service, Robbinsville, New Jersey (PDA/1 Influenza A virus 2002, 2003) 
286. Bull, R. L., Naval Medical Research Center, Silver Spring, Maryland (MDA/4/5 
Bacillus anthracis 2002, PDA/1 Bacillus anthracis 2004, PDA/1 Clostridium botulinum 
2005) 
287. Burgess, R. J., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Francisella tularensis 2003) 
288. Burke, D. J., University of Virginia, Charlottesville, Virginia (PDA/1 Foot and 
mouth disease virus 2002) 
289. Burke, E., Scripps Research Institute, La Jolla, California (EDA/2 Zaire ebolavirus 
2003) 
290. Burkhalter, K., Centers for Disease Control and Prevention, Fort Collins, 
Colorado/Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Eastern equine encephalitis virus 2003) 
291. Burkhardt, N. Y., University of Minnesota, St. Paul, Minnesota (PDA/1 Rickettsia 
rickettsii 2004) 
292. Burland, V., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
293. Burnett, S. H., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2005) 
294. Burr, D. H., United States Food and Drug Administration, Summit-Argo, Illinois 
(PDA/1 Clostridium botulinum 2005) 
295. Burrage, T. G., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2000, 2001, 2004, 
PDA/1 Foot and mouth disease virus 2000) 
296. Burridge, M. J., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2000, 2001, 2002) 
297. Burris, K., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus anthracis 2003, MDA/4/5 Yersinia pestis 2003) 
298. Burton, D. R., Scripps Research Institute, La Jolla, California (EDA/2 Zaire 
ebolavirus 2002, PDA/1 Bovine spongiform encephalopathy prion 2002) 
299. Busch, J. D., Northern Arizona University, Flagstaff, Arizona (EDA/5 Bacillus 
anthracis 2003, PDA/1 Bacillus anthracis 2002, 2004) 
300. Busch, M., Zoological Society of San Diego, San Diego, California (PDA/1 
Mycoplasma mycoides mycoides 2005)  
301. Bush, G. V., United States Army Medical Research Institute of Infectious 




302. Butts, J. D., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Rickettsia prowazekii 2000, PDA/1 Rickettsia rickettsii 2000) 
303. Byers, B. R., University of Mississippi, Jackson, Mississippi (PDA/1 Bacillus 
anthracis 2004) 
304. Byrne, W. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Coxiella burnetii 2002, PDA/1 Burkholderia 
mallei 2001) 
305. Bystrom, S. L., California Department of Health Services, Richmond, California 
(PDA/1 Brucella melitensis 2004) 
306. Cai, S., University of Massachusetts Dartmouth, North Dartmouth, Massachusetts 
(PDA/1 Clostridium botulinum 2001) 
307. Calampa, C., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
308. Calderon, Leilani, California Institute for Medical Research, San Jose, California 
(PDA/1 Coccidioides immitis 2000, PDA/1 Coccidioides posadasii 2000) 
309. Call, J., United States Department of Agriculture, Agricultural Research Service, 
Wyndmoor, Pennsylvania (PDA/1 Bacillus anthracis 2005) 
310. Callahan, A., United States Department of Agriculture, Agricultural Research 
Service, Kearneysville, West Virginia (PDA/1 Plum pox virus 2001) 
311. Callahan, J. D., Tetracore Inc., Gaithersburg, Maryland (PDA/1 African swine 
fever virus 2005, PDA/1 Classical swine fever virus 2003, 2005, PDA/1 Foot and mouth 
disease virus 2002) 
312. Calvert, C. L., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000) 
313. Cambier, S., University of California, San Francisco, California (PDA/1 Foot and 
mouth disease virus 2004) 
314. Campbell, G. A., University of Texas Medical Branch, Galveston, Texas (EDA/2 
Omsk hemorrhagic fever virus 2005, PDA/1 Eastern equine encephalitis virus 2004) 
315. Campbell, K. P., University of Iowa, Iowa City, Iowa (EDA/2 Guanarito virus 
2002, EDA/2 Machupo virus 2002, PDA/1 Sabiá virus 2002, PDA/1 Flexal virus 2002) 
316. Campbell, M. S., National Institutes of Health, Bethesda, Maryland (MDA/6 
Langat virus 2000) 
317. Canavessi, A. M., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
318. Cannon, P., Children’s Hospital, Los Angeles, California (EDA/2 Junín virus 
2003, 2004) 
319. Cannons, A., University of South Florida, Tampa, Florida (PDA/1 Bacillus 
anthracis 2003) 
320. Cao, G.-L., University of Maryland Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2005) 
321. Capitanio, J., University of California-Davis, Davis, California (PDA/1 
Cercopithecine herepesvirus 1 2003) 




323. Cararra, S., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Eastern equine encephalitis virus 2004) 
324. Carbonara, C., Stony Brook University, Stony Brook, New York (PDA/1 
Francisella tularensis 2003) 
325. Cardon, M. L., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
326. Cardwell, J., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002, 2004) 
327. Carlson, R. W., East Carolina University School of Medicine, Greenville, North 
Carolina (PDA/1 Brucella melitensis 2004) 
328. Carmichael, K. P., Southeast Poultry Research Laboratory, United States 
Department of Agriculture, Athens, Georgia (PDA/1 Newcastle disease virus 2002, 2003) 
329. Carnes, R. Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2003) 
330. Carney, J. Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2003) 
331. Caron, L., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003) 
332. Carra, J. H., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2005) 
333. Carrara, A.-S., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2003, 2004) 
334. Carreno, A., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2005) 
335. Carrillo, C, Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2005) 
336. Carrington, James C., Oregon State University, Corvallis, Oregon (EDA/4 Plum 
pox virus 2002) 
337. Carter, L. G., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Francisella tularensis 2004, PDA/1 Yersinia pestis 2000) 
338. Carter, V., University of Washington, Seattle, Washington (EDA/1 “1918 
Influenza virus” 2004) 
339. Carty, H. A., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Coxiella burnetii 2003) 
340. Casey, L., Elusys Therapeutics Inc., Pine Brook, New Jersey (MDA/4/5 Bacillus 
anthracis 2005) 
341. Casey, M., Medical College of Wisconsin, Milwaukee, Wisconsin (PDA/1 
Francisella tularensis 2004) 
342. Castillo, U. F., Montana State University, Bozeman, Montana (PDA/1 Bacillus 
anthracis 2002, 2003) 
343. Castle, K. T., United States Geological Survey, Fort Collins, Colorado (PDA/1 
Yersinia pestis 2001) 
344. Caswell-Stephan, K., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
345. Catalan, J., Acambis Inc., Cambridge, Massachusetts (PDA/1 Japanese 




346. Catlin, K. M. K., Uniformed Services University of the Health Sciences, Bethesda, 
Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
347. Cattani, J., University of South Florida, Tampa, Florida (PDA/1 Bacillus anthracis 
2003) 
348. Caughlan, R., University of Illinois at Urbana-Champaign, Urbana, Illinois 
(PDA/1 Yersinia pestis 2002) 
349. Cauthen, A. N., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2000)  
350. Cello, J., State University of New York at Stony Brook, Stony Brook, New York 
(MDA/6 Poliovirus 2002) 
351. Cendrowski, S., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2004) 
352. Chabot, D. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
353. Chada, K., University of Medicine and Dentistry of New Jersey, Piscataway, New 
Jersey (PDA/1 Newcastle disease virus 2002) 
354. Chada, V. G. R., Illinois Institute of Technology, Chicago, Illinois (PDA/1 
Bacillus anthracis 2003) 
355. Chaga, O. Y., North-Western University, Chicago, Illinois (PDA/1 Rickettsia 
rickettsii 2004) 
356. Chain, P. S. G., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Francisella tularensis 2005, PDA/1 Yersinia pestis 2003, 2004) 
357. Chambers, E., Northern Arizona University, Flagstaff, Arizona (PDA/1 
Francisella tularensis 2004) 
358. Chambers, J. P., University of Texas San Antonio, San Antonio, Texas University 
of Texas San Antonio, San Antonio, Texas 
359. Chambers, T. J., St. Louis University, St. Louis, Missouri (PDA/1 Japanese 
encephalitis virus 2001) 
360. Chan, B., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
361. Chan, S. Y., Gladstone Institute of Virology and Immunology, San Francisco, 
California/University of California, San Francisco, California (EDA/2 Lake Victoria 
marburgvirus 2001, EDA/2 Zaire ebolavirus 2001) 
362. Chandhoke, V., George Mason University, Fairfax, Virginia (PDA/1 Bacillus 
anthracis 2005) 
363. Chandler, L. M., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2001) 
364. Chandran, K., Harvard Medical School, Boston, Massachusetts (EDA/2 Zaire 
ebolavirus 2005) 
365. Chang, C.-J., University of Georgia, Griffin, Maryland (PDA/1 Xylella fastidiosa 
2002) 
366. Chang, G.-J. J., Centers for Disease Control and Prevention, Fort Collins, 




367. Chang, J. T., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
368. Chang, T., Y., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot and 
mouth disease virus 2001, 2002) 
369. Chao, C.-C., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Rickettsia prowazekii 2004)  
370. Chapman, G., Naval Medical Research Center, Rockville, Maryland (PDA/1 
Bacillus anthracis 2005) 
371. Chapman, J., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 Foot and 
mouth disease virus 2002) 
372. Charles, P. C., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Venezuelan equine encephalitis virus 2000, 2001) 
373. Chaturvedi, Vishnu, New York State Department of Health, Albany, New York 
(PDA/1 Coccidioides immitis 2000) 
374. Chea, F. P., Rutgers - The State University of New Jersey, New Brunswick, New 
Jersey (PDA/1 Clostridium botulinum 2000) 
375. Chelius, D., Thermo Finnigan, San Jose, California (PDA/1 Rickettsia prowazekii 
2004)  
376. Chen, C., University of Georgia, Athens, Georgia (PDA/1 Newcastle disease virus 
2003) 
377. Chen, I-H., Auburn University, Auburn, Alabama (PDA/1 Bacillus anthracis 
2004) 
378. Chen, J., Florida A&M University, Tallahassee, Florida (PDA/1 Xylella fastidiosa 
2002) 
379. Chen, J., Massachusetts Institute of Technology, Cambridge, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
380. Chen, P., University of Alabama at Birmingham, Birmingham, Alabama (PDA/1 
Bacillus anthracis 2003, 2004) 
381. Chen, X., University of California, San Francisco, California (PDA/1 Newcastle 
disease virus 2004) 
382. Chen, Y., Rutgers - The State University of New Jersey, New Brunswick, New 
Jersey (PDA/1 Clostridium botulinum 2000) 
383. Chen, Y., Texas A&M University, Houston, Texas/University of Texas, Houston, 
Texas (PDA/1 Bacillus anthracis 2003, 2004, 2005) 
384. Cherepanov, P., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2000) 
385. Cherni, A., Argonne National Laboratory, Argonne, Illinois (PDA/1 Bacillus 
anthracis 2004) 
386. Cherry, S., National Cancer Institute Frederick, Maryland (PDA/1 Yersinia pestis 
2005) 
387. Cheville, N. F., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 
2000) 
388. Ching, W.-M., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 




389. Chinsangaram, J., Plum Island Animal Disease Center, United States Department 
of Agriculture, Greenport, New York/University of Georgia, Athens, Georgia (PDA/1 
Foot and mouth disease virus 2000, 2001, 2003) 
390. Chirgwin, S. R., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
391. Chiu, W., Baylor College of Medicine, Houston, Texas (PDA/1 Venezuelan 
equine encephalitis virus 2001, 2003) 
392. Chiueh, T.-S., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Japanese encephalitis virus 2003) 
393. Chizhikov, V., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (EDA/1 Variola virus 2003, PDA/1 Bacillus 
anthracis 2004, PDA/1 Monkeypox virus 2003) 
394. Cho, D., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Influenza A virus 2003) 
395. Choi, M. W., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2005) 
396. Chopra, A. P., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 
Bacillus anthracis 2003)  
397. Chou, T.-H., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Yersinia pestis 2004) 
398. Choudhary, A., Uniformed Services University, Bethesda, Maryland (PDA/1 
Hendra virus 2005, PDA/1 Nipah virus 2005) 
399. Choudhry, V., National Cancer Institute, Frederick, Maryland (PDA/1 Hendra 
virus 2005, PDA/1 Nipah virus 2005) 
400. Christian, L., University of Arizona, Tucson, Arizona (PDA/1 Coccidioides 
immitis 2000, PDA/1 Coccidioides posadasii 2000) 
401. Chromy, B. A., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004, 2005) 
402. Chu, C. K., College of Pharmacy, The University of Georgia, Athens, GA (EDA/1 
Variola virus 2003, PDA/1 Monkeypox virus 2003) 
403. Chu, M. C., Centers for Disease Control and Prevention, Atlanta, Georgia/Ft. 
Collins, Colorado (PDA/1 Francisella tularensis 2002, 2003, 2004, 2005, PDA/1 Yersinia 
pestis 2000, 2001, 2002, 2003, 2005) 
404. Chuang, Y.-Y. E., National Cancer Institute, National Institutes of Health, 
Gaithersburg, Maryland (PDA/1 Rickettsia prowazekii 2003, 2004) 
405. Chumakov, K., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (EDA/1 Variola virus 2003, PDA/1 Monkeypox 
virus 2003) 
406. Chunhong, T., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
407. Churas, C., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
408. Ciblak, M. A., Centers for Disease Control and Prevention, Atlanta, Georgia 




409. Cirillo, J. D., University of Nebraska, Lincoln, Nebraska (PDA/1 Francisella 
tularensis 2004) 
410. Clafin, L. E., Kansas State University, Manhattan, Kansas (PDA/1 Xanthomonas 
oryzae 2004) 
411. Clagett, M., Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2005) 
412. Clapham, P., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Yersinia pestis 2004) 
413. Clark Burton, N., Centers for Disease Control and Prevention, Cincinnati, Ohio 
(MDA/4/5 Bacillus globigii 2005) 
414. Clark, L. K., Purdue University, West Lafayette, Indiana (PDA/1 Foot and mouth 
disease virus 2003) 
415. Clarridge III, J. E., Veterans Affairs Medical Center, Houston, Texas (PDA/1 
Francisella tularensis 2000) 
416. Claus, J. R., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Clostridium botulinum 2000) 
417. Clemens, D. L., University of California Los Angeles, Los Angeles, California 
(PDA/1 Francisella tularensis 2003) 
418. Clemens, T., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2004)  
419. Clements, J. D., Tulane University, New Orleans, Louisiana (PDA/1 Influenza A 
virus 2001) 
420. Clemons, K. V., California Institute for Medical Research, San Jose, California 
(PDA/1 Coccidioides immitis 2000, 2002, 2003, PDA/1 Coccidioides posadasii 2000) 
421. Cline, R., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003) 
422. Clippinger, T. L., Zoological Society of San Diego, San Diego, California (PDA/1 
Mycoplasma mycoides mycoides 2005)  
423. Cloeckaert, A., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
424. Cloud, S. S., University of Delaware, Newark, Delaware (PDA/1 Newcastle 
disease virus 2003) 
425. Coalson, J. J., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides posadasii 2003) 
426. Cockerill III, F. R., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 
Bacillus anthracis 2002, PDA/1 Monkeypox virus 2002) 
427. Coffee, K. R., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
428. Coffey, L. L., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2004) 
429. Coffman, G. L., James Madison University, Harrisonburg, Virginia (PDA/1 
Yersinia pestis 2005) 
430. Cohen, D. A., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 




431. Coker, C., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2003) 
432. Coker, P. R., Lawrence Livermore National Laboratory, Livermore, 
California/Louisiana State University, Baton Rouge, Louisiana (PDA/1 Bacillus anthracis 
2002, 2003)  
433. Colby, L. A., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000, 2002) 
434. Cole, G. T., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides immitis 
2000, 2001, 2002, 2003, PDA/1 Coccidioides posadasii 2000, 2003) 
435. Cole, M. B., University of Massachusetts, Amherst, Massachusetts (PDA/1 
Clostridium botulinum 2000) 
436. Coleman, M. A., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
437. Coleman, R. E., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
438. Coleman, S. A., National Institutes of Health, Hamilton, Montana (PDA/1 Coxiella 
burnetii 2004) 
439. Coleman, S. U., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
440. Collier, R. J. Harvard Medical School, Boston, Massachusetts (PDA/1 Bacillus 
anthracis 2000) 
441. Collier, S. D., United States Department of Agriculture, Agricultural Research 
Service, Mississippi State, Mississippi (MDA/4/5 Mycoplasma gallisepticum 2005)  
442. Collins, J. K., University of Arizona, Tucson, Arizona (PDA/1 Alcelaphine 
herpesvirus 1,2 2001) 
443. Collins, L., US Army Edgewood Chemical Biological Center, Aberdeen Proving 
Ground, Maryland (PDA/1 Francisella tularensis 2003) 
444. Colombini, S. M., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (PDA/1 Francisella tularensis 2002) 
445. Colston Jr., B. W., Lawrence Livermore National Laboratory, Livermore, 
California (MDA/4/5 Bacillus anthracis 2003, 2005, MDA/4/5 Bacillus globigii 2005, 
MDA/4/5 Yersinia pestis 2003, 2005) 
446. Cominelli, F., University of Virginia, Charlottesville, Virginia (PDA/1 Japanese 
encephalitis virus 2001) 
447. Compans, R. W., Emory University, Atlanta, Georgia (EDA/2 Lassa virus 2002, 
2003) 
448. Condron, M. A. M., University of Washington, Seattle, Washington (PDA/1 
Bacillus anthracis 2002) 
449. Condron, M., Harvard Medical School, Boston, Massachusetts (PDA/1 Bacillus 
anthracis 2003) 
450. Connell, N. D., University of Medicine and Dentistry of New Jersey, Newark, 
New Jersey (PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 
451. Contreras, A., Virginia Polytechnic Institute and State University, Blacksburg, 




452. Cook, W. E., University of Wyoming, Laramie, Wyoming/Wyoming Game and 
Fish Laboratory, University Station, Laramie, Wyoming (PDA/1 Brucella melitensis 
2000, 2002) 
453. Cooper, A., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (PDA/1 Francisella tularensis 2002) 
454. Cooper, L. A., University of Maryland, College Park, Maryland (PDA/1 Eastern 
equine encephalitis virus 2000, 2001) 
455. Cooper, M., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Bacillus anthracis 2003) 
456. Cote, C. K., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004, 2005) 
457. Cote, M. A., BCR Diagnostics, Inc., Jamestown, Rhode Island (PDA/1 Bacillus 
anthracis 2004) 
458. Covert, J., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2005) 
459. Cowan, C., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 
2000, 2005) 
460. Cowin, P. G., United States Army Center for Health Promotion and Preventive 
Medicine, Aberdeen Proving Ground, Maryland (MDA/4/5 Bacillus anthracis 2002) 
461. Cowley, S. C., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (PDA/1 Francisella tularensis 2002, 2003, 2004) 
462. Cox, N., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Influenza A virus 2003) 
463. Cox, R. A., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002, 2003) 
464. Coyne, S. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 
2004) 
465. Crabtree, M. B., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Japanese encephalitis virus 2000, PDA/1 Rift Valley fever virus 2002) 
466. Craik, C. S., University of California, San Francisco, California (PDA/1 Yersinia 
pestis 2004) 
467. Crary, S. M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Sudan ebolavirus 2004, EDA/2 Zaire ebolavirus 2003, 2004) 
468. Craven, K. E., United States Food and Drug Administration, Atlanta, Georgia 
(PDA/1 Clostridium botulinum 2002) 
469. Craven, R. R., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (EDA/5 Francisella tularensis 2004) 
470. Cravero, S., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000) 
471. Craw, P. D., United States Army Medical Research Institute of Infectious 





472. Crawford, J. M., United States Department of Agriculture, Southeast Poultry 
Research Laboratory, Atlanta Georgia (PDA/1 Newcastle disease virus 2002) 
473. Crawford, R. M., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Brucella melitensis 2000) 
474. Crawford, T. B., United States Department of Agriculture, Agricultural Research 
Service, Dubois, Idaho/Washington State University, Pullman, Washington (MDA/4/5 
Alcelaphine herpesvirus 1,2 2004, 2005, PDA/1 Alcelaphine herpesvirus 1,2 2000, 2001, 
2002, 2003) 
475. Creighton, R., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
476. Criscuolo, C. J., Fraunhofer USA Center for Molecular Biotechnology, Newark, 
Delaware (PDA/1 Bacillus anthracis 2005) 
477. Crise, B., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2001, MDA/4/5 Venezuelan equine 
encephalitis virus 2001) 
478. Critchley, I. A., Focus Technologies, Herndon, Virginia (PDA/1 Bacillus anthracis 
2003) 
479. Crocquet-Valdes, P., University of Texas Medical Branch, Galveston, Texas 
(PDA/1 Rickettsia prowazekii 2000) 
480. Cropp, C. B., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Japanese encephalitis virus 2001)  
481. Cros, J., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2001, 2003, 2004, 2005) 
482. Crossley, B. M., California Animal Health and Food Safety Laboratory, Davis, 
California (PDA/1 Newcastle disease virus 2005) 
483. Crossno, J., University of Michigan Medical School, Ann Arbor, Michigan 
(PDA/1 Bacillus anthracis 2004) 
484. Csarary, C. M., United Cancer Research Institute, Alexandria, Virginia (PDA/1 
Newcastle disease virus 2004) 
485. Csarary, L. K., United Cancer Research Institute, Alexandria, Virginia (PDA/1 
Newcastle disease virus 2004) 
486. Cui, K., National Institutes of Health, Bethesda, Maryland (PDA/1 Newcastle 
disease virus 2004) 
487. Cunningham, J. M., Harvard Medical School, Boston, Massachusetts (EDA/2 
Zaire ebolavirus 2005) 
488. Curns, A. T., Center fo Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Coxiella burnetii 2004) 
489. Currie, D., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
490. Curwin, B. D., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
491. Custer, D., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Venezuelan equine 




492. Czerwieniec, G. A., University of California, Davis, California (MDA/4/5 Bacillus 
athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
493. d’Alessio, J., University of California, Berkeley, California (PDA/1 Rickettsia 
rickettsii 2004) 
494. d’Souza, M., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
495. d”Alia, G., Elusys Therapeutics Inc., Pine Brook, New Jersey (MDA/4/5 Bacillus 
anthracis 2005) 
496. Dai, Z.-D., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
497. Dale, N. M., University of Georgia, Athens, Georgia (PDA/1 Newcastle disease 
virus 2003) 
498. Damon, Inger K., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/1 Variola virus 2003, 2004, PDA/1 Camelpox virus 2003 2004, PDA/1 Monkeypox 
virus 2002, 2003, 2004) 
499. Damsteegt, V., United States Department of Agriculture, Agricultural Research 
Service, Fort Detrick, Frederick, Maryland (PDA/1 Plum pox virus 2001) 
500. Dang, J. L., Geo-Centers, Inc., Lanham, Maryland (PDA/1 Bacillus anthracis 
2001) 
501. Dang, J. L., US Army Edgewood Chemical Biological Center, Aberdeen Proving 
Ground, Maryland (PDA/1 Francisella tularensis 2003) 
502. Darby, C., Stanford University, Stanford, California/University of Alabama at 
Birmingham, Birmingham, Alabama (PDA/1 Yersinia pestis 2002, 2004) 
503. Das, A., University of Minnesota (EDA/5 Coccidoides immitis 2000) 
504. Das, R., Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004) 
505. Dasch, G. A., Naval Medical Research Institute, Bethesda, Maryland/Centers for 
Disease Control and Prevention, Atlanta, Georgia (PDA/1 Rickettsia rickettsii 2001, 2003) 
506. DasGupta, B. R., University of Wisconsin, Madison, Wisconsin (PDA/1 
Clostridium botulinum 2001) 
507. Daszak, Peter, Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Nipah virus 2003) 
508. Datskos, P. G., Oak Ridge National Laboratory, Oak Ridge, Tennessee (PDA/1 
Bacillus anthracis 2003) 
509. Datta, A., East Carolina University School of Medicine, Greenville, North 
Carolina (PDA/1 Brucella melitensis 2004) 
510. Dattwyler, R. J., Stony Brook University, Stony Brook, New York (PDA/1 
Yersinia pestis 2005) 
511. Daubenspeck, J. M., University of Alabama at Birmingham, Birmingham, 
Alabama (PDA/1 Bacillus anthracis 2004) 
512. Daugherty, S. C., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 




513. Daum, L. T., Brooks Air Force Base, San Antonio, Texas (PDA/1 Influenza A 
virus 2002, 2003) 
514. Dave, K., Centers for Disease Control and Prevention, Fort Collins, 
Colorado/Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Eastern equine encephalitis virus 2003) 
515. David, J. C., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Bacillus anthracis 2002, PDA/1 Francisella tularensis 2003) 
516. Davidsen, T. D., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
517. Davidsen, T. M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Coxiella burnetii 2003) 
518. Davis, B., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Japanese encephalitis virus 2000)  
519. Davis, C., University of South Florida, Tampa, Florida (PDA/1 Bacillus anthracis 
2003) 
520. Davis, D. S., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2000, 2002) 
521. Davis, K. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2001, 2002, 2003) 
522. Davis, N. L., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Influenza A virus 2000, PDA/1 Venezuelan equine encephalitis virus 
2000, 2001, 2003) 
523. Day, A. G., University of California, San Francisco, California (PDA/1 Yersinia 
pestis 2004) 
524. Day, J. B., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2000, 
2002, 2003, 2004) 
525. de Avila Botton, S., Plum Island Animal Disease Center, United States 
Department of Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 
2005) 
526. de Buysscher, E. V., North Carolina State University, Raleigh, North Carolina 
(PDA/1 Newcastle disease virus 2000) 
527. de Leon Gatti, N., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
528. de los Santos, T., Plum Island Animal Disease Center, United States Department 
of Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2005) 
529. De, B. K., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002, PDA/1 Brucella melitensis 2004, PDA/1 Burkholderia mallei 
2002, PDA/1 Burkholderia pseudomallei 2002) 
530. Deaghi, D. C., Focus Technologies, Herndon, Virginia (PDA/1 Bacillus anthracis 
2003) 
531. Deak, E., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia pestis 
2004) 
532. Deal, E. M., United States Army Medical Research Institute of Infectious 




533. Dean, C., BD Technologies, Research Triangle Park, North Carolina (PDA/1 
Bacillus anthracis 2005) 
534. DeArmond, S. J., University of California, San Francisco, California (PDA/1 
Bovine spongiform encephalopathy prion 2005) 
535. Deboy, R. T., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 
pseudomallei 2004, PDA/1 Coxiella burnetii 2003) 
536. Deering, C., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
537. Dekker III, J. P., BD Technologies, Research Triangle Park, North Carolina (PDA/1 
Bacillus anthracis 2005) 
538. del Giudice, R. A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2002) 
539. del Vecchio, V. G., University of Scranton, Scranton, Pennsylvania/Vital Probes 
Inc., Mayfield, Philadelphia (PDA/1 Bacillus anthracis 2001, 2002, 2003, 2004, PDA/1 
Brucella melitensis 2001, 2002) 
540. DeLeo, F. R., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004) 
541. Delgado, N., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
posadasii 2003) 
542. Delhon, G., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2005) 
543. deLiberto, T. J., Utah State University, Logan, Utah (PDA/1 Brucella melitensis 
2002) 
544. Delmar, V. A., University of California, San Francisco, California (PDA/1 
Yersinia pestis 2004) 
545. DeMartini, James C., Colorado State University, Fort Collins, Colorado (PDA/1 
Alcelaphine herpesvirus 1,2 2001) 
546. Demby, Austin H., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Lassa virus 2000) 
547. Demmin, G. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2005) 
548. den Hartigh, A. B., Texas A&M University, College Station, Texas (PDA/1 
Brucella melitensis 2002, 2004) 
549. Deng, W., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
550. Dertzbaugh, M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Bacillus anthracis 2001) 
551. DeShazer, D., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Burkholderia mallei 2005, PDA/1 
Burkholderia mallei 2000, 2001, 2002, 2004, PDA/1 Burkholderia pseudomallei 2001, 
2004) 
552. DeSilva, T. S., University of Alabama at Birmingham, Birmingham, Alabama 




553. Desjardins, N., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
554. Dewald, R., National Veterinary Services Laboratories, U.S, Department of 
Agriculture, Animal and Health Inspection Services, Ames, Iowa (PDA/1 Burkholderia 
mallei 2000) 
555. Dickson, D., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
556. Dickson, J. S., Iowa State University, Ames, Iowa (PDA/1 Bacillus anthracis 
2003) 
557. Didorenko, S., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
558. Diem, L. A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002) 
559. Dimalanta, E. T., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
560. Dimitrov, A. S., Uniformed Services University, Bethesda, Maryland (PDA/1 
Hendra virus 2005, PDA/1 Nipah virus 2005) 
561. Dimitrov, D. S., National Cancer Institute, Frederick, Maryland (PDA/1 Hendra 
virus 2005, PDA/1 Nipah virus 2005) 
562. Dimitrov, G., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
563. Dineen, S. S., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2000, 2003, 2004) 
564. Diop, M., University of California-Davis, Davis, California (PDA/1 Peste-des-
petits-ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
565. Diptee, M. D., University of California Davis, Davis, California (PDA/1 Brucella 
melitensis 2003) 
566. Dixon, J. D., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2000) 
567. Dixon, J. E., University of Michigan Medical School, Ann Arbor, Michigan 
(PDA/1 Yersinia pestis 2002) 
568. Dixon, T. C., Duke University, Durham, North Carolina/University of Michigan, 
Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2000) 
569. Dobson, M. E., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Francisella tularensis 2002) 
570. Dodge, D., Bayer Corporation, Emeryville, California (PDA/1 Mycoplasma 
capricolum capripneumoniae 2004, PDA/1 Mycoplasma mycoides mycoides 2004) 
571. Dodson, R. J., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 
pseudomallei 2004, PDA/1 Coxiella burnetii 2003) 





573. Dohm, D. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Rift Valley fever virus 2000, PDA/1 
Venezuelan equine encephalitis virus 2000, 2004) 
574. Doms, R. W., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Crimean-Congo hemorrhagic fever virus 2005, EDA/2 Zaire ebolavirus 2003) 
575. Dong, J., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2005) 
576. Dong, S., University of Alabama at Birmingham, Birmingham, Alabama (PDA/1 
Bacillus anthracis 2004) 
577. Donlan, R. M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2005, PDA/1 Yersinia pestis 2003) 
578. Dover, Jason E., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Zaire ebolavirus 2005) 
579. Dozier, III, W. A.,, United States Department of Agriculture, Agricultural 
Research Service, Mississippi State, Mississippi (MDA/4/5 Mycoplasma gallisepticum 
2005)  
580. Drader, J. J., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
581. Draper, K., Sierra Biomedical Inc., Sparks, Nevada/Tulane Regional Primate 
Center, Covington, Louisiana (PDA/1 Japanese encephalitis virus 2000, 2002) 
582. Dreisbach, V. C., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (PDA/1 Francisella tularensis 2000) 
583. Driks, A., Loyola University, Maywood, Illinois (PDA/1 Bacillus anthracis 2003) 
584. Driscol, J., National Cancer Institute, Bethesda, Maryland (EDA/2 Zaire 
ebolavirus 2000) 
585. Driskell, L. O., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2000, PDA/1 Rickettsia prowazekii 2003) 
586. Drysdale, M., University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 
2003, 2004, 2005) 
587. Du, Y., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia pestis 
2000) 
588. Dubensky Jr., T. W., Chiron, Emeryville, California (PDA/1 Venezuelan equine 
encephalitis virus 2003) 
589. Duckers, H. J., National Institutes of Health, Bethesda, Maryland (EDA/2 Zaire 
ebolavirus 2000) 
590. Duckett, N. S., Albany Medical College, Albany, New York (PDA/1 Francisella 
tularensis 2005) 
591. Duesbery, N. S., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 
Bacillus anthracis 2001, 2003)  
592. Duesbery, N. S., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 
Bacillus anthracis 2001)  
593. Dukerich, M., Northern Arizona University, Flagstaff, Arizona (PDA/1 




594. Dunhamel, G. E., University of Nebraska, Lincoln, Nebraska (PDA/1 Francisella 
tularensis 2004) 
595. Dunkel, V. C., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003) 
596. Dunowska, Magdalena, Colorado State University, Fort Collins, Colorado (PDA/1 
Alcelaphine herpesvirus 1,2 2001) 
597. Duque, H., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2004, 
2005) 
598. Durkin, A. S., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 
pseudomallei 2004) 
599. Durno, M. A., United States Environmental Protection Agency Region 5, 
Westlake, Ohio (MDA/4/5 Bacillus anthracis 2002) 
600. Durrant, D. M., Albany Medical College, Albany, New York (PDA/1 Francisella 
tularensis 2005) 
601. Dworzanski, J. P., Geo-Centers, Inc., Aberdeen Proving Ground, Maryland 
(PDA/1 Bacillus anthracis 2004) 
602. Dwyer, K. G., University of Scranton, Scranton, Pennsylvania/University of 
Texas, Dallas, Texas (PDA/1 Bacillus anthracis 2004) 
603. Dybing, J. K., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia (EDA/1 “1918 Influenza virus” 2001, PDA/1 Influenza A 
virus 2000) 
604. Dzenitis, J. M., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus anthracis 2005, MDA/4/5 Bacillus globigii 2005, MDA/4/5 Yersinia 
pestis 2005) 
605. Easterday, W. R., Northern Arizona University, Flagstaff, Arizona (PDA/1 
Bacillus anthracis 2005, PDA/1 Yersinia pestis 2004) 
606. Eberle, R., Oklahoma State University, Stillwater, Oklahoma/University of 
California-Davis, Davis, California (PDA/1 Cercopithecine herepesvirus 1 2002, 2003, 
2005) 
607. Eblen, B. S., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Clostridium botulinum 2005) 
608. Eckels, K. H., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Japanese encephalitis virus 2001) 
609. Ecker, D. J., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
610. Eckman, L., University of California, San Diego, California (PDA/1 Bacillus 
anthracis 2004) 
611. Edmonds, M. D., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2000, 2001, 2002) 
612. Edmonds, P., United States Food and Drug Administration, Atlanta, Georgia 




613. Edwards, H., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2002) 
614. Eggers, C. T., University of California, San Francisco, California (PDA/1 Yersinia 
pestis 2004) 
615. Eggers, J., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus anthracis 
2002) 
616. Egziabher, B., University of California-Davis, Davis, California (PDA/1 Peste-
des-petits-ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
617. Eisen, J. A., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, PDA/1 Coxiella burnetii 2003) 
618. Ekkelenkamp, M., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Japanese encephalitis virus 2003) 
619. Eklund, M. W., Unites States Department of Commerce, Seattle, Washington 
(PDA/1 Clostridium botulinum 2002, 2004) 
620. el Tayeb, A. B., Ohio State University, Columbus, Ohio (PDA/1 Newcastle 
disease virus 2001, 2002) 
621. Elankumaran, S., University of Maryland, College Park, Maryland (PDA/1 
Newcastle disease virus 2004) 
622. el-Hajj, H., Public Health Research Institute, Newark, New Jersey (PDA/1 
Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 
623. Elkins, K. L., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Rockville, Maryland (PDA/1 Francisella tularensis 2000, 2001, 2002, 
2003, 2004) 
624. Elkins, R., National Institutes of Health, Bethesda, Maryland (EDA/2 Tick-borne 
encephalitis virus 2001) 
625. Eller, N. L., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Brucella melitensis 2001) 
626. Ellingsworth, L. R., IOMAI, Gaithersburg, Maryland (PDA/1 Bacillus anthracis 
2004) 
627. Elliott, J. L., Harvard Medical School, Boston, Massachusetts (PDA/1 Bacillus 
anthracis 2000) 
628. Elliott, J. M., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2002, 2003, 2004) 
629. Elliott, T. B., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
(PDA/1 Bacillus anthracis 2001, 2002) 
630. Ellis, S. J., Tetracore Inc, Gaithersburg, Maryland (PDA/1 Foot and mouth disease 
virus 2002) 
631. Elmets, C. A., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2004) 
632. Elzer, P. H., Louisiana State University, Baton Rouge, Louisiana (PDA/1 Brucella 
melitensis 2000, 2001, 2002, 2003) 
633. Emanuel, P. A., US Army Edgewood Chemical Biological Center, Aberdeen 





634. Emmerich, E., Centers for Disease Control and Prevention, Fort Collins, 
Colorado/Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Eastern equine encephalitis virus 2003) 
635. Empig, C. J., University of California, San Francisco, California (EDA/2 Lake 
Victoria marburgvirus 2001, EDA/2 Zaire ebolavirus 2001) 
636. Enama, J. T., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Yersinia pestis 2005) 
637. Endley, S., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2001) 
638. Endy, T. P., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(EDA/2 Crimean-Congo hemorrhagic fever virus 2004) 
639. Engelthaler, D. M., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Yersinia pestis 2000, 2002) 
640. England, M. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Coxiella burnetii 2002) 
641. Enright, F. M., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2000, 2001, 2002) 
642. Epstein, S. L., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Influenza A virus 2004)Ha, Y., Harvard 
Medical School, Boston, Massachusetts (PDA/1 Influenza A virus 2004) 
643. Ermeeva, M. E., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
rickettsii 2001, 2003) 
644. Ernst, R. K., University of Washington, Seattle, Washington (PDA/1 Francisella 
tularensis 2004, PDA/1 Yersinia pestis 2004) 
645. Eschenbrenner, M., University of Scranton, Scranton, Pennsylvania (PDA/1 
Brucella melitensis 2002) 
646. Eskra, L., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2003, 2005) 
647. Esposito, Joseph J., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/1 Variola virus 2000, 2001, 2003, PDA/1 Camelpox virus 2003, PDA/1 
Monkeypox virus 2001, 2002, 2003) 
648. Espy, Mark J., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Monkeypox 
virus 2002) 
649. Estacio, P. L., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
650. Estep, J., Battelle, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2003, PDA/1 
Bacillus anthracis 2004) 
651. Estrada-Franco, J. G., University of Texas Medical Branch, Galveston, Texas/ 
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, 
Frederick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2003, 2004) 
652. Evans, J. D., United States Department of Agriculture, Agricultural Research 
Service, Mississippi State, Mississippi (MDA/4/5 Mycoplasma gallisepticum 2005)  




654. Ewalt, D. R., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000, 2001, 2003) 
655. Ewert, M., University of South Florida, Tampa, Florida (PDA/1 Bacillus anthracis 
2003) 
656. Eze, M. O., Walter Reed Army Institute of Research, Washington, D.C. (PDA/1 
Brucella melitensis 2000) 
657. Ezelle, H. J., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2004) 
658. Ezzel, J. W., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2002, 2005) 
659. Fadl, A. A., University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 2000) 
660. Fair, J. M., University of Missouri-St. Louis, St. Louis, Missouri (PDA/1 
Newcastle disease virus 2002) 
661. Falkow, S., Stanford University, Stanford, California (PDA/1 Yersinia pestis 2002, 
2004) 
662. Fan, W., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Yersinia pestis 2001, 2003) 
663. Fanning, T. G., Armed Forces Institute of Pathology, Washington, D.C. (EDA/1 
“1918 Influenza virus” 2001) 
664. Farlow, J., Northern Arizona University, Flagstaff, Arizona (PDA/1 Francisella 
tularensis 2001) 
665. Farrow, S. W., United States Army Dugway Proving Grounds, Dugway, Utah 
(MDA/4/5 Bacillus anthracis 2005, MDA/4/5 Bacillus globigii 2005, MDA/4/5 Yersinia 
pestis 2005) 
666. Fayzulin, R. Z., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2003) 
667. Feldblyum, T., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
668. Feldman, S. H., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
669. Feldstein, M. J., Naval Research Laboratory, Center for Bio, Washington, D. C. 
(PDA/1 Bacillus anthracis 2002) 
670. Fellows, P. F., Southern Research Institute, Frederick, Maryland/United States 
Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 
(MDA/4/5 Bacillus anthracis 2001, 2002, PDA/1 Bacillus anthracis 2001, 2003, 2004, 
2005) 
671. Feng, H. M., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia prowazekii 2001) 
672. Feng, J., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2001) 
673. Feng, Y.-R., Uniformed Services University, Bethesda, Maryland (PDA/1 Hendra 
virus 2005, PDA/1 Nipah virus 2005) 





675. Fenselau, C., University of Maryland, Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2003, 2004) 
676. Ferencko, L., BCR Diagnostics, Inc., Jamestown, Rhode Island (PDA/1 Bacillus 
anthracis 2004) 
677. Fergenson, D. P., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
678. Ferguson, G. P., Massachusetts Institute of Technology, Cambridge, 
Massachusetts (PDA/1 Brucella melitensis 2004) 
679. Ferman, G. S., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2005) 
680. Fernandes, B., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Eastern equine encephalitis virus 2003) 
681. Fernandez, R, United States Naval Medical Research Center Detachment, Lima, 
Peru (PDA/1 Eastern equine encephalitis virus 2004, PDA/1 Venezuelan equine 
encephalitis virus 2000) 
682. Fernandez-Prada, C. M., Walter Reed Army Institute of Research, Washington, 
D.C. (PDA/1 Brucella melitensis 2001, 2003) 
683. Ferracci, F., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2003, 
2004) 
684. Ferrance, J. P., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
685. Ferrari, M., Vical Inc., San Diego, California (MDA/4/5 Bacillus anthracis 2004) 
686. Ferreira, J. L., United States Food and Drug Administration, Atlanta, Georgia 
(PDA/1 Clostridium botulinum 2002, 2003, 2004) 
687. Ferriter, M., BD Technologies, Research Triangle Park, North Carolina (PDA/1 
Bacillus anthracis 2005) 
688. Fetherston, J. D., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2000, 2001, 2002, 2003, 2004 
689. Fey, P. D., University of Nebraska, Omaha, Nebraska (PDA/1 Francisella 
tularensis 2004) 
690. Ficht, T. A., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2000, 2001, 2002, 2004) 
691. Field, A. E., Johns Hopkins University, Baltimore, Maryland (PDA/1 Newcastle 
disease virus 2002, 2003) 
692. Fierer, J., University of California, San Diego, California (PDA/1 Coccidioides 
immitis 2000, PDA/1 Coccidioides posadasii 2005) 
693. Finberg, R. W., Dana Farber Cancer Institute, Massachussetts (PDA/1 Human 
enterovirus B 2000) 
694. Fingerhut, G. A., United States Food and Drug Administration, Summit-Argo, 
Illinois (PDA/1 Clostridium botulinum 2000) 
695. Fischer, E. R., National Institutes of Health, Hamilton, Montana (PDA/1 Coxiella 
burnetii 2004, PDA/1 Yersinia pestis 2004) 
696. Fischer, R., University of Alabama at Birmingham, Birmingham, Alabama (PDA/1 




697. Fischetti, V. A., Rockefeller University, New York, New York (PDA/1 Bacillus 
anthracis 2002) 
698. Fisher, M. C., University of California at Berkeley, Berkeley, California (PDA/1 
Coccidioides immitis 2000, PDA/1 Coccidioides posadasii 2000) 
699. Fisher-Hoch, S. P., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Lassa virus 2000) 
700. Fitch, J. P., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004, 2005) 
701. Fitzgerald, C. C., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
702. Foil, L. D., Louisiana State University, Baton Rouge, Louisiana (PDA/1 Rickettsia 
prowazekii 2000)  
703. Forbes, L. B., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000) 
704. Ford, E. J., Montana State University, Bozeman, Montana (PDA/1 Bacillus 
anthracis 2002, 2003) 
705. Forde, C. E., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
706. Forestal, C. A., Stony Brook University, Stony Brook, New York (PDA/1 
Francisella tularensis 2003, 2005) 
707. Forrest, D., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
708. Forsberg, A., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2000) 
709. Fosgate, G. T., University of California Davis, Davis, California (PDA/1 Brucella 
melitensis 2003) 
710. Foster, K. W., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2004) 
711. Fouts, D. E., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
712. Fowler, J., Michigan State University, East Lansing, Michigan (PDA/1 Yersinia 
pestis 2004) 
713. Fox, A., University of South Carolina, Columbia South Carolina (PDA/1 Bacillus 
anthracis 2004) 
714. Fox, J. W., University of Virginia, Charlottesville, Virginia (PDA/1 Foot and 
mouth disease virus 2002) 
715. Fox, J., Northern Arizona University, Flagstaff, Arizona (PDA/1 Francisella 
tularensis 2004) 
716. Fox, K. F., University of South Carolina, Columbia South Carolina (PDA/1 
Bacillus anthracis 2004) 
717. Fox, N., University of South Carolina, Columbia South Carolina (PDA/1 Bacillus 
anthracis 2004) 
718. Frace, A. M., Centers for Disease Control and Prevention, Atlanta, Georgia 




719. Francis, A. W., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2005) 
720. Francis, C. W., University of Rochester Rochester, New York (PDA/1 Rickettsia 
rickettsii 2003, 2004) 
721. Frank, D. W., Medical College of Wisconsin, Milwaukee, Wisconsin (PDA/1 
Francisella tularensis 2004) 
722. Frank, M., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
723. Frank, R. S., Heska Corporation, Fort Collins, Colorado (PDA/1 Yersinia pestis 
2003) 
724. Franklin, G., Scripps Research Institute, La Jolla, California (PDA/1 Yersinia 
pestis 2004) 
725. Frans, G., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2002) 
726. Fraser, C. M., Institute for Genomic Research, Rockville, Maryland/University of 
Texas, Houston, Texas/US Army Medical Research Institute for Infectious Diseases, Ft. 
Detrick, Maryland (PDA/1 Bacillus anthracis 2002, 2003, 2004, PDA/1 Burkholderia 
mallei 2004, PDA/1 Burkholderia pseudomallei 2004, PDA/1 Coxiella burnetii 2003) 
727. Fredeking, T. M., Antibody Systems, Hurst, Texas (EDA/2 Zaire ebolavirus 2003) 
728. Freed, J. A., Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002)  
729. Freier, J. E., United States Department of Agriculture Center for Animal Disease 
Information and Analysis, Fort Collins, Colorado (PDA/1 Venezuelan equine encephalitis 
virus 2001) 
730. French, F. E., Georgia Southern University, Statesboro, Georgia (PDA/1 
Mycoplasma capricolum capripneumoniae 2004, PDA/1 Mycoplasma mycoides mycoides 
2004) 
731. French, R. A., Department of Pathobiology, University of Connecticut, Storrs, 
Connecticut (PDA/1 African swine fever virus 2005, PDA/1 Classical swine fever virus 
2005) 
732. French, S. A., IOMAI, Gaithersburg, Maryland (PDA/1 Bacillus anthracis 2004) 
733. Frias-Stäheli, N., Mount Sinai School of Medicine, New York, New York (EDA/2 
Crimean-Congo hemorrhagic fever virus 2005) 
734. Friedlander, A. M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Bacillus anthracis 2001, 2003 PDA/1 
Bacillus anthracis 2001, 2002, 2004, 2005, PDA/1 Yersinia pestis 2000, 2002, 2004) 
735. Fritsche, K. L., University of Missouri, Columbia, Missouri (PDA/1 Newcastle 
disease virus 2000) 
736. Fritz, D. L., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (MDA/4/5 Burkholderia pseudomallei 2003, PDA/1 Bacillus 
anthracis 2001, PDA/1 Burkholderia mallei 2000, 2001, 2002, PDA/1 Eastern equine 
encephalitis virus 2005) 
737. Frolov, I., University of Texas Medical Branch, Galveston, Texas (PDA/1 




738. Fry, F. S., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003) 
739. Frye, M. S., Loveless, B., Geo-Centers, Newtown, Massachusetts (PDA/1 Bacillus 
anthracis 2004) 
740. Fryxell, K. J., George Mason University, Fairfax, Virginia (PDA/1 Bacillus 
anthracis 2005) 
741. Fujihashi, K., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2003) 
742. Fulhorst, C. F., University of Texas Medical Branch, Galveston, Texas (EDA/2 
Guanarito virus 2000, 2002, 2003, EDA/2 Junín virus 2002, 2003, EDA/2 Machupo virus 
2002, 2003, EDA/2 Lassa virus 2002, 2003) 
743. Fuller, C. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2005) 
744. Fuller, F. J., North Carolina State University, Raleigh, North Carolina (PDA/1 
Newcastle disease virus 2000) 
745. Fuller, J. R., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (EDA/5 Francisella tularensis 2004) 
746. Fulroth, B., Purdue University, West Lafayette, Indiana (PDA/1 Bacillus anthracis 
2005) 
747. Fulton, W. T., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2001, 2002) 
748. Furie, M. B., Stony Brook University, Stony Brook, New York (PDA/1 
Francisella tularensis 2003, 2005) 
749. Gabriel, D. W., University of Florida, Gainesville, Florida (PDA/1 Xylella 
fastidiosa 2003) 
750. Gaffney, K. L., Naval Research Laboratory, Center for Bio/Molecular Science and 
Engineering, Washington, D. C./Tetracore Inc, Gaithersburg, Maryland (PDA/1 Foot and 
mouth disease virus 2002, PDA/1 Francisella tularensis 2000) 
751. Gage, K. L., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Francisella tularensis 2004, PDA/1 Yersinia pestis 2000, 2003, 2005) 
752. Galeano, B., University of Arizona, Tucson, Arizona (PDA/1 Bacillus anthracis 
2003) 
753. Galgiani, J. N., University of Arizona, Tucson, Arizona (EDA/5 Coccidioides 
immitis 2000, PDA/1 Coccidioides immitis 2002, PDA/1 Coccidioides posadasii 2005) 
754. Galloway, D., Naval Medical Research Center, Silver Spring, Maryland/Ohio State 
University, Columbus, Ohio (MDA/4/5 Bacillus anthracis 2004, PDA/1 Bacillus 
anthracis 2004) 
755. Gamez-Chin, Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2001) 
756. Ganta, R. R., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2001) 
757. Garber, L. P., Centers for Epidemiology and Animal Health, National Animal 




758. Garcia, E., Ciphergen Biosystems, Fremont, California/Lawrence Livermore 
National Laboratory, Livermore, California (PDA/1 Francisella tularensis 2005, PDA/1 
Yersinia pestis 2001, 2002, 2003, 2004) 
759. Garcia, M., Southeast Poultry Research Laboratory, United States Department of 
Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2000) 
760. Garcia-Sastre, A., Mount Sinai School of Medicine, New York, New York (EDA/1 
“1918 Influenza virus” 2001, 2002, 2004, EDA/2 Crimean-Congo hemorrhagic fever 
virus 2005, EDA/2 Zaire ebolavirus 2003, PDA/1 Influenza A virus 2003, PDA/1 
Newcastle disease virus 2001, 2003, 2004, 2005) 
761. Gard, E. E., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
762. Gardner, D., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2005) 
763. Gardner, M. J., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
posadasii 2003) 
764. Garic-Stankovic, A., University of Wisconsin, Madison, Wisconsin (PDA/1 
Yersinia pestis 2002) 
765. Garner, B. L., University of Mississippi, Jackson, Mississippi (PDA/1 Bacillus 
anthracis 2004) 
766. Garner, H. R., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 Bacillus 
anthracis 2004) 
767. Garnham, J. B., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
768. Garrett, J. L., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Brucella melitensis 2001) 
769. Garrison, A. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Venezuelan 
equine encephalitis virus 2003) 
770. Garrison, J., Battelle, Columbus, Ohio (PDA/1 Bacillus anthracis 2003, 2004) 
771. Garrison, K., University of New Mexico, Albuquerque, New Mexico (PDA/1 
Bacillus anthracis 2004) 
772. Gasbarre, L. C., United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Brucella melitensis 2002) 
773. Gaske, K. S., Naval Surface Warfare Center, Dahlgren, Virginia (PDA/1 Bacillus 
anthracis 2005) 
774. Gaspard, R., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2005) 
775. Gasparich, G. E., Towson University, Towson, Maryland (PDA/1 Mycoplasma 
capricolum capripneumoniae 2004, PDA/1 Mycoplasma mycoides mycoides 2004) 
776. Gasper, P. W., University of Maryland, College Park, Maryland (PDA/1 Yersinia 
pestis 2001) 
777. Gauntt, C. J., University of Texas San Antonio, San Antonio, Texas (PDA/1 




778. Gaywee, J., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2002) 
779. Gbakima, A., Morgan State University, Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2003) 
780. Ge, H., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Rickettsia prowazekii 2003, 2004) 
781. Ge, H., Novozymes Biotech Inc., Davis, California (PDA/1 Bacillus anthracis 
2003) 
782. Gebhardt, J. S., Naval Medical Research Center, Silver Spring, Maryland 
(MDA/4/5 Bacillus anthracis 2002) 
783. Gee, J. E., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Brucella melitensis 2004, PDA/1 Burkholderia mallei 2002, PDA/1 Burkholderia 
pseudomallei 2002) 
784. Geisbert, J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2000, 2001, EDA/2 Lassa 
virus 2001, EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, 2004) 
785. Geisbert, T. W., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/1 Variola virus, EDA/2 Lake Victoria 
marburgvirus 2000, 2002, EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, 2004, 
MDA/4/5 Monkeypox virus 2001, PDA/1 Venezuelan equine encephalitis virus 2003) 
786. Gendel, S. M., United States Food and Drug Administration, Summit-Argo, 
Illinois (PDA/1 Clostridium botulinum 2000) 
787. Gendron-Fitzpatrick, A., University of Wisconsin, Madison, Wisconsin (PDA/1 
Brucella melitensis 2002) 
788. Geoffroy, V. A., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2000, 2001, 2002) 
789. Georgescu, A. M., Lawrence Livermore National Laboratory, Livermore, 
California (PDA/1 Yersinia pestis 2002, 2004) 
790. Gerrard, Sonja R, Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rift Valley fever virus 2002)  
791. Gerstein, M., Yale University, New Haven, Connecticut (PDA/1 Yersinia pestis 
2001) 
792. Ghori, N., Stanford University, Stanford, California (PDA/1 Yersinia pestis 2002) 
793. Ghosh, A. K., St. Louis University, St. Louis, Missouri (PDA/1 Newcastle disease 
virus 2003) 
794. Gibaja, V., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 Foot and 
mouth disease virus 2002) 
795. Gibb, T. R., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2004) 
796. Gibb, T. R., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2000, 2001, EDA/2 Sudan 




797. Gibbs, P. H., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Bacillus anthracis 2001, MDA/4/5 Coxiella 
burnetii 2002, PDA/1 Bacillus anthracis 2001, 2002, 2004) 
798. Gibson, B. W., University of California, San Francisco, San Francisco (PDA/1 
Francisella tularensis 2004) 
799. Gidlewski, T., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000, 2001, 2004) 
800. Giehl, T., University of Massachusetts, Worcester, Massachusetts (PDA/1 Yersinia 
pestis 2004) 
801. Gifford, H., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus 
anthracis 2002) 
802. Gil, H., Stony Brook University, Stony Brook, New York (PDA/1 Francisella 
tularensis 2004) 
803. Gill, S. R., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003) 
804. Gilmore, Jr., R. D., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Francisella tularensis 2004) 
805. Gilsdorf, M. J., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa/United States Department of Agriculture, Animal and Plant Health 
Inspection Service, Riverdale, Maryland (PDA/1 Brucella melitensis 2000, 2001) 
806. Gingrich, E., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
807. Giordano, B. C., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
808. Giorno, R., Loyola University, Maywood, Illinois (PDA/1 Bacillus anthracis 
2003) 
809. Girshick, T., Charles River SPAFAS, Inc., Storrs, Connecticut (PDA/1 Newcastle 
disease virus 2002) 
810. Glasner, J. D., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
811. Glass, J. D., Brookhaven National Laboratory, Upton, New York (PDA/1 Yersinia 
pestis 2005) 
812. Glass, J., Institute for Biological Energy Alternatives, Manassas, Virginia (PDA/1 
Mycoplasma capricolum capripneumoniae 2004, PDA/1 Mycoplasma mycoides mycoides 
2004) 
813. Glass, K. A., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2004) 
814. Glass, M. B., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Burkholderia mallei 2002, 2005, PDA/1 Burkholderia pseudomallei 2002, 2005) 
815. Glenn, G. M., IOMAI, Gaithersburg, Maryland (PDA/1 Bacillus anthracis 2004) 
816. Glover, D. A., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
817. Gnade, B. T., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 




818. Godsey, M. S., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rift Valley fever virus 2002)  
819. Goff, J., United States Department of Agriculture, Agricultural Research Service, 
Ames, Iowa (PDA/1 Brucella melitensis 2004) 
820. Goguen, J., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Bacillus anthracis 2003, PDA/1 Yersinia pestis 2001, 2004) 
821. Gold, J. A., New York University, New York, New York (PDA/1 Bacillus 
anthracis 2004) 
822. Golde, W. T., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2004, 
2005) 
823. Golding, B., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004, PDA/1 Brucella 
melitensis 2001) 
824. Goldsmith, C. S., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Zaire ebolavirus 2005, PDA/1 Nipah virus 2000, 2003) 
825. Goldsmith, M. A., Gladstone Institute of Virology and Immunology, San 
Francisco, California/University of California, San Francisco, California (EDA/2 Lake 
Victoria marburgvirus 2001, EDA/2 Zaire ebolavirus 2001) 
826. Golenbock, D. T., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Coxiella burnetii 2004) 
827. Goley, E. D., University of California, Berkeley, California (PDA/1 Rickettsia 
rickettsii 2004) 
828. Goltsman, E., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
829. Gomes-Solecki, M. J. C., Stony Brook University, Stony Brook, New York 
(PDA/1 Yersinia pestis 2005) 
830. Gong, S., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 
2001) 
831. Gonzalez, A. D., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004, 2005) 
832. Gonzalez, G. M., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2001, 2002) 
833. Gonzalez, M. D., University of Illinois at Urbana-Champaign, Urbana, Illinois 
(PDA/1 Yersinia pestis 2002) 
834. Goode, M. T., United States Army Edgewood Research, Aberdeen Proving 
Ground, Maryland University of Texas San Antonio, San Antonio, Texas 
835. Goodin, J. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Yersinia pestis 2005) 
836. Goodnough, M., United States Food and Drug Administration, Atlanta, Georgia 
(PDA/1 Clostridium botulinum 2003) 
837. Gostomski, M., United States Army Edgewood Chemical Biological Center, 




838. Gottfried, K. L., Centers for Disease Control and Prevention, Fort Collins, 
Colorado/Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Eastern equine encephalitis virus 2003) 
839. Govindarajan, D., University of Maryland, College Park, Maryland (PDA/1 
Newcastle disease virus 2004) 
840. Govorkova, E. A., St. Jude Children’s Research Hospital, Memphis, Tennessee 
(PDA/1 Influenza A virus 2002, 2005) 
841. Gowen, B. B., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004, 2005) 
842. Goyal, S. M., University of Minnesota, St. Paul, Minnesota (PDA/1 Newcastle 
disease virus 2004) 
843. Grabenstein, J. P., State University of New York at Stony Brook, Stony Brook, 
New York (PDA/1 Yersinia pestis 2004) 
844. Gravel, K., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Newcastle disease virus 2002, 2003)  
845. Graves, I. L., Johns Hopkins University, Baltimore, Maryland (PDA/1 Newcastle 
disease virus 2001) 
846. Graves, M. H., California Department of Health Services, Richmond, California 
(PDA/1 Brucella melitensis 2004) 
847. Graybill, J. R., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2001, 2002) 
848. Greene, I. P., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2003, 2004, 2005) 
849. Greengard, O., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2004) 
850. Greer, C. E., Chiron, Emeryville, California (PDA/1 Venezuelan equine 
encephalitis virus 2003) 
851. Greer, P. Centers for Disease Control and Prevention, Atlanta, Georgia (EDA/2 
Zaire ebolavirus 2004, 2005, PDA/1 Bacillus anthracis 2003) 
852. Gregg, D., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2004) 
853. Gregory, J. B., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003) 
854. Grene, E., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002, 2003, 2004) 
855. Grieder, B. F., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina/ Uniformed Services University of the Health Sciences, Bethesda, Maryland 
(PDA/1 Venezuelan equine encephalitis virus 2000, 2003) 
856. Grieshaber, S. S., University of Wyoming, Laramie, Wyoming (PDA/1 Rickettsia 
rickettsii 2003) 
857. Grinshpun, S. A., Centers for Disease Control and Prevention, Cincinnati, Ohio 




858. Grippe, V. K., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland/Louisiana State University, Shreveport, Louisiana 
(PDA/1 Bacillus anthracis 2004, PDA/1 Brucella melitensis 2000) 
859. Grogan, C., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2003 EDA/2 Zaire ebolavirus 
2003) 
860. Groisman, E. A., Washington University, St. Louis, Missouri (PDA/1 Yersinia 
pestis 2005) 
861. Gromadzki, Sally G., New York State Department of Health, Albany, New York 
(PDA/1 Coccidioides immitis 2000) 
862. Gronenborn, A. M., National Institutes of Health, Bethesda, Maryland (EDA/2 
Zaire ebolavirus 2003) 
863. Groth, D., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
864. Grubman, M. J., Oak Ridge Institute, Oak Ridge, Tennessee/Plum Island Animal 
Disease Center, United States Department of Agriculture, Greenport, New 
York/University of Georgia, Athens, Georgia (PDA/1 Foot and mouth disease virus 2000, 
2001, 2002, 2003, 2005) 
865. Gu, P. P., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
866. Guarner, J., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2003) 
867. Guarro, J., University of California Berkeley, California (PDA/1 Coccidioides 
immitis 2003, PDA/1 Coccidioides posadasii 2003) 
868. Gubler, D. J., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Japanese encephalitis virus 2003, PDA/1 Nipah virus 2000) 
869. Guebre-Xabier, M., IOMAI, Gaithersburg, Maryland (PDA/1 Bacillus anthracis 
2004) 
870. Guest, S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2000) 
871. Guevara, C., Naval Medical Research Center Detachment, NAMRID, Peru 
(PDA/1 Venezuelan equine encephalitis virus 2004) 
872. Guevara-Olvera, L., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
immitis 2000) 
873. Guiney, D. G., University of California, San Diego, California (PDA/1 Bacillus 
anthracis 2004) 
874. Guirakhoo, F., Orovax Inc./ Acambis Inc., Cambridge, Massachusetts (PDA/1 
Japanese encephalitis virus 2000, 2001, 2002, 2004) 
875. Guller, I., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2000) 
876. Gupta, M., Centers for Disease Control and Prevention, Atlanta, Georgia/Emory 
University, Atlanta, Georgia (EDA/2 Zaire ebolavirus 2001, 2003, 2004, 2005) 
877. Gupta, P., Uniformed Services University of the Health Sciences, Bethesda, 




878. Gursel, I., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2005) 
879. Gutierrez, D. M., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus anthracis 2005, MDA/4/5 Bacillus globigii 2005, MDA/4/5 Yersinia 
pestis 2005) 
880. Gutting, B. W., Naval Surface Warfare Center, Dahlgren, Virginia (PDA/1 
Bacillus anthracis 2005) 
881. Guzman, H., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Japanese encephalitis virus 2002, PDA/1 Venezuelan equine encephalitis virus 2004) 
882. Gwinn, M. L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia 
pseudomallei 2004) 
883. Haanes, E. J., Heska Corporation, Fort Collins, Colorado (PDA/1 Yersinia pestis 
2003) 
884. Hackney, C. R., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Clostridium botulinum 2000) 
885. Hadfield, T. L., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Bacillus anthracis 2002, PDA/1 Brucella melitensis 2000, 2001, 2002, 2003, 2004, 
PDA/1 Francisella tularensis 2002, 2003, PDA/1 Monkeypox virus 2002) 
886. Hadjipanayis, A. G., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2003) 
887. Hadley, R. T., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
888. Haff, W. B., Brooks Air Force Base, San Antonio, Texas (PDA/1 Yersinia pestis 
2003) 
889. Haft, D. H., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 
2004) 
890. Hagius, S. D., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2000, 2001, 2002, 2003) 
891. Halfmann, P., University of Wisconsin, Madison, Wisconsin (EDA/1 “1918 
Influenza virus” 2004) 
892. Hall, H. L., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
893. Hall, H., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Influenza A virus 2003) 
894. Hall, J. D., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (EDA/5 Francisella tularensis 2004) 
895. Halling, S. M., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2003) 
896. Halpin, K., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Nipah virus 2001, 2004) 





898. Hammamieh, R., Walter Reed Army Institute of Research, Silver Spring, 
Maryland (PDA/1 Bacillus anthracis 2004) 
899. Hammer, R. P., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
900. Hammock, B. D., University of California, Davis, California (PDA/2 Autographa 
californica multiple nucleopolyhedrovirus 2003) 
901. Hammond, R. W., United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Newcastle disease virus 2005) 
902. Han, Z., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 Zaire 
ebolavirus 2003) 
903. Hance, I. R., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
904. Hanley, K. A., National Institutes of Health, Bethesda, Maryland (EDA/2 Tick-
borne encephalitis virus 2001) 
905. Hanna, P. C., Johns Hopkins University, Baltimore, Maryland/University of 
Michigan, Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2000, 2002, 2003, 2004, 
2005) 
906. Hannis, J. C., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
907. Hanson, R. P., Ohio State University, Columbus, Ohio (PDA/1 Newcastle disease 
virus 2001, 2002) 
908. Harakava, R., University of Florida, Gainesville, Florida (PDA/1 Xylella fastidiosa 
2003) 
909. Harcourt, B. H., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Hendra virus 2002, PDA/1 Nipah virus 2000, 2001, 2002, 2005) 
910. Harding, R. A., Armed Forces Radiobiology Research Institute, Bethesda, 
Maryland (PDA/1 Bacillus anthracis 2001, 2002) 
911. Harlander, R. S., University of Wyoming, Laramie, Wyoming (PDA/1 Rickettsia 
rickettsii 2003) 
912. Harms, J., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
913. Harper, J. D., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
914. Harper, J. K., Montana State University, Bozeman, Montana (PDA/1 Bacillus 
anthracis 2003) 
915. Harrison, M. A., United States Food and Drug Administration, Atlanta, Georgia 
(PDA/1 Clostridium botulinum 2002) 
916. Hart, J. A., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Brucella melitensis 2001) 
917. Hart, M. K., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2000, 2001, 2003, PDA/1 
Bacillus anthracis 2002, PDA/1 Venezuelan equine encephalitis virus 2000, 2001, PDA/1 




918. Hartings, J. M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Burkholderia pseudomallei 2003) 
919. Hartley, H. A., Cornell University, Ithaca, New York (PDA/1 Bacillus anthracis 
2003) 
920. Hartung, John S., United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Xylella fastidiosa 2002) 
921. Harty, R. N., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2002, 2003, 2004, 2005) 
922. Harvey, S. P., US Army Edgewood Chemical Biological Center, Aberdeen 
Proving Ground, Maryland (PDA/1 Burkholderia mallei 2005) 
923. Haseman, J. R., University of Minnesota, Minneapolis, Minnesota (PDA/1 
Bacillus anthracis 2004) 
924. Hassett, D. J., University of Cincinnati, Cincinnati, Ohio (PDA/1 Francisella 
tularensis 2004) 
925. Hatfill, S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2001) 
926. Hatta, M., University of Wisconsin, Madison, Wisconsin (EDA/1 “1918 Influenza 
virus” 2004) 
927. Hauser, L. J., Oak Ridge National Laboratory, Oak Ridge, Tennessee (PDA/1 
Yersinia pestis 2004) 
928. Havig, A., Medical College of Wisconsin, Milwaukee, Wisconsin (PDA/1 
Francisella tularensis 2004) 
929. Hayes, S. F., National Institutes of Health, Hamilton, Montana (PDA/1 Rickettsia 
prowazekii 2000, PDA/1 Rickettsia rickettsii 2000) 
930. Hazbon, M. H., University of Medicine and Dentistry of New Jersey, Newark, 
New Jersey (PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 
931. Hazen, A., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, 2004) 
932. He, B. University of Illinois at Chicago (EDA/2 Zaire ebolavirus 2003, 2004) 
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Bacillus anthracis 2002) 
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Rickettsia prowazekii 2000, PDA/1 Rickettsia rickettsii 2000, 2003, 2004) 
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anthracis 2003) 
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2002, 2003, PDA/1 Yersinia pestis 2002, 2003) 
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pestis 2005) 
945. Hendrix, L. R., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2004, 2005) 
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2004) 
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Monkeypox virus 2001, MDA/4/5 Variola virus 2004) 
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2004) 
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tularensis 2000, PDA/1 Rickettsia prowazekii 2002) 
962. Hill, K. K., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2003, 2004, PDA/1 Yersinia pestis 2000) 
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herpesvirus 1 2002, 2003) 
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anthracis 2003, 2004) 
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968. Hines, J., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 
2001) 
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anthracis 2000, 2002) 
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2004) 
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University, Pullman, Washington (PDA/1 Coxiella burnetii 2000, 2002, 2003, 2004, 
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melitensis 2001) 
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melitensis 2002) 
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2004) 
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Influenza A virus 2003) 
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immitis 2000, 2001, 2002, PDA/1 Coccidioides posadasii 2000, 2003) 
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(PDA/1 Eastern equine encephalitis virus 2003) 
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anthracis 2003) 
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2004, 2005) 
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(EDA/2 Lassa virus 2000) 
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anthracis 2004) 
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1036. Ikegami, T., Centers for Disease Control and Prevention, Atlanta, 
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virus 2005)  
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Coccidioides immitis 2000, PDA/1 Coccidioides posadasii 2000) 
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Michigan, Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2002) 
1045. Italo, J. K., Stony Brook University, Stony Brook, New York (PDA/1 Francisella 
tularensis 2003, 2005) 
1046. Ivanova, N., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
1047. Ives, T. J., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Rickettsia prowazekii 2000, PDA/1 Rickettsia rickettsii 2000) 
1048. Ivey, F. D., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002, 2003) 
1049. Ivins, B., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, MDA/4/5 Bacillus anthracis 2001, 
PDA/1 Bacillus anthracis 2001, 2002, 2004, 2005, PDA/1 Venezuelan equine 
encephalitis virus 2003) 
1050. Iwen, P. C., University of Nebraska, Omaha, Nebraska (PDA/1 Francisella 
tularensis 2004) 
1051. Iyer, S., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2005) 
1052. Izadjoo, M. J., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Brucella melitensis 2000, 2002, 2004) 
1053. Jaax, N. K., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2000, EDA/2 Zaire 
ebolavirus 2000, 2001) 
1054. Jablonski, L., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
1055. Jackman, J., Johns Hopkins University, Laurel, Maryland (PDA/1 Bacillus 
anthracis 2004) 
1056. Jackson 3rd, W. E., Armed Forces Radiobiology Research Institute, Bethesda, 
Maryland? (MDA/4/5 Venezuelan equine encephalitis virus 2001) 
1057. Jackson, M. W., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 
2000, 2004, 2005) 
1058. Jackson, P. J., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2000, 2003, 2004, PDA/1 Newcastle disease virus 2004, 




1059. Jacobs, M. F., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
1060. Jahan, N., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Yersinia pestis 2001) 
1061. Jahrling, Peter B., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/1 Variola virus 2003, 2004, EDA/2 Lassa virus 
2001, EDA/2 Lake Victoria marburgvirus 2000, 2001, EDA/2 Zaire ebolavirus 2000, 
2001, 2002, 2003, 2004, MDA/4/5 Monkeypox virus 2001, MDA/4/5 Variola virus 2004, 
PDA/1 Camelpox virus 2003, PDA/1 Monkeypox virus 2001, 2002, 2003, PDA/1 
Venezuelan equine encephalitis virus 2003) 
1062. Jama, Y., Advanced Biosystems Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2004) 
1063. Janczewski, T. A., Armed Forces Institute of Pathology, Washington, D.C. 
(EDA/1 “1918 Influenza virus” 2001) 
1064. Janda, J. M., California Department of Health Services, Berkeley, California 
(PDA/1 Yersinia pestis 2000) 
1065. Jaramillo, M., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
1066. Jardieu, P., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
1067. Jarrett, C. O., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004) 
1068. Jarvis, B. W., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2003) 
1069. Javid, M. P., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2005) 
1070. Jayarama, V., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 Foot 
and mouth disease virus 2002) 
1071. Jeddeloh, J. A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Burkholderia pseudomallei 2003, PDA/1 
Burkholderia mallei 2002, 2004, 2005, PDA/1 Burkholderia pseudomallei 2001) 
1072. Jeng, R. L., University of California, Berkeley, California (PDA/1 Rickettsia 
rickettsii 2004) 
1073. Jenny, A. L., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Venezuelan equine encephalitis virus 2003) 
1074. Jensen, A. E., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000, 2003) 
1075. Jensen, B., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2004, 2005) 
1076. Jensen, D., University of Minnesota, St. Paul, Minnesota (PDA/1 Newcastle 
disease virus 2002) 
1077. Jensen, J. B., Brigham Young University, Provo, Utah/Harvard Medical School, 




1078. Jensen, R. B., Louisiana State University, Shreveport, Louisiana (PDA/1 Brucella 
melitensis 2000) 
1079. Jeor, S. C. St., University of Nevada at Reno, Reno, Nevada (EDA/2 Junín virus 
2000) 
1080. Jett, M., Walter Reed Army Institute of Research, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004) 
1081. Jiang, C., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002) 
1082. Jiang, G., BD Technologies, Research Triangle Park, North Carolina (PDA/1 
Bacillus anthracis 2005) 
1083. Jiang, L., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2002, 2003) 
1084. Jiang, X., University of Massachusetts, Amherst, Massachusetts (PDA/1 Brucella 
melitensis 2000, 2001) 
1085. Jiang, Y., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
1086. Jin, Y. H., College of Pharmacy, The University of Georgia, Athens, GA (EDA/1 
Variola virus 2003, PDA/1 Monkeypox virus 2003) 
1087. Johannesson, H., University of California Berkeley, California (PDA/1 
Coccidioides immitis 2003, PDA/1 Coccidioides posadasii 2003) 
1088. Johnson III, L. H., Naval Medical Research Institute, Bethesda/Silver Springs, 
Maryland (PDA/1 Francisella tularensis 2000, 2002) 
1089. Johnson, C., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2003) 
1090. Johnson, E. A., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2000, 2003, 2004, 2005) 
1091. Johnson, F., Purdue University, West Lafayette, Indiana (PDA/1 Bacillus 
anthracis 2004) 
1092. Johnson, J., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Eastern equine encephalitis virus 2003) 
1093. Johnson, L. H., Naval Research Laboratory, Center for Bio/Molecular Science and 
Engineering, Washington, D. C. (PDA/1 Francisella tularensis 2000) 
1094. Johnson, W. O., University of California Davis, Davis, California (PDA/1 Brucella 
melitensis 2003) 
1095. Johnston, R. E., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Influenza A virus 2000, PDA/1 Venezuelan equine encephalitis virus 
2000, 2001, 2003) 
1096. Johnston, S. A., University of Texas SW Med Ctr., Dallas, Texas/Vitruvius 
Biosciences, The Woodlands, Texas (PDA/1 Bacillus anthracis 2004, PDA/1 
Coccidioides immitis 2003) 
1097. Joiner, K. A., Yale University, New Haven, Connecticut (PDA/1 Coxiella burnetii 
2000) 





1099. Jones, J. W., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
1100. Jones, L. A., University of California-Davis, Davis, California (PDA/1 Peste-des-
petits-ruminants virus 2003, PDA/1 Rinderpest virus 2002, 2003) 
1101. Jones, M. B., New York University, New York, New York (PDA/1 Bacillus 
anthracis 2003, 2004, 2005) 
1102. Jones, M. E., Focus Technologies, Herndon, Virginia (PDA/1 Bacillus anthracis 
2003) 
1103. Jones, S., Elusys Therapeutics Inc., Pine Brook, New Jersey (MDA/4/5 Bacillus 
anthracis 2005) 
1104. Jones, Y. L., Tuskegee University, Tuskegee, Alabama (PDA/1 Influenza A virus 
2004) 
1105. Joshi, S. G., University of Rochester Rochester, New York (PDA/1 Rickettsia 
rickettsii 2003, 2004, PDA/1 Yersinia pestis 2004) 
1106. Kachman, M. T., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2003) 
1107. Kachur, S. M., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
1108. Kagan, E., Uniformed Services University of the Health Sciences, Bethesda, 
Maryland (EDA/2 Zaire ebolavirus 2003) 
1109. Kajava, A. V., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2001) 
1110. Kallstrom, G. H., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, 2005) 
1111. Kalnin, K. V., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
1112. Kalns, J., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus anthracis 
2002) 
1113. Kalns, J., Veridian, Inc., San Antonio, Texas (PDA/1 Bacillus anthracis 2000) 
1114. Kamberi, P., California Institute for Medical Research, San Jose, California 
(PDA/1 Coccidioides immitis 2003) 
1115. Kamper, S. M., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2001) 
1116. Kand, M. L., Oak Ridge National Laboratory, Oak Ridge, Tennessee (PDA/1 
Yersinia pestis 2004) 
1117. Kandil, A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Influenza A virus 2001) 
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1119. Kang, W., University of Texas Medical Branch, Galveston, Texas (PDA/1 
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2005) 
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1232. Krak, S. J., Battelle, Columbus, Ohio (PDA/1 Francisella tularensis 2000) 
1233. Kramer, E., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2000, 2001, 
2002, 2003, 2005) 
1234. Kramer, F. R., Public Health Research Institute, Newark, New Jersey (PDA/1 
Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 
1235. Krauss, S. L., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2000, 2001, 2003, 2005) 
1236. Kraycer, J. A., University of Scranton, Scranton, Pennsylvania (PDA/1 Brucella 
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Bacillus anthracis 2003) 
1243. Kuehne, A., United States Army Medical Research Institute of Infectious Diseases, 




1244. Kulesh, D. A., United States Army Medical Research Institute of Infectious 
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Service, Ames, Iowa (PDA/1 Influenza A virus 2002, PDA/1 Newcastle disease virus 
2004) 
1704. Pannucci, J., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2002) 
1705. Pappagianis, D., University of California Davis, Davis, California (PDA/1 
Coccidioides immitis 2000, 2002, 2003, PDA/1 Coccidioides posadasii 2000) 
1706. Paragas, J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Crimean-Congo hemorrhagic fever virus 2004, 2005, 
EDA/2 Zaire ebolavirus 2003, 2005) 
1707. Paranavitana, C. M., Walter Reed Army Institute of Research, Washington, D.C. 
(PDA/1 Brucella melitensis 2000, 2004) 
1708. Paranjpye, R. N., Unites States Department of Commerce, Seattle, Washington 
(PDA/1 Clostridium botulinum 2002, 2004) 
1709. Pardington, P. E., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2004) 
1710. Paredes, A., Baylor College of Medicine, Houston, Texas (PDA/1 Venezuelan 
equine encephalitis virus 2001, 2003) 
1711. Parent, M., University of Massachusetts, Amherst, Massachusetts (PDA/1 Brucella 
melitensis 2001, 2002) 
1712. Park, C., Oakland Research Institute, Oakland, California (PDA/1 Bacillus 
anthracis 2005) 





1714. Park, J.-B., Jefferson Medical College, Philadelphia, Pennsylvania (PDA/1 
Clostridium botulinum 2004) 
1715. Park, M.-S., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2001, 2003, 2004, 2005) 
1716. Park, S., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2000) 
1717. Parker, J. E., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus 
anthracis 2000, 2002) 
1718. Parker, M. D., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lassa virus 2001, EDA/2 Zaire ebolavirus 
2000, 2001, MDA/4/5 Venezuelan equine encephalitis virus 2005, PDA/1 Eastern equine 
encephalitis virus 2002, 2005) 
1719. Parker, S., Vical Inc., San Diego, California (MDA/4/5 Bacillus anthracis 2004) 
1720. Parren, W. H. I., Scripps Research Institute, La Jolla, California (EDA/2 Zaire 
ebolavirus 2002) 
1721. Parsons, Joseph M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/1 Variola virus 2000) 
1722. Parthasarathy, N., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2005) 
1723. Pasarel, Lester, University of Texas Medical Branch, Galveston, Texas (PDA/1 
Coccidioides immitis 2000) 
1724. Pasnik, D. J., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2003) 
1725. Passalacqua, K. D., University of Michigan Medical School, Ann Arbor, Michigan 
(PDA/1 Bacillus anthracis 2005) 
1726. Patch, J. R., Uniformed Services University, Bethesda, Maryland (PDA/1 Hendra 
virus 2005, PDA/1 Nipah virus 2005) 
1727. Patnayak, D. P., University of Minnesota, St. Paul, Minnesota (PDA/1 Newcastle 
disease virus 2004) 
1728. Patra, G., University of Scranton, Scranton, Pennsylvania (PDA/1 Bacillus 
anthracis 2001, 2002, 2003, 2004, PDA/1 Brucella melitensis 2002) 
1729. Patrusheva, I., Georgia State University, Atlanta, Georgia (PDA/1 Cercopithecine 
herpesvirus 1 2002, 2003) 
1730. Paul, A. V., State University of New York at Stony Brook, Stony Brook, New 
York (MDA/6 Poliovirus 2002) 
1731. Paul, S., Rockefeller University, New York, New York (PDA/1 Coxiella burnetii 
2000) 
1732. Paulsen, I. T., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003, PDA/1 Coxiella burnetii 2003) 
1733. Payton, M. E., Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Cercopithecine herpesvirus 1 2005) 
1734. Peacock, S. J., Armed Forces Radiobiology Research Institute, Bethesda, 




1735. Pearson, T., Northern Arizona University, Flagstaff, Arizona (EDA/5 Bacillus 
anthracis 2003, PDA/1 Bacillus anthracis 2004) 
1736. Pedersen, D. D., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Venezuelan equine encephalitis virus 2003) 
1737. Pedersen, J. C., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Influenza A virus 2002, PDA/1 Newcastle disease virus 
2004, 2005) 
1738. Pedersen, L., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2004) 
1739. Peeples, M. E., Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 
(PDA/1 Newcastle disease virus 2001) 
1740. Pei, J., Texas A&M University, College Station, Texas (PDA/1 Brucella melitensis 
2004) 
1741. Peleg, M., University of Massachusetts, Amherst, Massachusetts (PDA/1 
Clostridium botulinum 2000) 
1742. Pelroy, G. A., Unites States Department of Commerce, Seattle, Washington 
(PDA/1 Clostridium botulinum 2002, 2004) 
1743. Peng, T., University of Arizona, Tucson, Arizona (PDA/1 Coccidioides immitis 
2002) 
1744. Penrose, K. J., National Cancer Institute Frederick, Maryland (PDA/1 Yersinia 
pestis 2005) 
1745. Percival, A., University of Nevada School of Medicine, Reno, Nevada (PDA/1 
Bacillus anthracis 2004) 
1746. Percy-Fine, S., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2002) 
1747. Perdue, M. L., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia/United States Department of Agriculture, Agricultural 
Research Service, Beltsville, Maryland (EDA/1 “1918 Influenza virus” 2001, PDA/1 
Bacillus anthracis 2003, PDA/1 Influenza A virus 2000, 2001, 2002, 2003) 
1748. Perelygina, L., Georgia State University, Atlanta, Georgia (PDA/1 Cercopithecine 
herpesvirus 1 2002, 2003)  
1749. Peretz, D., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2005) 
1750. Perez, D. R., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2003, 2004) 
1751. Perez, M., Scripps Research Institute, La Jolla, California (EDA/2 Lassa virus 
2005) 
1752. Perkins, B. A., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2003) 
1753. Perkins, J. G., Walter Reed Army Medical Center, Washington, D.C. (EDA/2 
Zaire ebolavirus 2004) 
1754. Perkins, J., Lawrence Livermore National Laboratory, Livermore, California 




1755. Perkins, L. E. L., Southeast Poultry Research Laboratory, United States 
Department of Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2002) 
1756. Perna, N. T., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
1757. Perri, S., Chiron, Emeryville, California (PDA/1 Venezuelan equine encephalitis 
virus 2003) 
1758. Perrill, R., University of Arizona, Tucson, Arizona (PDA/1 Coccidioides immitis 
2002) 
1759. Perry, R. D., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 
2000, 2001, 2002, 2003, 2004) 
1760. Perumaalla, V. S., Louisiana State University, Shreveport, Louisiana (PDA/1 
Brucella melitensis 2000) 
1761. Peruski, A. H., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004, PDA/1 Francisella tularensis 2002) 
1762. Peruski, L. F., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Francisella tularensis 2002) 
1763. Peters, C. J., Centers for Disease Control and Prevention, Atlanta, 
Georgia/University of Texas Medical Branch, Galveston, Texas (EDA/2 Lassa virus 2000, 
EDA/2 Reston ebolavirus 2001, PDA/1 Nipah virus 2000, PDA/1 Rift Valley fever virus 
2003, 2005)  
1764. Petersen, J. M., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Francisella tularensis 2003, 2004) 
1765. Peterson, A., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2004, 2005) 
1766. Peterson, J. D., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
1767. Peterson, M. E., Unites States Department of Commerce, Seattle, Washington 
(PDA/1 Clostridium botulinum 2002, 2004) 
1768. Peterson, S. N., Institute for Genomic Research, Rockville, Maryland/George 
Washington University, Washington, D.C. (PDA/1 Bacillus anthracis 2003, 2004) 
1769. Petrenko, V. A., Auburn University, Auburn, Alabama (PDA/1 Bacillus anthracis 
2004) 
1770. Petrovick, M. S., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
1771. Pettigrew, C. A., Procter and Gamble, St. Bernard, Ohio (PDA/1 Bacillus 
anthracis 2004, 2005) 
1772. Petty, Howard R., Wayne State University, Detroit, Michigan (EDA/2 Zaire 
ebolavirus 2000) 
1773. Pezzanite, L., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rift Valley fever virus 2002) 
1774. Pfannkoch, C., Institute for Biological Energy Alternatives, Rockville, Maryland 
(PDA/6 Enterobacteria phage φX174 2003) 





1776. Pharr, G. T., Mississippi State University, Mississippi State, Mississippi 
(MDA/4/5 Mycoplasma gallisepticum 2005,) 
1777. Philipovskiy, A. V., University of Kentucky, Lexington, Kentucky (PDA/1 
Yersinia pestis 2005) 
1778. Philips, L. R., National Cancer Institute, Fort Detrick, Frederick, Maryland 
(PDA/1 Bacillus anthracis 2005) 
1779. Philips, M., Department of Health, New York City, New York (PDA/1 Bacillus 
anthracis 2003) 
1780. Phillips, N. J., University of California, San Francisco, San Francisco (PDA/1 
Francisella tularensis 2004) 
1781. Phillips, R. W., Massachusetts Institute of Technology, Cambridge, Massachusetts 
(PDA/1 Brucella melitensis 2000, 2001) 
1782. Philo, L. M., United States Department of Agriculture, Bozeman, Montana (PDA/1 
Brucella melitensis 2001) 
1783. Phuangsab, A., Cook County Hospital, Chicago, Illinois (PDA/1 Newcastle 
disease virus 2001) 
1784. Piccone, M. E., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2004, PDA/1 Foot 
and mouth disease virus 2005) 
1785. Pickering, A. K., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
1786. Piedrahita, J. A., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2001) 
1787. Pier, G. B., Harvard Medical School, Boston, Massachusetts (PDA/1 Yersinia 
pestis 2005) 
1788. Pierson, M. D., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Clostridium botulinum 2000) 
1789. Pillai, S. P., Florida Department of Health, State Public Health Laboratory-Miami, 
Miami, Florida (MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 
2004) 
1790. Pincus, S., Elusys Therapeutics Inc., Pine Brook, New Jersey (MDA/4/5 Bacillus 
anthracis 2005) 
1791. Pitesky, M. E., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
1792. Pitha, P. M., Johns Hopkins University, Baltimore, Maryland (PDA/1 Newcastle 
disease virus 2002, 2003) 
1793. Pitha, P. M., Johns Hopkins University, Baltimore, Maryland (PDA/1 Newcastle 
disease virus 2001) 
1794. Pitt, M. L. M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Bacillus anthracis 2001, MDA/4/5 Brucella 
melitensis 2004, MDA/4/5 Coxiella burnetii 2002, PDA/1 Bacillus anthracis 2001, 2004, 
PDA/1 Yersinia pestis 2002) 
1795. Plano, G. V., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2000, 




1796. Plaut, R. D., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
1797. Pletnev, A., National Institutes of Health, Bethesda, Maryland (EDA/2 Tick-borne 
encephalitis virus 2000, 2001, MDA/6 Langat virus 2000, 2001) 
1798. Plummer, A. L., Tetracore Inc., Gaithersburg, Maryland (PDA/1 Francisella 
tularensis 2000)  
1799. Plunkett III., G., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
1800. Pöhlmann, S., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
1801. Poland, G. A., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Monkeypox 
virus 2002) 
1802. Polo, J. M., Chiron, Emeryville, California (PDA/1 Venezuelan equine 
encephalitis virus 2003) 
1803. Polotsky, Y., Walter Reed Army Institute of Research, Forest Glen, Maryland 
(PDA/1 Brucella melitensis 2000) 
1804. Pombo, M., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
1805. Pomerantsev, A. P., National Institutes of Health, Bethesda, Maryland (PDA/1 
Bacillus anthracis 2003, 2004) 
1806. Pomerantseva, O. M., Naval Medical Research Center, Rockville, Maryland 
(PDA/1 Bacillus anthracis 2004) 
1807. Pop, M., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2002, 2003) 
1808. Pope, C. R., University of Delaware, Newark, Delaware (PDA/1 Newcastle 
disease virus 2003) 
1809. Popov, S., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002, 2003, 2004, 2005) 
1810. Popov, V. L., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia prowazekii 2001, PDA/1 Rickettsia rickettsii 2004) 
1811. Popova, T. Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002, 2003, 2004, 2005) 
1812. Popovic, T., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002, 2003, 2005, PDA/1 Brucella melitensis 2004, PDA/1 
Burkholderia mallei 2002, 2005, PDA/1 Burkholderia pseudomallei 2002, 2005) 
1813. Porotto, M., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2004) 
1814. Porschen, R., Focus Technologies, Cypress, California (PDA/1 Bacillus anthracis 
2003) 
1815. Porter, H., Brigham Young University, Provo, Utah/Harvard Medical School, 
Boston, Massachusetts (PDA/1 Bacillus anthracis 2002, 2003) 
1816. Portner, A., St. Jude Children's Research Hospital, Memphis, Tennessee (PDA/1 




1817. Powdrill, T. F., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 Bacillus 
anthracis 2004) 
1818. Powell, B. S., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Yersinia pestis 2005) 
1819. Powell, T. D., Heska Corporation, Fort Collins, Colorado (PDA/1 Yersinia pestis 
2003, 2004) 
1820. Power, M. E., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
1821. Powers, A. M., University of Texas Medical Branch, Galveston, Texas/Centers for 
Disease Control and Prevention, Fort Collins, Colorado (PDA/1 Venezuelan equine 
encephalitis virus 2000, 2001, 2002, 2003, 2004) 
1822. Poysky, F. T., Unites States Department of Commerce, Seattle, Washington 
(PDA/1 Clostridium botulinum 2002, 2004) 
1823. Prabakaran, S., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2001) 
1824. Prashar, Y., Yale University, New Haven, Connecticut (PDA/1 Yersinia pestis 
2001) 
1825. Pratt, R. W., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Venezuelan equine encephalitis virus 2005, 
PDA/1 Venezuelan equine encephalitis virus 2000, 2001, 2003) 
1826. Price, L. B., Johns Hopkins University, Baltimore, Maryland/Northern Arizona 
University, Flagstaff, Arizona (EDA/5 Bacillus anthracis 2003, PDA/1 Bacillus anthracis 
2000, PDA/1 Yersinia pestis 2001) 
1827. Price, R. L., University of South Carolina, Columbia South Carolina (PDA/1 
Bacillus anthracis 2004) 
1828. Pritchard, D. G., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2004) 
1829. Probert, W. S., California Department of Health Services, Richmond, California 
(PDA/1 Brucella melitensis 2004) 
1830. Prusiner, S. B., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002, 2005) 
1831. Pryor, H. I., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
(PDA/1 Bacillus anthracis 2001) 
1832. Przygodzki, R. M., Armed Forces Institute of Pathology, Washington, D.C. 
(EDA/1 “1918 Influenza virus” 2004) 
1833. Pujol, C., State University of New York at Stony Brook, Stony Brook, New York 
(PDA/1 Yersinia pestis 2003, 2004) 
1834. Pulendran, Bali, Emory Vaccine Research Center and Department of Pathology, 
Emory University, Atlanta, Georgia (EDA/2 Lassa virus 2003, EDA/2 Zaire ebolavirus 
2003) 
1835. Purmal, A., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 Foot and 




1836. Pushko, P., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lassa virus 2001, EDA/2 Zaire ebolavirus 2000, 2001, 
2002, PDA/1 Venezuelan equine encephalitis virus 2004) 
1837. Putnak, J. R., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Japanese encephalitis virus 2001) 
1838. Qi, J., University of Tennessee, Memphis, Tennessee (PDA/1 Bacillus anthracis 
2004) 
1839. Qi, Y., University of Scranton, Scranton, Pennsylvania/University of Texas, 
Dallas, Texas (PDA/1 Bacillus anthracis 2001, 2002) 
1840. Qin, A., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2004) 
1841. Quackenbush, J., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2005) 
1842. Quinn, C. P., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2003) 
1843. Qureshi, N., University of Missouri, Kansas City, Missouri (PDA/1 Brucella 
melitensis 2004) 
1844. Raab, R. W., James Madison University, Harrisonburg, Virginia (PDA/1 Yersinia 
pestis 2005) 
1845. Rabinovitch, M., Rockefeller University, New York, New York (PDA/1 Coxiella 
burnetii 2000) 
1846. Rachek, L. I., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2000) 
1847. Radnegde, L., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Bacillus anthracis 2001, 2002, 2003) 
1848. Radulovic, S., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2002, 2003) 
1849. Radune, D., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 
2004) 
1850. Radyuk, S. N., Advanced Biosystems, Inc., Manassas, Virginia/George Mason 
University, Manassas, VA (PDA/1 Bacillus anthracis 2003) 
1851. Ragland, D., Purdue University, West Lafayette, Indiana (PDA/1 Foot and mouth 
disease virus 2003) 
1852. Rajashekara, G., University of Wisconsin, Madison, Wisconsin (PDA/1 Brucella 
melitensis 2004) 
1853. Rama Krishna, N., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2004) 
1854. Ramanculov, E., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Yersinia pestis 2003) 
1855. Ramirez, D. M., National Institutes of Health, Bethesda, Maryland (PDA/1 
Bacillus anthracis 2002) 
1856. Ramponi, A. J., Lawrence Livermore National Laboratory, Livermore, California 




1857. Rao, M., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(EDA/2 Zaire ebolavirus 2002) 
1858. Rasko, D. A., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2004) 
1859. Rasooly, A., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2004) 
1860. Ratterree, M., Sierra Biomedical Inc., Sparks, Nevada (PDA/1 Japanese 
encephalitis virus 2000) 
1861. Raulie, E. K., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Francisella tularensis 2004) 
1862. Rautenschlein, S., University of Minnesota, St. Paul, Minnesota (PDA/1 
Newcastle disease virus 2002) 
1863. Ravel, J., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2004) 
1864. Ray, R. B., St. Louis University, St. Louis, Missouri (PDA/1 Newcastle disease 
virus 2003) 
1865. Ray, R., St. Louis University, St. Louis, Missouri (PDA/1 Newcastle disease virus 
2003) 
1866. Raymond, J. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2002) 
1867. Rea, K. M., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
1868. Read, R. D. A., East Carolina University, Greenville, North Carolina (PDA/1 
Brucella melitensis 2004) 
1869. Read, T. D., Institute for Genomic Research, Rockville, Maryland/University of 
Maryland, Baltimore, Maryland (PDA/1 Bacillus anthracis 2002, 2003, 2004, PDA/1 
Coxiella burnetii 2003) 
1870. Rebeil, R., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004) 
1871. Reddy, N. R., United States Food and Drug Administration, Summit-Argo, Illinois 
(PDA/1 Clostridium botulinum 2003) 
1872. Redkar, R. J., Schott Glass Technologies Inc., Duryea, Pennsylvania/University of 
Scranton, Scranton, Pennsylvania (PDA/1 Bacillus anthracis 2001, 2002, 2004, PDA/1 
Brucella melitensis 2001, 2002) 
1873. Redmond, C., University of Maryland, Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2003) 
1874. Reed, D. S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, 2004, MDA/4/5 Andes virus 2002, 
MDA/4/5 Venezuelan equine encephalitis virus 2001) 
1875. Reeves, J. D., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
1876. Regala, W. M., Lawrence Livermore National Laboratory, Livermore, California 




1877. Regnery, R. L., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rickettsia prowazekii 2000, PDA/1 Rickettsia rickettsii 2000)  
1878. Reichard, K. W., Cook County Hospital, Chicago, Illinois (PDA/1 Newcastle 
disease virus 2001) 
1879. Reichhardt, U., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
immitis 2000, 2002) 
1880. Reid, A. H., Armed Forces Institute of Pathology, Washington, D.C. (EDA/1 
“1918 Influenza virus” 2001) 
1881. Reinders, M. O., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2004) 
1882. Reisenauer, A., Louisiana State University, Shreveport, Louisiana (PDA/1 
Brucella melitensis 2000) 
1883. Reitter, J. N., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Newcastle disease virus 2003)  
1884. Relman, D. A., Stanford University, Stanford, Connecticut (EDA/1 Variola virus 
2004, MDA/4/5 Variola virus 2004) 
1885. Ren, D., Cornell University, Ithaca, New York (PDA/1 Bacillus anthracis 2005) 
1886. Ren, Q., University of Wyoming, Laramie, Wyoming (PDA/1 Coxiella burnetii 
2003, PDA/1 Rickettsia rickettsii 2003) 
1887. Renshaw, M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Influenza A virus 2001) 
1888. Reponen, T., Centers for Disease Control and Prevention, Cincinnati, Ohio 
(MDA/4/5 Bacillus globigii 2005) 
1889. Resau, J., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 Bacillus 
anthracis 2001)  
1890. Rest, R. F., Drexel University, Philadelphia, Pennsylvania (PDA/1 Bacillus 
anthracis 2003, 2004) 
1891. Reyes, A. E., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004) 
1892. Reynolds, D. L., Iowa State University, Ames, Iowa (PDA/1 Newcastle disease 
virus 2000) 
1893. Reznik, G., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
1894. Rhodehamel, E. J., United States Food and Drug Administration, Summit-Argo, 
Illinois (PDA/1 Clostridium botulinum 2003) 
1895. Rhoton, S. D., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
1896. Rhyan, J. C., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2000, 2001, 2004) 
1897. Riberday, J. M., St. Jude Children’s Research Hospital, Memphis, Tennessee 
(PDA/1 Influenza A virus 2000) 
1898. Ribot, E., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 




1899. Ribot, W. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004, 2005) 
1900. Rice, C. M., Rockefeller University, New York, New York (PDA/1 Japanese 
encephalitis virus 2003) 
1901. Rice, E. W., United States Environmental Protection Agency, Cincinnati, Ohio 
(PDA/1 Bacillus anthracis 2005) 
1902. Richards, A. L., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Rickettsia prowazekii 2004)  
1903. Richardson, A. P., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2004) 
1904. Richmond, K., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Newcastle disease virus 2004) 
1905. Ricklefs, R. E., University of Missouri-St. Louis, St. Louis, Missouri (PDA/1 
Newcastle disease virus 2002) 
1906. Rico-Hesse, Rebeca, Southwest Foundation for Biomedical Research, San 
Antonio, Texas (EDA/2 Lassa fever virus 2002, EDA/2 Guanarito virus 2002, EDA/2 
Junín virus 2002, EDA/2 Machupo virus 2002, PDA/1 Flexal virus 2002, PDA/1 Sabiá 
virus 2002) 
1907. Rider, T. H., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
1908. Riley, J. L., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 Zaire 
ebolavirus 2003) 
1909. Rilstone, J. Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003) 
1910. Rinaldi, M. G., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2001, 2002) 
1911. Ringpis, F., ClinCyte, LLC, San Diego, California (PDA/1 Brucella melitensis 
2000) 
1912. Risatti, G. R., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2005, PDA/1 
Classical swine fever virus 2003, 2005)  
1913. Ritchey, J. W., Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Cercopithecine herpesvirus 1 2005) 
1914. Rittner, C. M., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Yersinia pestis 2000) 
1915. Robbins, J. B., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
1916. Robertson, G. T., Louisiana State University, Shreveport, Louisiana (PDA/1 
Brucella melitensis 2000, 2002, 2003) 
1917. Robertson, M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Frederick, Maryland (PDA/1 Venezuelan equine encephalitis virus 
2001) 
1918. Robertson, S. J., University of California, San Francisco, California (PDA/1 




1919. Robinson, H. L., Emory University, Atlanta, Georgia (PDA/1 Influenza A virus 
2003) 
1920. Robinson, R., Pfizer, Lincoln, Nebraska (PDA/1 Foot and mouth disease virus 
2004) 
1921. Robinson, T. M., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2004) 
1922. Robison, R., Brigham Young University, Provo, Utah/Harvard Medical School, 
Boston, Massachusetts (PDA/1 Bacillus anthracis 2002, 2003) 
1923. Rocco, J. M., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
1924. Rock, D. L., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York/University of Connecticut, Storrs, Connecticut (PDA/1 
African swine fever virus 2000, 2001, 2002, 2004, 2005, PDA/1 Camelpox virus 2002, 
PDA/1 Classical swine fever virus 2005, PDA/1 Foot and mouth disease virus 2002, 
PDA/1 Goatpox virus 2002, PDA/1 Lumpy skin disease virus 2001, 2003, PDA/1 
Sheeppox virus 2002) 
1925. Rocke, T. E., United States Geological Survey, Madison, Wisconsin (PDA/1 
Yersinia pestis 2003, 2004) 
1926. Rockemann, D. D., S., University of Maryland, College Park, Maryland (PDA/1 
Newcastle disease virus 2004) 
1927. Rodriguez, L. L., Plum Island Animal Disease Center, United States Department 
of Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003) 
1928. Roehrig, J. T., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Eastern equine encephalitis virus 2001, PDA/1 Japanese encephalitis virus 2003, 
PDA/1 Nipah virus 2000) 
1929. Roffe, T. J., United States Department of the Interior, Bozeman, Montana (PDA/1 
Brucella melitensis 2001) 
1930. Rogers, K., Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Cercopithecine herpesvirus 1 2003) 
1931. Rohrer, A. J., United States Air Forsce Academy, Colorado Springs, Colorado 
(PDA/1 Yersinia pestis 2003) 
1932. Rojek, J. M., Scripps Research Institute, La Jolla, California (EDA/2 Lassa virus 
2005) 
1933. Rollin, P. E., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Guanarito virus 2002, EDA/2 Lassa virus 2000, 2003, EDA/2 Machupo virus 
2002, EDA/2 Omsk hemorrhagic fever virus 2004, EDA/2 Reston ebolavirus 2001, 
EDA/2 Sudan ebolavirus 2004, EDA/2 Zaire ebolavirus 2000, 2001, 2003, 2004, 2005, 
PDA/1 Rift Valley fever virus 2002, PDA/1 Sabiá virus 2002, PDA/1 Flexal virus 2002, 
PDA/1 Hendra virus 2002, PDA/1 Nipah virus 2000, 2001, 2002, 2003) 
1934. Romero, C. M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
1935. Romero, G.,United States Army Medical Research Institute of Infectious Diseases, 




1936. Romero, R. E., Chiron, Emeryville, California (PDA/1 Venezuelan equine 
encephalitis virus 2003) 
1937. Romoser, W. S., Ohio University, Athens, Ohio (PDA/1 Venezuelan equine 
encephalitis virus 2004) 
1938. Ronning, C. M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
1939. Roop II, R. M., East Carolina University, Greenville, North Carolina/Louisiana 
State University, Baton Rouge, Louisiana (PDA/1 Brucella melitensis 2000, 2001, 2002, 
2003, 2004) 
1940. Rose, D. J., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
1941. Rose, L. J., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2004, 2005, PDA/1 Yersinia pestis 2003) 
1942. Rose, S., University of Scranton, Scranton, Pennsylvania/University of Texas, 
Dallas, Texas (PDA/1 Bacillus anthracis 2001, 2002, PDA/1 Brucella melitensis 2001) 
1943. Roselle, B. J., Procter and Gamble, St. Bernard, Ohio (PDA/1 Bacillus anthracis 
2004, 2005) 
1944. Rosen, G. M., University of Maryland Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2005) 
1945. Rosenberger, J. K., University of Delaware, Newark, Delaware (PDA/1 Newcastle 
disease virus 2003) 
1946. Rosenblatt, J. E., , Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Bacillus 
anthracis 2002) 
1947. Rosenzweig, J. A., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 
2005) 
1948. Ross, C. L., University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 2003) 
1949. Ross, T. M., East Carolina University, Greenville, Nort Carolina (PDA/1 Influenza 
A virus 2003) 
1950. Rossi, C., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Bacillus anthracis 2001 
,PDA/1 Venezuelan equine encephalitis virus 2003) 
1951. Rota, P. A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Hendra virus 2002, PDA/1 Nipah virus 2000, 2001, 2002, 2003, 2005) 
1952. Rote, W. W., Corvas International, San Diego, California (EDA/2 Zaire ebolavirus 
2003) 
1953. Rotman, B., BCR Diagnostics, Inc., Jamestown, Rhode Island/Brown University, 
Providence, Rhode Island (PDA/1 Bacillus anthracis 2004) 
1954. Rottinghaus, G. E., University of Missouri, Columbia, Missouri (PDA/1 Newcastle 
disease virus 2000) 
1955. Roudabush, R. M., Brooks Air Force Base, San Antonio, Texas (PDA/1 
Francisella tularensis 2004) 
1956. Roush, W. B., United States Department of Agriculture, Agricultural Research 
Service, Mississippi State, Mississippi (MDA/4/5 Mycoplasma gallisepticum 2005)  




1958. Rowe, T.,, Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Influenza A virus 2001, 2003) 
1959. Rowehl, R., Brookhaven National Laboratory, Upton, New York (PDA/1 Yersinia 
pestis 2005) 
1960. Rowland, G. N., University of Georgia, Athens, Georgia (MDA/4/5 Mycoplasma 
synoviae 2001) 
1961. Rowton, E. D., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Rift Valley fever virus 2000) 
1962. Roy, C. J., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (MDA/4/5 Yersinia pestis 2003, PDA/1 Bacillus anthracis 2005) 
1963. Roy, C. R., Yale University, New Haven, Connecticut (PDA/1 Coxiella burnetii 
2003, 2004) 
1964. Roy, C., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2001, MDA/4/5 Burkholderia mallei 
2005, MDA/4/5 Cowpox virus 2002) 
1965. Rubins, K. H., Stanford University, Stanford, Connecticut (EDA/1 Variola virus 
2004, MDA/4/5 Variola virus 2004) 
1966. Rudnick, S., Harvard School of Public Health, Boston, Massachusetts (MDA/4/5 
Human Rhinovirus 2003) 
1967. Rudolph, A. E., National Institutes of Health, Hamilton, Montana/University of 
Michigan Medical School, Ann Arbor, Michigan (PDA/1 Yersinia pestis 2000, 2002) 
1968. Ruel, T. D., Yale University School of Medicine, New Haven Connecticut (PDA/1 
Rift Valley fever virus 2000) 
1969. Ruff, A., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Venezuelan equine 
encephalitis virus 2003) 
1970. Ruggiero, C. E., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2005) 
1971. Runnheim, R., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
1972. Rurangirwa, F. R., Washington State University, Pullman, Washington (PDA/1 
Ehrlichia ruminantium 2000, PDA/1 Mycoplasma mycoides mycoides 2000) 
1973. Rusalov, D., Vical Inc., San Diego, California (MDA/4/5 Bacillus anthracis 2004) 
1974. Russell, K. E., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2004, 2005) 
1975. Russell, K. L., Naval Medical Research Center Detachment, NAMRID, Peru 
(PDA/1 Venezuelan equine encephalitis virus 2000, 2004) 
1976. Russell, S. C., University of California, Davis, California (MDA/4/5 Bacillus 
athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
1977. Ruthel, G., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2002, 2003, 2004, EDA/2 
Zaire ebolavirus 2002, 2003, 2004, 2005, PDA/1 Bacillus anthracis 2004, 2005, PDA/1 




1978. Ryan, J. R., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Eastern equine encephalitis virus 2003) 
1979. Ryan, J., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Brucella melitensis 2003, PDA/1 Eastern equine encephalitis virus 2003) 
1980. Rybachuck, G., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Bacillus anthracis 2003)  
1981. Rycerz, T., University of South Florida, Tampa, Florida (PDA/1 Bacillus anthracis 
2003) 
1982. Rydkina, E., University of Rochester Rochester, New York (PDA/1 Rickettsia 
rickettsii 2002, 2003) 
1983. Sabin, R., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2002) 
1984. Sacchi, C. T., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002, PDA/1 Burkholderia mallei 2002, PDA/1 Burkholderia 
pseudomallei 2002) 
1985. Sacci, J. B., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2003) 
1986. Safar, J. G., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
1987. Sahm, D. F., Focus Technologies, Herndon, Virginia (PDA/1 Bacillus anthracis 
2003) 
1988. Sahni, A., University of Rochester Rochester, New York (PDA/1 Rickettsia 
rickettsii 2002) 
1989. Sahni, S. K., University of Rochester Rochester, New York (PDA/1 Rickettsia 
rickettsii 2002, 2003, 2004) 
1990. Sahu, S. P., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Venezuelan equine encephalitis virus 2003) 
1991. Saif, Y. M., Ohio State University, Wooster, Ohio (PDA/1 Newcastle disease virus 
2002) 
1992. Saikh, K. U., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Bacillus 
anthracis 2005, PDA/1 Yersinia pestis 2004) 
1993. Saile, E. , University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 2002) 
1994. Saleh, S. S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/1 Variola virus 2003, PDA/1 Camelpox virus 2003, PDA/1 
Monkeypox virus 2003, PDA/1 Rift Valley fever virus 2005) 
1995. Salvato, M., University of Maryland, Baltimore, Maryland (EDA/2 Lassa virus 
2002, 2003, 2004) 
1996. Salvatore, M., Mount Sinai School of Medicine, New York, New York (EDA/1 
“1918 Influenza virus” 2001) 
1997. Salzberg, S. L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2002, 2003) 
1998. Samaan, M. N., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 




1999. Samal, S. K., University of Maryland, College Park, Maryland (PDA/1 Newcastle 
disease virus 2001, 2003, 2004) 
2000. Samartino, L. E., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2001, 2002) 
2001. Samrakandi, M. M., University of Nebraska, Lincoln, Nebraska (PDA/1 
Francisella tularensis 2004) 
2002. Samuel, C. E., University of California at Santa Barbara, Santa Barbara, California 
(PDA/1 Newcastle disease virus 2001) 
2003. Samuel, J. E., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2001, 2002, 2003, 2004, 2005) 
2004. Sanchez, A. J., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Crimean-Congo hemorrhagic fever virus 2002, EDA/2 Sudan ebolavirus 2004) 
2005. Sanchez, A., Centers for Disease Control and Prevention, Atlanta, Georgia (EDA/2 
Sudan ebolavirus 2004, EDA/2 Zaire ebolavirus 2000, 2003) 
2006. Sandem, G. N., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
2007. Sander, J. E., University of Georgia, Athens, Georgia (PDA/1 Newcastle disease 
virus 2003) 
2008. Sanderson, W. T., , Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
2009. Sandfort, R. F., California Department of Health Services, Berkeley, California 
(PDA/1 Yersinia pestis 2000) 
2010. Sanstad, E. A., Loyola University, Maywood, Illinois (PDA/1 Bacillus anthracis 
2003) 
2011. Santucci-Domotor, L. A., University of Maryland, Baltimore, Maryland (PDA/1 
Rickettsia rickettsii 2003) 
2012. Sardelis, M. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
2013. Sarr, J., University of California-Davis, Davis, California (PDA/1 Peste-des-petits-
ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
2014. Sarria, S., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2015. Sathiyaseelan, J., University of Massachusetts, Amherst, Massachusetts (PDA/1 
Brucella melitensis 2000, 2001) 
2016. Sautter, T. E., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
(PDA/1 Bacillus anthracis 2001) 
2017. Savage, Harry M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Rift Valley fever virus 2002) 
2018. Savitt, A. G., Brookhaven National Laboratory, Upton, New York (PDA/1 
Yersinia pestis 2005) 
2019. Sayeedur Rahman, M., University of Maryland, Baltimore, Maryland (PDA/1 
Rickettsia rickettsii 2003, 2005) 
2020. Scanlan, D., Institute for Genomic Research, Rockville, Maryland (PDA/1 




2021. Schafferman, A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
2022. Schaffner, D. W., Rutgers - The State University of New Jersey, New Brunswick, 
New Jersey (PDA/1 Clostridium botulinum 2000, 2002) 
2023. Schaller, R. A., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
immitis 2002) 
2024. Scharf, O., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Brucella melitensis 2001) 
2025. Schesser, K., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2005) 
2026. Schilling, A. S., Naval Surface Warfare Center, Dahlgren, Virginia (PDA/1 
Bacillus anthracis 2005) 
2027. Schilling, B., Buck Institute for Age Research, Novato, California (PDA/1 
Francisella tularensis 2004) 
2028. Schlievert, P. M., University of Minnesota Medical School, Minneapolis, 
Minnesota (PDA/1 Bacillus anthracis 2005) 
2029. Schmaljohn, A. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/1 Variola virus 2003, EDA/2 Crimean-Congo 
hemorrhagic fever virus 2005, EDA/2 Lake Victoria marburgvirus 2001, 2002, 2003, 
2004, 2005, EDA/2 Zaire ebolavirus 2000, 2001, 2002, 2003, 2005, PDA/1 Camelpox 
virus 2003, PDA/1 Monkeypox virus 2003, PDA/1 Venezuelan equine encephalitis virus 
2003) 
2030. Schmaljohn, C., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2001, 2002, EDA/2 
Zaire ebolavirus 2002, 2003, 2004, Andes virus 2002, PDA/1 Rift Valley fever virus 
2005, PDA/1 Venezuelan equine encephalitis virus 2003) 
2031. Schmitt, B. J., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Venezuelan equine encephalitis virus 2003) 
2032. Schneerson, R., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2002, 2003) 
2033. Schneider, J. L., Purdue University, West Lafayette, Indiana (PDA/1 Foot and 
mouth disease virus 2003) 
2034. Schoepp, R. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Eastern equine encephalitis virus 2002, 2005) 
2035. Schokman, R. United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2005) 
2036. Schoneboom, A., Uniformed Services University of the Health Sciences, Bethesda, 
Maryland (PDA/1 Venezuelan equine encephalitis virus 2003) 
2037. Schoneboom, B. A., Uniformed Services University of the Health Sciences, 
Bethesda, Maryland (PDA/1 Venezuelan equine encephalitis virus 2000) 
2038. Schrader, K. N., California Department of Health Services, Richmond, California 
(PDA/1 Brucella melitensis 2004) 
2039. Schrenzel, M. D., Zoological Society of San Diego, San Diego, California (PDA/1 




2040. Schriefer, M. E., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Francisella tularensis 2004) 
2041. Schroeder-Tucker, L., United States Department of Agriculture, Agricultural 
Research Service, Ames, Iowa (PDA/1 Bacillus anthracis 2003) 
2042. Schubit, F. D., National Cancer Institute Frederick, Maryland (PDA/1 Yersinia 
pestis 2005) 
2043. Schuch, R., Rockefeller University, New York, New York (PDA/1 Bacillus 
anthracis 2002) 
2044. Schuetz, J. F., University of Medicine and Dentistry of New Jersey, Piscataway, 
New Jersey (PDA/1 Newcastle disease virus 2002) 
2045. Schultz, W., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2002) 
2046. Schultz-Cherry, S., Southeast Poultry Research Laboratory, United States 
Department of Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2000, 2003)  
2047. Schumacher, J. A., University of Scranton, Scranton, Pennsylvania/University of 
Texas, Dallas, Texas (PDA/1 Bacillus anthracis 2004) 
2048. Schupp, J. M., Northern Arizona University, Flagstaff, Arizona (EDA/5 Bacillus 
anthracis 2003, PDA/1 Bacillus anthracis 2000, 2002, 2004, PDA/1 Yersinia pestis 2001) 
2049. Schurig, G. G., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000, 2001, 2002, 2003) 
2050. Schwan, T. G., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2000, 2002) 
2051. Schwartz, D. C., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia 
pestis 2002) 
2052. Schwoebel, E. D., Massachusetts Institute of Technology, Lexington, 
Massachusetts (PDA/1 Yersinia pestis 2003) 
2053. Scorpio, A., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
2054. Scorza, R., United States Department of Agriculture, Agricultural Research 
Service, Kearneysville, West Virginia (PDA/1 Plum pox virus 2001) 
2055. Scott, D. E., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Brucella melitensis 2001) 
2056. Scott, D. P., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003) 
2057. Scott, M. R., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002, 2005) 
2058. Scott, M. S., United States Department of Agriculture, Southeast Poultry Research 
Laboratory, Atlanta Georgia (PDA/1 Newcastle disease virus 2005) 
2059. Scott, T. W., University of Maryland, College Park, Maryland (PDA/1 Eastern 
equine encephalitis virus 2000, 2001) 
2060. Scouten, A. J., University of Georgia, Griffin, Georgia (PDA/1 Bacillus anthracis 
2004, 2005) 
2061. Scroggs, R. A., St. Jude Children's Research Hospital, Memphis, Tennessee 




2062. Scruggs, J., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus 
anthracis 2002) 
2063. Seal, B. S., United States Department of Agriculture, Southeast Poultry Research 
Laboratory, Atlanta Georgia (PDA/1 Bluetongue virus 2000, PDA/1 Newcastle disease 
virus 2000, 2001, 2002, 2003, 2004, 2005) 
2064. Sears, J., Montana State University, Bozeman, Montana (PDA/1 Bacillus anthracis 
2003) 
2065. Sebbane, F., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004, 2005) 
2066. Seiler, P., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2003) 
2067. Seitz, T. A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002) 
2068. Sekellick, M. J., University of Connecticut, Storrs, Connecticut (PDA/1 Newcastle 
disease virus 2001) 
2069. Selengut, J., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2070. Selkov, E., Integrated Genomics, Inc., Chicago, Illinois (PDA/1 Brucella 
melitensis 2002) 
2071. Sellers, H. S., United States Department of Agriculture, Southeast Poultry 
Research Laboratory, Atlanta Georgia (PDA/1 Newcastle disease virus 2001, 2002, 2004) 
2072. Senne, D. A., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Influenza A virus 2002, 2003, 2004, PDA/1 Newcastle 
disease virus 2004, 2005) 
2073. Serban, H., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
2074. Seshadri, R., Institute for Genomic Research, Rockville, Maryland/Texas A&M 
University, College Station, Texas (PDA/1 Coxiella burnetii 2001, 2003, 2004) 
2075. Seshan, K. R., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
immitis 2002, PDA/1 Coccidioides posadasii 2000) 
2076. Seth, P., Uniformed Services University of the Health Sciences, Bethesda, 
Maryland (PDA/1 Venezuelan equine encephalitis virus 2003) 
2077. Setlur, U. S., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus anthracis 2005, MDA/4/5 Bacillus globigii 2005, MDA/4/5 Yersinia 
pestis 2005) 
2078. Severin, D. D. M., Centers for Disease Control and Prevention, Fort Collins, 
Colorado (PDA/1 Francisella tularensis 2003) 
2079. Severin, J., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
2080. Sha, Z., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 2000) 
2081. Shah, J., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia pestis 
2003) 





2083. Shamblin, C., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2084. Shannon, J. G., Drexel University, Philadelphia, Pennsylvania (PDA/1 Bacillus 
anthracis 2003) 
2085. Shapiro, L., Louisiana State University, Shreveport, Louisiana (PDA/1 Brucella 
melitensis 2000) 
2086. Sharma, J. M., University of Minnesota, St. Paul, Minnesota (PDA/1 Newcastle 
disease virus 2002, 2005) 
2087. Sharma, S. K., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland/University of Massachusetts Dartmouth, North 
Dartmouth, Massachusetts (PDA/1 Clostridium botulinum 2003, 2004, 2005) 
2088. Shatalin, K. Y., University of Illinois, Chicago, Illinois (PDA/1 Bacillus anthracis 
2005) 
2089. Shaw, E. I.,, Center fo Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Coxiella burnetii 2004) 
2090. Shaw, M., Mount Sinai School of Medicine, New York, New York (PDA/1 
Newcastle disease virus 2003) 
2091. Shealy, D., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus anthracis 
2002) 
2092. Shelton, D. R., United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Bacillus anthracis 2003) 
2093. Shen, M., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot and 
mouth disease virus 2001, 2002) 
2094. Sheppard, D., University of California, San Francisco, California (PDA/1 Foot and 
mouth disease virus 2000, 2001, 2002) 
2095. Sherman, D., Purdue University, West Lafayette, Indiana (PDA/1 Bacillus 
anthracis 2004) 
2096. Shetron-Rama, L. M., University of Michigan Medical School, Ann Arbor, 
Michigan (PDA/1 Bacillus anthracis 2005) 
2097. Shi, R.-J., University of Rochester, Rochester, New York (PDA/1 Rickettsia 
rickettsii 2000) 
2098. Shieh, W.-J., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Zaire ebolavirus 2004, 2005, PDA/1 Bacillus anthracis 2003, PDA/1 Nipah virus 
2000, 2003) 
2099. Shields, R. L., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
2100. Shih, L. M., California Animal Health and Food Safety Laboratory, Davis, 
California (PDA/1 Newcastle disease virus 2005) 
2101. Shih, M.-T. P., Florida Department of Health, State Public Health Laboratory-
Miami, Miami, Florida (MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus 
thuringiensis 2004) 
2102. Shiloach, J., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 




2103. Shipley, M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Francisella tularensis 2000) 
2104. Shirako, Y., California Institute of Technology, Pasadena, California (PDA/1 
Venezuelan equine encephalitis virus 2001) 
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States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 
(PDA/1 Bacillus anthracis 2002, 2003, PDA/1 Yersinia pestis 2002, 2003) 
2106. Shoemaker, M. O., Armed Forces Radiobiology Research Institute, Bethesda, 
Maryland (PDA/1 Bacillus anthracis 2002) 
2107. Shoemaker, T., Centers for Disease Control and Prevention, Atlanta, Georgia/ 
Armed Forces Radiobiology Research Institute, Bethesda, Maryland (PDA/1 Rift Valley 
fever virus 2002, MDA/4/5 Venezuelan equine encephalitis virus 2001, EDA/2 Zaire 
ebolavirus 2003) 
2108. Shompole, S., Washington State University, Pullman, Washington (PDA/1 
Ehrlichia ruminantium 2000, PDA/1 Mycoplasma mycoides mycoides 2000) 
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Emerging Infectious Diseases and Sealy Center for Vaccine Development, University of 
Texas Medical Branch, Galveston, Texas (EDA/2 Omsk hemorrhagic fever virus 2003, 
2004, PDA/1 Japanese encephalitis virus 2000, 2004, PDA/1 Venezuelan equine 
encephalitis virus 2001, 2004) 
2110. Shoulars, K. S., Tetracore Inc, Gaithersburg, Maryland (PDA/1 Foot and mouth 
disease virus 2002) 
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2002) 
2112. Shumway, M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2002) 
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EDA/5 Monkeypox virus 2002) 
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posadasii 2005) 
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2004) 
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rickettsii 2000, 2001, 2002, 2003, 2004) 
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Zaire ebolavirus 2003) 
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2002) 
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anthracis 2004, 2005) 
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Clostridium botulinum 2004) 
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rickettsii 2003, 2004, 2005) 
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Bacillus anthracis 2004) 
2129. Sirota, L., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004) 
2130. Sisler, J. R., National Institute of Allergy and Infectious Diseases (NIAID), 
Bethesda, Maryland (PDA/1 Monkeypox virus 2001, 2002) 
2131. Skinner, G. E., United States Food and Drug Administration, Summit-Argo, 
Illinois (PDA/1 Clostridium botulinum 2000) 
2132. Skowronski, E. W., California Animal Health and Food Safety Laboratory, Davis, 
California (PDA/1 Newcastle disease virus 2005) 
2133. Skrzypek, E., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2001, 2003) 
2134. Slaterbeck, A. F., Naval Surface Warfare Center, Dahlgren, Virginia (PDA/1 
Bacillus anthracis 2005) 
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(PDA/1 Yersinia pestis 2002, 2004) 
2136. Sloan, L. M., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Bacillus 
anthracis 2002) 
2137. Small, D. S., IT Corporation, Washington, D.C. (PDA/1 Bacillus anthracis 2002) 
2138. Smee, D. F., Utah State University, Logan, Utah (EDA/5 Camelpox virus 2002, 
EDA/5 Monkeypox virus 2002, MDA/4/5 Cowpox virus 2000, PDA/1 Camelpox virus 
2001, PDA/1 Monkeypox virus 2001) 
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Venezuelan equine encephalitis virus 2001, PDA/1 Eastern equine encephalitis virus 
2002, PDA/1 Venezuelan equine encephalitis virus 2000, 2001, 2003) 
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Livermore, California (PDA/1 Bacillus anthracis 2000, 2001, 2002, 2003, 2004, PDA/1 
Francisella tularensis 2001) 
2144. Smith, M. J., Orion Genomics, St. Louis, Missouri (PDA/1 Burkholderia mallei 
2005) 
2145. Smith, S. A., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2003) 
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(MDA/4/5 Bacillus anthracis 2005, MDA/4/5 Bacillus globigii 2005, MDA/4/5 Yersinia 
pestis 2005) 
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Yersinia pestis 2003, 2004) 
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anthracis 2002, PDA/1 Monkeypox virus 2002) 
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(PDA/1 Japanese encephalitis virus 2000) 
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(PDA/1 Yersinia pestis 2004)  
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2152. Snyder, A. P., United States Army Edgewood Chemical Biological Center, 
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anthracis 2005) 
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Valley fever virus 2005) 
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Illinois (PDA/1 Clostridium botulinum 2003) 
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Japanese encephalitis virus 2003) 
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melitensis 2004) 
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Bacillus anthracis 2005) 
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(PDA/1 Coccidioides immitis 2000, PDA/1 Coccidioides posadasii 2000) 
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anthracis 2004)  
2167. Sout, G. W., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2000) 
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(PDA/1 Yersinia pestis 2004) 
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Newcastle disease virus 2003, 2004) 
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anthracis 2005) 
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melitensis 2000, 2002, 2003, 2004, 2005) 
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2176. Spron, L. A., University of Maryland, Baltimore, Maryland/University of 
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Maryland (PDA/1 Japanese encephalitis virus 2001) 
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2181. Stabler, K., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2001) 
2182. Stahl, D. A., Northwestern University, Evanston, Illinois/University of 
Washington, Seattle, Washington (PDA/1 Bacillus anthracis 2001, 2004) 
2183. Stalis, I. H., Zoological Society of San Diego, San Diego, California (PDA/1 
Mycoplasma mycoides mycoides 2005)  
2184. Stallknecht, D. E., University of Georgia, Athens, Georgia (PDA/1 Influenza A 
virus 2004) 
2185. Stanley, M., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Francisella tularensis 2004) 
2186. Steel, A., MetriGenix, Inc., Gaithersburg, Maryland (PDA/1 Influenza A virus 
2004) 
2187. Steele, K. E., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2000, EDA/2 Zaire 
ebolavirus 2000, 2001, PDA/1 Venezuelan equine encephalitis virus 2000) 
2188. Steele, P. T., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
2189. Steele, R., St. Louis University, St. Louis, Missouri (PDA/1 Newcastle disease 
virus 2003) 
2190. Steichen, C., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2003, 2004) 
2191. Steigerwalt, A., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
2192. Stephenson, I., National Veterinary Services Laboratories, U.S, Department of 
Agriculture, Animal and Health Inspection Services, Ames, Iowa/Centers for Disease 
Control and Prevention, Atlanta, Georgia (PDA/1 Influenza A virus 2005) 
2193. Stevens, D. A., California Institute for Medical Research, San Jose, California 
(PDA/1 Coccidioides immitis 2000, 2002, 2003, PDA/1 Coccidioides posadasii 2000) 
2194. Stevens, D., University of Washington, Seattle, Washington (PDA/1 Bacillus 
anthracis 2002) 
2195. Stevenson, H. L., Centers for Disease Control and Prevention, Atlanta, Georgia/Ft. 
Collins, Colorado (PDA/1 Yersinia pestis 2003) 
2196. Stinchcomb, D. T., Heska Corporation, Fort Collins, Colorado (PDA/1 Yersinia 
pestis 2003, 2004) 
2197. Stoffregen, W. C., United States Department of Agriculture, Agricultural Research 
Service, Ames, Iowa (PDA/1 Brucella melitensis 2003, 2004) 
2198. Stopa, P. J., United States Army Edgewood Chemical and Biological Center, 
Aberdeen Proving Ground, Maryland (PDA/1 Bacillus anthracis 2000) 
2199. Stout, G., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2002) 
2200. Stoutland, P. O., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
2201. Strachan, S. D., United States Army Medical Research Institute of Infectious 




2202. Straley, S. C., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2000, 2001, 2002, 2003, 2004, 2005) 
2203. Strauss, E. G., California Institute of Technology, Pasadena, California (PDA/1 
Venezuelan equine encephalitis virus 2001) 
2204. Strauss, J. H., California Institute of Technology, Pasadena, California (PDA/1 
Venezuelan equine encephalitis virus 2001) 
2205. Strecker, K., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Crimean-Congo hemorrhagic fever virus 2005) 
2206. Stribling, L. J. V., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus 
anthracis 2000, 2002) 
2207. Strobel, G. A., Montana State University, Bozeman, Montana (PDA/1 Bacillus 
anthracis 2002, 2003) 
2208. Suarez, D. L., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia (PDA/1 Influenza A virus 2000, 2002, 2003, 2004, 
PDA/1 Newcastle disease virus 2004) 
2209. Subbarao, K., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Influenza A virus 2003) 
2210. Subrahmanyam, Y. V. B. K., Yale University, New Haven, Connecticut (PDA/1 
Yersinia pestis 2001) 
2211. Succi, J., University of Texas, Houston, Texas (PDA/1 Bacillus anthracis 2003) 
2212. Suderman, M. T., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Japanese encephalitis virus 2004) 
2213. Suhan, M. L., West Virginia University, Morgantown, West Virginia (EDA/5 
Coxiella burnetii 2000) 
2214. Sullivan, L. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Venezuelan equine encephalitis virus 2005) 
2215. Sullivan, N. J., National Institutes of Health, Bethesda, Maryland (EDA/2 Zaire 
ebolavirus 2000, 2005) 
2216. Sullivan, S. A., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2217. Sullivan, V. J., BD Technologies, Research Triangle Park, North Carolina (PDA/1 
Bacillus anthracis 2005) 
2218. Sultana, A., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Yersinia pestis 2004) 
2219. Sun, Y.-H., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2002, 2004) 
2220. Sunyer, J. O., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
2221. Sur, J. H., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2002, PDA/1 
Goatpox virus 2002, PDA/1 Sheeppox virus 2002) 
2222. Suresh, M., University of Wisconsin, Madison, Wisconsin (EDA/1 “1918 




2223. Sutton, D. A.,, University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002) 
2224. Sutton, F. N., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Bacillus anthracis 2004) 
2225. Sviat, S. L., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Francisella tularensis 2004) 
2226. Svitkina, T. M., North-Western University, Chicago, Illinois (PDA/1 Rickettsia 
rickettsii 2004) 
2227. Swanson, J. A., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2000) 
2228. Swayne, D. E., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia (EDA/1 “1918 Influenza virus” 2001, 2002, 2004, PDA/1 
Influenza A virus 2000, 2001, 2002, 2003, 2004, 2005, PDA/1 Newcastle disease virus 
2004) 
2229. Swearengen, J. R., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Monkeypox virus 2001) 
2230. Swenson, D. L. United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2004, 2005, EDA/2 
Zaire ebolavirus 2004, 2005) 
2231. Syzmajda, U., University of Scranton, Scranton, Pennsylvania (PDA/1 Bacillus 
anthracis 2001) 
2232. Tafaro, A., University of Alabama at Birmingham, Birmingham, Alabama (PDA/1 
Bacillus anthracis 2003) 
2233. Tagaya, Y., National Institutes of Health, Bethesda, Maryland (PDA/1 Newcastle 
disease virus 2000) 
2234. Tailor, P., National Institutes of Health, Bethesda, Maryland (PDA/1 Newcastle 
disease virus 2004) 
2235. Taitt, C. R., Naval Research Laboratory, Center for Bio, Washington, D. C. 
(PDA/1 Bacillus anthracis 2002) 
2236. Takimoto, T., St. Jude Children's Research Hospital, Memphis, Tennessee (PDA/1 
Newcastle disease virus 2000, 2002) 
2237. Tall, B. D., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003) 
2238. Tamin, A., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Hendra virus 2002, PDA/1 Nipah virus 2000, 2001, 2002) 
2239. Tammariello, R. F., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2001, MDA/4/5 
Coxiella burnetii 2002, MDA/4/5 Venezuelan equine encephalitis virus 2001, PDA/1 
Venezuelan equine encephalitis virus 2000, 2001, PDA/1 Yersinia pestis 2002) 
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Yersinia pestis 2004) 
2241. Tang, D. B., Walter Reed Army Medical Center, Washington, D.C. (PDA/1 




2242. Tang, D.-C. C., University of Alabama at Birmingham, Birmingham, 
Alabama/Vaxin Inc., Birmingham, Alabama (PDA/1 Bacillus anthracis 2004) 
2243. Tang, Y.-W., Vanderbilt University Medical Center, Nashville, Tennessee (EDA/2 
Crimean-Congo hemorrhagic fever virus 2003) 
2244. Tang, Z., Chiron, Emeryville, California (PDA/1 Venezuelan equine encephalitis 
virus 2003) 
2245. Tarcha, E., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
posadasii 2003) 
2246. Targonski, P. V., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
2247. Tassello, J., V. I. Technologies, Inc., Watertown, Massachusetts (PDA/1 Foot and 
mouth disease virus 2002) 
2248. Tatti, K., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2003) 
2249. Taubenberger, J. K., Armed Forces Institute of Pathology, Washington, D.C. 
(EDA/1 “1918 Influenza virus” 2001, 2002, 2003, 2004, 2005) 
2250. Taus, N. S., Washington State University, Pullman (MDA/4/5 Alcelaphine 
herpesvirus 1,2 2004, 2005) 
2251. Taylor, J. W., University of California at Berkeley, Berkeley, California (PDA/1 
Coccidioides immitis 2000, 2003, PDA/1 Coccidioides posadasii 2000, 2003) 
2252. Taylor, L., Centers for Disease Control and Prevention, Atlanta, Georgia (PDA/1 
Bacillus anthracis 2002) 
2253. Teale, J. M., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Francisella tularensis 2004) 
2254. Temenak, J. J., Naval Medical Research Center, Silver Spring, 
Maryland/University of South Florida, Tampa, Florida/University of Missouri–Columbia, 
Columbia, Missouri/Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Rickettsia prowazekii 2003, 2004, PDA/1 Rickettsia rickettsii 2001) 
2255. Temple, R. M. S., Pukkerbush Veterinary Clinic, Bristolville, Ohio (PDA/1 
Brucella melitensis 2001) 
2256. Templeton, J. W., Texas A&M University, College Station, Texas (PDA/1 
Brucella melitensis 2001) 
2257. Tenover, F. C., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002, 2003, 2004) 
2258. Teplow, D. B., Harvard Medical School, Boston, Massachusetts/University of 
Washington, Seattle, Washington (PDA/1 Bacillus anthracis 2002, 2003) 
2259. Tepp, W. H., University of Wisconsin, Madison, Wisconsin (PDA/1 Clostridium 
botulinum 2001, 2005) 
2260. Tesh, R. B., University of Texas Medical Branch, Galveston, Texas (EDA/2 
Guanarito virus 2000, PDA/1 Japanese encephalitis virus 2002) 
2261. Tettelin, H., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 




2262. Tetzloff, R. C., United States Food and Drug Administration, Summit-Argo, 
Illinois (PDA/1 Clostridium botulinum 2003) 
2263. Thakar, J. H., Armed Forces Radiobiology Research Institute, Bethesda, Maryland 
(PDA/1 Bacillus anthracis 2001) 
2264. Thanassi, D. G., Stony Brook University, Stony Brook, New York (PDA/1 
Francisella tularensis 2004) 
2265. Thoen, C. O., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 
2000, 2001) 
2266. Thomas, P. W., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides 
immitis 2000) 
2267. Thomason, B., Johns Hopkins University, Baltimore, Maryland/University of 
Michigan Medical School, Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2003, 2004) 
2268. Thompson, H. A., Centers for Disease Control and Prevention, Atlanta, 
Georgia/West Virginia University, Morgantown, West Virginia (EDA/5 Coxiella burnetii 
2000, PDA/1 Coxiella burnetii 2002, 2003, 2004) 
2269. Thompson, J. M., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2003) 
2270. Thompson, J., Armed Forces Institute of Pathology, Washington, D.C. (PDA/1 
Francisella tularensis 2003) 
2271. Thorkildson, P., University of Nevada School of Medicine, Reno, Nevada (PDA/1 
Bacillus anthracis 2004) 
2272. Thorne, E. T., Wyoming Game and Fish Laboratory, University Station, Laramie, 
Wyoming (PDA/1 Brucella melitensis 2000, 2002) 
2273. Thorpe, P., University of Texas SW Med Ctr., Dallas, Texas (EDA/2 Lassa virus 
2003, 2004, 2005) 
2274. Thudium, K., Chiron, Emeryville, California (PDA/1 Venezuelan equine 
encephalitis virus 2003) 
2275. Thulasiraman, V., Ciphergen Biosystems, Fremont, California (PDA/1 Yersinia 
pestis 2001) 
2276. Thwaite, J. E., University of Maryland, Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2003) 
2277. Ticknor, L. O., Los Alamos National Laboratory, Los Alamos, New Mexico 
(PDA/1 Bacillus anthracis 2003, 2004) 
2278. Tijerina, R., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2002) 
2279. Tims, T. B., University of South Florida, Tampa, Florida (PDA/1 Bacillus 
anthracis 2004) 
2280. Tinsley, E., University of Pittsburgh, Pittsburgh, Pennsylvania (PDA/1 Bacillus 
anthracis 2003, 2004) 
2281. Tipton-Hunton, C., Northern Arizona University, Flagstaff, Arizona (PDA/1 
Bacillus anthracis 2002) 
2282. Tirrell, M. V., University of California Santa Barbara, Santa Barbara, California 




2283. Tobery, S. A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2004) 
2284. Tobioas, H. J., Lawrence Livermore National Laboratory, Livermore, California 
(MDA/4/5 Bacillus athropaeus 2004, MDA/4/5 Bacillus thuringiensis 2004) 
2285. Todd III, Robert F., University of Michigan, Ann Arbor, Michigan (EDA/2 Zaire 
ebolavirus 2000) 
2286. Toledo, R. T., University of Georgia, Athens, Georgia (PDA/1 Clostridium 
botulinum 2003) 
2287. Tomasula, P., United States Department of Agriculture, Agricultural Research 
Service, Wyndmoor, Pennsylvania (PDA/1 Bacillus anthracis 2005) 
2288. Tompkins, S. M., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Influenza A virus 2004)  
2289. Tong, M., Naval Medical Research Center, Silver Spring, Maryland (PDA/1 
Rickettsia prowazekii 2004)  
2290. Tonks, M., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Bacillus anthracis 2004) 
2291. Tonsky, K., Vical Inc., San Diego, California (MDA/4/5 Bacillus anthracis 2004) 
2292. Torres-Vellez, F., University of Georgia, Athens, Georgia (EDA/2 Nipah virus 
2004, 2005) 
2293. Toth, T. E., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000, 2002) 
2294. Tourasse, N., George Washington University, Washington D.C. (PDA/1 Bacillus 
anthracis 2003) 
2295. Towle, A. C., CJ America, Ridgefield Park, New Jersey/Walter Reed Army 
Institute of Research, Silver Spring, Maryland (PDA/1 Japanese encephalitis virus 2001) 
2296. Towner, J. S, Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Zaire ebolavirus 2005) 
2297. Towner, J. S., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Sudan ebolavirus 2004, EDA/2 Zaire ebolavirus 2003, 2004, 2005) 
2298. Traul, D. L., Washington State University, Pullman (MDA/4/5 Alcelaphine 
herpesvirus 1,2 2004, 2005) 
2299. Travassos da Rosa, A. P. A., University of Texas Medical Branch, Galveston, 
Texas (PDA/1 Japanese encephalitis virus 2002, PDA/1 Venezuelan equine encephalitis 
virus 2004) 
2300. Tremblay, M. E., Procter and Gamble, St. Bernard, Ohio (PDA/1 Bacillus 
anthracis 2004, 2005) 
2301. Trent, D. W., Acambis Inc., Cambridge, Massachusetts (PDA/1 Japanese 
encephalitis virus 2004) 
2302. Trgovcich, J., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Venezuelan equine encephalitis virus 2001) 
2303. Tripathi, A., Geo-Centers, Inc., Aberdeen Proving Ground, Maryland (PDA/1 
Bacillus anthracis 2004) 
2304. Trock, S., Southeast Poultry Research Laboratory, United States Department of 




2305. Tropea, J. E., National Cancer Institute Frederick, Maryland (PDA/1 Yersinia 
pestis 2005) 
2306. Tsai, M.-H., National Cancer Institute, National Institutes of Health, Gaithersburg, 
Maryland (PDA/1 Rickettsia prowazekii 2004) 
2307. Tsai, P., University of Maryland Baltimore, Maryland (PDA/1 Bacillus anthracis 
2005) 
2308. Tsang, K. W., United States Army Dugway Proving Grounds, Dugway, Utah 
(MDA/4/5 Bacillus anthracis 2003, MDA/4/5 Yersinia pestis 2003) 
2309. Tsolis, R. M., Texas A&M University, College Station, Texas (PDA/1 Brucella 
melitensis 2000, 2002, 2004) 
2310. Tucker, A. M., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2000, 2004, PDA/1 Rickettsia prowazekii 2003) 
2311. Tulman, E. R., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York/University of Connecticut, Storrs, Connecticut (PDA/1 
Camelpox virus 2002, PDA/1 Classsical swine fever virus 2003, PDA/1 Foot and mouth 
disease virus 2005, PDA/1 Goatpox virus 2002, PDA/1 Lumpy skin disease virus 
2001PDA/1 Sheeppox virus 2002) 
2312. Tumas, D. B., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
2313. Tumpey, T. M., Southeast Poultry Research Laboratory, United States Department 
of Agriculture, Athens, Georgia/Centers for Disease Control and Prevention, Atlanta, 
Georgia (EDA/1 “1918 Influenza virus” 2002, 2004, PDA/1 Influenza A virus 2000, 
2001, 2002, 2003, 2004, PDA/1 Newcastle disease virus 2003) 
2314. Tung, C.-H., Harvard Medical School, Boston, Massachusetts (PDA/1 Coxiella 
burnetii 2002) 
2315. Tupin, E. A., Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002)  
2316. Turell, M. J., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland/Walter Reed Army Institute of Research, Silver Spring, 
Maryland (PDA/1 Eastern equine encephalitis virus 2000, 2003, PDA/1 Rift Valley fever 
virus 2000, PDA/1 Venezuelan equine encephalitis virus 2000, 2001, 2002, 2003, 2004) 
2317. Turnbough Jr., C. L., University of Alabama at Birmingham, Birmingham, 
Alabama (PDA/1 Bacillus anthracis 2003, 2004) 
2318. Turnbull, P. C. B., Naval Medical Research Center, Silver Spring, Maryland 
(PDA/1 Bacillus anthracis 2004) 
2319. U’Ren, J. M., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004) 
2320. Ueda, Masahiro, Oklahoma State University, Stillwater, Oklahoma (PDA/1 
Cercopithecine herepesvirus 1 2002) 
2321. Uhl, J. R., Mayo ClinicFoundation, Rochester, Minnesota (PDA/1 Bacillus 
anthracis 2002) 
2322. Ulaszek, J., United States Food and Drug Administration, Summit-Argo, Illinois 
(PDA/1 Clostridium botulinum 2000) 




2324. Ulrich, M. P., Goldbelt Raven, LLC, Frederick, Maryland (PDA/1 Bacillus 
anthracis 2004, PDA/1 Yersinia pestis 2004) 
2325. Ulrich, R. G., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2003, PDA/1 Bacillus 
anthracis 2005, PDA/1 Yersinia pestis 2004) 
2326. Ulrich, R.L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Burkholderia mallei 2005, PDA/1 Bacillus 
anthracis 2004) 
2327. Ulrich, S. K., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Francisella tularensis 2002) 
2328. Umayam, L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2002) 
2329. Vagnozzi, A., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York/University of Connecticut, Storrs, Connecticut (PDA/1 
Foot and mouth disease virus 2005) 
2330. Vajdy, M., Chiron, Emeryville, California (PDA/1 Venezuelan equine encephalitis 
virus 2003) 
2331. Valdes, J. J., United States Army Edgewood Research, Aberdeen Proving Ground, 
Maryland University of Texas San Antonio, San Antonio, Texas 
2332. van de Verg, L. L., Walter Reed Army Institute of Research, Silver Spring, 
Maryland (PDA/1 Brucella melitensis 2001, 2002) 
2333. van Ert, M. N., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004, 2005) 
2334. van Kampen, K. R., University of Alabama at Birmingham, Birmingham, Alabama 
(PDA/1 Bacillus anthracis 2004) 
2335. van Kessel, J. A., United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Bacillus anthracis 2003) 
2336. van Kirk, L. S., University of Wyoming, Laramie, Wyoming (PDA/1 Rickettsia 
prowazekii 2000, PDA/1 Rickettsia rickettsii 2000) 
2337. van Rensburg, H. G., Plum Island Animal Disease Center, United States 
Department of Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 
2004) 
2338. Vandenbergh, J. G., North Carolina State University, Raleigh, North Carolina 
(PDA/1 Rickettsia rickettsii 2003) 
2339. Vandenberghe, L. H., University of Pennsylvania, Philadelphia, Pennsylvania 
(EDA/2 Zaire ebolavirus 2003) 
2340. VanderZanden, L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2001, EDA/2 Zaire 
ebolavirus 2003, PDA/1 Venezuelan equine encephalitis virus 2003) 
2341. Varghees, S., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2002) 
2342. Varma-Basil, M., University of Medicine and Dentistry of New Jersey, Newark, 
New Jersey (PDA/1 Bacillus anthracis 2004, PDA/1 Yersinia pestis 2004) 




2344. Vaughn, D. W., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Japanese encephalitis virus 2001) 
2345. Vazquez, J. A., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2003) 
2346. Vazquez, S., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2003) 
2347. Vemulapalli, R., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2000, 2001, 2002, 2003) 
2348. Venkateswaran, K. S., Lawrence Livermore National Laboratory, Livermore, 
California (MDA/4/5 Bacillus anthracis 2003, 2005, MDA/4/5 Bacillus globigii 2005, 
MDA/4/5 Yersinia pestis 2003, 2005) 
2349. Vennari, J., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
2350. Venter, J. C., Institute for Biological Energy Alternatives, Rockville, Maryland 
(PDA/6 Enterobacteria phage φX174 2003) 
2351. Verardi, P. H., University of California-Davis, Davis, California (PDA/1 Peste-
des-petits-ruminants virus 2003, PDA/1 Rinderpest virus 2002, 2003) 
2352. Vergara, J., University of California, San Francisco, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
2353. Vergez, L. M., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Francisella tularensis 2005, PDA/1 Yersinia pestis 2004) 
2354. Versage, J. L., Centers for Disease Control and Prevention, Fort Collins, Colorado 
(PDA/1 Francisella tularensis 2003) 
2355. Vetter, S. M., University of Minnesota Medical School, Minneapolis, Minnesota 
(PDA/1 Bacillus anthracis 2005) 
2356. Vidal, P., University of California Berkeley, California (PDA/1 Coccidioides 
immitis 2003, PDA/1 Coccidioides posadasii 2003) 
2357. Vidaver, Anne K., University of Nebraska, Lincoln, Nebraska (PDA/1 Xylella 
fastidiosa 2002) 
2358. Villasmil, R., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002) 
2359. Villinger, F., Emory University, Atlanta, Georgia (EDA/2 Reston ebolavirus 2001) 
2360. Vimr, E. R., University of Illinois at Urbana-Champaign, Urbana, Illinois (PDA/1 
Yersinia pestis 2002) 
2361. Vincent, M. J., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Crimean-Congo hemorrhagic fever virus 2002, EDA/2 Sudan ebolavirus 2004, 
PDA/1 Rift Valley Fever virus 2002) 
2362. Viriyakosol, S., University of California, San Diego, California PDA/1 
Coccidioides posadasii 2005) 
2363. Vivekanada, J., Brooks Air Force Base, San Antonio, Texas (PDA/1 Bacillus 
anthracis 2002) 





2365. Vogel, P., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Burkholderia mallei 2000, PDA/1 Eastern equine 
encephalitis virus 2005, PDA/1 Venezuelan equine encephalitis virus 2001, PDA/1 
Yersinia pestis 2002) 
2366. Vogler, A. J., Northern Arizona University, Flagstaff, Arizona (EDA/5 Bacillus 
anthracis 2003, PDA/1 Bacillus anthracis 2002, PDA/1 Yersinia pestis 2004, 2005) 
2367. Volokhov, D., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Kensington, Maryland (PDA/1 Bacillus anthracis 2004) 
2368. Voss, T., Southern Research Institute, Frederick, Maryland (PDA/1 Bacillus 
anthracis 2004) 
2369. Waag, D. M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Burkholderia mallei 2005, MDA/4/5 
Burkholderia pseudomallei 2003, MDA/4/5 Coxiella burnetii 2002, PDA/1 Burkholderia 
mallei 2000, 2001, 2002, PDA/1 Coxiella burnetii 2000) 
2370. Wagg, J. K., SRI International, Menlo Park, California (PDA/1 Francisella 
tularensis 2005) 
2371. Wagner, D. M., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2004, 2005, PDA/1 Yersinia pestis 2004, 2005) 
2372. Wagner, M. A., Mujer, C., University of Scranton, Scranton, Pennsylvania (PDA/1 
Brucella melitensis 2002) 
2373. Wagoner, K. D., Centers for Disease Control and Prevention, Atlanta, Georgia 
(EDA/2 Lassa virus 2000, EDA/2 Sudan ebolavirus 2004) 
2374. Waldmann, T. A., National Institutes of Health, Bethesda, Maryland (PDA/1 
Newcastle disease virus 2000) 
2375. Walfield, A. M., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot 
and mouth disease virus 2001, 2002) 
2376. Walker, B., Louisiana State University, Baton Rouge, Louisiana (PDA/1 Brucella 
melitensis 2000) 
2377. Walker, D. H., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia prowazekii 2000, 2001, PDA/1 Rickettsia rickettsii 2005) 
2378. Walker, G. C., Massachusetts Institute of Technology, Cambridge, Massachusetts 
(PDA/1 Brucella melitensis 2000, 2004) 
2379. Walker, J. V. Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2001, 2002, 2003) 
2380. Walker, T., Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002)  
2381. Waller, L. N., University of South Carolina, Columbia South Carolina (PDA/1 
Bacillus anthracis 2004) 
2382. Walls, L., University of California, San Diego, California (PDA/1 Coccidioides 
immitis 2000) 
2383. Walter, M. H., University of Northern Iowa, Cedar Falls, Iowa (PDA/1 Bacillus 
anthracis 2003) 





2385. Wamwayi, H., University of California-Davis, Davis, California (PDA/1 Peste-
des-petits-ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
2386. Wang, C. Y., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot and 
mouth disease virus 2001, 2002) 
2387. Wang, E., University of Louisville, Louisville, Kentucky (PDA/1 Bacillus 
anthracis 2004) 
2388. Wang, E., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2001, 2003) 
2389. Wang, H., University of Connecticut, Storrs, Connecticut (PDA/1 Newcastle 
disease virus 2002) 
2390. Wang, H.-Q., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Eastern equine encephalitis virus 2004) 
2391. Wang, J., University of Georgia, Athens, GA (EDA/1 Variola virus 2003, PDA/1 
Monkeypox virus 2003) 
2392. Wang, J., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
2393. Wang, J.-G., Bayer Corporation, Clayton, North Carolina (PDA/1 Venezuelan 
equine encephalitis virus 2001) 
2394. Wang, R., Illinois Institute of Technology, Chicago, Illinois (PDA/1 Bacillus 
anthracis 2003) 
2395. Wang, S., University of Massachusetts, Worcester, Massachusetts (PDA/1 
Yersinia pestis 2004) 
2396. Wang, T. T., Oakland Research Institute, Oakland, California (PDA/1 Bacillus 
anthracis 2004) 
2397. Ward, M. D., North Carolina State University, Raleigh, North Carolina (PDA/1 
Newcastle disease virus 2000) 
2398. Ward, N. L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Coxiella burnetii 2003) 
2399. Warfield, K. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2004, 2005, EDA/2 
Zaire ebolavirus 2003, 2004, 2005) 
2400. Warnock, D. W., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Coccidioides immitis 2000) 
2401. Warren, R. L., Walter Reed Army Institute of Research, Washington, D.C. (PDA/1 
Brucella melitensis 2000) 
2402. Warscheid, B., University of Maryland, Baltimore, Maryland (PDA/1 Bacillus 
anthracis 2003, 2004) 
2403. Wasieloski Jr., L. P., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (PDA/1 Venezuelan equine encephalitis virus 2004) 
2404. Watanabe, S., University of Wisconsin, Madison, Wisconsin (EDA/1 “1918 
Influenza virus” 2004, EDA/2 Zaire ebolavirus 2003) 
2405. Waterston, A. M., BD Technologies, Research Triangle Park, North Carolina 




2406. Watkins, K. L. Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
2407. Watowich, S. J., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2001, 2003) 
2408. Watson, R. P., University of Maryland, College Park, Maryland (PDA/1 Yersinia 
pestis 2001) 
2409. Watts, D. M., Naval Medical Research Center Detachment, NAMRID, Peru/ 
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, 
Maryland (PDA/1 Venezuelan equine encephalitis virus 2000, 2004) 
2410. Waugh, D. S., National Cancer Institute Frederick, Maryland (PDA/1 Yersinia 
pestis 2005) 
2411. Weaver, S. C., University of Texas Medical Branch, Galveston, Texas (EDA/2 
Guanarito virus 2000, PDA/1 Eastern equine encephalitis virus 2004, PDA/1 Venezuelan 
equine encephalitis virus 2000, 2001, 2002, 2003, 2004, 2005) 
2412. Webb, C. P., Van Andel Research Institute, Grand Rapids, Missouri (PDA/1 
Bacillus anthracis 2001)  
2413. Webb, K., United States Department of Agriculture, Agricultureal Research 
Service, Appalachian Fruit Research Station, Kearneysville, West Virgina (PDA/1 Plum 
pox virus 2001) 
2414. Webby, R. J., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2005) 
2415. Webster, R. G., St. Jude Children’s Research Hospital, Memphis, Tennessee 
(PDA/1 Influenza A virus 2000, 2002, 2003, 2004, 2005) 
2416. Weeks, S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2002) 
2417. Weiden, M. D., New York University, New York, New York (PDA/1 Bacillus 
anthracis 2004) 
2418. Weidman, J. F., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
2419. Weigend, S., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 
2001) 
2420. Weil, R., Vitruvius Biosciences, The Woodlands, Texas (PDA/1 Bacillus anthracis 
2004) 
2421. Weinstein, R. S., George Mason University, Fairfax, Virginia (PDA/1 Bacillus 
anthracis 2005) 
2422. Weis, C. P., United States Environmental Protection Agency, Denver, Colorado 
(MDA/4/5 Bacillus anthracis 2002) 
2423. Weissman, S. M., Yale University, New Haven, Connecticut (PDA/1 Yersinia 
pestis 2001) 
2424. Welch, M. D., University of California, Berkeley, California (PDA/1 Rickettsia 
rickettsii 2004) 
2425. Welcher, B. C., United States Army Medical Research Institute of Infectious 




2426. Welkos, S., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (PDA/1 Bacillus anthracis 2001, 2002, 2003, 2004, PDA/1 
Yersinia pestis 2002, 2004) 
2427. Wells, J., Southern Research Institute, Frederick, Maryland (PDA/1 Bacillus 
anthracis 2004) 
2428. Welte, F. J., University of California, San Francisco, California (EDA/2 Lake 
Victoria marburgvirus 2001, EDA/2 Zaire ebolavirus 2001) 
2429. Weltman, G., University of Miami, Miami, Florida (PDA/1 Yersinia pestis 2005) 
2430. Weltzin, R., Orovax Inc., Cambridge, Massachusetts (PDA/1 Japanese encephalitis 
virus 2000) 
2431. Werther, W., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
2432. West, M., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (MDA/4/5 Cowpox virus 2002) 
2433. Weyant, R. S., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002, PDA/1 Burkholderia mallei 2002, PDA/1 Burkholderia 
pseudomallei 2002) 
2434. Whaley, D. N., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
2435. Wheeler, K., Oakland Research Institute, Oakland, California (PDA/1 Bacillus 
anthracis 2005) 
2436. Whelan, S. P., Harvard Medical School, Boston, Massachusetts (EDA/2 Zaire 
ebolavirus 2005) 
2437. Whistler, Toni, Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Nipah virus 2003) 
2438. Whitbeck, J. C., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
2439. Whitcomb, R. F. United States Department of Agriculture, Agricultural Research 
Service, Beltsville, Maryland (PDA/1 Mycoplasma capricolum capripneumoniae 2004, 
PDA/1 Mycoplasma mycoides mycoides 2004) 
2440. White, L. J., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Venezuelan equine encephalitis virus 2001) 
2441. White, O., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003, PDA/1 Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 
2004) 
2442. White, P. S., Los Alamos National Laboratory, Los Alamos, New Mexico (PDA/1 
Newcastle disease virus 2004) 
2443. White, S. W., St. Jude Children's Research Hospital, Memphis, 
Tennessee/University of Tennessee, Memphis, Tennessee (PDA/1 Bacillus anthracis 
2004) 
2444. White, T. J., Roche Molecular Systems, Alameda, California (PDA/1 Coccidioides 
immitis 2000, PDA/1 Coccidioides posadasii 2000) 





2446. Whitehouse, C. A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Crimean-Congo hemorrhagic fever virus 2004) 
2447. Whiting, R. C., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Clostridium botulinum 2005) 
2448. Whitlow, V., Vical Inc., San Diego, California (MDA/4/5 Bacillus anthracis 2004) 
2449. Whitmire, W. M., University of Florida, Gainesville, Florida (PDA/1 Ehrlichia 
ruminantium 2001) 
2450. Whitney, A. M., Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002, PDA/1 Brucella melitensis 2004, PDA/1 Burkholderia 
mallei 2002, PDA/1 Burkholderia pseudomallei 2002) 
2451. Whitney, A. R., National Institutes of Health, Hamilton, Montana (PDA/1 Yersinia 
pestis 2004) 
2452. Whitney, R. W., Stanford University, Stanford, Connecticut (EDA/1 Variola virus 
2004) 
2453. Whittaker, P., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003) 
2454. Whitworth, T., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia rickettsii 2005) 
2455. Wick, C. H., United States Army Edgewood Chemical Biological Center, 
Aberdeen Proving Ground, Maryland (PDA/1 Bacillus anthracis 2004) 
2456. Wiegand, E., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2002, EDA/2 Zaire 
ebolavirus 2002, PDA/1 Burkholderia pseudomallei 2001) 
2457. Wild, M. A., Wildlife Research Center, Fort Collins, Colorado (PDA/1 Brucella 
melitensis 2000) 
2458. Wildes, M. J., Georgia State University, Atlanta, Georgia (PDA/1 Cercopithecine 
herpesvirus 1 2003) 
2459. Wilhelmsen, C. L., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Brucella melitensis 2004, PDA/1 
Burkholderia mallei 2003, PDA/1 Coxiella burnetii 2000) 
2460. Will, A. B., United States Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2002, EDA/2 Zaire 
ebolavirus 2002, 2005) 
2461. Williams, A. W., University of Kentucky, Lexington, Kentucky (PDA/1 Yersinia 
pestis 2002) 
2462. Williams, D. D., University of Alabama at Birmingham, Birmingham, 
Alabama/Auburn University, Auburn, Alabama (PDA/1 Bacillus anthracis 2003, 2004) 
2463. Williams, E. S., University of Wyoming, Laramie, Wyoming (PDA/1 Brucella 
melitensis 2000, 2002) 
2464. Williams, L. E., University of Scranton, Scranton, Pennsylvania (PDA/1 Bacillus 
anthracis 2001, 2002, 2004) 
2465. Williams, P. L., California Institute for Medical Research, San Jose, 
California/Kaweah Delta District Hospital, Visalia, California (PDA/1 Coccidioides 




2466. Williamson, C., University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina (PDA/1 Influenza A virus 2000) 
2467. Williamson, D. L., State University of New York at Stony Brook, Stony Brook, 
New York (PDA/1 Mycoplasma capricolum capripneumoniae 2004, PDA/1 Mycoplasma 
mycoides mycoides 2004) 
2468. Williamson, R. A., Scripps Research Institute, La Jolla, California (PDA/1 Bovine 
spongiform encephalopathy prion 2002) 
2469. Wilson, J. A., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Zaire ebolavirus 2000, 2001) 
2470. Wilson, K. E. Centers for Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Bacillus anthracis 2002) 
2471. Wilson, W. C., United States Department of Agriculture, Arthropod-borne Animal 
Diseases Research Laboratory, Laramie, Wyoming (PDA/1 Bluetongue virus 2000, 2001) 
2472. Wimmer, E., State University of New York at Stony Brook, Stony Brook, New 
York (MDA/6 Poliovirus 2002) 
2473. Wimsatt, J., Colorado State University, Fort Collins, Colorado (PDA/1 Yersinia 
pestis 2001) 
2474. Winfield, M. D., Washington University, St. Louis, Missouri (PDA/1 Yersinia 
pestis 2005) 
2475. Winkler, H. H., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2000, PDA/1 Rickettsia prowazekii 2003) 
2476. Wirtz, R., Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Eastern equine encephalitis virus 2003) 
2477. Wise, M. G., Southeast Poultry Research Laboratory, United States Department of 
Agriculture, Athens, Georgia (PDA/1 Newcastle disease virus 2004, 2005) 
2478. Woitanske, M. D., University of Texas San Antonio, San Antonio, Texas (PDA/1 
Coccidioides immitis 2003) 
2479. Wolf, A. M., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Bacillus anthracis 2003) 
2480. Wolfe, K. A., University of Virginia, Charlottesville, Virginia (PDA/1 Bacillus 
anthracis 2003) 
2481. Wong, A. C. L., University of Wisconsin, Madison, Wisconsin (PDA/1 Bacillus 
anthracis 2004) 
2482. Wong, J. D., California Department of Health Services, Berkeley, California 
(PDA/1 Francisella tularensis 2001, PDA/1 Yersinia pestis 2000, 2001) 
2483. Wood, D. O., University of South Alabama, Mobile, Alabama (EDA/5 Rickettsia 
prowazekii 2000, 2004, PDA/1 Rickettsia prowazekii 2003) 
2484. Wood, T. K., University of Connecticut, Storrs, Connecticut (PDA/1 Bacillus 
anthracis 2005) 
2485. Woodland, D. L., St. Jude Children’s Research Hospital, Memphis, Tennessee 
(PDA/1 Influenza A virus 2000) 
2486. Woolcock, P. R., University of California Davis, Davis, California (PDA/1 




2487. Woolfit, A. R., Center fo Disease Control and Prevention, Atlanta, Georgia 
(PDA/1 Coxiella burnetii 2004) 
2488. Woollen, N., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (EDA/2 Lake Victoria marburgvirus 2001, EDA/2 
Sudan ebolavirus 2001, EDA/2 Zaire ebolavirus 2001, 2002) 
2489. Worsham, P. L., U.S. Army Medical Research Institute of Infectious Diseases, 
Fort Detrick, Maryland (MDA/4/5 Yersinia pestis 2003, PDA/1 Yersinia pestis 2000, 
2001, 2002, 2004) 
2490. Wright Valderas, M., East Carolina University, Greenville, North Carolina (PDA/1 
Brucella melitensis 2004) 
2491. Wright, N. T., University of Pennsylvania, Philadelphia, Pennsylvania (EDA/2 
Zaire ebolavirus 2003) 
2492. Wright, R., Louisiana State University, Shreveport, Louisiana (PDA/1 Brucella 
melitensis 2000) 
2493. Wrin, T., Genentech, Inc, South San Francisco, California (MDA/4/5 Human 
respiratory syncytial virus 2001) 
2494. Wu, A., Advanced Biosystems, Inc., Manassas, Virginia (PDA/1 Bacillus 
anthracis 2002, 2003) 
2495. Wu, Q., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003, 2005) 
2496. Wu, T., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
2497. Wu., M., Institute for Genomic Research, Rockville, Maryland (PDA/1 Bacillus 
anthracis 2003) 
2498. Wulff-Strobel, C. R., University of Kentucky, Lexington, Kentucky (PDA/1 
Yersinia pestis 2002, 2005) 
2499. Wyrobek, A. J., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2004) 
2500. Xiao, S.-Y., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Japanese encephalitis virus 2002) 
2501. Xie, H., Center for Biologics Evaluation and Research, Food and Drug 
Administration, Bethesda, Maryland (PDA/1 Bacillus anthracis 2004, 2005) 
2502. Xu, W., University of Maryland, Baltimore, Maryland (PDA/1 Rickettsia 
prowazekii 2002) 
2503. Xu, Y., Texas A&M University, Houston, Texas (PDA/1 Bacillus anthracis 2004) 
2504. Xue, J., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides posadasii 
2003) 
2505. Yamaga, S., Yale University, New Haven, Connecticut (PDA/1 Yersinia pestis 
2001) 
2506. Yamshchikov, V. F. University of Virginia, Charlottesville, Virginia (PDA/1 
Japanese encephalitis virus 2001) 
2507. Yang, Z.-Y., National Institutes of Health, Bethesda, Maryland/University of 




2508. Yanoviak, S., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Venezuelan equine encephalitis virus 2004) 
2509. Yates III, J., Scripps Research Institute, La Jolla, California (PDA/1 Bacillus 
anthracis 2004) 
2510. Yaver, D., Novozymes Biotech Inc., Davis, California (PDA/1 Bacillus anthracis 
2002, 2003) 
2511. Ye, J., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot and mouth 
disease virus 2001, 2002) 
2512. Yeh, H. Y., University of Minnesota, St. Paul, Minnesota (PDA/1 Newcastle 
disease virus 2002) 
2513. Yen, G., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
2514. Yergey, A., National Institutes of Health, Bethesda, Maryland (PDA/1 Bacillus 
anthracis 2003) 
2515. Yesus, M., University of California-Davis, Davis, California (PDA/1 Peste-des-
petits-ruminants virus 2003, PDA/1 Rinderpest virus 2003) 
2516. Yilma, Tilahun D., University of California-Davis, Davis, California (PDA/1 
Peste-des-petits-ruminants virus 2003, PDA/1 Rinderpest virus 2002, 2003) 
2517. Yokoyama, W. M., Washington University, St. Louis, Missouri (EDA/2 Zaire 
ebolavirus) 
2518. Yokum, T. S., Louisiana State University, Baton Rouge, Louisiana (PDA/1 
Brucella melitensis 2002) 
2519. Yoon, S.-S., University of Cincinnati, Cincinnati, Ohio (PDA/1 Francisella 
tularensis 2004) 
2520. York, J., University of Montana, Missoula, Montana (EDA/2 Junín virus 2004) 
2521. Young, A. M., Massachusetts Institute of Technology, Lexington, Massachusetts 
(PDA/1 Yersinia pestis 2003) 
2522. Young, H. A., National Cencer Institute, Frederick, Maryland (EDA/2 Zaire 
ebolavirus 2002, 2003, 2004, 2005) 
2523. Yu, J., IOMAI, Gaithersburg, Maryland (PDA/1 Bacillus anthracis 2004) 
2524. Yu, J.-J., Medical College of Ohio, Toledo, Ohio (PDA/1 Coccidioides immitis 
2000, 2001, 2002, PDA/1 Coccidioides posadasii 2003) 
2525. Yu, Q., United States Department of Agriculture, Southeast Poultry Research 
Laboratory, Atlanta Georgia (PDA/1 Newcastle disease virus 2005) 
2526. Yu, X. J., University of Texas Medical Branch, Galveston, Texas (PDA/1 
Rickettsia prowazekii 2000) 
2527. Yu, Y., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2528. Yuan, L., Walter Reed Army Institute of Research, Washington, D.C. (PDA/1 
Brucella melitensis 2000, 2002) 
2529. Yunus, A. S., University of Maryland, College Park, Maryland (PDA/1 Newcastle 




2530. Yurawecz, M. P., Center for Food Safety and Applied Nutrition, Food and Drug 
Administration, College Park, Maryland (PDA/1 Bacillus anthracis 2003)Reid, T. D., 
University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus anthracis 2003) 
2531. Yusibov, V., Fraunhofer USA Center for Molecular Biotechnology, Newark, 
Delaware (PDA/1 Bacillus anthracis 2005) 
2532. Zafar, N., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2533. Zaffuto, K. M., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2004) 
2534. Zahrt, T. C., Medical College of Wisconsin, Milwaukee, Wisconsin (PDA/1 
Francisella tularensis 2004) 
2535. Zakhariev, V., Argonne National Laboratory, Argonne, Illinois (PDA/1 Bacillus 
anthracis 2004) 
2536. Zaki, S. R., Centers for Disease Control and Prevention, Atlanta, Georgia (EDA/2 
Zaire ebolavirus 2004, 2005, PDA/1 Bacillus anthracis 2003, PDA/1 Influenza A virus 
2000, PDA/1 Nipah virus 2000, 2003, PDA/1 Rickettsia rickettsii 2003) 
2537. Zakowska, D., University of Scranton, Scranton, Pennsylvania (PDA/1 Bacillus 
anthracis 2001, 2004) 
2538. Zamboni, D. S., Yale University, New Haven, Connecticut (PDA/1 Coxiella 
burnetii 2003, 2004) 
2539. Zaucha, G. M., United States Army Medical Research Institute of Infectious 
Diseases, Fort Detrick, Maryland (MDA/4/5 Monkeypox virus 2001) 
2540. Zelazowska, E. B., Armed Forces Institute of Pathology, Washington, D.C. 
(PDA/1 Brucella melitensis 2003) 
2541. Zeng, H., University of Alabama at Birmingham, Birmingham, Alabama (PDA/1 
Bacillus anthracis 2004) 
2542. Zeytun, A., Virginia Polytechnic Institute and State University, Blacksburg, 
Virginia (PDA/1 Brucella melitensis 2001) 
2543. Zhang, C. G., Lawrence Livermore National Laboratory, Livermore, California 
(PDA/1 Yersinia pestis 2005) 
2544. Zhang, C., University of Nebraska, Lincoln, Nebraska (PDA/1 Francisella 
tularensis 2004) 
2545. Zhang, G. Q., Texas A&M University, College Station, Texas (PDA/1 Coxiella 
burnetii 2003, 2004, 2005) 
2546. Zhang, K., University of Michigan, Ann Arbor, Michigan (PDA/1 Bacillus 
anthracis 2004) 
2547. Zhang, L., Allergan Inc., Irvine, California (PDA/1 Clostridium botulinum 2003) 
2548. Zhang, L., University of Texas Medical Branch, Galveston, Texas (MDA/1 
Pichinde virus 2001) 
2549. Zhang, M. L., United Biomedical, Inc., Hauppauge, New York (PDA/1 Foot and 
mouth disease virus 2001) 





2551. Zhang, T., Thermo Finnigan, San Jose, California (PDA/1 Rickettsia prowazekii 
2004)  
2552. Zhang, Y., St. Jude Children’s Research Hospital, Memphis, Tennessee (PDA/1 
Influenza A virus 2003) 
2553. Zhang, Z.-X., Orovax Inc./ Acambis Inc., Cambridge, Massachusetts (PDA/1 
Japanese encephalitis virus 2000, 2001, 2002) 
2554. Zhao, B. Walter Reed Army Institute of Research, Silver Spring, Maryland 
(PDA/1 Japanese encephalitis virus 2001) 
2555. Zhao, B. Y., Kansas State University, Manhattan, Kansas (PDA/1 Xanthomonas 
oryzae 2004) 
2556. Zhao, K., National Institutes of Health, Bethesda, Maryland (PDA/1 Newcastle 
disease virus 2004) 
2557. Zhao, L., Rutgers - The State University of New Jersey, New Brunswick, New 
Jersey (PDA/1 Clostridium botulinum 2002) 
2558. Zhao, Q.-Z., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 Foot and mouth disease virus 2003) 
2559. Zhao, S., National Cancer Institute, National Institutes of Health, Gaithersburg, 
Maryland (PDA/1 Rickettsia prowazekii 2003, 2004) 
2560. Zhao, Y., United States Department of Agriculture, Agricultural Research Service, 
Beltsville, Maryland (PDA/1 Newcastle disease virus 2005) 
2561. Zheng, H., Mount Sinai School of Medicine, New York, New York (EDA/1 “1918 
Influenza virus” 2001, PDA/1 Newcastle disease virus 2001) 
2562. Zhou, E.-M., Iowa State University, Ames, Iowa (PDA/1 Foot and mouth disease 
virus 2004) 
2563. Zhou, H., Iowa State University, Ames, Iowa (PDA/1 Brucella melitensis 2001) 
2564. Zhou, L., Institute for Genomic Research, Rockville, Maryland (PDA/1 
Burkholderia mallei 2004, PDA/1 Burkholderia pseudomallei 2004) 
2565. Zhou, S. S., University of California-Davis, Davis, California (PDA/1 
Cercopithecine herepesvirus 1 2003) 
2566. Zhou, S., University of Wisconsin, Madison, Wisconsin (PDA/1 Yersinia pestis 
2002) 
2567. Zhou, Y., University of Massachusetts Dartmouth, North Dartmouth, 
Massachusetts (PDA/1 Clostridium botulinum 2004) 
2568. Zhu, Li, Georgia State University, Atlanta, Georgia (PDA/1 Cercopithecine 
herpesvirus 1 2003) 
2569. Zinser, G., Northern Arizona University, Flagstaff, Arizona (PDA/1 Bacillus 
anthracis 2000) 
2570. Zollinger, W. D., Walter Reed Army Institute of Research, Washington, D.C. 
(PDA/1 Brucella melitensis 2002) 
2571. Zsak, A., Plum Island Animal Disease Center, United States Department of 
Agriculture, Greenport, New York (PDA/1 African swine fever virus 2005) 
2572. Zsak, L., Plum Island Animal Disease Center, United States Department of 




2004, 2005, PDA/1 Camelpox virus 2002, PDA/1 Goatpox virus 2002, PDA/1 Lumpy 
skin disease virus 2001, 2003, PDA/1 Sheeppox virus 2002) 
2573. Zurkuhlen, Holley, Georgia State University, Atlanta, Georgia (PDA/1 
Cercopithecine herpesvirus 1 2002, 2003) 
2574. Zwiers, S. H., United States Army Medical Research Institute of Infectious 







Overall, the proposed oversight system (“CISSM Controlling Dangerous Pathogens 
Project”) would have had little impact on overall US research activities had the system 
existed between 2000 and 2005 
1. The majority (>99%) of US research publications related to unlisted agents 
(several thousand) and related agents (appr. 1,725) would not have been 
affected at all by the proposed system 
2. However, the oversight system would have had some impact on research with 
listed agents (appr. 56), although mostly on a local (PDA/LPRC), and NOT on 
a national (MDA/NPRA) or international (EDA/IPRA) level 
3. The proposed oversight system would have had considerable impact on 
research activities with “eradicated” (2) and BSL-4 agents (15), and on 
research using aerosols, most of which, however, is conducted at few facilities 
by few people  
4. Only a handful of published US research projects of 2000-2005 fall into the 
created Dangerous Activitiy subcategories other than PDA/1, PDA/6, MDA/6, 
or EDA/2, emphasizing that the proposed oversight system would mostly 




5. With the exception of research projects performed at US military institutions, 
which may be considered as biodefense projects by definition, almost no 
project falling under the oversight system was a definite biodefense project 
(although, after 9/11/2001, many research papers refer to the relevance to 
biodefense of the results presented) 
6. Almost all US research classified as a Dangerous Activity under the proposed 
oversight system was obviously performed with “good” intentions with public 
health aspects being addressed. Few “controversial” US papers, e.g. the 
creation of antibiotic-resistant poxviruses and certain aerosol challenge 
studies, were identified by the author. The author also has the impression 
that, considering the overall number of US research publications on a 
particular agent, most “dangerous” activities are performed with agents that 
are classified as “dangerous”. 
 
Quantitative Assessment: 
Had the proposed oversight system existed between 2000 and mid-2005, a total of at least 
310 US facilities and 2,574 US researchers would have been affected (at least 231 US 
facilities and 2,119 US researchers were involved in PDA; 14 US facilities and 133 US 
researchers were involved in MDA; 12 US facilities and 185 US researchers were involved 
in EDA; and 53 US facilities and 137 US researchers were involved in PDA + MDA, PDA + 






1. Screening for “US publications” was a rather simple albeit very time-
consuming process because the majority of these publications are listed in the 
most commonly used and openly accessible databases; and because the author 
had full-text access to >75% of these articles. Screening “foreign” 
publications would be much harder and impossible without visiting libraries 
in foreign countries. This is because many foreign publications are still 
published in foreign languages in journals with low impact factor (which, in 
turn, are not listed in common electronic databases), and because full-text 
access is almost never provided 
2. Most of the “US publications” reviewed for this working paper fit neatly into 
the different Dangerous Activity subcategories defined by the CISSM 
Controlling Dangerous Pathogens Project. The author did not find 
publications that would have to be defined borderline between the three 
major catogories, PDA, MDA, or EDA. However, several publications fit into 
several subcatogories (e.g. publications that addressed several select agents at 
the same time) 
3. The number of publications addressing a given agent differs dramatically 
from country to country and most often directly reflects the endemicity of this 
agent. For example, many “exotic” lifestock pathogens, for which almost no 
“US” publications were identified, are heavily researched in other countries 




4. The number of “dubious” research papers, i.e. papers that report 
experiments that could be considered offensive bioweapons research or at 
least borderline/dual-use differs dramatically from country to country 
5. Most agents are tightly associated with a particular kind of research (e.g. 
most research employing lymphocytic choriomeningtitis virus is immunology-
related; most research employing bacilli is related to the identification of 
novel enzymes; most research employing listed agents infecting animals are 
epidemiological and related to lifestock industry, most research on avian 
influenzaviruses and brucellae is vaccine-related etc.) 
6. There was no obvious difference in the amount of publications fitting the 
various subcategories prior and post 9/11. An overall slight increase in 
publications was noted, probably reminiscent of the overall growing research 
activities in the US. However, notable exceptions are Bacillus anthracis, 
Francisella tularensis, and Yersinia pestis, all of which have substantially been 
more researched post 9/11 compared to pre 9/11; and Brucella melitensis, on 
which considerably less papers have been published after 9/11 
7. Most institutions/people affected were either associated with one particular 
listed or non-listed agent only and work on it consistently over the years, 
employing the same principal researchers; or were involved in particular 
projects only. However, some instutions (CDC, UC Davis, UTMB, 
USAMRIID etc.) were involved in work with many listed and related agents 




8. The number of collaborations, i.e. the number of articles written by authors 
from several different institutions (all from the US or from US and from 




Observed Shortcomings of the Oversight System: 
1. Research on emerging or novel agents might not be covered by the system as 
long as the agents are not classified as select agents/BSL-4 agents (e.g., 
research on severe acute respiratory syndrome coronavirus is only covered by 
the PDA categories (unlisted agent) at the moment) 
2. The term “exotic” in the US Select Agent list needs to be specified for the 
system. Likewise, the terminus “large quantities” for BSL-4 agents needs to 
be specified 
3. A definition of “de novo synthesis” needs to be established 
4. The problem of changing taxonomy of agents needs to be addressed 
5. Some obvious dual-use articles would only fall into the PDA/1 category (e.g. 
the challenge of irradiated animals with listed agents)  
 
